Playbook, Perspective and Pattern for founders raising now. This report strips out giant rounds and public market traffic so you can read the part of the market that actually prices your round. Every figure below was checked against at least two independent sources across three verification passes, the last of them adversarial.

Healthcare took $393.5M of the $901.2M that cleared the US mid-market this week. That is 43.7% of the capital, up from 23.1% one week earlier. Nine healthcare rounds closed. Every one of the nine had a prior investor writing again.

That is the shift. Capital did not chase healthcare as a category. It followed people who had already seen the inside of a company and came back with a bigger check. Across all 26 verified rounds, 19 carried a returning investor, and those 19 took 86.0% of the dollars. The seven rounds without one averaged $18.0M. The nineteen with one averaged $40.8M.

The second pattern sits underneath the first. The rounds where an outside party had already underwritten something- a rating agency, a reinsurer, a state Medicaid program, a government-funded deployment, a named enterprise buyer- took 54.4% of the capital from 42.3% of the deals. Investors priced in conviction that someone else had already paid for.

For founders, the consequence is blunt. The fastest path to a term sheet this quarter runs through two groups you already know: the investors on your cap table and the counterparties who have already bet money or reputation on you. If neither group is in your process, you are raising toward the $18.0M average, not the $40.8M one.

The Week in One Sentence

Primary insight. Band capital reached its highest level in six issues, concentrating in rounds where an insider or an outside underwriter had already said yes, and healthcare met both tests most often.

· Total capital deployed. $901.2M in new primary capital across 26 verified US rounds between $5M and $100M, up 12.5% from $800.9M across 22.

· Against prior issues. In the $10M to $100M band, this series has tracked 22 rounds and $873.0M since September, up from 19 rounds and $778.5M last week. Capital up 12.1%, deal count up 15.8%. The highest band total in six issues.

· Average round size. $34.66M across the full set, down 4.8% from $36.40M. On the $10M to $100M band, $39.68M against $40.97M, down 3.1%.

· Median round size. $24.0M across the full set, down 20.0% from $30.0M. On the $10M to $100M band, $29.5M against $30.0M, down 1.7%.

· Largest tracked round. Estuary Biotherapeutics at $93.0M, a Series A. Smallest: Zaria Systems at $5.2M, a seed.

· Highest Eisen score. Stands at 73. Lowest: Evos and Othello at 33. A band of 40 points. Five of 26 rounds cleared 65 and none reached 75. Mean 49.9, median 48.

· Named institutional lead. 25 of 26 rounds (96.2%), up from 19 of 22 (86.4%) last week. Only Othello closed without a designated lead in its anchor sources.

· Strategic or customer-side capital. 10 of 26 rounds, or 38.5%, carried $497.0M, or 55.1% of the week’s capital, versus 8 of 22 (36.4%) and 40.3% last week.

· Returning investors. 19 of 26 rounds, or 73.1%, carried at least one investor from a prior round, against 13 of 22, or 59.1%, last week. Five were led or co-led by a prior investor.

The Deal Scorecard

Eisen Fundability Scores run across five dimensions: Founder-Investor Dynamics (30), Traction to Conviction Conversion (25), Narrative Power (20), Deal Architecture (20) and Capital Planning (5). Scores of 90 to 100 signal an inevitable, market-defining outcome. 85 to 89 signals extremely strong execution. 75 to 84 signals solid fundamentals. 65 to 74 signals a good company with some gaps. Below 65 signals an early-stage or structurally incomplete round.

What the scorecard says at a glance

Read the top of the table and the bottom of the table separately. The top five scores belong to rounds where something outside the company had already been committed: rated insurance carriers and named reinsurers at Stand, a prior participant stepping into the lead at Albert, state Medicaid provider status at Abby Care, a cement major deploying the product at Pathways, and distribution partners writing again at Suki. The bottom of the table is not weak companies. It is first institutional rounds, pre-seed and seed checks, and extensions, where nobody outside the founding team and the lead had put anything on the line yet.

The second read is concentration. The three largest rounds took $265.0M, or 29.4% of the week. Nine rounds of $50M or more totaled $615.0M. California held 11 rounds and $558.2M, or 61.9% of capital, with an average round of $50.75M. New York held 9 rounds and $170.5M, averaging $18.94M. New York produced the deal count. California produced dollars.

The third read is the lead seat. Only one round, Othello, closed without a designated lead. Every other round had a firm willing to price it. That is a tighter market than it looks: lead discipline rose while the median check fell.

What Changed This Week

Five shifts, ranked by structural impact on founder fundraising rather than by deal size. Each is built on verified deal records and ends with what it means for your raise.

1. Healthcare Rounds Ran on Insiders

Pattern, what happened. Healthcare closed nine rounds for $393.5M, 43.7% of the week, against three rounds and 23.1% the prior week. Healthcare rounds averaged $43.72M against $29.86M for everything else. All nine carried a prior investor: Khosla, Thrive and Sequoia back at Abby Care, Venrock, Flare, Hedosophia, Philips Ventures and Zoom Ventures back at Suki, 4BIO and GV back at Estuary, Avidity leading Sirona Medical again, Index and GV co-leading Allara again, and Left Lane and First Round returning to co-lead Brellium. Three of the week’s five insider-led rounds were healthcare.

Perspective, what it means. This is not a quality premium. Healthcare averaged 51.3 against 49.2 for the rest of the field, and five of the nine carried no externally controlled validation in the record. What healthcare had was continuity. Investors who have sat on a clinical software, women’s health or radiology board know the reimbursement cycle and the sales cycle from inside. They underwrite the next round on information a new investor cannot get from a deck. New leads followed because the insiders had already absorbed the information risk.

Founder Blindspot, what most miss. Founders read 43.7% as “healthcare is hot” and pitch the category. The capital did not go to the category. It went to companies whose existing investors were willing to be counted again. A healthcare company with a disengaged cap table gets nothing from this week.

Playbook, what to do. Before you contact a single new investor, hold a 30-minute call with each existing investor and ask one question: will you take your pro rata, and will you say so in writing to the new lead? Collect the answers before you build the target list.

Contrast. Last week enterprise AI and software led with $245.9M across eight rounds and healthcare took $185.0M across three. This week healthcare took more than enterprise AI and software, which fell to $232.0M across seven.

What this means for your raise: In regulated categories, insider support is the price of entry, not a bonus.

2. The Participant Became the Price-Setter

Pattern, what happened. 19 of 26 rounds carried a returning investor, 73.1%, up from 13 of 22, or 59.1%. Those 19 took $775.0M, 86.0% of the week. The 7 rounds without a returning investor averaged $18.03M against $40.79M. Five rounds were led or co-led by a prior investor: TCV at Albert, Avidity Partners at Sirona Medical, Index Ventures and GV at Allara, Left Lane Capital and First Round Capital at Brellium, and Draper Associates at Mogul. Last week, only one of thirteen insider rounds had a prior investor in the lead seat.

Perspective, what it means. A returning investor is the only party in a process who has seen the board deck, the bank statements and the founder under pressure. When that investor writes again, every new investor reads it as a diligence shortcut. When that investor sets the price, it removes the question every new investor asks: what do the people who already know you think? Rounds with a returning investor scored 53.3 against 40.9, a 12.4-point gap. The Insider Support sub-dimension is worth two points; remove it from both groups and 11.1 points remain. The returning rounds were better constructed across the other four dimensions, not just credited for the re-up.

Founder Blindspot, what most miss. Founders treat the insider check as a formality to collect at the end, and they treat the prior lead as the only insider who could lead again. This week, two of the five insider leads, TCV at Albert and Draper Associates at Mogul, had only participated in the prior round. The minority holder with the most conviction is often the next lead.

Playbook, what to do. Rank every investor on your cap table by fund size and category conviction. Give the top two the same monthly reporting you give your lead, and ask them six months before your raise whether they want the lead seat. Convert any yes into a written, sized commitment conditional on terms.

Contrast. The share of rounds with a returning investor rose 14.0 points week over week, and insider-led rounds rose from one to five. Insider support moved from a premium signal to a baseline, and the finer signal moved to who leads.

What this means for your raise: Your last investor is your first reference. Your quietest minority investor may be your next lead.

3. Third Parties Underwrote the Top

Pattern, what happened. 11 of 26 rounds carried an externally controlled validation. Those 11 took $490.0M, 54.4% of the week, and averaged $44.55M against $27.41M for the 15 without one. Four rounds earned the significant validation tier: Stand, through rated carriers and a named reinsurance panel; Abby Care, through operating as a Medicaid provider across eight states; Switched Source, through a five-year, $99M Department of Energy grid program project; and Probably Genetic, through an ARPA-H diagnostics contract of up to $10M. Those four averaged an Eisen score of 61.8, compared with 47.8.

Perspective, what it means. Investors paid for risk this week that someone else had already priced in. A reinsurer that takes a share of the book has run its own model with its own capital. A state Medicaid program that pays a provider has credentialed it. A federal grid program that funds a five-year deployment has diligenced the hardware. A federal health research agency that awards a diagnostics contract has reviewed the method. Each is checkable with one call, and the company cannot influence it. Rounds with any independent validation scored 59.8 against 42.7. Strip the Independent Validation sub-dimension, and the residual is 11.9 points. The validated companies were stronger on founders, deal architecture and capital planning as well.

Founder Blindspot, what most miss. Founders outside medtech assume independent validation means an FDA clearance and decide it does not apply to them. This week the validators were two insurance rating agencies, five reinsurers, Medicaid programs in eight states, a federal grid program and a federal health research agency. Every category has a counterparty that underwrites risk for a living.

Playbook, what to do. Name the one external body in your category whose sign-off a skeptical investor would trust more than your deck. Write down what it takes to get that sign-off, who owns it inside your company and the date you could have it.

Contrast. Last week, nine rounds carried at least one external validation, and the strongest of them were defense contract vehicles. This week the validators moved into insurance, Medicaid, utilities and federal health research, and three of the four significant-tier rounds sat in the top six scores.

What this means for your raise: One validation a stranger can confirm beats ten claims only you can confirm.

4. Buyers Moved Onto Cap Tables

Pattern, what happened. Strategic or customer-side capital appeared in 10 of 26 rounds (38.5%), holding $497.0M (55.1%) of the week, up from 40.3% the prior week. Three rounds had a buyer, distributor or manufacturer on the cap table: Suki, with Zoom Ventures and Philips Ventures returning while Zoom ships Suki inside its own telehealth product; Switched Source, with ABB, Southwire and Southern States, all of which sell into utility procurement; and Pathways, with Heidelberg Materials and Titan, both of which run the product in their own plants. Those three averaged 65.0 against 48.0. Strip Customer-Side Capital from the score and 12.0 points remain. The seven rounds with a corporate venture arm and no stated commercial tie, among them Intel Capital, Applied Ventures, M12, IQT, Hitachi Ventures, CVS Health Ventures, Biogen New Ventures and Circle Ventures, averaged 56.1. No customer led a round this week.

Perspective, what it means. A financial investor is buying a forecast of demand. A buyer that invests has already tested that forecast through its own procurement, so its check is a receipt. That is why deploying buyers outscored brand-name corporate arms. Intel Capital on a cap table says a powerful company wants exposure. Heidelberg Materials on Pathways’ cap table says a cement producer intends to keep using the product across three continents.

Founder Blindspot, what most miss. Founders chase the biggest corporate brand for the round. The signal is not the brand. It is whether the corporate uses the product. Founders also miss the cost: a buyer on the cap table can ask for a right of first refusal, category exclusivity or information rights that narrow your exit and your customer base for good.

Playbook, what to do. List your three largest customers and three largest channel partners. For each, find the person who runs their venture or strategic investment function, and ask your internal champion for the introduction, framed around their own deployment rather than your round. Before any of them offers, agree your position on first refusal, exclusivity and information rights with counsel.

Contrast. Strategic share of rounds rose for a second consecutive week, from 26.7% two weeks ago to 36.4% and now 38.5%. Strategic share of capital rose from 40.3% to 55.1%. Last week, three rounds had a buyer or channel on the cap table, and one of them was led by its channel owner. This week three rounds had one and none was led by it.

What this means for your raise: A customer on the cap table is the shortest diligence call a lead will ever make. Rank corporate investors by the customer they bring, not by the logo.

5. The Pedigree Seed Lane Closed and Late Stage Reopened

Pattern, what happened. Seed and pre-seed produced 4 rounds totaling $28.2M, averaging $7.05M. The prior week produced 6 such rounds totaling $212.9M, averaging $35.48M, driven by large seed checks to pedigreed teams. Seed alone averaged $6.4M this week against $41.54M. At the other end, Series C, D, and E produced 4 rounds for $282.0M, 31.3% of the week, after producing none the prior week, and those four averaged 65.0. Series A deepened to 10 rounds averaging $30.6M, up from $25.11M on 9 rounds, with a median of only $14.0M. Series B thinned to 4 rounds averaging $48.5M, down from $64.3M on 5.

Perspective, what it means. Capital moved up the stack to companies with operating history and an insider base. The four late-stage rounds, Abby Care, Stand, Sirona Medical and Suki, all had a prior investor writing again and averaged $70.5M. The large seed check to a famous team was absent. The seed rounds that did close were sized to a first milestone: $5.2M, $6.0M, $8.0M and a $9.0M pre-seed. Series A split in two: a handful of large rounds above $50M and a long tail near the $14.0M median.

Founder Blindspot, what most miss. Seed founders see a $41.54M prior-week average and size their raise to it. That number was a handful of pedigree outliers. This week’s seed market priced to milestones, and the top-five seed round was $6.0M, with a deploying buyer on the cap table. The other two seeds, without one, scored 33 and 35.

Playbook, what to do. Rebuild your seed ask from the bottom up. Name the one milestone that makes the Series A inevitable, cost it, add nine months of runway, and stop there. If you are at Series B, open growth-fund conversations now while the late-stage lane is visibly open, and bring your insiders’ commitments with you.

Contrast. Seed averaged $41.54M on 5 rounds the prior week and $6.4M on 3 rounds this week. Late stage went from zero rounds to four.

What this means for your raise: At seed, size to a milestone. At Series C and beyond, the round goes to the company whose insiders write first.

The Deals That Matter

Five deep dives across catastrophe insurance, chemistry AI, home care, industrial carbon data and clinical AI. These are the week's five highest-scoring rounds. All facts are verified against two or more sources and re-checked in a second pass.

Stand

Catastrophe-Risk Home Insurance | Series C | $70.0M | Led by Saga Ventures

Eisen Fundability Score: 73 / 100

Why this scored. The highest score of the week, on the only round that combined a serial-exit founding team, a third-party underwriting stack of rated carriers and a named reinsurance panel, and a re-underwrite twelve months after the last round at twice the size. It lost points in one place above all, customer-side capital, and still finished first.

The Setup. Stand, headquartered in San Francisco and founded in 2024, insures homes in areas where traditional carriers have pulled back. It uses remote sensing and property-level modeling of wind, heat and ember exposure to price risk and recommend specific resilience upgrades. Chief executive Dan Preston previously ran Metromile. The founding team also includes Jason Mueller, who led product at Policygenius, Sam Shank, former chief executive of HotelTonight, and Bill Clerico, former chief executive of WePay. The buyers are homeowners in high-risk geographies, starting with California and Florida.

The Deal. $70.0M Series C led by Saga Ventures, announced October 15, 2026, with Lowercarbon, Eclipse, Equal Ventures, Inspired Capital, Neotribe and Jackson Square Ventures participating. All equity. The $35M Series B, led by Eclipse, was announced in October 2025. Policies are issued by Concert Specialty Insurance Company, rated A minus by AM Best, in California, and by Stand Insurance Exchange, rated A by Demotech, in Florida. The reinsurance panel includes Arch, RenaissanceRe, Hannover, Nephila and Hiscox. Stand added Drew Saad, former chief underwriting officer at PURE Insurance, as president of property and casualty, and Tony Landi, formerly of Nephila, as chief financial officer.

The Pattern. This is the underwritten-risk round. In insurance, the real diligence happens before the venture round. A rating agency rates the carrier. A reinsurer takes a share of the losses. Two rating agencies and five reinsurers had already underwritten part of Stand before the venture lead priced the round, each with its own model and its own capital.

The Perspective. Founders in any regulated or risk-bearing category should ask who in their value chain already prices risk for a living. That party’s participation is a stronger signal than any internal model. Stand did not ask investors to trust its model. It showed them the counterparties who had already bet on it.

The Playbook. Map your value chain for risk-bearing counterparties: insurers, reinsurers, lenders, sureties, rating agencies, auditors. Pick one whose participation you can secure before your next round and work backward from what it requires.

The Founder Mistake to Avoid. Copying the team, not the structure. A serial-founder roster earned Stand a full founder score, but the score leader was built by the underwriting stack. A strong team without external underwriters lands in the middle of this week’s table.

Founder lesson. Bring the counterparty that already prices your risk into the room before the venture investor arrives.

Founder trap. Leading with the model. Investors discount internal models. They do not discount a reinsurer’s signature.

Albert

Chemistry-Native AI for Industrial R&D | Series B | $55.0M | Led by TCV

Eisen Fundability Score: 70 / 100

Why this scored. The strongest insider-led round of the week. A participant in the Series A stepped up to lead the Series B, the founder came out of a buyer’s own R&D organization, and the named customer list spans chemicals, materials and consumer goods. Its Founder-Investor Dynamics mark of 23 of 30 is second only to Stand’s in the issue.

The Setup. Albert, headquartered in Oakland, California, builds software and models for formulation chemists, trained on roughly 15 million chemical structures and the public chemical patent record. Chief executive Nick Talken co-founded the company in 2022 after serving as head of digital R&D at Henkel, where the company first built the product internally and then spun it out. Named customers include BASF, Henkel, Clorox, Kenvue, AkzoNobel, Avient, Chemours and Nouryon.

The Deal. $55.0M Series B led by TCV, announced October 13, 2026, with new investors Delta-v Capital, Socium Ventures, HighSage Ventures, Coral Capital and Legion VC, and existing investors Coatue, J.P. Morgan Growth Equity Partners, Index Ventures and Applied Ventures. All equity. TCV participated in the $22.5M Series A led by Coatue in December 2024 and now leads. The most recent prior financing was a $20M growth investment led by J.P. Morgan in February 2025.

The Pattern. This is the insider step-up round. The strongest signal in venture is a participant becoming a lead. TCV spent nearly two years as a minority investor and then chose to set the price. Every new investor in the syndicate inherited that diligence.

The Perspective. Treat every minority investor in your last round as a potential next lead. They have the information advantage, and their decision to lead removes the question every new investor asks. Applied Ventures, the venture arm of Applied Materials, is on the cap table without a stated commercial tie, which is why customer-side capital scored 3, not 6.

The Playbook. Identify the minority investor in your last round with the largest fund and the deepest category conviction. Give it the same monthly data you give the lead, and ask it six months before your raise whether it wants the lead seat.

The Founder Mistake to Avoid. Waiting for the prior lead to lead again. Prior leads often cap their exposure. The step-up from participant to lead compresses a process.

Founder lesson. Your next lead may already be a minority holder on your cap table. Cultivate it like a lead.

Founder trap. Over-crediting the logo wall. The customer list matters, but an insider decided the round by choosing to price it.

Abby Care

Paid Family Caregiving Through Medicaid | Series C | $82.0M | Led by Transformation Capital

Eisen Fundability Score: 67 / 100

Why this scored. Operating as a Medicaid provider across eight states is external validation a new investor can confirm with state agencies, and the round arrived 14 months after the last one at more than twice the size. The founder is a first-time founder, which held P1 to 20 of 30, and the rest of the record carried it into the top three.

The Setup. Abby Care, headquartered in San Francisco, trains family members to become certified caregivers, employs them, pays them weekly and supports them with registered nurse care managers. It operates as a Medicaid provider, works with health plans to arrange home care for people with disabilities and complex needs, and is active in eight states. Founder and chief executive Havi Nguyen grew up handling Medicaid paperwork for her own family.

The Deal. $82.0M Series C led by Transformation Capital, announced October 15, 2026, with new investors CVS Health Ventures, Frist Cressey Ventures and Pivotal Ventures, and existing investors Khosla Ventures, Thrive Capital and Sequoia Capital. All equity. The prior round, $35M, was announced in August 2025.

The Pattern. This is the licensed-provider round. Medicaid participation across eight states means eight sets of state reviewers have looked at the company’s operations, credentialing and billing. It is a moat a competitor needs years to replicate, and an investor needs only a phone call to confirm.

The Perspective. In reimbursement-driven categories, the license is the product. The investor does not need to believe the founder’s projections. It needs to believe the payer will keep paying, and state participation is the evidence. CVS Health Ventures joining matters, but it scored as a corporate arm because no commercial agreement is attached in the record.

The Playbook. List every license, enrollment, accreditation and payer contract your category requires. Rank them by how long a competitor would need to obtain them. Make the top one the milestone your next round funds.

The Founder Mistake to Avoid. Treating licensure as back-office compliance. In this category, investors are pricing the asset.

Founder lesson. A license a regulator controls is the hardest proof to fake and the easiest to check.

Founder trap. Expanding to a ninth state before the first eight are operating cleanly. The participation is only valuable if it holds.

Pathways

Verified Environmental Data for Building Materials | Seed | $6.0M | Led by Sorenson Capital

Eisen Fundability Score: 67 / 100

Why this scored. The only seed round in the top five and the second smallest round in the set. Two building materials manufacturers invested and deploy the product in their own operations, earning 17 of 25 on Traction to Conviction, tied with Suki for the highest mark in that dimension.

The Setup. Pathways, headquartered in New York and launched in 2023 by Leise Sandeman and Alexander Cooper, turns manufacturers’ operational data into environmental product declarations, the independently verified documents that report a building material’s environmental impact. The product also shows manufacturers which materials and processes drive emissions and lets them model alternatives before changing production. The buyers are cement, aggregates and building materials producers.

The Deal. $6.0M Seed led by Sorenson Capital, announced October 13, 2026, with Pi Labs, Zacua Ventures, Blue Lion, Positive Ventures and Great Wave, plus strategic investors Titan Ventures and Heidelberg Materials. All equity. Pi Labs and Zacua co-led the $2.5M pre-seed in February 2024. Heidelberg Materials is also Pathways’ largest customer, with a contract spanning sites in North America, Europe and Australia, and both strategic investors use the platform in their own operations.

The Pattern. This is the buyer-backed seed. A buyer on the cap table that also deploys is the strongest possible signal at seed. It answers the question no seed investor can answer from outside: will a large, conservative manufacturer actually change its process for this product?

The Perspective. At seed, a single reference-grade customer that also invests is worth more than a long list of pilots. It is a procurement decision and an investment decision made by the same organization. That is why a $6.0M seed outscored 21 larger rounds.

The Playbook. Ask your largest pilot customer for two things in the same meeting: a multi-site expansion and a strategic allocation in your round. If the champion cannot secure the second, the first tells you how deep the commitment runs.

The Founder Mistake to Avoid. Taking strategic money from a company that does not use the product. A passive corporate check scores 3 of 8 on customer-side capital. A deploying buyer scores 6. The difference is the deployment.

Founder lesson. At seed, one buyer who deploys and invests outweighs a dozen pilots.

Founder trap. Announcing the corporate name without the deployment. Investors check whether the corporation uses the product.

Suki

Ambient Clinical AI | Series E | $90.0M | Led by Healthier Capital

Eisen Fundability Score: 66 / 100

Why this scored. The second largest round of the week and the only late-stage round with distribution partners on the cap table. Zoom Ventures and Philips Ventures wrote again, and athenahealth and Zoom both ship Suki inside their own products. It lost the most points of any top-five round on deal architecture because a venture lender in the syndicate left the equity-and-credit split unresolved.

The Setup. Suki, headquartered in Redwood City, California, turns clinical conversations into documentation, coding support, order staging and other workflow output. Founder and chief executive Punit Soni is a former product executive at Google and Motorola and was chief product officer at Flipkart. Suki integrates with Epic, Oracle Health, athenahealth and MEDITECH. athenahealth’s Ambient Notes and Zoom’s telehealth ambient documentation are both powered by Suki, and Optum is a named partner.

The Deal. $90.0M Series E led by Healthier Capital, announced October 13, 2026, with new investors Crosslink Capital and Hercules Capital and all existing institutional investors returning, including Venrock, Flare Capital Partners, Hedosophia, Philips Ventures and Zoom Ventures. Aman Mahajan of Healthier Capital joins the board. Hercules Capital is a venture lender, and no source separates equity from credit. The $70M Series D was announced in October 2024.

The Pattern. This is the distribution-partner round. When the products clinicians already use, an EHR and a video platform, ship your feature under their own name, their distribution underwrites your adoption. Zoom writing again as an investor confirms the partnership is a strategy, not a pilot.

The Perspective. A full insider re-up into a Series E is a strong signal. So is a new specialist lead taking the board seat. What a lead will still ask is how much of the $90M is equity. Capital stack design scored 0 because the record cannot answer that.

The Playbook. If a platform ships your product inside its own, ask its venture arm into your next round, and state the equity and debt split in the announcement so a reader never has to guess.

The Founder Mistake to Avoid. Letting a blended headline stand. A round that mixes venture debt into the number reads larger and diligences slower. State the split.

Founder lesson. Get the platform that ships your product to invest in it, and say so plainly.

Founder trap. Treating a larger blended headline as a stronger signal. Diligence starts by taking it apart.

The Fundraising Playbook

Five plans, each producing a concrete artifact you can use this week. Each is built directly from this week’s verified signals.

1. The Underwriter-First Narrative (Narrative and Investor Framing)

Focus. Reframe your category claim around who has already underwritten you.

Why this matters. All five rounds clearing 65 opened with external counterparties or insiders, not internal projections. Rounds with independent validation averaged $44.55M against $27.41M.

Exact deliverable. A one-page narrative and a rewritten deck headline. The headline is a risk-reduction claim that names the strongest external commitment you hold, followed by the category claim and the one sentence that makes your company must-understand. Example structure: “Two rating agencies and five reinsurers already carry our risk. We insure the homes others will not.”

Time estimate. Four hours, plus one hour testing it with an investor you trust.

Expected outcome. A first meeting that starts with a fact the investor can confirm, not a claim the investor must believe.

The reframe. Wrong approach: “We are building the AI platform for X.” Right approach: “Heidelberg Materials deploys us in its own plants and invested in this round.”

2. Obtain One Externally Controlled Fact (Proof Architecture)

Focus. Acquire one validation that someone other than you grants and records.

Why this matters. Four rounds earned the significant validation tier and averaged 61.8 against 47.8; with the sub-dimension stripped, 8.0 points remain. Across all eleven rounds with any validation, the residual is 11.9.

Exact deliverable. A three-column inventory: every validation a third party could grant you in the next two quarters, the body that grants it, and the earliest date it could land. Insurance ratings and reinsurance treaties, state Medicaid participation, FDA clearances, federal research contracts, government grid programs, SOC 2 or ISO certification, or a reference-grade customer that also invests. Pick the fastest one, assign an owner and file this week.

Time estimate. Three hours for the inventory. Two to six months to obtain the first validation, which is why the filing date matters more than the announcement date.

Expected outcome. You open your process with a fact a partner can confirm without you.

The reframe. Wrong approach: collecting more pilot logos. Right approach: converting one pilot into a deployment with a procurement contact the lead can call.

3. Eisen Self-Score and Gap Diagnosis (Readiness)

Focus. Score your round on the five dimensions and decide between a process now and a repair sprint first.

Why this matters. The board ran from 33 to 73 with a mean of 49.9. Traction to Conviction averaged 5.6 of 25, the weakest dimension relative to its maximum. Ten rounds scored zero on it and still closed, but they averaged $16.42M against $46.06M for the sixteen that scored above zero.

Exact deliverable. A one-page score: Founder-Investor Dynamics (30), Traction to Conviction (25), Narrative Power (20), Deal Architecture (20), Capital Planning (5), with an evidence line for each sub-dimension. Score only what a stranger could confirm. Circle your two lowest dimensions. Above 65, run a parallel process with a hard deadline. Between 50 and 65, spend four to six weeks repairing the lowest dimension first. Below 50, the gap is structural, meaning no lead, no returning investor or no external validation, and a better deck will not close it.

Expected outcome. A decision about process design, made before the first meeting rather than after the tenth pass.

The reframe. Wrong approach: scoring yourself on what your deck says. Right approach: scoring yourself only on what a stranger could confirm, then fixing the two lowest dimensions first.

4. The Insider Lead and the Target List (Deal Architecture and Investor Targeting)

Focus. Lock the insider position, secure a price-setter and target only firms that lead at your stage.

Why this matters. 25 of 26 rounds had a named lead. 19 of 26 had a returning investor, and those rounds took 86.0% of the capital. Five rounds had a prior investor lead, against one a week earlier.

Exact deliverable. Three items. First, a written insider commitment: a number from each existing investor, conditional on terms, and a yes or no on leading. Second, a target list cut from 120 names to 35, each annotated with a round the firm led at your stage in the last 90 days, including the firms that led this week: RA Capital Management, Healthier Capital, Transformation Capital, Saga Ventures, Maverick Silicon, PeakSpan Capital, TCV, Top Tier Capital Partners, Prysm Capital, Avidity Partners, Index Ventures, GV, Vertex Ventures SEA and India, CAVU Consumer Partners, Left Lane Capital, First Round Capital, Volition Capital, Cubit Capital, Draper Associates, Z47, Threshold Ventures, FirstMark, Define Ventures, Pantera Capital, Uncork Capital, Field Ventures, Sorenson Capital and Lightspeed Venture Partners. Third, split your use of funds into unproven-outcome and predictable-cash-cycle columns and total the second; that total is the debt conversation, and stating the split avoids the blended headline that cost Suki its capital stack score.

Time estimate. Two weeks of calendar for the insider conversations, one day for the list, one hour with counsel on first refusal, exclusivity and information rights.

Expected outcome. A process that opens with insider support in hand and a short list of firms that actually lead at your stage.

The reframe. Wrong approach: accepting a second commitment before anyone has agreed to lead. Right approach: getting one investor to confirm in writing that it will lead, price the round and take the seat before you accept a second check.

5. The Milestone-Timed Process (Momentum and Conversion)

Focus. Design a process where insiders and counterparties create the momentum.

Why this matters. Six rounds this week closed within 18 months of the last one, at a larger size, and each had a returning investor. They averaged 59.5 against 47.0; with velocity stripped, 10.1 points remain.

Exact deliverable. A 14-day follow-up cadence tied to dated milestones. Day 0: open with the insider commitment letter and the validation already in hand. Day 3: send every active firm one dated progress note. Day 7: first lead meetings close out and customer reference calls are scheduled. Day 10: second note with a named customer or partner development. Day 14: term sheet deadline. Every touch carries a fact, never a check-in.

Time estimate. Three hours to design, two weeks to execute.

Expected outcome. Competition builds on evidence, not pressure, and the deadline forces a decision.

The reframe. Wrong approach: following up with “checking in.” Right approach: following up with “our second plant went live this week, and here is the plant manager’s number.”

Looking Forward

Three evidence-based scenarios and one wild card for the next one to three weeks. Each is anchored to this week’s verified data.

Scenario 1: Healthcare Concentration Holds Through Year-End (High Probability)

Why this is likely. All nine healthcare rounds this week had returning investors, three of the five insider-led rounds were healthcare, and the sector’s share rose from 23.1% to 43.7% in one week. Insiders defending positions ahead of year-end marks tend to keep writing.

What founders should watch. Whether new healthcare leads keep appearing alongside insiders, or whether rounds tilt to insider-only. A second week above 35% with new leads confirms the trend.

What founders should do before others notice. Lock insider commitments now, before year-end allocation decisions are made.

Scenario 2: Late Stage Keeps Absorbing Mid-Market Capital (Medium-High Probability)

Why this is likely. Series C to E produced four rounds and $282.0M after producing none the prior week, all four with returning investors, and they averaged 65.0.

What founders should watch. The count of Series C and later rounds in the band next week. Two or more confirms the trend.

What founders should do before others notice. Series B founders should open conversations with growth funds now, while the late-stage lane is visibly open, and bring insider commitments to the first meeting.

Scenario 3: The Insider Lead Becomes the Standard (Medium Probability)

Why this is likely. Insider-led rounds rose from 1 of 13 to 5 of 19 in one week. When returning investors make up 73.1% of rounds, the market looks for a finer signal, and the lead seat is it.

What founders should watch. Whether insider-led rounds hold at three or more next week, and whether the score gap between insider-led and insider-participating rounds widens.

What founders should do before others notice. Ask your largest existing investor this month whether it would lead your next round if no new firm does. A yes is the strongest signal you can carry. A no tells you what to fix before you open.

Wild Card: A Buyer Takes the Lead Seat (Medium Probability)

Evidence from this week. Three rounds had a buyer, distributor or manufacturer on the cap table and averaged 65.0, but none was led by one. Grid equipment makers, a cement producer and a video platform are all writing checks into companies they buy from or distribute. Last week a channel owner led a Series B.

What founders should do before others notice. Ask your largest customer whether it would lead, not just participate. Prepare your exclusivity position first, because a buyer lead will ask for one.

The Bottom Line

The real insight is not the $901.2M. It is that the capital went to companies where someone with information or money at stake had already said yes. Nineteen of 26 rounds carried a returning investor and took 86.0% of the dollars. Eleven carried a fact an outside body controls and took 54.4%. Five had a prior investor take the lead. That produced three conviction profiles.

Profile 1: Companies whose risk is already underwritten. Stand (73) carries rated carriers and a five-firm reinsurance panel. Abby Care (67) operates as a Medicaid provider across eight states. Switched Source (62) is inside a five-year, $99M Department of Energy grid program project. Probably Genetic (45) holds an ARPA-H contract of up to $10M. Eleven rounds had at least one external validation and averaged 59.8 against 42.7, and 11.9 points of that gap survive removal of the sub-dimension.

Profile 2: Companies whose insiders set the price. Albert (70) had TCV step up from participant to lead. Brellium (55) had returning investors Left Lane and First Round co-lead. Sirona Medical (54) had its Series C lead return as lead. Allara (45) had Index Ventures and GV co-lead again. Mogul (46) had Draper Associates lead after participating in its seed. Nineteen rounds had a returning investor and averaged 53.3, up from 40.9.

Profile 3: Companies whose buyer wrote a check. Pathways (67) took money from Heidelberg Materials and Titan, which run its product. Suki (66) had Zoom and Philips write again while Zoom ships it. Switched Source (62) took money from ABB, Southwire and Southern States, which sell into the same utility procurement offices. These three averaged 65.0, and 12.0 points of their 17.0-point gap survived removing the sub-dimension.

Everything else competed for the residual. Seven rounds raised with no returning investor and averaged $18.03M. The bottom of the board, Evos and Othello at 33, Confido Health at 34, Fragment and Zaria Systems at 35, share one shape: an early or extension round with no counterparty in the record and nothing an outside party has validated. The money is real. The proof is still to come, and the next investor will ask for it.

Five New Rules for Founders

1. Bring an underwriter, not a narrator. Rounds with independent validation took 54.4% of capital from 42.3% of deals.

2. Your last investor is your first reference. Rounds with returning investors took 86.0% of capital, and five were led by an insider.

3. Put a buyer on the cap table only if it deploys. Buyer-backed rounds outscored the field by 12.0 points after stripping the credit; corporate arms with no commercial tie averaged 56.1.

4. Size seed to a milestone, not a pedigree. Seed averaged $6.4M this week, and the only top-five seed was $6.0M with a deploying buyer.

5. Name the lead before you raise. 25 of 26 rounds had one.

Four Actions

1. Call every existing investor and ask for a written commitment conditional on terms, plus a yes or no on leading.

2. Name the one external body whose sign-off would convince a skeptical investor, and set a date to obtain it.

3. Ask your largest customer whether it has a strategic investment budget, who controls it, and whether it would lead.

4. Cut your target list to 35 firms that led a round at your stage in the last 90 days.

Twenty-six companies cleared this week, and the money followed the people who already knew them. Nineteen had an investor who had funded them before. Eleven had a fact somebody else controls. You cannot manufacture either by Friday, but you can start both on Monday, with two calls to people who already take yours.

Research Methodology, Sources and Verification

Data collection period and verification standard

Data collection period: October 12 to 18, 2026. Verified primary announcements cluster between October 13 and October 16. No verified US mid-market round in the set was announced on October 12, a federal holiday, or on October 17 and 18, a Saturday and Sunday. Verification standard: at least two independent sources per deal, with a company release, investor post, filing or regulated newswire (PR Newswire, Business Wire, GlobeNewswire) as the anchor where one exists, plus at least one independent outlet. Three passes were run: a primary collection pass, an independent second pass against alternative sources, and a third pass on October 19 that re-checked every amount, stage, lead, date, headquarters, prior round and validation and was directed at finding errors in the first two. All arithmetic was recomputed after the final pass. Eisen Fundability Scores are proprietary analytical estimates, not endorsements or investment advice.

Core capital totals and what they include

The $901.2M weekly total includes only the 26 verified US rounds in the scorecard, each counted at new primary capital at close. Mid-market is defined as a US-headquartered round between $5M and $100M. Because earlier issues in this series used a $10M to $100M band, week-over-week comparisons are also calculated on that subset: 22 rounds totaling $873.0M at an average of $39.68M and a median of $29.5M, against 19 rounds totaling $778.5M at an average of $40.97M and a median of $30.0M in the prior issue. Full-set comparisons use the prior issue’s 22 rounds totaling $800.9M at an average of $36.40M and a median of $30.0M.

Excluded from counted amounts: credit facilities and venture debt where separable, secondary purchases, previously closed rounds announced alongside new ones, SAFE conversions, non-dilutive grants and cumulative totals. Two restatements follow from this rule. Estuary Biotherapeutics launched with $103M, comprising a $93M Series A led by RA Capital Management and a previously closed $10M seed co-led by GV and 4BIO Capital; $93.0M is counted. Confido Health’s $12.5M extension brings its Series A to $22.5M; $12.5M is counted. Reach Security (”more than $50 million”) and Switched Source (”more than $17 million”) are counted at their stated floors.

Stage subtotals: Series A $306.0M across ten rounds including one extension; Series B $194.0M across four; Series C $152.0M across two; no series letter $91.0M across four; Series E $90.0M across one; Series D $40.0M across one; Seed $19.2M across three; Pre-seed $9.0M across one. Sector subtotals: Healthcare $393.5M across nine; Enterprise AI and software $232.0M across seven; Fintech and insurance $112.7M across five; Industrial and hardware $88.0M across three; Consumer $75.0M across two. Geography: California $558.2M across eleven rounds, New York $170.5M across nine, Oregon $65.0M, Texas $29.0M, Florida $25.0M, Massachusetts $21.0M, Illinois $17.0M and the District of Columbia $15.5M across one each. Each set sums to $901.2M across 26 rounds.

Scoring calibration notes

All rounds are scored on the v2 rubrics in the project framework. Founder Track Record is scored on the verifiable public record of prior companies, exits, operating roles and domain tenure, and is scored 0 where no relevant background was locatable. Intermediate values were used where evidence fell between bands: Investor Quality 5, 8 and 9; Independent Validation 8; Investor Alignment 5 and 6. Round-to-round velocity of 30 to 36 months scored 1, between the 18 to 30 month band (2) and the more than 36 month band (0). Prior round dates confirmed by only one source were not credited for velocity. A corporate venture arm without a stated commercial relationship was scored 3 on Customer-Side Capital. Facts available only from aggregators were not credited. The round with no designated lead, Othello, is scored on the institutional quality present rather than at zero.

Circularity control. Where a finding rests on a dimension that is itself a scored input, the sub-dimension is removed from both sides and the residual is published alongside the headline. Returning investor: 12.4 points as measured, 11.1 with Insider Support removed. Strategic or customer-side capital: 14.4 and 10.5. Buyer, distributor or manufacturer on the cap table: 17.0 and 12.0. Any independent validation: 17.1 and 11.9. Significant validation tier: 14.0 and 8.0. Re-underwritten within 18 months at a larger size: 12.5 and 10.1.

Deal citations

Stand, $70.0M Series C. PR Newswire company release dated October 15, 2026; Fortune; Coverager; The SaaS News; Pulse 2.0; Intelligent Insurer for the October 2025 Series B. Rated HIGH.

Albert, $55.0M Series B. Business Wire company release dated October 13, 2026; CHEManager; Tech Startups; The SaaS News; VC News Daily; TechCrunch and Homebrew for the prior rounds. Rated HIGH.

Abby Care, $82.0M Series C. Fortune dated October 15, 2026; Fierce Healthcare fundraising tracker; Fundz; Runtime Wire; Axios for the August 2025 round. Rated HIGH.

Pathways, $6.0M Seed. AlleyWatch daily funding report dated October 13, 2026; Dealroom; Startups Magazine; Inforcapital; Axios for the February 2024 pre-seed. Rated HIGH.

Suki, $90.0M Series E. Fierce Healthcare, Healthcare Dive and MobiHealthNews dated October 13, 2026; Axios and Inc. for the lead attribution; AI Weekly. Rated MEDIUM on the unresolved equity and credit split.

Switched Source, $17.0M. Business Wire company release and Pulse 2.0 dated October 13, 2026; VC News Daily; Fortune Term Sheet. Rated HIGH.

Mueon, $65.0M Series A. PR Newswire company release dated October 15, 2026; SiliconANGLE; Startup Researcher; Intel Capital for the September 2025 seed. Rated HIGH.

Estuary Biotherapeutics, $93.0M Series A. Company release dated October 16, 2026; Fierce Biotech; BioPharma Dive; BioPharm International; Crunchbase News. Rated HIGH.

Brellium, $23.0M. AlleyWatch dated October 13, 2026; The SaaS News; Tech Startups. Rated MEDIUM.

Sirona Medical, $40.0M Series D. PR Newswire company release via BioSpace dated October 15, 2026; AuntMinnie; Pulse 2.0; AuntMinnie and Radiology Business for the November 2024 Series C. Rated HIGH.

North.cloud, $60.0M Series B. PR Newswire company release dated October 15, 2026; Pulse 2.0; Unite.AI; Pulse 2.0 and TMCnet for the July 2025 Series A. Rated HIGH.

Reach Security, $50.0M Series B. GlobeNewswire company release dated October 13, 2026; Pulse 2.0; The SaaS News; SecurityWeek and FinTech Global for the July 2025 M12 round. Rated HIGH.

EZ Bombs, $25.0M Series A. Just Food dated October 15, 2026; Startup Researcher; Ventureburn. Rated HIGH.

Mogul, $15.5M Series A. PR Newswire company release dated October 13, 2026; Crowdfund Insider; Dealroom; VC News Daily; Crowdfund Insider for the November 2023 seed. Rated HIGH.

Fission, $10.0M Series A. PR Newswire company release dated October 15, 2026; Fortune; The SaaS News; VC News Daily. Rated HIGH.

Allara, $30.0M. AlleyWatch and FemTech Insider dated October 13, 2026; Fierce Healthcare; TechCrunch for the January 2025 Series B. Rated HIGH.

Probably Genetic, $12.0M Series A. Fierce Healthcare dated October 14, 2026; CB Insights; for the ARPA-H award, the company release dated August 31, 2026, GenomeWeb and Unite.AI. Rated MEDIUM.

Tamr, $21.0M. PR Newswire company release dated October 14, 2026; Dealroom; Fundz. Rated HIGH.

RapidCanvas, $29.0M Series B. Company release via The Tech Outlook dated October 16, 2026; The Next Web; DealStreetAsia; AI Weekly. Rated MEDIUM.

Chubby Group, $50.0M Series A. PR Newswire company release dated October 15, 2026; VC News Daily; Inforcapital. Rated HIGH.

Readily, $11.0M Series A. Fierce Healthcare dated October 14, 2026; MobiHealthNews; The SaaS News. Rated HIGH.

Fragment, $12.0M Series A. AlleyWatch and The SaaS News dated October 14, 2026; FF News; Dealroom. Rated HIGH.

Zaria Systems, $5.2M Seed. VC News Daily dated October 14, 2026; company announcement. Rated HIGH.

Confido Health, $12.5M Series A extension. Fierce Healthcare and AlleyWatch dated October 14, 2026; DealStreetAsia. Rated HIGH.

Evos, $9.0M Pre-seed. Pulse 2.0 dated October 14, 2026; AlleyWatch; The SaaS News; VC News Daily. Rated HIGH.

Othello, $8.0M Seed. AlleyWatch and VC News Daily dated October 14, 2026; The SaaS News; Traded. Rated MEDIUM.

Market comparison sources

Crunchbase News, the week’s 10 biggest funding rounds, published October 16, 2026, totaling $1,655M: Modal Labs ($750M), Icon ($200M), Soufflé Therapeutics ($135M), Estuary Biotherapeutics ($103M as listed), Labelbox ($100M), Suki ($90M), Abby Care ($82M), Stand ($70M), Mueon ($65M) and North.cloud ($60M). Six of the ten sit inside this report’s band. Ramp’s $1.85B round, announced October 15, is used as contrast only. VC News Daily funding records, used as a candidate source and date-checked against primary releases because its posting dates lag by one to five days. AlleyWatch daily New York funding reports, The SaaS News, Pulse 2.0, Dealroom news and the Fierce Healthcare fundraising tracker for October 12 to 16, 2026.

Prior-period comparisons are drawn from the final published figures of earlier issues in this series. The $10M to $100M band ran 21 rounds and $769.0M in the week of September 7, 22 rounds and $837.5M in the week of September 14, 17 rounds and $655.0M in the week of September 21, 11 rounds and $457.5M in the week of September 28, and 19 rounds and $778.5M in the week of October 5. Strategic participation shares as published: 54.2%, 28.0%, 27.8%, 26.7% and 36.4%. The October 5 issue’s stage averages ($5.2M pre-seed, $41.54M seed, $25.11M Series A, $64.3M Series B, $20.25M no series letter), sector figures, designated leads (19 of 22), returning investors (13 of 22) and insider-led rounds (one) are used for week-over-week contrast.

Verification notes

Twenty-one of 26 rounds are rated HIGH source confidence: a company, investor, filing or regulated newswire source plus at least one independent outlet, with no unresolved conflict affecting the round. Five are rated MEDIUM. Suki: Hercules Capital, a venture lender, is in the syndicate and the equity and credit split could not be isolated across sources, so Capital Stack Design was scored 0; Healthier Capital is named as lead by Axios, Inc. and AI Weekly and listed as a new investor by Fierce Healthcare. RapidCanvas: the company releases names Vertex Ventures SEA and India as lead, while one outlet reports Hitachi Ventures as co-lead; the release is used. Brellium: the round carries no series letter, and the prior round is described as a combined seed and Series A in one source and as a Series A in another. Probably Genetic: the round rests on one independent outlet plus a data provider; the ARPA-H award is credited after confirmation in the company release, GenomeWeb and Fierce Healthcare. Othello: the anchor sources designate no lead while one outlet names two, and the round overlaps a $6.85M Form D filed in August by its parent, Cicero, Inc.; it is counted once, at the $8.0M announced. Confido Health states that its extension was completed in February 2026; it was first announced on October 14 and is counted in this week. Every third-party validation credited under Independent Validation was checked against the announcement of the award, rating or deployment rather than a company characterization of it.

Exclusions and documented rationale

News-cycle resurfaced, excluded from every total, chart and score. Vitalize, $31M, announced October 6. Navra, $19M, announced October 6. Fortem, $50M, announced September 30. TriGemX, $94M, announced October 1. Elorian, a $55M seed, was announced in April 2026 and recirculated this week. VC News Daily listed several rounds on October 14, including Vinci, Arena, TypeSafe, Atomic Machines, Voltus, and Ledgebrook, announced October 6 to 9 and belonging to the prior issue.

Non-US or dual headquarters, excluded for scorecard comparability. Harmonic Security (San Francisco and London), Duvo (New York and London), Clueso (California and Bengaluru), Causa Prima (Madrid and Munich), Pluto Security (Israel), Scarlet (United Kingdom), OMass Therapeutics (United Kingdom), Salience (United Kingdom), Skeleton (Estonia), Dougs (France), Epyr (France), CarbonFarm (France), Scimplify (India), Mesa (India), GreenCell (India), Ubitium (Germany), 1KOMMA5 (Germany), Scanntech (Uruguay), and Astribot, Yanchao, Sankai, Yisheng, Jinghua, Machxin, Yuangui, Velotric, SUNMMIO and Yundie (China).

Structural exclusions. Labelbox, a $ 100M+ headline that includes a credit facility, with new equity not isolable and the round at the band ceiling. Prolific Machines, a $50M Series B2 initial closing. Origin, a $20M cumulative figure. Scuba, $34M combining pre-seed and seed. Aatmunn, an up-to figure of $8M. Sensydia, an initial closing of $6M or more. Sonilo, headquarters not verified. DATA Network, $30M not verified across two sources.

Single anchor source this pass. Forgepoint ($9.8M), Swamp Club ($7M), Otter Health ($8M) and Allswell ($7M).

Below the floor. Leela ($4.6M) and Collective X Health ($3.2M).

Above the ceiling, contrast set only. Ramp ($1.85B), Modal Labs ($750M), Icon ($200M) and Soufflé Therapeutics ($135M).

Deals analyzed and excluded

Deals analyzed: 26 verified US mid-market rounds of new primary capital between $5M and $100M. Deals excluded: 5 resurfaced from earlier weeks, 28 non-US or dual-headquarters rounds, 8 on structural or verification grounds, 4 on a single anchor source, 2 below the $5M floor and 4 above the $100M ceiling. Second-pass changes: three scores corrected (Probably Genetic from 38 to 45 on its confirmed ARPA-H award, Reach Security from 48 to 51 on its July 2025 M12 round, Fission from 45 to 46 on returning investors), two confidence ratings changed (Fragment to HIGH, Othello to MEDIUM), and no amount, stage, lead, date or headquarters changed.

Research completion

Research completed October 19, 2026, after a third verification pass, adversarial and directed at finding errors in the second.

DISCLAIMER: This article is for informational and strategic intelligence purposes only. It does not constitute investment advice. The Eisen Fundability Score is a proprietary diagnostic within Fundables OS™, not a financial recommendation.

If this article was useful, share it with founders who are about to raise.

— Leon Eisen, Venture Partner @NetworkVC · 4x founder · Capital and Growth Strategic Partner · Bestselling Author of Invisible Game: The Secrets of the Term Sheet Magnet.

Startups raise again quickly when their progress outpaces the valuation of their last round. Runway has little to do with it. Here is what the fastest raisers of the past year did, and how to build that speed into your own company.

The median US startup waited 28 months between its Series A and its Series B in 2024, the longest gap Crunchbase had recorded since 2012.

Now look at a different list.

Lovable raised a $200M Series A in July 2025 and a $330M Series B five months later.

Harvey raised three times in 2025: in February, in June and in December.

Stuut announced a $52.5M Series B last week, ten months after its Series A.

Monid raised a $7.7M seed last week, five weeks after a $2.1M pre-seed.

None of these gaps fit a runway story. Five weeks is too short to spend a pre-seed. Five months isn't enough time to spend $200M.

Startups raise again fast when their progress outruns the price of their last round.

What the fast raisers had in common

Lovable. The company says it reached $100M in annual recurring revenue within eight months of launch, then doubled it in about four more. Its valuation rose from $1.8B at Series A to $6.6B at Series B, led by CapitalG and Menlo Ventures. Eight months later, in August 2026, Menlo led a $400M Series C at $13.3B. Lovable said its ARR had nearly tripled since the Series B.

Harvey. Sequoia led a $300M Series D at $3B in February 2025. A $300M Series E followed in June at $5B. Andreessen Horowitz led a $160M round at $8B in December. In between, Harvey said it passed $100M in ARR.

Stuut. Insight Partners led the Series B, and Andreessen Horowitz came back. Stuut said revenue grew more than 90% quarter over quarter, across more than 150 customers, including Honeywell, ZoomInfo, and Verifone.

Monid. A $2.1M pre-seed, then a $7.7M seed led by Long Journey Ventures five weeks later.

Different stages, different sizes, different sectors. One pattern.

Where the companies shared their numbers, the story is the same: new evidence arrived faster than the last price could absorb. The round closed on one set of facts. A few months later the facts had moved so far that the old price no longer described the company.

The invisible clock

Founders plan the next raise around runway. Eighteen months of cash; start fundraising at month twelve. That’s the visible clock.

A second clock exists, and investors watch it more closely. It measures the distance between what your last price assumed and what your company has since become.

In Invisible Game, I wrote that the next round starts the moment you close the current round. The fast raisers show what that looks like at full speed. The day the round closes, the price becomes a snapshot. Every month of strong progress ages the snapshot.

When the gap gets wide enough, two people notice before anyone else.

The first is your existing investor. They see your numbers every month. They know that each month they wait, someone else may price the company higher and dilute the share they could have bought. That’s how an insider ends up leading the next round. Menlo led Lovable’s Series B and came back eight months later to lead the Series C.

The second is the investor who passed last time. Few things sting more in venture than watching a company you declined reprice twice in a year. Loss aversion, the same force I describe in the book’s chapter on investor psychology, now works for the founder. The question in the partner meeting shifts from “is this real?” to “can we still get in?”

That’s when a company stops raising and starts being offered money.

The honest caveat

Speed carries its own risk.

Reporting on Harvey’s third round noted that its valuation grew faster than the revenue it disclosed, raising the question of a bubble. A fast round can reflect real momentum. It can also reflect investors racing each other on a story.

And every fast round sets the next bar higher, faster. A company that triples its price in five months has to keep producing evidence at that pace, or the next investor will see the gap open the other way.

The fast raisers earned their speed with evidence the next investor could check: revenue figures, named customers, growth rates. That’s what separates momentum from hype when the next round arrives.

What founders miss

Most founders raise when they need to. The fast raisers raised when they could.

Raising on the runway clock means you walk in with the clock against you. Investors can see your cash position as well as you can, and time pressure shifts power to the side of the table that can wait.

Raising on the evidence clock means you walk in with the gap in your favor. You have money in the bank, and the old price is visibly wrong in the direction everyone wants.

You can’t control how fast the market moves. You can control how quickly you produce facts, and who is watching when you do.

New rules

Track the gap, not the runway. Know at any moment how far your company has moved past what the last price assumed.

Your insiders see it first. Keep them close enough to want to lead.

Keep the investors who passed in the loop. Their regret is your fastest next round.

Raise from strength. Start the next conversation while you still have a year of cash.

Below is the playbook for building that speed into your own company.

Read more

Playbook, Perspective and Pattern for founders raising now. This report strips out giant rounds and public market traffic so you can read the part of the market that actually prices your round. Every figure below was checked against at least two independent sources across repeated verification passes, the last of them adversarial.

This week the average seed round in the US mid-market was $41.54M. The average Series A was $25.11M. Seed checks ran 65% larger than the next stage. Seven days earlier, the average seed round in the same set was $9.50M across two rounds. Five seed rounds were announced this week and three of them were $50M or more.

That would be a story about exuberance if the bigger checks had bought more of what this report measures. They did not. Take out the one seed round with no investor named anywhere in the record and the four remaining seeds averaged 9.25 of 10 on Investor Quality against 7.22 for the nine Series A rounds. On Traction to Conviction, the dimension that scores what outside parties have already underwritten, the same four seeds averaged 3.0 of 25. The Series A rounds averaged 5.78. The overall scores landed within 1.3 points of each other. Same band, opposite ingredients.

So two different markets cleared in the same five days. At seed, capital priced the people: the founders’ last employer and the firm writing the check. At Series A and beyond, capital priced the paper: a government contract vehicle, a buyer on the cap table, a named deployment somebody else can confirm. The five highest scores of the week all belong to Series A, Series B or unlettered rounds, and every one of those five carried a validation that a government body or a named customer controls.

Consequence for Monday. If you're going to price your round on pedigree, you already know it, and you don't need this report. Everyone else is in the second market. In that market, the check is smaller, the process takes the same amount of time, and a partner moves on a fact you don't control. Find out this week how many of those you hold.

The Week in One Sentence

Primary insight. Seed checks outgrew Series A checks because top-tier firms paid for founder pedigree in very young companies, while every one of the five rounds clearing 65 carried both third-party proof and an investor from a prior round.

· Total capital deployed. $800.9M in new primary capital across 22 verified US rounds between $5M and $100M.

· Against prior issues. In the $10M to $100M band, this series has tracked 19 rounds and $778.5M since September, versus 11 rounds and $457.5M last week. Capital up 70.2%, deal count up 72.7%.

· Average round size. $36.40M across the full set, up 12.7% from $32.31M. On the $10M to $100M band, $40.97M against $41.59M, down 1.5%.

· Median round size. $30.0M across the full set, up 36.4% from $22.0M. On the $10M to $100M band, $30.0M against $38.0M, down 21.1%.

· Largest tracked round. Nous Research at $90.0M, a Series B. Smallest: Zeroset at $5.2M, a pre-seed.

· Highest Eisen score. Gallatin AI at 70. Lowest: TeddyHoldings.AI at 17. Five of 22 rounds cleared 65. Mean 52.3, median 53.0.

· Named institutional lead. 19 of 22 rounds (86.4%), up from 14 of 15 (93.3%) last week.

· Strategic or customer-side capital. 8 of 22 rounds (36.4%) carried $322.7M (40.3%) of the week’s capital, up from 4 of 15 (26.7%) last week.

· Returning investors. 13 of 22 rounds, or 59.1%, carried at least one investor from a prior round, against 7 of 15, or 46.7%, last week.

The Deal Scorecard

Eisen Fundability Scores run across five dimensions: Founder-Investor Dynamics (30), Traction to Conviction Conversion (25), Narrative Power (20), Deal Architecture (20) and Capital Planning (5). Scores of 90 to 100 signal an inevitable, market-defining outcome. 85 to 89 signals extremely strong execution. 75 to 84 signals solid fundamentals. 65 to 74 signals a good company with some gaps. Below 65 signals an early-stage or structurally incomplete round.

Amounts reflect new primary capital at close. Healthleap is counted at its $30.0M Series A; the $8.0M seed announced alongside it closed earlier and is excluded. Torch Systems is counted at $9.5M of equity; its $2.0M venture debt facility is excluded. Melius is counted at its $20.0M Series A. Stage labels are reported as each company applies them.

What the scorecard says at a glance

The top of the board is a Series A and B board. Gallatin AI at 70, Ampersand at 69, Clockwork.io at 68, Pro Shop and Stuut at 67. Five rounds cleared 65; each had a prior investor writing again, and each carried a third-party validation. Not one seed round made the top eight.

The highest score went to a round with no designated lead. Gallatin AI raised $50.0M from new and existing investors including 8VC and Silent Ventures, and no source names a price-setter. It still finished first on the highest Independent Validation mark in the set: a Direct-to-Phase II SBIR award through the Army Applications Laboratory, a Defense Innovation Unit contract and an agreement with III Armored Corps. Proof carried around the syndicate didn't structure.

The cheapest top-three round cost $15.0M. Ampersand is tied for the smallest Series A of nine and scored 69 because Yelp sits on its cap table while a Yelp company is a customer. A buyer that also invests settles the two hardest Series A questions with one reference call.

The floor is about missing structure. TeddyHoldings.AI raised a $60.0M seed with no lead and no investor identified anywhere in the record, and scored 17. Siena scored 33 on a $17.0M Series A with zero on Traction to Conviction. Zeroset scored 35 on a pre-seed.

Size and score barely moved together. The correlation between round size and score across the 22 rounds was 0.16. The eight rounds of $50M or more averaged 53.8. The fourteen below $50M averaged 51.5.

What Changed This Week

Four shifts, ranked by structural impact on founder fundraising rather than by deal size. Each is built on verified deal records and ends with what it means for your raise.

Shift 1: The Seed Round Outgrew Series A

Pattern, what happened. Five seed rounds raised $207.7M, averaging $41.54M and with a median of $50.0M. Nine Series A rounds raised $226.0M, averaging $25.11M and with a median of $24.0M. Three seeds reached $50M or more: Hone at $60.0M behind Benchmark and Index Ventures, Sabi at $50.0M behind Khosla Ventures, and TeddyHoldings.AI at $60.0M with no lead. Catalyst added $30.0M behind Sequoia Capital. Last week the same full set produced two seed rounds averaging $9.50M.

Perspective, what it means. A seed check above $30M is not a seed check in the old sense. It is a bet on a team large enough to skip the proof stage, written by firms that can afford to be wrong on the company and right on the people. That is why the four led seeds averaged 9.25 of 10 on Investor Quality, above every stage average in the set, and 3.0 of 25 on Traction to Conviction. Investors were underwriting what these founders had done somewhere else, not what these companies had done.

Founder Blindspot, what most miss. Founders read a $50M seed as evidence that the round size ceiling has lifted for everyone. It has lifted for a very small group with a very specific credential: a recent role at a company those investors already know. Strip TeddyHoldings.AI out, and the four led seeds averaged 52.0, versus 53.3 for Series A. The checks were 47% larger and the score was slightly lower. If you do not carry the credential, a seed process pitched at that size will spend three months proving you do not.

Playbook, what to do. Write one sentence that names the specific prior result your lead investor would be underwriting if they backed you on pedigree alone. A shipped product at scale, a team you built, a company that was acquired. If you cannot write it with a name and a date, size your round to the next proof point.

Contrast. Last week the full set carried two seed rounds averaging $9.50M. This week seed took 25.9% of capital against 28.2% for Series A, and the average seed check rose more than fourfold.

What this means for your raise: A large seed is a pedigree instrument. If your case rests on what your company has done, raise the round that the proof supports, and expect investors to read the proof.

Shift 2: Proof Someone Else Holds Topped the Board

Pattern, what happened. Nine rounds carried at least one validation that a party outside the company controls: a government award, a named enterprise customer, a named hospital or platform deployment. Those nine averaged 64.8 against 43.7 for the thirteen without, a 21.1-point gap. Remove the Independent Validation sub-dimension from both sides and 16.3 points remain. Two of the nine carried government-grade validation. Gallatin AI holds a Direct-to-Phase II SBIR award, a Defense Innovation Unit contract for US Army Europe and Africa, and an agreement with III Armored Corps. Kapta Space holds a $1.8M Department of Defense grant. Those two averaged 65.5 and took $74.0M, or 9.2% of capital.

Perspective, what it means. A government contract or a named customer is the hardest form of proof to manufacture. Someone outside the company ran a competition or a procurement, committed budget, and left a record. An investment committee can confirm it without the company in the room. That is why these rounds also scored well on everything around the validation: experienced operators, specialist investors and prior investors back.

Founder Blindspot, what most miss. Founders confuse achievement with validation. Fortastra put two prototype spacecraft in orbit on October 1, a week before announcing its Series A, and still scored zero on Independent Validation because a launch is the company’s own milestone, not a third-party confirmation. It finished eighth on the strength of its team, investors and round construction. Eight rounds scored zero on all of Traction to Conviction, and together they raised $259.2M.

Playbook, what to do. List every external body that could grant you something checkable within two quarters: a contract vehicle, a clearance, a certification, a standards listing, a named reference account with a procurement function. Pick the fastest one and file for it this week.

Contrast. Last week semiconductors, robotics and defense took $116.0M as one category. This week defense, space and industrial took $113.5M across four rounds, almost the same capital, and placed three rounds in the top eight.

What this means for your raise: Count the facts about your company that somebody else certifies. Nine rounds this week had at least one and averaged 64.8. Thirteen had none and averaged 43.7.

Shift 3: More Insiders Came Back. Almost None Led.

Pattern, what happened. Thirteen of 22 rounds carried at least one investor from a prior round, against 7 of 15 last week. Those thirteen took $511.2M, or 63.8% of the week’s capital. They averaged 58.5 against 43.3 for the nine without, a 15.2-point gap. The Insider Support sub-dimension is worth two points; remove it and 14.1 points remain. Remove both Capital Planning items and 12.1 points remain. Seven rounds were re-underwritten within eighteen months at a larger size: Gallatin AI, Clockwork.io, Stuut, Fortastra, Nous Research, Monid and Santé. Monid raised its seed five weeks after a $2.1M pre-seed. Those seven averaged 59.4 against 49.0.

Perspective, what it means. A returning investor is the only party in a round who has seen the company from inside. That is why the gap survives with the mechanical scoring removed. But look at who led. Of the thirteen rounds with a returning investor, only Nous Research had a prior backer take the lead, with Robot Ventures leading its $90.0M Series B. In the other twelve, the insider followed a new price-setter.

Founder Blindspot, what most miss. Founders treat insider participation as the finish line. This week, it showed up in most rounds. What separated the field was whether a new firm was willing to set the price on top of it. Gallatin AI had its seed lead back and no one designated to lead; it scored 5 of 10 on Round Competition. Stuut had its Series A lead, Andreessen Horowitz, back and Insight Partners leading; it scored 7.

Playbook, what to do. Get your insiders’ number in writing four weeks before you open, then use it as the floor in front of new leads rather than as the round.

Contrast. Last week seven of fifteen rounds had an insider back, and they took 68.6% of capital. This week the share of rounds rose to 59.1% while the capital share slipped to 63.8%. Insiders spread across more rounds, and the new money still decided the price.

What this means for your raise: Your existing investors get you into the room. A new lead willing to price the round is what gets you out of it.

Shift 4: The Buyer Bought In

Pattern, what happened. Eight of 22 rounds carried strategic, corporate or customer-side capital, or 36.4%, up from 26.7% last week. In three of them, the investor buys, distributes, or produces in the company’s market. Arthur M. Blank Sports and Entertainment, which owns PGA Tour Superstore, led Pro Shop’s $24.0M Series B and put the Superstore chief executive on the board, with the PGA Tour returning. Yelp joined Ampersand’s $15.0M Series A while Hatch, a Yelp company, is a customer. AstraZeneca joined Multiply Labs’ $75.0M Series B as a maker of the biologic medicines Multiply’s robots are built to produce, though the two have not stated a commercial agreement. Those three averaged 66.3 against 50.1. With the scored sub-dimension removed, 10.4 points of the 16.2-point gap remain. The five rounds carrying corporate venture arms without a stated commercial tie, among them e& Capital, Microsoft’s M12, NVIDIA, Samsung, Coinbase and Google’s Gradient, averaged 55.0. Across all eight rounds, the gap was 10.9, and 6.5 after removal.

Perspective, what it means. A financial investor is buying a forecast of demand. An investing buyer has already tested that forecast through its own procurement, so its check is a receipt. A corporate venture arm with no commercial tie says a powerful company wants exposure. A channel owner on the board says the product will reach the shelf.

Founder Blindspot, what most miss. Founders rank corporate venture arms by logo. This week the logo mattered less than the commercial relationship behind it: 55.0 for the five rounds with a corporate venture arm and no stated tie, 66.3 for the three with a buyer or channel. The cost is in the terms: first refusal, exclusivity and information rights can narrow your exit for good.

Playbook, what to do. List your three largest customers and three largest channel partners. For each, find the person who runs their venture or strategic investment function. Settle your exclusivity position with counsel before the first meeting.

Contrast. Strategic participation has run at 54.2%, 28.0%, 27.8% and 26.7% of rounds over the last four issues. This week’s 36.4% is the first rise in a month, and a channel owner took both the lead seat and the board seat in the same round.

What this means for your raise: Rank investors by the customer they can deliver, not the logo they add. And settle your exclusivity position before anyone offers.

The Deals That Matter

Five deep dives across military logistics software, AI integration infrastructure, AI cluster infrastructure, golf media and enterprise AI agents. Four come from the week's top five scores. The fifth, Hone, is the most instructive seed round in the set. All facts are verified against two or more sources.

Gallatin AI

Military Logistics Software | Series A | $50.0M | No designated lead; 8VC and Silent Ventures

Eisen Fundability Score: 70 / 100

Why this scored. The highest score of the week, on a Traction to Conviction mark of 15 of 25 that only Pro Shop beat: three government-controlled awards, active users in two military services, and a round more than three times the size of the seed eighteen months later. It lost points in one place above all, the lead seat, and still finished first.

The Setup. Gallatin AI, based in El Segundo, California, builds AI-native logistics software for the US military. Its platform, Navigator, supports sustainment decisions in contested logistics, meaning how fuel, parts and munitions reach units when supply lines are under threat. Woody Glier is chief executive. Co-founder Daniel Buchmueller previously co-founded Amazon Prime Air, and the leadership team draws on Palantir, Scale AI and Amazon. The customers are Army and Air Force units.

The Deal. $50.0M Series A announced October 8, 2026, backed by new and existing investors including 8VC and Silent Ventures. No source names a lead. 8VC led the $15.0M seed announced in April 2025, so this round arrived eighteen months later at more than three times the size. Axios puts total capital at $70M, all equity. Third-party milestones: a Direct-to-Phase II SBIR award under the Army Applications Laboratory’s PORTAL program in March 2026, an Other Transaction Agreement with III Armored Corps in June 2026, and a Defense Innovation Unit contract for US Army Europe and Africa in July 2026.

The Pattern. This is the proof-carried round. In a week where the largest seed checks went to résumés, the top score went to a company whose central claims are recorded by contracting offices.

The Perspective. Look at what the missing lead cost. Gallatin AI scored 5 of 10 on Round Competition because nobody set the price. Every other dimension was strong. That tells you how much work the validation was doing: a round with no price-setter still outscored rounds led by Bessemer, Insight and Sequoia. A Series B lead will start diligence by asking who priced this one.

The Playbook. If you sell to government, map every contract vehicle you hold or can enter: SBIR and STTR phases, Direct-to-Phase II, Other Transaction Authority agreements, DIU commercial solutions openings. Then get one investor to commit in writing to lead, price and take the seat before you accept the second commitment.

The Founder Mistake to Avoid. Founders copy the validation and skip the structure. A round assembled from strong participants with nobody leading gets a good close and a hard next round, because the next investor has no prior price-setter to benchmark against or call.

Ampersand

Integration Infrastructure for AI Agents | Series A | $15.0M | Led by Bessemer Venture Partners

Eisen Fundability Score: 69 / 100

Why this scored. The tightest investor alignment in the set at a $15.0M check. Bessemer leads with its partner joining the board, Matrix and Flex Capital return, and Yelp invests while a Yelp company buys the product. It is the only Series A in the set with a buyer on the cap table.

The Setup. Ampersand, based in San Francisco, provides integration infrastructure that connects AI agents to the enterprise software stack: the CRMs, ERPs and systems of record agents need to read from and write to. Chief executive Ayan Barua previously co-founded Siftery, which G2 acquired, and then served as vice president of engineering at G2. Co-founder Lauren Long built Firebase Extensions at Google. Its customers are companies whose AI agents need to act inside enterprise systems.

The Deal. $15.0M Series A announced October 6, 2026, led by Bessemer Venture Partners, with partner Lauri Moore joining the board. Matrix and Flex Capital return. Yelp, Tenacity Capital, CTO Fund and Mana Ventures join. Hatch, which Yelp agreed to acquire in January 2026, is a named customer. The prior round was a $4.7M seed led by Matrix in April 2023. All equity.

The Pattern. This is the buyer-in-the-syndicate round. Yelp’s participation alongside Hatch’s customer relationship means the investor and the operating business confirmed the same product through two different processes.

The Perspective. Notice what Ampersand did not score. Velocity was 0 of 3 because forty-two months separate the seed and the Series A. In a framework that rewards speed, the company still finished second.

The Playbook. If one of your customers belongs to a larger group, find out whether the parent has a venture or strategic investment function. A small check from the parent turns a customer reference into a cap table fact.

The Founder Mistake to Avoid. Founders take any corporate check from a customer’s parent without separating the investing arm from the operating business. The investment approval and the operating unit’s purchase are two different decisions. Ampersand has both.

Clockwork.io

AI Cluster Infrastructure Software | No series letter | $31.0M | Co-led by Premji Invest, Wing VC and Seligman Ventures

Eisen Fundability Score: 68 / 100

Why this scored. A co-founder with a prior acquisition by Google, three co-leads, returning investors, named deployments across three customer types and a round re-underwritten about thirteen months after the last one at a larger size. Strong on every dimension, spectacular on none.

The Setup. Clockwork.io, based in Palo Alto, builds a fault-tolerance software layer that keeps large AI training and inference clusters running when hardware or network links fail. Its founders are Stanford professor Balaji Prabhakar, Yilong Geng, whose Stanford research produced the Huygens clock-synchronization technology behind the platform, and Deepak Merugu, who previously co-founded Urban Engines, acquired by Google. Mendel Rosenblum, a VMware co-founder, is chief scientist. Suresh Vasudevan, formerly chief executive of Nimble Storage and Sysdig, is chief executive. LinkedIn, Together AI and WhiteFiber are named deployments.

The Deal. $31.0M announced October 6, 2026, co-led by Premji Invest, Wing VC and Seligman Ventures, with NEA and e& Capital, the venture arm of the telecom group e&, returning. The company applies no series letter. A round of roughly $20.5M was recorded in September 2025, and NEA led a $21M Series A in March 2022. Total capital $73M.

The Pattern. This is the infrastructure re-underwriting round. AI cluster software sells to a small number of very large buyers, so each named deployment carries weight. LinkedIn is an enterprise operator, Together AI is an AI cloud, WhiteFiber is an infrastructure provider.

The Perspective. Three co-leads can mean overwhelming demand or a round nobody would take whole. Here, two facts point to demand: the round came about thirteen months after the last one and it was larger.

The Playbook. Map your named deployments by customer segment, not by logo size. If all your references are in one segment, a new lead will discount them as one data point. Pick the adjacent segment where you could land a reference account inside two quarters and assign an owner to it this week.

The Founder Mistake to Avoid. Founders with a prior exit treat the exit as the case. Clockwork.io scored 7 of 10 on Founder Track Record, not 10, because the top mark requires a verified exit above $100M. The round cleared on the team, plus the deployments, plus the velocity.

Pro Shop

Golf Media and Entertainment | Series B | $24.0M | Led by Arthur M. Blank Sports and Entertainment

Eisen Fundability Score: 67 / 100

Why this scored. The highest Traction to Conviction mark in the set at 19 of 25. The lead investor owns a retail channel for the company’s commerce business and placed that channel’s chief executive on the board. The PGA Tour has returned as an investor and named Pro Shop Studios its preferred production studio.

The Setup. Pro Shop, based in Ponte Vedra Beach, Florida, is a golf media, entertainment and commerce company. Its founders are Chad Mumm, formerly chief creative officer of Vox Media Studios and an executive producer of Netflix’s Full Swing; Joe Purzycki, formerly chief executive of Puck; David Miller, formerly the PGA Tour’s lead media lawyer; and Mark Olsen.

The Deal. $24.0M Series B announced October 5, 2026, led by Arthur M. Blank Sports and Entertainment, with Troy Rice, chief executive of PGA Tour Superstore, an AMBSE company, joining the board. Causeway Media Partners and the Ares Sports, Media and Entertainment funds join. The PGA Tour and Powerhouse Capital, which led the Series A, return. The prior round was a $20.0M Series A in March 2024. All equity.

The Pattern. This is the channel-led round. AMBSE is not a venture firm, and the rubric marks Investor Quality down for that: 5 of 10. But the same structure earns the maximum on Customer-Side Capital, because the lead owns the retail channel through which Pro Shop’s golf commerce reaches buyers.

The Perspective. Founders tend to see a corporate lead as a weaker signal than a venture lead, and on pure investor brand, they are right. What they miss is that a channel owner taking the board seat converts a distribution plan into a governance fact.

The Playbook. List the three companies that control how your product reaches customers: retailers, marketplaces, platforms, distributors. For each, find out whether it has an investment arm or a holding company that does. Where distribution is the bottleneck, a channel lead can be worth more than a brand-name venture firm.

The Founder Mistake to Avoid. Founders take channel money without channel terms. Before a distributor leads your round, decide your position on exclusivity, most-favored-nation pricing and rights of first refusal.

Hone

Autonomous Enterprise AI Agents | Seed | $60.0M | Led by Benchmark, co-led by Index Ventures

Eisen Fundability Score: 59 / 100

Why this scored. The strongest Founder-Investor Dynamics mark in the set at 26 of 30 and the weakest Capital Planning score possible at 0 of 5. Hone is the clearest example of the pedigree market: two top-tier co-leads, a founder from one of the most closely watched AI companies, and a company reported to be five months old.

The Setup. Hone, based in San Francisco, builds what it calls Engines: AI agents that take ownership of a business goal over weeks rather than completing one task at a time. Chief executive Moritz Stephan was one of Cognition’s first employees and became chief of staff to its chief executive. Co-founder Oliver Brady was an early engineer at Harvey, and co-founder Carlo Kobe is a Thiel Fellow who started the app Fizz. Named customers include Cognition and Modal.

The Deal. $60.0M seed announced October 8, 2026, led by Benchmark, with Index Ventures co-leading. Elad Gil, Hanabi, Definition, Diffusion and SV Angel participate, and Cognition chief executive Scott Wu invested personally. Peter Fenton of Benchmark and Shardul Shah of Index join the board. This is the company’s first round. All equity.

The Pattern. This is the pedigree round at full size. Two firms famous for selectivity co-led a first round in a company with two named customers, one of them the founder’s previous employer.

The Perspective. The score shows where the risk sits. Round Construction scored 2 of 8 because $60.0M is materially oversized for a company that has not yet set a milestone the round is built to reach. Capital Planning scored zero because there is no prior round to re-underwrite. The investors have taken the proof risk onto their own balance sheet, and the Series A investor will ask for it back.

The Playbook. If you have the pedigree for a round like this, use the size to buy proof quickly. Name the two milestones that would let a Series A investor underwrite the company rather than the team, put dates on them, and size the hiring plan to hit both inside eighteen months.

The Founder Mistake to Avoid. Founders without the credential copy the size. A $60M seed works when the investor is underwriting someone they've already watched succeed. Without that, the same ask turns into a slow no from twenty firms.

The Fundraising Playbook

Five plans, each producing a concrete artifact you can use this week. Each is built directly from this week’s verified signals.

Plan 1: The Pedigree or Proof Decision (Narrative and Investor Framing)

Focus. Decide which market your round clears in before you write a word of the deck.

Why this matters. The four led seed rounds averaged 9.25 on Investor Quality and 3.0 of 25 on Traction to Conviction. The nine Series A rounds averaged 7.22 and 5.78. The two groups landed 1.3 points apart overall on opposite ingredients.

Exact deliverable. One headline sentence for your deck, written as a risk-reduction claim. If you are in the pedigree market, it names the prior result your investor is underwriting: the product you shipped, the team you scaled, the company that was acquired. If you are in the proof market, it names the fact a third party controls: the contract, the clearance, the named deployment. Then cut every slide that argues for the other market.

Time estimate. Two hours to draft, one hour with an investor you trust to test it.

Expected outcome. A partner understands in one sentence why backing you is lower risk than it looks, and the rest of the deck supports that sentence instead of hedging between two stories.

The reframe. Wrong approach: pitch the vision and hope the credential carries it. Right approach: name the single fact that reduces the investor’s risk, and build the deck around it.

Plan 2: Obtain One Externally Controlled Fact (Proof Architecture)

Focus. Acquire one validation that someone other than you grants and records.

Why this matters. Nine rounds with at least one independent validation averaged 64.8. Thirteen without averaged 43.7. With the sub-dimension removed, 16.3 points of the 21.1-point gap remain. The two rounds with government-grade validation averaged 65.5. Eight rounds scored zero across all of Traction to Conviction.

Exact deliverable. A three-column inventory: every validation a third party could grant you in the next two quarters, the body that grants it, and the earliest date it could land. Contract vehicles, clearances, certifications, standards listings, reference-grade customer accounts with a procurement function. Pick the fastest one, assign an owner and file this week.

Time estimate. Three hours for the inventory. It takes two to four months to get the first validation, which is why the filing date matters more than the announcement date.

Expected outcome. You open your process with a fact a partner can confirm without you.

The reframe. Wrong approach: treat your own milestones as proof. Right approach: obtain one fact somebody else certifies, then raise after it lands.

Plan 3: Eisen Self-Score and Gap Diagnosis (Readiness)

Focus. Score your round on the five dimensions and decide between a process now and a repair sprint first.

Why this matters. The board ran from 17 to 70 with a mean of 52.3. Five rounds cleared 65 and every one had a prior investor back. The three led seed rounds of $30M or more scored between 48 and 59.

Exact deliverable. A one-page score: Founder-Investor Dynamics (30), Traction to Conviction (25), Narrative Power (20), Deal Architecture (20), Capital Planning (5). Circle your two lowest dimensions. If you score above 65, run a parallel process with a hard deadline. If you score 50 to 65, spend four to six weeks repairing the lowest dimension first. Below 50, the gap is structural, meaning no lead, no returning investor or no external validation, and a better deck will not close it.

Expected outcome. A decision about process design, made before the first meeting rather than after the tenth pass.

The reframe. Wrong approach: score yourself, feel discouraged, rewrite the deck. Right approach: find your two lowest dimensions and decide this week whether to raise now or repair first.

Take the Score here.

Plan 4: The Lead Seat and the Buyer List (Deal Architecture and Investor Targeting)

Focus. Secure a price-setter and rank investors by what they deliver.

Why this matters. Thirteen of 22 rounds had an insider back, but only one had a prior investor lead. Gallatin AI scored 5 of 10 on Round Competition because no one set the price. Three rounds with a buyer or channel on the cap table averaged 66.3, and with the sub-dimension removed 10.4 points of the gap remain.

Exact deliverable. Three items. First, cut your target list to 35 names where you can cite a round each firm led at your stage in the last 90 days, and add the firms that led this week: Bessemer, Insight Partners, Arthur M. Blank Sports and Entertainment, Premji Invest, Wing VC, Seligman Ventures, First In, NantWorks, Washington Harbour Partners, Hummingbird Ventures, Benchmark, Index Ventures, Robot Ventures, Alta Partners, Long Journey Ventures, Khosla Ventures, FINTOP, Sequoia Capital, CRV, Maveron, Gradient, 2048 Ventures and York IE. Second, a buyer list of six names: your three largest customers and three largest channels, each with the person who runs their investment function. Third, split your use of funds into two columns, unproven outcomes and predictable cash cycles, and total the second. That total is the part a lender could finance instead of equity.

Time estimate. One day for the lists. One hour with counsel to pre-draft positions on first refusal, exclusivity and information rights.

Expected outcome. You get one investor to confirm in writing that they will lead, price the round and take the seat before you accept a second commitment, and you know which corporate checks bring a customer.

The reframe. Wrong approach: collect commitments and hope a lead emerges. Right approach: secure the lead first, then let insiders and buyers fill the round behind the price.

Plan 5: The Milestone-Timed Process (Momentum and Conversion)

Focus. Run a short process that opens after your next validation lands and creates competition through dated milestones.

Why this matters. Seven rounds were re-underwritten within eighteen months at a larger size and averaged 59.4 against 49.0. Fortastra announced its Series A one week after its first spacecraft reached orbit. Monid raised its seed five weeks after its pre-seed.

Exact deliverable. A 14-day follow-up cadence tied to dated milestones. Day 0: open with the validation already in hand. Day 3: send every active firm one dated progress note. Day 7: second note with a named customer or partner development. Day 10: insider commitment confirmed in writing. Day 14: term sheet deadline.

Time estimate. Four hours to build the calendar and draft the notes, plus the discipline to hold the deadline.

Expected outcome. Investors see the company moving between meetings, the process stays short enough to create urgency, and the deadline forces a decision.

The reframe. Wrong approach: open the process and follow up when someone asks. Right approach: time the open to your validation and give every investor a new dated fact every few days.

Looking Forward

Three evidence-based scenarios and one wild card for the next one to three weeks. Each is anchored to this week’s verified data.

Scenario 1: Pedigree Seeds Keep Clearing Above $30M (High Probability)

Why this is likely. Three of five seed rounds this week were led by Benchmark and Index, Khosla or Sequoia, at $30.0M to $60.0M. Last week the full set carried two seeds averaging $9.50M.

What founders should watch. Whether two or more seed rounds above $30M appear in the next issue, and whether their founders again come from a short list of AI labs and agent companies. If they do, the large seed is a durable lane for that profile, not a market-wide change.

What founders should do before others notice. If you do not carry that credential, size your seed to your next proof point and close it fast while top-tier attention is on the pedigree lane. If you do, raise now: the firms competing for you this month may not be competing in the next.

Scenario 2: Defense and Space Keep Outscoring Their Capital Share (Medium-High Probability)

Why this is likely. Defense, space and industrial averaged 57.8 against 52.3 for the whole set while taking 14.2% of capital. The two rounds with government-grade validation averaged 65.5 and took 9.2%. Specialist firms such as 8VC, First In, Washington Harbor Partners and Bison Ventures were active in the same week.

What founders should watch. Whether the next issue shows a defense or space round above $50M with a named lead, and whether generalist firms appear in these syndicates.

What founders should do before others notice. If you sell to government, file for the next contract vehicle now. If you do not, build the equivalent: the procurement-grade reference account or certification that does for your category what a DIU contract does for defense.

Scenario 3: The Insider Lead Becomes the Differentiator (Medium Probability)

Why this is likely. Returning investors appeared in 59.1% of rounds, up from 46.7% last week. When a signal becomes that common, the market looks for a finer one. Only one of thirteen insider rounds this week had a prior investor in the lead seat.

What founders should watch. Whether the share of rounds with a returning investor holds above half and whether the score gap narrows. If the share stays high and the gap compresses, the edge will shift to whether an insider leads.

What founders should do before others notice. Ask your largest existing investor this month whether they would lead your next round if no new firm does.

Wild Card: Channel Owners Take the Lead Seat (Medium Probability)

Evidence from this week. Arthur M. Blank Sports and Entertainment led Pro Shop’s Series B and seated the chief executive of PGA Tour Superstore on the board. Yelp joined Ampersand while a Yelp company is a customer. AstraZeneca joined Multiply Labs. Three rounds with a buyer or channel averaged 66.3, the highest of any group measured in this report.

What founders should do before others notice. Identify the holding company or corporate parent behind your most important distribution channel and approach its investment function before a competitor does. Prepare your exclusivity position first, because a channel lead will ask for one.

The Bottom Line

The real insight is not the $800.9M. It is that two markets cleared in the same week on different evidence. Top-tier firms paid more for seed rounds than the market paid for Series A, and they paid for people. Everyone else got funded on facts somebody else had already confirmed. The five rounds clearing 65 all had a prior investor back, all five carried a third-party validation, and two had a buyer or channel on the cap table. That produced three conviction profiles.

Profile 1: Companies whose proof is held by a third party. Gallatin AI (70) holds a Direct-to-Phase II SBIR award, a III Armored Corps agreement and a DIU contract. Clockwork.io (68) is deployed at LinkedIn, Together AI and WhiteFiber. Kapta Space (61) holds a Department of Defense grant. Healthleap (59) runs in more than 50 hospitals, including Penn Medicine and Cedars-Sinai. Nine rounds had at least one external validation and averaged 64.8 against 43.7.

Profile 2: Companies whose buyer or channel wrote a check. Ampersand (69) took money from Yelp while a Yelp company is a customer. Pro Shop (67) was led by the PGA Tour Superstore owner. Multiply Labs (63) added AstraZeneca. These three averaged 66.3, and 10.4 points of their 16.2-point gap survive removal of the scored sub-dimension.

Profile 3: Companies whose founders were the asset. Hone (59) raised $60.0M behind Benchmark and Index in its first round. Catalyst (51) raised $30.0M behind Sequoia. Sabi (48) raised $50.0M behind Khosla. These rounds scored 10 of 10 on Investor Quality and between 0 and 9 of 25 on Traction to Conviction. The capital is real. The proof is still to come, and the next investor will ask for it.

Five New Rules for Founders

1. Know which market you are in. The four led seeds were 47% larger than the average Series A and scored 1.3 points lower. Pedigree buys size. Proof buys score.

2. Own one fact you do not control. Nine rounds with external validation averaged 64.8 against 43.7 for thirteen without, and 16.3 points of that gap survive removal of the sub-dimension.

3. Insiders get you in; a lead gets you priced. Thirteen of 22 rounds had an insider back, and only one had an insider leading. Secure a price-setter before a second commitment.

4. Rank corporate investors by the customer they bring. Three rounds with a buyer or channel averaged 66.3. Five with a corporate venture arm and no stated commercial tie averaged 55.0.

5. Time the round to the milestone. Seven rounds re-underwritten within eighteen months averaged 59.4 against 49.0. Open after the validation lands, not before.

Four Actions

1. Write the one sentence that says which market you are raising in, and name the prior result or the third-party fact it rests on.

2. Build the validation inventory: every fact a third party could grant you in two quarters, the granting body and the earliest date. File for the fastest one.

3. Ask your largest existing investor for a number in writing and a yes or no on leading if no new firm steps in.

4. List your three largest customers and three largest channels with the person who runs each one’s investment function, and agree your exclusivity position with counsel before you call.

Twenty-two companies cleared this week, and the board split along a single line: whether the case rested on a person or on a fact someone else controls. You cannot change your résumé by Friday. You can start the contract, the certification or the customer reference that changes what an investor reads about you, and you can start it on Monday.

Research Methodology, Sources and Verification

Data collection period and verification standard

Data collection period: October 5 to 11, 2026. Verified primary announcements cluster between October 5 and October 9. No verified US mid-market round was announced on October 10 or 11, a Saturday and Sunday. Verification standard: at least two independent sources per deal, with a company release, investor post, filing or regulated newswire (PR Newswire, Business Wire, GlobeNewswire) as the anchor where one exists, plus at least one independent outlet. We ran passes independently, and the last was adversarial, aimed at finding errors in the one before it. All arithmetic was recomputed from the final deal record. Eisen Fundability Scores are proprietary analytical estimates, not endorsements or investment advice.

Core capital totals and what they include

The $800.9M weekly total includes only the 22 verified US rounds in the scorecard, each counted at new primary capital at close. Mid-market is defined as a US-headquartered round between $5M and $100M. Because earlier issues in this series used a $10M to $100M band, week-over-week comparisons are also calculated on that subset: 19 rounds totaling $778.5M at an average of $40.97M and a median of $30.0M, against 11 rounds totaling $457.5M at an average of $41.59M and a median of $38.0M in the prior issue. Full-set comparisons use the prior issue’s 15 rounds totaling $484.6M at an average of $32.31M and a median of $22.0M.

Excluded from counted amounts: credit facilities and venture debt, secondary purchases, previously closed rounds announced alongside new ones, SAFE conversions, non-dilutive grants and cumulative totals. Three restatements follow from this rule. Healthleap announced $38M across an $8M seed co-led by Sequoia and First Round and a $30M Series A led by Hummingbird Ventures; the seed is a previously closed round and only the $30.0M Series A is counted. Torch Systems announced $11.5M comprising $9.5M of equity and $2.0M of venture debt from First Citizens Bank; $9.5M is counted. Melius announced $25M comprising a $20M Series A led by CRV and a $5M seed led by General Catalyst; $20.0M is counted.

Stage subtotals: Series B $321.5M across five rounds; Series A $226.0M across nine; Seed $207.7M across five; no series letter $40.5M across two; Pre-seed $5.2M across one. Sector subtotals: Enterprise AI and software $245.9M across eight; Healthcare and life sciences $185.0M across three; Consumer, media and services $159.0M across four; Defense, space and industrial $113.5M across four; Fintech and financial software $97.5M across three. Geography: California $473.4M across 13 rounds, New York $279.5M across seven, Florida $24.0M and Washington $24.0M across one each. Each set sums to $800.9M across 22 rounds.

Scoring calibration notes

All rounds are scored on the v2 rubrics in the project framework. Founder Track Record is scored on the verifiable public record of prior companies, exits, operating roles and domain tenure. Rounds with no designated lead are scored on the institutional quality actually present rather than at zero, consistent with prior issues; this applied to Gallatin AI and Torch Systems, and the absence of a price-setter is reflected in Round Competition. TeddyHoldings.AI scores zero on Investor Quality because no investor of any kind is identified. Rounds with no verifiable prior round or returning investor in the record score zero on both Capital Planning items, which applied to Hone, Sabi, Catalyst, Healthleap, Zeroset, Torch Systems, Wally, Melius and TeddyHoldings.AI. Pro Shop’s 31-month interval falls between the standard and late bands and scores 1 on velocity. Corporate venture arms are scored 3 on Customer-Side Capital unless a commercial relationship is stated; a buyer, channel or strategic buyer participating scores 6; a channel owner leading scores 8. Independent Validation credits only awards, grants, contracts and named customers or deployments that a party outside the company controls; launches, memoranda of understanding and contracts described only by the company are not credited.

Circularity control. Where a finding rests on a scored input, the sub-dimension is removed from both sides and the residual is published alongside the headline. Returning investor: 15.2 measured, 14.1 without Insider Support, 12.1 without both Capital Planning items. Any independent validation: 21.1 and 16.3. Government-grade validation: 14.5 and 8.4, on two rounds. Buyer or channel on the cap table: 16.2 and 10.4. Any strategic capital: 10.9 and 6.5. Named institutional lead: 11.6 and 8.7. Re-underwritten within eighteen months: 10.4 and 7.8. The seed against Series A comparison was tested the same way: with TeddyHoldings.AI removed and Capital Planning stripped from both sides, the four led seeds average 51.0 against 51.4 for Series A, so the score difference between the stages is negligible and the central finding rests on composition and check size, not on the total score. Score bands are stated once, in The Deal Scorecard.

Deal citations

Gallatin AI, $50.0M Series A. PR Newswire company release and Axios exclusive dated October 8, 2026; SiliconANGLE; Defense Daily; Pulse 2.0; runtimewire. Seed terms from FreightWaves dated April 8, 2025, which calls the round both pre-seed and seed. Validations from TechEdge AI (Direct-to-Phase II SBIR through the Army Applications Laboratory, March 16, 2026), Soldier Systems (III Armored Corps Other Transaction Agreement, June 11, 2026) and AJOT (DIU Joint Sustainment Decision Tool contract, July 15, 2026). No source names a lead. Pulse 2.0 and SiliconANGLE date the seed to 2024 against the April 2025 announcement; Axios gives total capital of $70M against $65M implied by the two rounds. Rated HIGH on the round itself.

Ampersand, $15.0M Series A. PR Newswire company release dated October 6, 2026; Pulse 2.0; The SaaS News; Startup Researcher. Seed terms from TechCrunch dated April 13, 2023. Yelp’s agreement to acquire Hatch from Pulse 2.0 dated January 22, 2026. Rated HIGH.

Clockwork.io, $31.0M. Company release dated October 6, 2026, read through HPCwire; The SaaS News; TechFundingNews; Pulse 2.0; runtimewire. Series A terms from Venture Capital Journal dated March 17, 2022. The September 2025 round appears only in data aggregators at $20.5M to $20.6M. One aggregator labels this round a Series C; the company applies no letter and none is used. Rated HIGH.

Pro Shop, $24.0M Series B. PR Newswire company release dated October 5, 2026; MediaPost; The SaaS News; EssentiallySports; VC News Daily. Series A terms and founder backgrounds from the PGA Tour’s announcement dated March 7, 2024. Rated HIGH.

Stuut, $52.5M Series B. Insight Partners investment post; Pulse 2.0; The Next Web; AlleyWatch; VC News Daily. Series A terms from Fortune dated November 20, 2025. Rated HIGH.

Multiply Labs, $75.0M Series B. MobiHealthNews; Pharma Manufacturing; The AI Insider; Axios; VC News Daily. No source describes AstraZeneca as a customer. Rated HIGH.

Kapta Space, $24.0M Series A. GeekWire dated October 9, 2026; company release reported by VC News Daily; Dealroom. Seed terms from Techleap. The company release reports multiple classified moving-target-indication contracts; these cannot be confirmed independently and are not credited. Rated HIGH.

Fortastra, $30.0M Series A. Payload dated October 8, 2026; Raksha Anirveda; runtimewire; VC News Daily. Seed terms from Payload dated December 11, 2025. A Space Force award reported in an earlier pass could not be confirmed and is not used; RTX Ventures participation appears in a single source and is not counted. Rated HIGH.

Healthleap, $30.0M Series A. TechCrunch; MobiHealthNews; Fierce Healthcare; Tech Startups dated October 7, 2026; citybiz. Rated HIGH.

Hone, $60.0M Seed. Bloomberg report dated October 8, 2026; FinSMEs; Trending Topics; runtimewire. The five-month company age appears in a single outlet and is reported as such. Rated HIGH.

Nous Research, $90.0M Series B. The Wall Street Journal and TechCrunch reports dated October 7, 2026; Dealroom; Tech Startups. Robot Ventures is identified as a prior backer by The Block. Headquarters is variously given as New York, Austin and Saratoga, all US. Rated MEDIUM on the headquarters conflict and reliance on reported rather than company-stated terms.

KymaThera, $80.0M Series B. PR Newswire company release dated October 6, 2026; Pulse 2.0; Dealroom; Pharmacally. The chief executive’s twenty years at Pfizer are from a Business Wire release dated July 8, 2020. Rated HIGH.

Catalyst, $30.0M Seed. Fortune exclusive dated October 8, 2026; Pulse 2.0; Crypto Briefing; CryptoRank. The company calls the round a seed and one aggregator a Series A; the company’s label is used. Rated MEDIUM on the stage conflict.

Monid, $7.7M Seed. Dealroom dated October 6, 2026; Forkast; Crypto Briefing; Tech Startups dated October 7, 2026. Rated HIGH.

Sabi, $50.0M Seed. Company release dated October 9, 2026; Forbes; AI Weekly; VC News Daily. VC News Daily places the company in San Francisco and AI Weekly in Palo Alto, both California. Rated HIGH.

Santé, $15.0M Series A. PR Newswire company release dated October 6, 2026; AlleyWatch; VC News Daily; Tech Startups. Seed terms from Axios Pro and Pulse 2.0, February 2026. Rated HIGH.

Melius, $20.0M Series A. TechCrunch dated October 6, 2026; Dealroom; The SaaS News; Fundz. No source confirms General Catalyst, the seed lead, in the Series A, so no returning investor is credited. Rated HIGH.

Wally, $25.0M Series A. AlleyWatch; Becker’s Dental Review; Pulse 2.0; VC News Daily; runtimewire. No source describes Bling Capital or any other participant as a returning investor, so none is credited. Rated HIGH.

Torch Systems, $9.5M equity. Company release reported by VC News Daily; Pulse 2.0; Unite.AI; Startup Researcher. Khosla Ventures is named first among equity investors and no source designates a lead. Rated HIGH.

Zeroset, $5.2M Pre-seed. Pulse 2.0; FinSMEs; runtimewire; Signalbase. Co-led by Gradient and 2048 Ventures. Rated HIGH.

Siena, $17.0M Series A. Business Wire company release dated October 6, 2026; The SaaS News; VC News Daily; Fundz. Rated HIGH.

TeddyHoldings.AI, $60.0M Seed. Pulse 2.0; VC News Daily; Fundz; ValueAdd VC. No investor is named in any source. Rated MEDIUM.

Market comparison sources

VC News Daily funding records for October 5 to 10, 2026, used as a candidate source and date-checked against primary releases. Tech Startups daily funding roundups for October 6 to 9, 2026. AlleyWatch daily New York funding reports for October 6 to 8, 2026. FinSMEs US listings for October 5 to 9, 2026. The SaaS News, Pulse 2.0 and Dealroom news for October 5 to 9, 2026. Prior-period comparisons are drawn from the final published figures of earlier issues in this series and limited to figures that do not depend on the scoring rubric: the $10M to $100M band ran 21 rounds and $769.0M in the week of September 7, 22 rounds and $837.5M in the week of September 14, 17 rounds and $655.0M in the week of September 21, and 11 rounds and $457.5M in the week of September 28. The September 28 issue’s final figures for designated leads (14 of 15), returning investors (7 of 15, 68.6% of capital) and strategic capital (4 of 15) are used. Strategic participation shares are as published in each issue.

Contrast set above the $100M ceiling, drawn from the same feeds, used for context only and not summed or scored: Oratomic ($475M Series B), Oxide ($445M Series D), Vinci ($250M), Voltus ($225M Series D), GMI Cloud ($223M equity alongside a $445M credit facility), Arena ($200M Series B), Type One Energy ($200M Series B), Valon ($150M Series D), Matchpoint ($150M Series B), MMI ($125M Series D), Capitolis ($120M Series E) and General Medicine ($120M Series B). Parallel Systems ($100M) sits at the ceiling and is excluded on that ground.

Verification notes

Nineteen of the 22 featured rounds are rated HIGH source confidence: a company, investor, filing or regulated newswire source plus at least one independent outlet, with no unresolved conflict affecting the round. Three are rated MEDIUM: Nous Research, Catalyst and TeddyHoldings.AI, for the reasons stated in the citations. Every third-party validation credited under Independent Validation was checked against the announcement of the award, grant or deployment rather than a company characterization of it.

The final pass re-checked every amount, stage, lead, syndicate, prior round, founder background and validation against its sources. Amounts, stages, leads and the deal set did not change. Seven scores did. Fortastra fell from 67 to 60 and Kapta Space from 62 to 61, because a Space Force award could not be confirmed and classified contracts described only by the company are not credited. Pro Shop fell from 68 to 67 on a Series A dated March 2024. Melius and Wally each fell one point because we couldn't confirm any returning investors. Catalyst rose from 47 to 51 once we located its founders’ prior company and Worldcoin tenure. Founder descriptions for Gallatin AI, Ampersand, Clockwork.io, Pro Shop and Hone were corrected to what the sources state.

Deals analyzed and excluded

Deals analyzed: 22 verified US rounds of new primary capital between $5M and $100M.

Non-US or US headquarters not verifiable, excluded for scorecard comparability: Mecka (Toronto and New York), Rein Security (New York and Tel Aviv), Vocca (Paris and New York), MintNeuro (United Kingdom), pubX (headquarters not verifiable), OneByZero (Singapore), Pandektes (Denmark), Fleuret AI (France), Celaid (Japan), Spiko (United Kingdom and France), RougeTx (Netherlands), Hadrian (Netherlands), WhiteLab Genomics (France), Procuros (Germany), Cleavr (France), calliora (Germany), Garuda (India), Quanfluence (India), byteXL (India), Sunfox (India), Cori Clinical (United Kingdom), Desible.ai (India), Universal Quantum (United Kingdom), TrueLayer (United Kingdom), Helical Fusion (Japan), UniSieve (Switzerland), Verso (France), Golbriak (Estonia), IMMIX (United Kingdom), BloomX (Israel), THE PHAGE (Japan), Ocean (Japan), Scanntech (Uruguay and Brazil), Phantom GI (Israel), Manus (Singapore) and Konsileo (United Kingdom).

Outside the date window, marked news-cycle resurfaced: Beyond Reach Labs ($10M, closed July 2026) and Elio Mortgage ($5.1M, covered in the September 28 issue).

Structural or verification exclusions: Aventra ($17.5M, includes a Western Alliance Bank facility and equity cannot be isolated), Rebel Audio (targets a $10M close, not closed), Outro ($7M across pre-seed and seed with no split or dates), At Home Harmony (about $5M in a single outlet against a $4.75M filing, floor not confirmed), Reactor (about $15M, amount inferred by outlets), Clasp ($13.2M, filing only), True, PreciseDx and Negosh (filing-only records with no company announcement confirming terms), Exthymic (up to $25M, not a closed amount), Umia (token sale), and Primitive Labs and Factory (no amount stated).

Giant rounds by editorial scope: the twelve rounds listed in the contrast set and Parallel Systems at the ceiling.

Below the $5M floor: Peppermint ($4.7M), Hilt ($4.2M), Agentiq ($4M), Guardrail (about $3M) and Eden AI ($1.5M).

Research completion timestamp: October 12, 2026, after a further verification pass, adversarial and directed at finding errors in the one before it.

DISCLAIMER: This article is for informational and strategic intelligence purposes only. It does not constitute investment advice. The Eisen Fundability Score is a proprietary diagnostic within Fundables OS™, not a financial recommendation.

If this article was useful, share it with founders who are about to raise.

— Leon Eisen, 4x Founder, Venture Capitalist, Author of Invisible Game: The Secrets of the Term Sheet Magnet.

Smart people keep drawing straight lines through a curved world. The reason has little to do with math, and it shapes how founders plan and pitch their next round.

In 1980, America's largest phone company asked one of the world's most respected consulting firms a simple question.

How many Americans will have a mobile phone subscription by the year 2000?

The answer came back: about 900,000.

In 2000, there were 109 million.

The forecast missed by a factor of 121. Careful, expensive people made it with good data and every reason to get it right.

And the company believed it. It treated mobile as a niche and stepped back. Between 1992 and 1994, it paid more than fifteen billion dollars to buy its way back in.

This story usually gets told as a joke about consultants. I went looking for why it happened, and it stopped being funny. The first two explanations I found sounded right, but both fell apart when I tested them. What sat underneath is something I now see in almost every plan a founder shows me.

It wasn’t bad luck

The usual defense goes like this. The technology was new, the future is unknowable, nobody could have known.

It sounds fair. So I checked whether it holds.

If the future were simply unpredictable, forecasting errors would scatter. Some plans would come in high, some low, and across enough plans the misses would roughly cancel out.

They don’t cancel.

Bent Flyvbjerg at Oxford has built a database of more than 16,000 major projects: bridges, IT systems, rail lines, buildings, energy plants. Only 8.5% came in on budget and on time. Only 0.5% came in on budget, on time, and delivered the benefits they promised.

Ninety-nine and a half percent missed on something. And the misses point the same way, over and over.

The mobile forecast wasn’t a lone mistake either. A trade magazine published its own forecast that same November and projected about 700,000 AT&T subscribers by 2000. Two forecasters, working separately, landed in nearly the same place, and both landed more than 100 million away from the truth.

When independent errors agree, they share a method.

Luck doesn’t explain that. Something systematic was bending every forecast the same way.

It wasn’t bad math

The second explanation comes from behavioral economics, and it is a good one.

Read more

Playbook, Perspective and Pattern for founders raising now. This report strips out giant rounds and public market traffic so you can read the part of the market that actually prices your round. Every round below was verified against at least two independent sources then re-checked in an adversarial pass aimed at date windows, amount composition, headquarters and returning-investor claims, and finally re-verified in a second full pass that checked every fact and recomputed every figure. This is the fourth issue scored on the v2 rubrics, so scores compare directly with the September 13, September 20 and September 27 issues and with nothing before them.

Two weeks ago the mid-market band held twenty-two rounds and $837.5M. This week it held eleven rounds and $457.5M. Half the rounds and 45.4% of the capital are gone in two issues, and the average check rose in each, from $38.07M to $38.53M to $41.59M. This week alone the median jumped 46.2%, from $26.0M to $38.0M, and deal count fell to the lowest level in the seven issues back to August 17.

The shrinkage has an address. Series A produced fourteen rounds in the week of September 7, nine the week after, eight last week and six this week. It has fallen every week on the Series A. Series B held between two and seven rounds, and this week its average check rose to $62.33M while the Series A check fell to $27.58M.

This report has already shown that returning investors matter; the September 13 issue made them the headline. What is new is the direction. The share of rounds with a returning investor has sat between 44% and 48% for three issues, but the premium attached to it has widened twice in a row, from 6.8 points to 11.6 to 15.7 this week. The seven renewal rounds this week took 68.6% of capital at $47.5M a round. The eight rounds with no follow-on averaged $19.0M.

Consequence for Monday. The market is not closing. It is consolidating toward later, larger, insider-anchored rounds, and it is thinning fastest at the first institutional round. If you are raising a Series A this quarter, you are raising into the lane that lost more than half its rounds in four weeks. Before you put a number in a deck, find out whether anyone who has already wired you money will do it again, and in writing.

The Week in One Sentence

Primary insight. For a second straight week, the mid-market shed rounds faster than capital, the average check rose for a third straight week, and Series A fell for a third straight week to six rounds, leaving a market increasingly made of later, insider-backed rounds.

Total tracked mid-market capital, 15 verified rounds: $484.6M in new primary capital, every deal between $5M and $100M, every company US-headquartered, every announcement dated September 28 to October 2, 2026.

Like-for-like against the prior issue: $457.5M across 11 rounds in the $10M to $100M band, against $655.0M across 17 rounds. Capital down 30.2%, deal count down 35.3%.

Average round size: $32.31M across the full set, against $36.76M a week earlier. On a like-for-like basis, $41.59M against $38.53M, up 7.9%.

Median round size: $22.0M across the full set. On a like-for-like basis, $38.0M against $26.0M, up 46.2%.

Largest tracked round: Efficient Computer, a $97.0M Series B in energy-efficient processors. Smallest: F2 at $5.0M, a strategic investment from Golub Capital.

Rounds with a designated lead investor: 14 of 15, or 93.3%, against 17 of 18, or 94.4%, last week. Biotia is the only round without one, and three of its eleven named investors backed earlier rounds.

Rounds carrying strategic, corporate or customer-side capital: 4 of 15, or 26.7%, moving $180.0M or 37.1% of capital, against 5 of 18, or 27.8%, and 24.4% of capital last week. Efficient Computer, ai3Bio, Link Cell Therapies and F2.

Rounds with at least one prior investor returning: 7 of 15, or 46.7%, against 8 of 18, or 44.4%, last week. Those seven averaged 58.4 against 42.8 for the eight without, a gap of 15.7 against 11.6 a week earlier.

Highest Eisen Fundability Score: Link Cell Therapies at 69. Lowest: Daptic at 33. A 36-point band, with 2 of 15 rounds clearing 65 and a mean of 50.1 against 56.7 last week.

Defining structural feature: Series A has fallen from fourteen rounds to six across the four v2 issues, while every Series B this week had a returning investor. The market is consolidating toward later-stage renewals.

Framework note: this is the fourth issue on the v2 rubrics. Capital, deal count, check size, stage, sector, geography and investor behavior remain comparable across the full series.

The Deal Scorecard

Eisen Fundability Scores are calculated across five weighted dimensions: Founder-Investor Dynamics (30), Traction to Conviction Conversion (25), Narrative Power (20), Deal Architecture (20) and Capital Planning (5). Scores of 90 and above signal an inevitable, market-defining outcome. Scores of 85 to 89 signal extremely strong execution. Scores of 75 to 84 signal solid fundamentals. Scores of 65 to 74 signal a good company with some gaps. Below 65 signals early-stage or structurally incomplete. Traction to Conviction measures only what third parties have already underwritten.

What the Scorecard Says at a Glance

The top two rounds both had a clinic attached and an insider in the round. Link Cell Therapies at 69 began dosing patients in a Phase 1 trial at MD Anderson and upsized a Series A that Johnson & Johnson’s venture arm led nine months earlier. TriGemX Bio at 67 is running a pivotal Phase 3 and raised $94M with The Column Group, one of its 2015 founding investors, back in the lead seat. Only one other round has both a regulator-controlled checkpoint and a returning investor: Biotia, at 46, with New York State approval for its urine assay and earlier backers in the round. The difference is everything around those two facts. Link Cell and TriGemX built tier-one syndicates and sized their rounds to dated trials. Biotia raised $9M with no designated lead.

The best value in the set is an $11M rocket seed. Hop Aero has never flown untethered, and it scored 56, four points above Efficient Computer’s $97.0M Series B. The difference sits in one sub-dimension: Hop Aero carries an Air Force Research Laboratory SBIR award, so a federal buyer has already paid for its work. Efficient Computer, which ships a processor in volume, has no named counterparty in the record. Size and score stayed uncorrelated again. Atomic at $12.5M outscored ai3Bio at $48.0M by sixteen points.

The most expensive lesson costs $38M. doxx.net raised a Series A led by Andreessen Horowitz, with a partner taking the board seat, and scored 8 of 10 on Investor Quality. It scored 37 overall because no founder background is in the public record reviewed, no counterparty is named, and no prior investor is confirmed by two sources. A tier-one lead carries one sub-dimension. It does not carry a round.

The floor is structural. Daptic at 33 raised $15M from Canvas Ventures with no founder background located in the record reviewed and no named counterparty. doxx.net at 37 and ai3Bio and Elio Mortgage at 40 sit just above it. These are real companies with real money. The score measures how much of the transaction a new investor could reconstruct from outside, and at the bottom of the band are the amount, the lead, and a little around them.

Read the scorecard by color, not by rank. The seven rounds with a returning investor run from 46 to 69, and six of the seven score 52 or higher. The eight without run from 33 to 56, and only two of them, Hop Aero and OuterSignal, cleared 50. A returning investor did not guarantee a high score. Its absence nearly guaranteed a low one.

What Changed This Week: Five Market Shifts

Each shift is verified against multiple sources and ranked by structural impact on founder fundraising, not by deal size. Every shift ends with what it means for your raise next week.

Shift 1: Half the Rounds Gone in Two Weeks, and the Check Grew Every Week

Pattern, what happened. On a like-for-like $10M to $100M band, the mid-market has shrunk two weeks in a row. It held twenty-two rounds and $837.5M in the week of September 14, seventeen rounds and $655.0M in the week of September 21, and eleven rounds and $457.5M this week. That is half the rounds and 45.4% of the capital gone in two issues. Over the same weeks, the average check rose each time, from $38.07M to $38.53M to $41.59M, and this week the median jumped 46.2% to $38.0M. Geography broke pattern too: New York took seven of fifteen rounds and 32.6% of capital, while California fell to 27.0% after taking more than half of capital in each of the three prior issues.

Perspective, what it means. A capital pool can shrink in three ways. It can reprice, where the same number of companies split less money. It can narrow, where capital and company count fall together and the check holds. Or it can concentrate, where company count falls faster than capital and the surviving checks get larger. The week of September 7 narrowed. The last two weeks concentrated, and the second week concentrated harder than the first. That is a direction, not a blip: the partners still writing are writing fewer, larger checks, and they are writing them to companies further along.

Founder Blindspot, what most miss. Founders see a 46% jump in the median and read it as a hot market, a reason to push the ask up. The median did not rise because any given company was priced higher. It rose because smaller, earlier rounds dropped out of the queue two weeks in a row. If you set your number off this week’s median without asking which rounds produced it, you are pricing yourself against companies with an insider in the room and a later stage on the cover page.

Playbook, what to do. Before you set a number, answer two questions in writing. Has anyone who already funded you committed to fund you again? Does your company carry a fact that someone outside it controls, such as a clearance, a contract award or a license? Seven in ten dollars this week went to rounds that could answer yes to at least one of the two. If both answers are no, size the round to one dated milestone and run a short, targeted process.

Contrast. The week of September 7 narrowed, with capital and count falling together and the check flat. The week of September 14 grew on every size metric. The weeks of September 21 and 28 both shrank, and the average check rose in both. Two consecutive weeks of concentration, with the check up three weeks running, is the first sustained trend in this series that points in one direction.

What this means for your raise: The market is consolidating, not repricing. Expect fewer slots and larger checks, and price your round off the rounds that look like yours.

Shift 2: Series A Has Shrunk Every Week Since September 7

Pattern, what happened. Series A produced fourteen rounds in the week of September 7, nine in the week of September 14, eight in the week of September 21 and six this week, counting Link Cell Therapies’ extension. That is three consecutive declines and 57% of the lane gone in four issues. The average Series A check moved from $30.14M to $28.33M to $34.44M and now $27.58M, down 19.9% this week. Series B did not follow: two, seven, four and now three rounds, with the average check at $62.33M this week, up 10.3%. All three Series B rounds this week had a returning investor. Only two of the six Series A rounds did: Link Cell and Atomic.

Perspective, what it means. The first institutional round is where consolidation happens. A Series B is usually a renewal: an existing investor has watched the company for a year and a half and can anchor the next price. A Series A is more often a sale to someone new, and a market that is concentrating on companies it already knows has less appetite for the sale. Three weeks of falling Series A counts, with the Series B lane holding, is what that preference looks like in the data.

Founder Blindspot, what most miss. Series A founders read the weekly totals, see large rounds still clearing, and assume their lane is open. The large rounds are later-stage renewals. The Series A lane has narrowed every week, and four of this week’s six Series A rounds closed with no prior investor confirmed.

Playbook, what to do. If you are raising a Series A in the next quarter, get your seed lead’s participation decision before you open, size the round to the milestone the money buys rather than to a weekly average, and plan for a shorter target list of firms that led a Series A in your category in the last ninety days. If you are raising a Series B, velocity is your argument: Flow Engineering came back eleven months after its Series A and Miter about sixteen months after its last round, both at a larger size.

Contrast. Across the four v2 issues, Series A went 14, 9, 8, and 6 rounds, while Series B went 2, 7, 4, and 3. The gap between the average Series A and Series B check widened from $22.06M last week to $34.75M this week.

What this means for your raise: The lane you are most likely raising in is the one that has shrunk every week. Bring an insider, or bring a smaller and sharper round.

Shift 3: The Insider Premium Widened for a Second Straight Week

Pattern, what happened. Returning investors are familiar with this report. The September 13 issue made them the headline, when sixteen of twenty-four rounds had one and the gap was 17.6 points. What has changed since is the direction. The share of rounds with a returning investor fell to 48.0% in the week of September 14 and has held near that level since, at 44.4% and now 46.7%. The premium attached to it has widened twice in a row: 6.8 points, then 11.6, then 15.7 this week, or 14.5 once the Insider Support sub-dimension is removed. This week the seven rounds with a returning investor, Efficient Computer, TriGemX Bio, Flow Engineering, Miter, Link Cell Therapies, Atomic and Biotia, took $332.5M, or 68.6% of capital, at $47.5M a round, against $19.0M for the eight without.

Perspective, what it means. A stable share with a rising premium means the same proportion of companies is getting insider support, and the market is paying more for it each week. That is what scarcity of outside conviction looks like. When new leads write fewer first checks, a round anchored by someone who already knows the company clears at a larger size and with a stronger structure, and the gap between the two groups grows even though the groups stay the same size. Remove Founder Track Record as well as Insider Support, because five rounds whose founder backgrounds were not located all sit in the group without an insider, and the gap still holds at 11.1.

Founder Blindspot, what most miss. Founders who read the September 13 issue may have concluded that insider support was a one-week story. The trend says the opposite: it has become more valuable each of the last two weeks, while the number of companies with it has not grown.

Playbook, what to do. Four weeks before you open, ask every investor with a board seat or a meaningful position for a specific number above pro rata, and whether they would co-lead if a new lead prices the round. Get both answers in writing. If an insider says no, ask what would have to be true for them to write again, and write the answer down.

Contrast. Share of rounds with a returning investor across the four v2 issues: 66.7%, 48.0%, 44.4%, 46.7%. Score premium: 17.6, 6.8, 11.6, 15.7. The share settled in mid-September and the premium has climbed since.

What this means for your raise: If the trend holds for another week, an insider commitment is no longer an advantage in this market. It is the entry ticket to a full-size round.

Shift 4: A Checkpoint Opened the Door but Did Not Carry the Round

Pattern, what happened. Five rounds carried a checkpoint that an outside body controls: TriGemX Bio, running a pivotal Phase 3 of its lead migraine drug; Link Cell Therapies, which began dosing patients in a Phase 1 trial at MD Anderson; Hop Aero, which holds an Air Force Research Laboratory SBIR award; Biotia, whose urine assay is approved by the New York State Department of Health; and Elio Mortgage, which operates as a licensed mortgage brokerage. Those five averaged 55.6 against 47.3 for the other ten, an 8.3-point gap that falls to 0.5 once the Independent Validation sub-dimension is removed. Healthcare and life sciences took $181.0M across four rounds, or 37.4% of capital, up from 22.2% a week earlier.

Perspective, what it means. A residual of 0.5 means the checkpoint rounds were not stronger on anything else. The checkpoint bought its own points and almost nothing more. Split the five and the pattern is plain. TriGemX and Link Cell paired the checkpoint with a top-tier syndicate, a returning investor and a round sized to a dated trial, and finished first and second. Hop Aero paired it with a strong story and a credible seed lead and finished tied for fourth. Biotia and Elio had the checkpoint with much less around it and scored 46 and 40. An outside fact makes a round easier to underwrite. It doesn't replace the people and structure that make the round worth underwriting.

Founder Blindspot, what most miss. Founders who win a clearance or a license treat it as the round. It is one input. This week the market paid for a checkpoint when it arrived with an insider and a dated use of funds, and paid little for it on its own. Founders outside regulated categories make the opposite mistake and skip checkpoints entirely. Hop Aero scored 56 on an $11M seed, above Efficient Computer’s $97.0M Series B and Miter’s $40.0M Series B, because a federal buyer had already reviewed and funded its work.

Playbook, what to do. List every gate in your category that a third party controls: a regulatory clearance, an SBIR or other federal research award, a state license, a certification, a standards listing, a contract vehicle. Mark the one you could obtain in the next two quarters and assign an owner and a submission date this week. Then build the round around it: secure the insider commitment before you open, and size the raise to the next dated milestone the checkpoint unlocks.

Contrast. Last week the checkpoint gap was 11.0 with a residual of 5.4. This week the gap is 8.3 and the residual is 0.5. Healthcare rose from 22.2% of capital to 37.4%, and the two healthcare rounds at the top of the band combined a clinical checkpoint with a returning investor.

What this means for your raise: Get the outside fact, then build the round around it. On its own it is worth a few points. Paired with an insider and a dated milestone, it put two companies at the top of the week.

Shift 5: Corporate Money Has Lost Its Signal Over Four Weeks

Pattern, what happened. Four of fifteen rounds carried strategic, corporate or customer-side capital: Efficient Computer with Toyota Ventures, ai3Bio with UPMC Enterprises, Link Cell Therapies with Johnson & Johnson, Bristol Myers Squibb and Kyowa Kirin, and F2 with Golub Capital. That is 26.7% of rounds and $180.0M, or 37.1% of capital. Those four averaged 51.0 against 49.7 for the rest, a 1.3-point gap that turns into a 4.2-point deficit once the Customer-Side Capital sub-dimension is removed.

Perspective, what it means. Corporate capital is a multiplier on substance, not a substitute. Link Cell scored 69 because its pharma investors sat on top of a clinical checkpoint and a returning syndicate. F2 has the purest buyer-as-investor structure in the set: Golub Capital, a private credit manager, invested and signed a strategic partnership in the same announcement, which scores 8 of 8 on Customer-Side Capital. F2 still scored 43 because the rest of the record around it is thin. The strategic tells a new investor the product has a buyer. It does not tell them the company can raise the next round.

Founder Blindspot, what most miss. Founders chase a recognizable corporate name to compensate for a thin round, on the theory that the logo will carry the process. This week the logo carried nothing on its own. The corporate rounds that scored well had a checkpoint or an insider underneath the corporate check.

Playbook, what to do. If you take strategic money, attach a commercial agreement to it, as F2 did, so the investment is a receipt rather than a hedge. Then stack it on a second fact a new investor can verify: a returning investor, an outside checkpoint or a named deployment. Decide your position on right of first refusal, exclusivity and information rights before the strategic offers, not under a signing deadline.

Contrast. In the week of September 7, thirteen of twenty-four rounds carried strategic capital and the buyer-on-the-cap-table structure was worth 12.1 points, 6.4 after removal. The share has since fallen to 28.0%, 27.8%, and now 26.7%, and the separating power has gone with it.

What this means for your raise: A corporate check proves you have a buyer. It does not prove you have a round. Put it on top of something else.

The Deals That Matter, Top 5

Five deep dives across logic-gated cell therapy, a migraine drug in Phase 3, AI for hardware engineering, supply chain planning and defense logistics. These are the week's five highest-scoring rounds. All facts are verified against two or more sources.

Link Cell Therapies

Logic-gated CAR-T for solid tumors | Series A extension | $30.0M | Series A led by Johnson & Johnson Innovation (JJDC)

Eisen Fundability Score: 69 / 100

Why this scored. The highest score of the week and the strongest Traction to Conviction mark in the set at 15 of 25. Link Cell is the only round that combines a regulator-controlled clinical checkpoint, three pharmaceutical companies on the cap table and a returning syndicate. It reopened its Series A on the strength of a dated external event, and new money came in as a result.

The Setup. Link Cell Therapies is a South San Francisco oncology cell therapy company founded in 2022 by Robbie Majzner, M.D., and Crystal Mackall, M.D., out of research at Stanford University. Its CAR-T cells are logic-gated: they are designed to activate only when they recognize a pair of antigens on a tumor cell, which should let a potent therapy attack solid tumors while sparing healthy tissue. The lead program, LNK001, is in a Phase 1 study at MD Anderson Cancer Center in advanced or metastatic clear cell renal cell carcinoma.

The Deal. A $30.0M expansion announced September 29, 2026, upsizing the Series A from $60M to $90M to advance a second solid tumor program in colorectal cancer and expand the pipeline, alongside first clinical dosing of LNK001 and three additions to the executive team. The original $60M Series A, announced December 15, 2025, was led by Johnson & Johnson Innovation through JJDC, with founding investors Samsara BioCapital and Sheatree Capital, Wing Venture Capital, and new investors including Bristol Myers Squibb, Kyowa Kirin, Sherpa Healthcare Partners, Western Technology Investment and the MD Anderson Cancer Focus Fund. Samsara and Sheatree led the 2022 seed. Seed and Series A together now total $122M.

The Pattern. This is the checkpoint-triggered upsize. Link Cell did not open a new round or raise a bridge. It went back into the round it had already priced, as it began dosing patients, and added $30M. The trigger was an event a regulator and a trial site control, not a date on the company’s calendar.

The Perspective. Look at who sits around the trial. The Phase 1 runs at MD Anderson, and the MD Anderson Cancer Focus Fund is in the syndicate. Johnson & Johnson, Bristol Myers Squibb and Kyowa Kirin are three companies that license and acquire oncology assets, which means the exit conversation started at the Series A. And the founding investors from 2022 are still in. Each party has a different reason to know whether the science works, and they're all on the same cap table.

The Playbook. Build the upsize into the original round. When you close a Series A ahead of a dated external milestone, such as first dosing, a clearance or a contract award, negotiate a right to extend the round at the same price for a set window after the milestone lands. You get a second close price before the good news, and new investors get a clear reason to come in. Then put the milestone and the extension in the same announcement.

The Founder Mistake to Avoid. Founders open an extension because they are running low on cash and call it momentum. The market reads that as a bridge, and the rubric scores it that way: an extension earns zero on Round-to-Round Velocity, which Link Cell took. What made this extension work is that it arrived with clinical dosing underway and new strategic names. Without the event, the same upsize reads as a company that could not raise its next round.

TriGemX Bio

Oral migraine drug in Phase 3 | No series letter applied | $94.0M | Led by The Column Group, TCGX and Viking Global

Eisen Fundability Score: 67 / 100

Why this scored. The highest Independent Validation mark in the set at 9 of 10 and the joint highest Deal Architecture mark at 18 of 20. TriGemX is the round with the most advanced external checkpoint of the week, a pivotal Phase 3, and it is led in part by one of the firms that funded the company’s first round eleven years ago.

The Setup. TriGemX Bio is the new name of Kallyope, the New York gut-brain axis company founded in 2015 by Columbia scientists Charles Zuker, Richard Axel and Thomas Maniatis and headquartered at the Alexandria Center for Life Science. The name refers to the trigeminal ganglion, the migraine-relevant structure where the drug’s target is expressed. The lead program, elismetrep, is an oral TRPM8 channel blocker for acute migraine. It reduced migraine pain and associated symptoms in a Phase 2b trial and was well tolerated. The company is running a pivotal Phase 3 and a long-term safety study and plans to start a second pivotal trial this month.

The Deal. $94.0M financing announced September 30, 2026, led by The Column Group, TCGX, and Viking Global Investors, with other investors, to advance elismetrep through Phase 3. Total equity raised since inception is $573M. The prior round was a $236M Series D in February 2022, co-led by Mubadala Investment Company and The Column Group. The Column Group was also in the company’s first financing, a $44M Series A in 2015 alongside Lux Capital and Polaris Partners. No series letter is applied to this round.

The Pattern. This is the reset round. A company more than four and a half years past its last financing renamed itself around a single late-stage asset and raised less than it raised last time, to fund one dated set of trials. It is the opposite of the platform story Kallyope told in 2022, and it scored well because it is the opposite.

The Perspective. The size went down and the underwriting got easier. A platform is hard to diligence from outside. A Phase 3 migraine drug with a Phase 2b readout behind it is a question a specialist can answer. Then look at who led. The Column Group has watched this company since 2015, and it came back to co-lead. TCGX, its crossover affiliate, came in alongside it, and crossover capital usually appears when a company is being prepared for a public-market path. Viking Global is a large public-markets investor. That is a syndicate assembled for the next financing, not just this one.

The Playbook. If your company has been private for years and its story has narrowed to one asset, rename and refocus around that asset before you raise, and size the round to the dated readout rather than to your last round. Then go to the investor who has known you longest and ask them to lead. A founding investor leading a late financing tells every new investor that the people with the most information still want more exposure.

The Founder Mistake to Avoid. Founders of older companies try to protect the size of their last round and keep pitching the platform, because a smaller round feels like an admission. TriGemX did the reverse and scored 67. The rubric penalized the 55 months since its last round with zero on velocity. It rewarded everything else, because a focused round with a dated pivotal trial and an insider lead is easier to underwrite than a large round with a broad story.

Flow Engineering

Agentic platform for hardware engineering | Series B | $50.0M | Co-led by Valor Equity Partners and Atreides Management

Eisen Fundability Score: 64 / 100

Why this scored. The strongest Market Adoption mark in the set at 7 of 7 and the joint highest Narrative Power mark at 17 of 20. Flow has six named customers across defense, electric vehicles, aviation and space, a returning Series A lead, and a Series B that arrived eleven months after the A at more than twice its size.

The Setup. Flow Engineering is a three-year-old San Francisco company whose AI agents automatically align CAD drawings with product requirements, simulation results, and test data- the verification work that slows down every hardware program. Chief executive Pari Singh founded the company in 2023, building on a tool he had developed to help design rocket engines. Named customers include Anduril, Rivian, Joby Aviation, GM PPU, a joint venture between General Motors and TWG Motorsports, RV Tech, the Rivian-Volkswagen joint venture, and Stoke Space.

The Deal. $50.0M Series B announced September 30, 2026, co-led by Antonio Gracias of Valor Equity Partners and Gavin Baker of Atreides Management. Sequoia Capital, which led the $23M Series A in October 2025, participated, alongside Human Capital, Evantic, SV Angel, Odyssey and EQT, with individual checks from Hugging Face co-founder Thomas Wolf, Mercedes-Benz chief information officer Jonas von Malottki and Formula 1 champion Nico Rosberg. Roelof Botha joined the board as an independent director and invested personally.

The Pattern. This is the customer-list round. Flow’s strongest asset is not its model; it is six named hardware companies across four segments whose engineers use the product, each one a reference call a new investor can make without Flow in the room. In a market that pays for what it can verify, a customer list spanning defense, automotive, aviation, and space is the software version of a regulatory checkpoint.

The Perspective. Look at the investor fit. Valor and Atreides both back capital-intensive hardware, which is exactly the kind of company Flow sells to. Sequoia stayed in after leading the A. An executive from an automaker also wrote a personal check. The syndicate reads like a map of Flow’s buyers and the people who fund them, which is why Investor Alignment scored 7 of 7. The round competition signal is strong too: two co-leads, a returning lead and an independent director joining, within a year of the last round.

The Playbook. Build a reference ladder before you open. List every named customer, the segment it sits in and the person who will take a reference call, and get their agreement in advance. Aim for at least three segments, because a customer list concentrated in one industry tells a new investor about that industry rather than about your product. Then hand the ladder to every new lead in the first meeting.

The Founder Mistake to Avoid. Founders with marquee customers lead with the logos and assume the round will follow. Flow’s customer list scored 7 of 7 and still left points on the table: no independent validation, no customer-side capital, and an insider who participated rather than led. A logo wall is one sub-dimension. If one of those customers’ venture arms had taken a position, Flow would likely have cleared 65.

Atomic

AI-native supply chain planning | Series A | $12.5M | Co-led by Klass Capital and Madrona

Eisen Fundability Score: 56 / 100

Why this scored. A Founder Track Record mark of 7 of 10 on the smallest round in the top five. Atomic’s founders built the planning system for Tesla’s Model 3 ramp, two named customers run on the product, and the studio that incubated the company stayed on as two new board members.

The Setup. Atomic is a Boston company that sells supply chain planning software built by the people who ran planning at Tesla. Chief executive Michael Rossiter and chief product officer Neal Suidan led sales and operations planning during the Model 3 production ramp, and former Tesla planning director Jeff Goodrich has joined as chief technology officer and third co-founder. The software models supply-chain scenarios to decide how much inventory a company should hold and where, then recommends or executes a response. Customers include DoorDash and HelloFresh. DVx Ventures, founded by former Tesla president Jon McNeill, incubated the company.

The Deal. $12.5M Series A announced September 29, 2026, led by Klass Capital and Madrona. Adrian Schauer of Klass Capital and Matt McIlwain of Madrona join the board alongside Jon McNeill. Alumni Ventures, Sandberg Bernthal Venture Partners and DVx also back the company, and total funding is just over $15M. Klass Capital is a Toronto firm whose portfolio includes supply chain software company Nulogy.

The Pattern. This is the operator-pedigree round. The product is a system its founders already ran at scale inside one of the most demanding supply chains in manufacturing, and the people who can vouch for that, starting with Tesla’s former president, are on the cap table. The diligence question shifts from whether the team can build it to whether other companies will buy it, and two named customers start to answer that.

The Perspective. Klass Capital is the investor most founders would skip past and the one worth studying. A growth firm that already owns a supply chain software business brings a buyer network and a view of what the category pays for. Pair that with Madrona and with DVx staying in, and Investor Alignment scores 7 of 7 on a $12.5M round. The constraint is the Traction dimension: two named customers and no outside validation leave it at 5 of 25.

The Playbook. If your founding story is that you built this inside a tier-one company, make it checkable. Name the system and the scale it ran at, and get the most senior person who can vouch for it onto your cap table or your board before you raise. A former executive who saw the work is a reference a new investor will call first.

The Founder Mistake to Avoid. Two co-leads, each taking a board seat, beside a studio founder already on the board, is three investor-affiliated directors on a $12.5M Series A. Founders accept that structure to secure both leads and discover at the Series B that the board math is already set. Count your seats before you accept a second lead, and negotiate an independent seat if the investor side is growing faster than the company.

Hop Aero

Autonomous suborbital cargo rockets for defense logistics | Seed | $11.0M | Led by Initialized Capital

Eisen Fundability Score: 56 / 100

Why this scored. The joint highest Narrative Power mark at 17 of 20 and one of five rounds in the set with an externally controlled checkpoint. Hop Aero scored 56 on an $11M seed with no prior institutional round, above two Series B rounds of $40M and $97M, because a federal research program has already funded its work.

The Setup. Hop Aero, founded in 2024 and based in Southern California, is building Rook, an autonomous cargo rocket designed to launch from a standard 40-foot shipping container, fly a suborbital arc and land cargo hundreds of miles away in minutes. Its first target is defense logistics: carrying swarms of autonomous systems into contested environments and deploying them on arrival. Co-founders are chief executive Matija Milenovic and chief technology officer Jacob Balaj. The company has completed a tethered flight of a small-scale prototype at an Oklahoma spaceport and hot-fired its engine. It has not yet flown untethered.

The Deal. $11.0M seed announced October 1, 2026, after the company’s Y Combinator Summer 2026 batch, led by Initialized Capital and structured on SAFEs. The capital funds the development of the full-scale Rook 2. The company holds an Air Force Research Laboratory SBIR Direct-to-Phase-II award.

The Pattern. This is the government-validated seed. Most seed rounds rest on a team and a demo. Hop Aero’s rests on a team, a demo and a federal technical review that ended in an award, which means a defense buyer has already looked at the work and paid for more of it.

The Perspective. Look at what the award does to an early-stage defense round. A seed investor in defense is betting that a government customer will eventually pay. An SBIR award moves part of that bet from the future to the past. It doesn't prove the rocket works, and the company hasn't flown untethered yet. It does prove that the buyer the company is pitching has already engaged. That is why a $11M seed with no institutional history scored higher than two Series B rounds this week.

The Playbook. If you sell to government, apply for an SBIR or STTR award before you raise, and use Direct-to-Phase-II where your prior work qualifies. Map your product to a specific open topic, name the program office, and put the submission date on your fundraising calendar. The award is small next to a seed round, but it changes the question a new investor asks from whether the government will care to how fast it will buy.

The Founder Mistake to Avoid. An $11M seed on SAFEs, where the company raised more than it planned, defers the price to the Series A. Founders celebrate the oversubscription and forget that every uncapped or high-cap SAFE converts into dilution on the day the A is priced. Model the conversion at three Series A prices before you accept the last SAFE, and set the cap with the A in mind, not this week’s demand.

The Fundraising Playbook, Five Tactical Plans

Five plans, each producing a concrete artifact you can use immediately. Each is built directly from this week’s verified signals.

1. The Dated Milestone Headline (Narrative and Investor Framing)

Why this matters. The two highest-scoring rounds of the week each raised against one dated external event. TriGemX Bio raised $94M to run a pivotal Phase 3 with a second pivotal trial starting this month. Link Cell Therapies added $30M as it began dosing patients to fund a second program. Both scored 18 of 20 on Deal Architecture because the round and the milestone were the same sentence. In a concentrating market, a partner with less time per company backs the round whose purpose fits on one line.

Exact deliverable. Rewrite your deck’s first slide into one sentence of the form: this round buys [named milestone] by [date], and [named third party] decides whether we hit it. Then write a one-page milestone memo behind it: the milestone, the date, who controls the outcome, what it costs to get there, and what the company is worth to the next investor if it lands. If you cannot name a third party in the sentence, that is the gap Plan 2 closes.

Time estimate. Two hours for the sentence, three hours for the memo, one review with your most skeptical board member.

Expected outcome. A headline that converts your round from a request into a schedule. New investors can test it against a date rather than against your enthusiasm, and the milestone becomes the anchor for size and timing.

The reframe. Wrong approach: open with the category and the vision, and get to the milestone on slide twelve. Right approach: open with the milestone, the date and the third party who controls it, and let the vision explain why it matters.

2. Obtain One Externally Controlled Checkpoint (Proof Architecture)

Why this matters. Five rounds carried a checkpoint an outside body controls and averaged 55.6 against 47.3 for the other ten. The two that paired it with a returning investor and a round sized to a dated trial, Link Cell Therapies and TriGemX Bio, took the top two places. One of the five is an $11M rocket seed: Hop Aero holds an Air Force Research Laboratory SBIR award and scored above two Series B rounds of $40M and $97M.

Exact deliverable. A one-page checkpoint plan with four columns: the checkpoint, the body that grants it, the earliest realistic decision date, and the internal owner. List every candidate in your category, including SBIR and STTR awards, regulatory clearances, certifications, standards listings and government contract vehicles. Pick the one you can obtain fastest, assign the owner this week, and put the submission date on the same calendar as your raise. The deliverable is a plan to obtain the checkpoint, not a plan to announce it.

Time estimate. Three hours for the plan. Two to six months to obtain most checkpoints, which is why the clock starts now rather than when the process opens.

Expected outcome. One fact about your company that a new investor can verify without calling you. On its own, this week, a checkpoint earned little beyond its own points. The rounds that turned one into a top-two finish paired it with an insider and a dated milestone, so run this plan together with Plans 1 and 4.

The reframe. Wrong approach: build a case an investor has to accept on trust and hope the deck carries it. Right approach: count the facts about you that somebody else certifies, and go get one more before you open.

3. Eisen Self-Score and Gap Diagnosis (Readiness)

Why this matters. The band ran from 33 to 69 with a mean of 50.1, and only two of fifteen rounds cleared 65. Seven of fifteen scored below 50, and six of those seven raised without a returning investor. The market discriminated hard, and it discriminated on structure.

Exact deliverable. Score your round on the five v2 dimensions: Founder-Investor Dynamics (30), Traction to Conviction (25), Narrative Power (20), Deal Architecture (20) and Capital Planning (5). Mark your two lowest dimensions. Then apply this week’s test. Above 60, with a returning investor committed, run a competitive process now with a hard deadline. Between 45 and 60, fix the lowest dimension before you open, because that is where this week’s rounds without an insider sat. Below 45, the problem is structural: no insider, no checkpoint, no named counterparty. A better deck will not fix it.

Time estimate. Two to three hours, repeated before every raise and again after every insider conversation.

Expected outcome. A decision between a competitive process and a repair sprint, made this week rather than in month three of a process that is not converting.

The reframe. Wrong approach: score yourself, feel discouraged and rewrite the deck. Right approach: score yourself, name the two lowest dimensions, and choose between a process and a repair sprint before you book a single meeting.

4. The Insider Commitment Gate (Deal Architecture and Investor Targeting)

Why this matters. This is the highest leverage plan in the issue. Seven rounds with a returning investor took 68.6% of the week’s capital at $47.5M a round. Eight without one averaged $19.0M. The score gap was 15.7 points, 14.5 with the insider sub-dimension removed. Every Series B this week had a returning investor.

Exact deliverable. Three outputs, in this order. First, four weeks before you open, a written number from every investor with a board seat or meaningful position, above pro rata where they will go there, plus a yes or no on co-leading. Second, a new-lead target list built only after those answers are in, limited to firms that led a round in your stage and category in the last ninety days. This week’s mid-market leads included TQ Ventures, Valor Equity Partners, Atreides Management, Battery Ventures, Klass Capital, Madrona, Initialized Capital, Long Journey Ventures, Abstract Ventures, Canvas Ventures, Base10 Partners, Bonfire Ventures, Andreessen Horowitz, Motive Partners, Social Leverage, The Column Group and Johnson & Johnson Innovation. Third, a one-page term position on right of first refusal, exclusivity and information rights, decided before any strategic offers.

Time estimate. Two weeks of calendar for the insider conversations and four hours of preparation.

Expected outcome. You open with a floor under the round and a number to quote to new leads, or you learn three months early that the people who know you best will not write again, and why.

The reframe. Wrong approach: run the new-money process first and go back to insiders if it stalls. Right approach: get the insider number and the co-lead answer in writing before the first new-lead meeting, and quote it as the floor.

5. The Milestone-Linked Close (Momentum and Conversion Mechanics)

Why this matters. Link Cell Therapies reopened its round as clinical dosing began and added $30M with new investors. Flow Engineering returned to market eleven months after its Series A at more than twice the size. Both used an external event to create a reason to decide now. In a market where partners are concentrating, a dated reason to decide is what turns a second meeting into a term sheet.

Exact deliverable. A fourteen-day follow-up cadence tied to dated milestones. Day one, the first meeting with the milestone memo from Plan 1. Day four, a written update on one concrete item: a signed customer, a submitted application, a test result. Day eight, a reference call with a named customer or the insider who committed in Plan 4. Day eleven, a second update tied to the milestone date. Day fourteen, a stated decision date. If your milestone lands mid-process, negotiate a second close at the same price for a fixed window after it, and put the milestone and the close in the same announcement.

Time estimate. One afternoon to build the cadence, then thirty minutes per investor per update.

Expected outcome. A process that creates urgency from facts rather than pressure, plus a second-close option that lets new money enter after good news without repricing the round.

The reframe. Wrong approach: send a deck, wait for feedback, and follow up when you remember. Right approach: run every active investor on the same fourteen-day clock, and give each touchpoint a new fact rather than a reminder.

Looking Forward, Next 1 to 3 Weeks

Three evidence-based scenarios and one wild card. Every prediction is anchored to this week’s verified data.

Scenario 1: The Fourth Quarter Opens Concentrated (High Probability)

Evidence from this week. Band deal count fell to eleven, the fewest in the seven issues back to August 17, while the median check rose 46.2% to $38.0M. Rounds with a returning investor took 68.6% of capital. This was the last week of the third quarter, and the pattern is what a market looks like when partners are finishing commitments to companies they already know.

What to watch. Whether band deal count recovers above fifteen in either of the next two issues. If it does and the median falls back toward $30M, this week was quarter-end timing. If count stays near eleven and the median holds above $35M, concentration is the fourth-quarter regime.

What founders should do before others notice. Treat the next six weeks as an insider market. Run Plan 4 now, while your existing investors are setting their fourth-quarter reserves, rather than in November when those reserves are allocated.

Scenario 2: The Series A Lane Keeps Thinning (Medium-High Probability)

Evidence from this week. Series A has fallen every week on the v2 series, from fourteen rounds to nine, eight and now six. This week the six averaged $27.58M, down 19.9%, and four of the six had no returning investor. Every Series B had one, and the Series B check rose 10.3%. The gap between the two stages widened from $22.06M to $34.75M in one week.

What to watch. Whether Series A falls below six rounds for a fourth straight decline, and whether the rounds that do clear keep carrying a returning investor. Two more weeks of that pattern makes insider participation the price of a full-size Series A.

What founders should do before others notice. If you are raising a Series A in the next quarter, secure your seed lead’s participation decision this month, and build your use of funds around one dated milestone so a smaller check still reaches it.

Scenario 3: Clinical Checkpoints Keep Pulling Healthcare’s Share Up (Medium Probability)

Evidence from this week. Healthcare and life sciences took 37.4% of capital, up from 22.2%, and the two highest scores of the week were both clinical-stage companies that combined a regulator-controlled checkpoint with a returning investor. Checkpoints alone did not separate the field: the gap was 8.3 with a residual of 0.5, against 11.0 and 5.4 last week.

What to watch. Whether healthcare’s share stays above 30% in the next issue, and whether the rounds that carry it remain clinical-stage rather than discovery-stage. A rising share made up of clinical rounds is a verification trade. A rising share made up of discovery rounds would be a sector rotation, which is a different signal.

What founders should do before others notice. Outside healthcare, borrow the mechanism, not the sector. Identify the regulatory, certification or government award gate in your category and start the application before you start the raise.

Wild Card: The Reset Round Becomes a Template (Medium Probability)

Evidence from this week. TriGemX Bio raised $94M more than four and a half years after a $236M Series D, renamed itself around one asset, and scored 67 with its founding investor co-leading. The rubric charged it zero for velocity and it still finished second, because the round was easy to underwrite.

What to watch. Whether other companies with long gaps since their last round follow the same pattern: a new name or a narrowed story, a round sized to one dated readout, and a founding or early investor in the lead seat. Two or three more in the next month would make the reset round a recognizable financing category.

What founders should do before others notice. If your last round was more than three years ago, stop trying to protect its size. Rebuild the story around the one asset or product closest to an external milestone, size the round to reach it, and ask your longest-standing investor to lead.

The Bottom Line

The real insight is not the $484.6M. It is the direction. In two weeks, the mid-market lost half its rounds while the average check rose every week, Series A fell for the third week in a row, and the premium for a returning investor widened for the second week in a row. This week, seven renewal rounds took two-thirds of the money, and eight first-time or outside-led rounds averaged $19.0M. That produced three conviction profiles.

Profile 1: Somebody came back. TriGemX Bio (67) had The Column Group, one of its 2015 founding investors, return to co-lead. Flow Engineering (64) had Sequoia back eleven months after leading its Series A. Atomic (56) kept DVx, the studio that incubated it. Miter (55) brought back Bessemer and Coatue. Efficient Computer (52) had Eclipse, which backed it from the start. Link Cell Therapies (69) upsized a round its syndicate already held. Biotia (46) brought back investors from its earlier rounds. The seven averaged 58.4 against 42.8 for the eight without a returning investor.

Profile 2: Somebody outside the company had already said yes, and an insider was in the room. TriGemX Bio is running a pivotal Phase 3. Link Cell Therapies is dosing patients at MD Anderson. Both also had a returning investor and a round sized to a data-driven trial, and they took the top two places. Three other rounds carried an outside checkpoint without that full combination: Hop Aero (56) with an Air Force Research Laboratory SBIR award, Biotia (46) with New York State approval, and Elio Mortgage (40) as a licensed brokerage. Across all five, the checkpoint was worth its own points and almost nothing more, a residual of 0.5. The checkpoint opened the door. The insider and the structure carried the round.

Profile 3: Somebody re-underwrote fast and bigger. Flow Engineering raised a Series B eleven months after a $23M Series A, at more than twice the size. Miter raised $40M about sixteen months after a $23M round. The two averaged 59.5 against 48.6 for the rest, a 10.9-point gap that holds at 8.2 after removing the velocity sub-dimension.

Everything else competed for the residual. Eight companies raised with no returning investor, and the bottom of the band shares one shape: Daptic at 33, doxx.net at 37 and ai3Bio at 40 each closed with a capable lead, no named counterparty and nothing an outside body has validated. These are real companies with real capital. What the score measures is how much of the transaction a new investor could reconstruct, and here the answer is the amount, the lead and little else.

Five New Rules for Founders

1. A consolidating market is not a hot market. The deal count fell from twenty-two to eleven in two weeks while the average check rose every week and the median jumped 46.2% this week. The check rose because small and early rounds left the queue. Price your round off the rounds that look like yours.

2. Renewals get funded, sales get discounted. Seven rounds with a returning investor averaged $47.5M and scored 58.4. Eight without averaged $19.0M and scored 42.8. Get a written number and a co-lead answer from your insiders before you open.

3. Own one fact you do not control, then build the round around it. Five rounds carried an outside checkpoint. The two that paired it with an insider and a dated trial finished first and second, and the three that didn't averaged 47.3. A pivotal trial, clinical dosing, a state approval and an Air Force award all count. None of them carried a round alone.

4. A corporate check is a multiplier, not a substitute. Strategic capital this week separated nothing on its own, a 1.3 point gap that turns negative after removal. Attach a commercial agreement and stack it with another fact.

5. Come back fast and come back bigger. Series A has shrunk every week since September 7, from fourteen rounds to six. Every Series B this week had a returning investor, and the two re-underwritten inside eighteen months at a larger size averaged 59.5. If your next round is more than eighteen months away, the step-up has to come from a milestone.

Four Monday Actions

1. Call every investor with a board seat or a meaningful position. Ask for a specific number above pro rata and a written yes or no on co-leading, four weeks before you open.

2. Write your dated milestone headline. One sentence: this round buys a named milestone by a date, and a named third party decides whether you hit it.

3. Start one checkpoint application. Pick the SBIR award, clearance, certification or contract vehicle you can obtain fastest, assign an owner and put the submission date on your fundraising calendar.

4. Score yourself on the five dimensions and decide between a competitive process and a repair sprint before you book a single new-lead meeting.

Fifteen companies closed this week, and two-thirds of the money went to the seven whose investors came back. The other eight were not worse companies. They were strangers to the people writing checks. You can change that this week with two calls you have been putting off and one application you have not started. Founders who make them walk into the fourth quarter with a renewal, not a pitch.

Research Methodology, Sources and Verification

Data Collection Period and Verification Standard

Data collection period: September 28 to October 4, 2026. Every verified US mid-market round was announced between Monday, September 28 and Friday, October 2. No qualifying round was found for Saturday, October 3 or Sunday, October 4, and any round announced over that weekend carries into the next issue. Verification standard: a minimum of two independent sources per deal, with company releases, investor posts and regulated newswires prioritized as anchor sources, plus at least one independent outlet. Every round was then rechecked in an adversarial pass aimed at four failure modes: announcements recirculated from earlier weeks, headline amounts that blend new capital with earlier closes or debt, headquarters outside the United States, and returning-investor or prior-round claims that rest on a single source. A second full verification pass then re-checked every fact behind every score, corrected the record where it was incomplete, and recomputed all arithmetic from the final deal record. Eisen Fundability Scores are proprietary analytical estimates, not endorsements or investment advice.

Core Capital Totals and What They Include

The $484.6M weekly total includes only the fifteen verified US rounds in the scorecard, each confirmed at the stated amount. Mid-market is defined as a US-headquartered round of new primary capital between $5M and $100M. Week-over-week structural comparisons use the $10M to $100M subset that every recent issue has published: eleven rounds totaling $457.5M at an average of $41.59M and a median of $38.0M, against seventeen rounds totaling $655.0M at an average of $38.53M and a median of $26.0M in the week of September 21. The four rounds below $10M, totaling $27.1M, are included in the scorecard, the scores and the sector and geography analysis, and excluded from every week-over-week structural comparison, including every stage average quoted in this issue.

Debt facilities, secondary purchases, previously closed tranches, majority private equity investments, binding term sheets that have not closed, and announcements that do not separate new capital from earlier closes are excluded from the counted amount. Link Cell Therapies is counted at the $30.0M expansion, not at the $90M upsized Series A total. Hop Aero’s seed is structured on SAFEs and is counted as new capital raised in the window. Sector subtotals ($181.0M healthcare and life sciences, $139.5M enterprise AI and software, $116.0M semiconductors, robotics and defense, $38.0M security and networking, $10.1M fintech), stage subtotals ($187.0M across three Series B rounds, $165.5M across six Series A rounds including one extension, $108.0M across three rounds with no series letter, $19.0M across two seed rounds and $5.1M in one pre-seed) and state subtotals ($158.1M New York, $131.0M California, $97.0M Pennsylvania, $60.5M Massachusetts, $38.0M Florida) each sum to $484.6M across fifteen deals.

Scoring Calibration Notes

Founder Track Record is scored on the verifiable public record. Where no founder background was located in the sources reviewed, the sub-dimension scores zero, which applied to doxx.net, Daptic, Destro AI, Elio Mortgage and F2. All five sit in the group without a returning investor, so the returning-investor gap is published three ways: 15.7 as measured, 14.5 without Insider Support, and 11.1 without Insider Support and Founder Track Record. Rounds with no designated lead are scored on the institutional quality actually present, which gives Biotia 4 of 10 on Investor Quality across eleven named investors. Newly formed companies with no prior institutional round score zero on velocity by construction. Extensions score zero on velocity by rule, which applied to Link Cell Therapies. Where a prior round’s date rests on a single source, the eighteen-month velocity credit is not applied, which held Efficient Computer and Atomic at 2 of 3. Returning-investor status requires two sources, which is why doxx.net is not counted as having a returning investor, although one profile lists a participant as an earlier backer.

Circularity control. Where a finding rests on a scored sub-dimension, that sub-dimension is removed from both sides and the residual is published alongside the headline. Returning investor: 15.7 and 14.5. Externally controlled checkpoint: 8.3 and 0.5. Re-underwritten within eighteen months at a larger size: 10.9 and 8.2. Named customer accounts: 4.3 and negative 0.4. Strategic or corporate capital: 1.3 and negative 4.2. Every pair appears in Chart 5.

Deal Citations, Two or More Sources per Deal

Link Cell Therapies, $30.0M Series A extension. PR Newswire company release of September 29, 2026, on first clinical dosing and the upsize from $60M to $90M; FinSMEs, September 29; Fundz. Series A history from the PR Newswire release of December 15, 2025, Precision Medicine Online and The Pharma Letter. Rated HIGH.

TriGemX Bio, $94.0M, no series letter. BusinessWire company release dated September 30, 2026; Fierce Biotech fundraising tracker entry for October 1; AlleyWatch daily funding report of October 2. Prior financing history from the BusinessWire Series D release of February 2022, BioSpace and BioPharma Dive. Rated HIGH.

Flow Engineering, $50.0M Series B. TechCrunch, read through syndication; VC News Daily, September 30; FinSMEs, October 1; company Series B memo listed by startups.gallery. Series A history from Fortune, October 2025. Rated HIGH.

Atomic, $12.5M Series A. TechCrunch of September 29, read through syndication; FinSMEs, September 29; VC News Daily; Pulse 2.0; The SaaS News; Tech Funding News for the investor list. Rated HIGH.

Hop Aero, $11.0M Seed. Payload exclusive; FinSMEs, October 1; Fundz for the SAFE structure. Air Force Research Laboratory award from the company’s Y Combinator profile as summarized by YesPress, corroborated by RuntimeWire. Rated HIGH.

Miter, $40.0M Series B. PR Newswire company release of September 30, 2026, read through Construction Dive; Pulse 2.0; Unite.AI; Axios via startups.gallery. Prior round from Axios and Pulse 2.0, May 2025. Rated HIGH.

Efficient Computer, $97.0M Series B. Company release datelined Pittsburgh, September 29, 2026; Reuters; Pulse 2.0; Unite.AI. Rated HIGH.

OuterSignal, $22.0M Series A. AlleyWatch daily funding report of September 30; FinSMEs, September 30; VC News Daily; Pulse 2.0; company about page for founder background and named customers. Rated HIGH.

F2, $5.0M. FinSMEs, September 28, for the Golub Capital investment and strategic partnership; AlleyWatch daily funding report of September 29. Rated HIGH.

Destro AI, $8.0M Seed. AlleyWatch daily funding report of September 30; Tech Startups funding report of September 30. Rated HIGH.

ai3Bio, $48.0M Series A. FinSMEs, September 29; Startup Researcher; Fierce Biotech; Fundz. Rated HIGH.

doxx.net, $38.0M Series A. SaasRise deal record of October 2, 2026; FinSMEs; CB Insights company profile for the Miami headquarters. Rated MEDIUM.

Biotia, $9.0M. AlleyWatch daily funding report of October 1 and AlleyWatch feature; FinSMEs, October 1. Prior investors from the August 2022 Series A release, read through HIT Consultant and Patsnap Synapse. New York State Department of Health approval of the BIOTIA-ID urine assay from Clinical Lab Products, corroborated by YesPress. Rated HIGH.

Daptic, $15.0M Series A. AlleyWatch daily funding report of October 1; FinSMEs, October 1. Rated HIGH.

Elio Mortgage, $5.1M Pre-seed. FF News, September 29, 2026; AlleyWatch daily funding report of September 29; FinSMEs, September 29; The SaaS News; Startup Researcher; National Mortgage Professional. Co-led by Motive Partners and Social Leverage, with Insight Partners co-founder Jeff Horing as an angel. Rated HIGH.

Market Comparison Sources

Contrast set: Crunchbase News ranking of the ten largest US rounds for September 26 to October 2, 2026, totaling $2,863.5M: Instinct ($1B), EliseAI ($350M), Armadin ($255.5M), Kahua ($250M), GMI Cloud ($223M plus $445M in debt), General Intuition ($220M), SiMa.ai ($150M), Supabase ($150M), CScale ($145M) and Homeward ($120M plus $330M in debt). Candidate sources: AlleyWatch daily funding reports for September 29 to October 2; FinSMEs USA listings for September 28 to October 2; Tech Startups funding reports for September 30 and October 1; VC News Daily funding records; startups.gallery funding feed; Fierce Biotech fundraising tracker for 2026. We used aggregator listings to find candidates and never treated them as sufficient on their own.

Prior periods. September 21 to 27: eighteen rounds totaling $661.7M, of which seventeen totaling $655.0M sat in the $10M to $100M band at an average of $38.53M and a median of $26.0M; Series A at $34.44M across eight rounds and Series B at $56.50M across four; healthcare 22.2% and California 56.5% of capital; mean score 56.7; returning-investor gap 11.6; checkpoint gap 11.0 with a residual of 5.4; eight of eighteen rounds with a returning investor. September 14 to 20: twenty-two rounds in the band totaling $837.5M at an average of $38.07M; mean score 51.4; Series A at $28.33M across nine rounds and Series B at $43.43M across seven; twelve of twenty-five rounds with a returning investor and a gap of 6.8; California 52.6% of capital. September 7 to 13: twenty-one rounds in the band totaling $769.0M at an average of $36.62M; fourteen Series A rounds at $30.14M and two Series B rounds at $55.00M; sixteen of twenty-four rounds with a returning investor and a gap of 17.6; thirteen of twenty-four rounds carried strategic capital; California 51.8% of capital.

Verification Notes

Fourteen of the fifteen rounds are rated HIGH source confidence, meaning each was confirmed by a company, investor or regulated newswire source plus at least one independent outlet with no unresolved conflict affecting the counted amount, the stage or the inclusion decision. One is rated MEDIUM: doxx.net, because its Miami headquarters rests on a single company profile and no founder is named in the sources reviewed.

Recorded source conflicts, not resolved by assertion. Atomic: an SEC filing cited by Tech Funding News shows $18.5M sold against the announced $12.5M; $12.5M is counted. Efficient Computer: Reuters first reported $100M and corrected the figure to $97M; the company states more than $97M, and $97.0M is counted. Flow Engineering: TechCrunch and VC News Daily list the company in San Francisco, while a Dealroom profile lists London and Los Angeles. Hop Aero: headquarters is reported as Orange, California and as Los Angeles. ai3Bio: Fierce Biotech’s coverage describes the pipeline’s mechanism differently from the company’s release, so this report describes the company only as autoimmune-focused. Link Cell Therapies: the release lists the full upsized Series A syndicate without allocating the $30M expansion among investors.

Changes from the second verification pass. Elio Mortgage: the first pass recorded no investors; four outlets confirm a pre-seed co-led by Motive Partners and Social Leverage, and two confirm the company operates as a licensed mortgage brokerage. Its score moves from 22 to 40 and its confidence from MEDIUM to HIGH. Biotia: the first pass missed New York State Department of Health approval of its urine assay and the return of investors from its 2022 Series A; its score moves from 36 to 46 and it joins the returning-investor group. TriGemX Bio: The Column Group is described as one of the company’s 2015 founding investors rather than as its founder. Link Cell Therapies: The release states that clinical dosing has begun, replacing earlier wording about a first patient dosed. Together, these moved the returning-investor gap from 20.5 to 15.7, the checkpoint gap from 19.8 to 8.3 with a residual of 0.5, the mean from 48.2 to 50.1, and the floor from 22 to 33. Shift 3: the playbook and the bottom line were rewritten to match.

Deals Analyzed and Excluded, With Rationale

Deals analyzed: 15 verified US mid-market rounds of new primary capital between $5M and $100M.

Giant rounds, rounds above the ceiling and non-venture financings, excluded by editorial scope: the ten Crunchbase contrast-set rounds above, plus Varda ($251M), PaleBlueDot AI ($200M), Quartermaster ($140M in Series B and debt), Hertha Metals ($133.65M Series A, including a $65M equity investment from the US government), Jeeves ($110M), NexBank Capital ($150M in non-voting common stock) and NorthStar Medical Technologies (a growth capital facility of up to $185M).

Non-US rounds, excluded for scorecard comparability. Metaview ($60M Series C) is the closest call: VC News Daily lists a San Francisco address, while the company’s 2025 financing was reported with a London headquarters and it operates hubs in both cities. Reco ($55M) is listed by FinSMEs in Altamonte Springs, Florida, while other coverage describes an Israeli startup, and its stage is reported as both a Series B extension and a Series C. The same treatment applied to Cymphony and AIR Security in earlier issues applies here. Also excluded: Breye Therapeutics (Denmark), AnaCardio (Sweden), Rayon (France), IPercept Technology (Sweden), Osavul (Luxembourg), Foundational (United Kingdom), Deepslate (Germany), Zenithon (United Kingdom), Gravity (India), Arivihan (India), Simple Energy (India), Seeds Fincap (India), Rig Security (Israel), Promenaut (United Kingdom), Heartbeats (Japan), OSCP (Canada, amount not stated, closed in August), Blue Health Intelligence (Netherlands) and syte (Germany).

Outside the date window: Chamelio ($26M Series A, scored in the September 27 issue and recirculated on October 1), Solcoa Industries ($75M seed) and Ando ($20M seed), both dated September 24 by their sources.

Structural exclusions. ArkeaBio: AgFunderNews reports a $15M Series A2 and FinSMEs a $7M Series A1, and a $7M first close was reported earlier, so we can't isolate new capital in the window. Kairos Power: a binding term sheet for a $100M strategic investment from Samsung C&T, not a closed round. Myriad360: a majority investment by One Equity Partners with no amount stated.

Single aggregator source, excluded until a second source confirms: Parakeet Health ($10M Series A), Rivet by MeantToBe ($10.5M seed), Presto Phoenix ($10M), AI Hospitality Group ($7.5M seed), RemoteThreat ($7M pre-seed) and HiringCafe ($6.8M pre-seed).

Below the $5M floor: Walapay ($4.6M), Tangent Robotics ($4.5M), Photon ($4.5M), Overlord Labs ($4.35M seed extension), SedMed ($4M), Mona ($3.5M) and Augmeta ($3M).

Deals excluded: 17 giant, above-ceiling or non-venture financings, 20 non-US rounds, 3 outside the date window, 3 on structure, 6 single-source and 7 below the floor.

Research Completion Timestamp

October 4, 2026, after the adversarial verification pass and a full recomputation of every total, average, median, subtotal, percentage and chart value.

DISCLAIMER: This article is for informational and strategic intelligence purposes only. It does not constitute investment advice. The Eisen Fundability Score is a proprietary diagnostic within Fundables OS™, not a financial recommendation.

If this article was useful, share it with founders who are about to raise.

— Leon Eisen, 4x Founder, Venture Capitalist, and Creator of Fundables OS™

You worked harder this quarter than last quarter.

Read more

In 2019, I had everything a pitch deck should have.

FDA clearance. Clinical validation. A patent portfolio. A wearable medical device company signing five new healthcare providers every month in an exploding remote patient monitoring market.

I sent the deck to dozens of investors over six months. Every deck was packed with clinical data, market projections, unit economics, and technical specifications. I assumed more data would create more interest. It had worked for me before.

It did not work. Meeting after meeting went nowhere. Conversations started warm and cooled by the following week. Competitors with weaker metrics and inferior technology raised millions while we burned runway. By the end of the year, we had laid off half the company, including engineers we had spent months recruiting.

The company was not the problem. The data was not the problem. I was speaking to the wrong brain.

That year taught me the most expensive lesson of my career. Fundraising is not a rational contest where the best company wins. It is a human decision made by people who are worried about their reputation, their partners, and their next fund. The founders who understand that raise faster, at better prices, from better partners. The founders who don’t keep polishing the deck.

If you are raising now, you know the sound of this. “Interesting.” “Keep us posted.” “Come back with more traction.” “We need a lead.” Then silence. You have a product. You have customers. Twenty meetings in, nobody is moving, and you are starting to wonder whether you just need more intros.

You don’t need more intros. Investors can’t fund what hasn’t been made fundable. Between your company and the money sits a layer most founders never see: Fundability. The rules that build it are what I call the Invisible Game.

In physics, the force that shapes the universe is invisible. Nothing pushes a planet around the sun. Nothing touches it. Mass bends the space around it, and everything nearby falls into orbit. We call that invisible force gravity.

Fundraising works the same way. Founders who close competing term sheets aren't pushing harder than everyone else. They have built mass: authority, proof, momentum, insiders who keep coming back. Capital bends toward them. The visible game is pushing. The invisible game is building gravity.

That is the goal of everything that follows. Not a better pitch. More gravity.

This post is the map. If you read one thing on Fundable Notes, read this.

Two Games, Same Market

Two ways to raise a round.

The Visible Game: more proof, more clinical data, more market projections, more unit economics, more technical detail.

The Invisible Game is a decision mechanism underneath: psychology, fundability, tonality, wording, momentum and charisma.

Here is the difference in practice. In my book, Invisible Game: The Secrets of the Term Sheet Magnet, I use a composite of two founders I see all the time. Both run B2B software platforms serving mid-market customers. Both sit at roughly $2M in annual recurring revenue. Both are raising a Series A to scale sales.

The first founder collects her thirteenth rejection in six months. Every one follows the same arc: a warm first meeting, sharp questions, genuine excitement, then a two-line email after the Monday partner meeting. She tells investors how badly she needs the money and how little runway is left. She thinks that creates urgency. It creates fear.

The second founder is juggling three term sheets. He is not pitching. He is running what he calls a selection process. He frames the round as capital to accelerate, not capital to survive. He mentions his path to profitability and a committed credit line. Four top-tier funds are evaluating him in the same two-week window, and each knows it.

Same market. Same traction. The second founder closes at roughly double the first founder’s best offer, within thirty days.

Then the first founder rebuilds her approach. Same business, same numbers. New positioning, new process, new sequencing. Her second attempt produces four term sheets, including two from funds that had already passed on her.

The business did not change. The system did.

That is the entire thesis of the Invisible Game. Most fundable companies fail to raise not because they lack potential, but because they misread how investment decisions are actually made. They optimize the wrong metrics. They tell stories that don’t move money. They hand control of the process to the investor. They react to feedback instead of shaping it.

The operating system has four layers. Here they are.

Layer 1: Investor Psychology

Three brains, one decision

Every investor decision passes through three systems, in a fixed order.

The Emotional Brain, roughly 50% of the decision. It fires first. Within the first thirty seconds of a meeting, it runs what VCs privately call the ten-year test: could I work with this person for the next decade? It responds to energy, trust and story. It rewards passion without desperation, confidence without arrogance, vision without delusion. When it engages, the investor starts rooting for you. When it doesn’t, your best retention number becomes one more data point to cross-examine.

The Social Brain, roughly 30%. It asks a completely different question: will this deal make me look smart to my partners, my LPs and my peers? It is why a single marquee customer can outweigh pages of metrics. It is why competition between funds triggers bidding wars that defy the model. It reads authority signals, and it worries more about missing the next breakout company than about quietly backing a failure.

The Rational Brain, roughly 20%. It loves your cohort analysis and your payback period. It is the brain investors believe is in charge. It gets a fifth of the vote, and by the time it starts working, the real decision has usually been made. Its job is to justify what the other two already concluded.

Treat the percentages as a weighting model, not a brain scan. The point is the order. Emotional first, social second, rational last. Most founders build their entire raise for the last one.

Five levers that move all three

1. Authority Signals. Humans use shortcuts to make complex decisions fast. In venture, the most powerful one is authority: if a respected party validated this, it must be good. That is why one marquee logo in your ideal customer profile can move an investment committee more than a perfect model. Rank what you have. Tier 1 is marquee customers, recognizable executives as investors or advisors, and government or regulatory validation. Tier 2 is university partnerships, patents, and serious technical publications. Tier 3 is certifications and partnership announcements. The same heuristic that let Theranos borrow credibility from a board of former cabinet secretaries works honestly for you when the authority is real and relevant.

2. BATNA. Your Best Alternative to a Negotiated Agreement. Losses hurt roughly twice as much as equivalent gains feel good, and that asymmetry is the most reliable force in a negotiation. When an investor believes you have real options, such as extended runway, venture debt, revenue-based financing, customer prepayments or a strategic investor, their loss aversion activates. They stop evaluating whether to take the deal and start worrying about losing it. When you signal need, you activate their risk aversion instead. “We are raising to accelerate market capture” and “we need funding to survive” can describe the same company. They produce opposite outcomes.

3. Consistency. Once a person commits to a position, even a small one, they defend it. Every investor relationship climbs a ladder of micro-commitments. The partner asks for updates. Then asks detailed questions. Then they introduce you to a portfolio company, a public signal. Then brings in a colleague. Then presents you to the investment committee, with their reputation now on the line. Then drafts the term sheet. Each rung raises the psychological cost of saying no. Elite founders design that ladder deliberately.

4. Parallel Process. When an investor knows other quality funds are evaluating you at the same time, four things fire at once: social validation, scarcity pressure, competitive curiosity about what the others see, and fear of missing the company of the year. A parallel process also removes the Social Brain’s biggest fear: being the only one who backed you.

5. Seven Touches. Trust rarely forms in one meeting. Most people need around seven meaningful exposures to move from awareness to conviction. First meeting. Follow-up materials. Customer reference call. Team and product. Market and competition. Terms and partnership vision. Investment committee. Amateurs spread those over six months. Elite founders compress them into three to four weeks by giving each touch a real reason to exist.

The partner is not your decision maker

This is the mistake almost every founder makes. The partner across the table does not decide. The investment committee does. The partner is your internal salesperson, and their real question is not whether you are a good company. It is whether they can win the internal debate without looking naive, and how much of their limited political capital they should spend on you.

So stop trying to convince the partner. Equip them. Pre-empt the objections they will face in the room you are not in. Give them shareable evidence. Make references available within 48 hours. Arm them with the competitive picture that supports their thesis.

And understand how committees behave. The first valuation mentioned becomes the anchor for everything after it. Committees prefer consensus to controversy and will pass on a great company rather than split the partnership. One strong champion can carry several lukewarm partners, but one determined opponent kills a deal whose champion is weak. Build one real champion. Neutralize the likely opponent. Introduce your valuation logic early, before someone else anchors it.

Layer 2: The 5Ps of Fundability

After studying hundreds of fundraising processes, five forces kept appearing in every round that produced competing term sheets. They became the Fundables OS™, and each carries a different weight. The weights are the part founders find shocking.

Process outweighs Proof. Read that again, because it breaks the most common belief in startups: that great companies raise themselves. They don’t. Great companies with poor process routinely stall, and average companies with superior process routinely close.

The forces compound

The 5Ps do not add. They multiply.

Proof × Positioning = Inevitability. Strong numbers with a weak story create interest without urgency. A great story with weak numbers creates excitement without confidence. Together they create the one feeling that moves capital: this company is going to win with or without me. That feeling changes the investor’s question from “should we invest” to “how do we get our allocation.”

Process × Packaging = Authority. Process control with sloppy materials looks amateur. Beautiful materials with no process control means the investor runs your timeline. Together they signal a founder who can execute.

Positioning × Process = Momentum. A great story without process fades as the timeline drifts. A tight process without a great story is efficient and cold. Together, they produce visible momentum that pulls in more investors on its own.

Founders who score 75 or above on the Eisen Fundability Score share one pattern. They are strong on at least four of the five forces, and Process is their defining strength.

Score yourself in five minutes: the Offer Power Index

The 5Ps tell you what to build. The Offer Power Index tells you whether your raise is actually ready to create competition. Score each item: 1 for yes, 0.5 for in progress, 0 for no.

1. Two or more serious lead candidates engaged inside the same 10-day window.

2. Weekly investor updates running, with a close deadline you have communicated.

3. 20 to 40% of the round soft-circled from insiders and angels before you open.

4. Three to five customer references ready to schedule within 48 hours.

5. Runway or alternative capital to cover 8 to 12 weeks of negotiation.

6. Valuation logic built on comparables, inside the presentation.

7. Your stance on board composition and option pool stated explicitly.

8. A tiered lead list with named partners and the recent deals each one led.

9. Your external milestones timed to land inside the close window.

10. Counsel on the calendar for 48- to 72-hour redlines.

Above 8, you are positioned for a premium outcome. Below 5, expect a long timeline and worse terms, regardless of how good the business is.

The market keeps proving it

I don’t ask you to take any of this on faith. Every Sunday, Fundable Notes publishes the weekly VC Market Intelligence Report and Playbook. It covers only the part of the market that prices your round: US mid-market rounds between $5M and $100M, no mega-rounds, no public market noise. We verify every deal against at least two independent sources across three passes, and we score every round on the Eisen Fundability Score.

The Invisible Game shows up in the data week after week. As an example, here is what the September 7 to 13 issue found across 24 verified rounds.

Consistency, measured. Sixteen of 24 rounds had at least one investor from a prior round writing again. Those sixteen averaged 61.7. The eight without a returning investor averaged 44.1. That is a 17.6-point gap, and 16.2 points of it survive after removing the sub-dimension that scores insider support directly. The people who watched you for twelve months are the only investors pricing information no diligence process can reproduce. That is the consistency ladder, fully climbed, and it is why item 3 on the Offer Power Index exists.

Authority, measured. Thirteen of 24 rounds carried strategic, corporate, or customer-side capital, moving 61.6% of the week’s money. One construction software company raised $12M with a general contractor’s venture arm on the cap table while that same contractor was a named customer. The investor was the buyer. It outscored rounds five times its size. That is the Social Brain at work: every other general contractor in the pipeline no longer has to be first.

External validation, measured. Five rounds carried a checkpoint controlled by an outside body: a regulatory clearance, a government contract vehicle, licenses granted by regulators. They averaged 65.4 against 53.3 for everyone else. Tier 1 authority signals, priced in real time.

BATNA, measured. Mid-market capital fell 16.8% that week, and deal count fell 16.0%. The median round rose 7.7%. Founders who read the headline and cut their ask handed back dilution to a market that didn't cut anything. The market got smaller, not cheaper. Knowing the difference is leverage.

The book explains the mechanics. The Sunday report measures them. Together they tell you what to change in your raise this week.

Layer 3: The Workflow

Psychology and the 5Ps tell you what matters. The workflow tells you what to do, in what order. Thirteen steps, from invisible to inevitable.

1. Investor Intelligence System. Four layers: fund, partner, deal, network. Partner-level intelligence matters more than fund-level, because individual decision-makers bring their own history, biases, and motivations. Roughly half the intelligence that actually changes outcomes comes from your network, not from public research.

2. Positioning and Why Now. A one-line narrative someone can repeat in a partner meeting you are not in. A why now built on a specific shift, not a trend.

3. Authority Signals. Assemble them before outreach. Logos, advisors, validations.

4. Target Investor List. Stage fit, thesis fit, a named partner, a warm path. No brand-only names.

5. First Meetings. Create curiosity. Surface the risks yourself. Never oversell.

6. Champion Development. Equip one partner to win the internal debate.

7. Weekly Updates. A fixed rhythm. One specific ask per update. Each one a rung on the consistency ladder.

8. Proof Drops. Release customer wins, references, and milestones across the process, not dumped in week one.

9. Parallel Process. Multiple live conversations on one shared timeline.

10. Social Proof and FOMO. Other funds engaged, real scarcity, real urgency.

11. IC Decision Window. Your champion sells internally, consensus forms, the deal moves to a term sheet.

12. Multiple Term Sheets. Competing offers, cleaner terms, better price.

13. Founder Becomes Selector. You choose the right partner. You stop chasing capital.

Twelve weeks, four phases: the DEAL Sprint

Most founders raise over six to eight months and lose momentum in month three. The DEAL Sprint compresses the workflow into twelve focused weeks.

Design scarcity into the round itself

Real FOMO is structural. It is built into how the round is designed, not performed in meetings. Compare two sentences.

The amateur: “We’re raising $2M to $3M for our Series A. We’d love to have you participate.”

The professional: “We’re raising $3M. $2M is allocated to our lead strategic partner, $750K to operators with customer networks, and $250K is reserved for our existing angels. We expect to be oversubscribed, and we’re selecting for strategic fit.”

Same company. Same money. The first sounds like hope. The second sounds like a partnership investors should compete to join.

One rule holds everything together: authentic scarcity beats artificial pressure every time. Running out of money never creates urgency. It creates desperation. A deadline with no business reason behind it reads as a tactic. Claiming other investors you don’t have is lying, and sophisticated investors spot it immediately. Urgency works when it comes from real product launches, real customer commitments, and real competitive timing.

Layer 4: The Conviction Loop

Every objection is information. Most founders treat it as rejection.

The Conviction Loop turns it into the next touch. An investor objects. You identify the missing proof behind the objection. You go get new evidence. You send it in your next update. New evidence creates stronger conviction, and stronger conviction creates a better next conversation. Run the loop three times, and the objection that nearly killed the deal becomes the reason the partner believes.

For objections in the room, use PIVOT.

Pause. A deliberate beat. It signals control, not hesitation.

Identify. Find the real concern under the surface question.

Validate. Acknowledge that the concern is legitimate. Respect is not surrender.

Offer. Give your view with evidence and reasoning, calmly.

Turn. Bring it back to your core advantage. That is the move from answering to leading.

A founder asked about competing with a giant does not defend. They widen the frame: the giant’s size is exactly why it cannot move fast enough on the specific workflow this company owns. The objection becomes the opportunity.

Three Levels of Fundraising

Every founder sits at one of three levels.

Level 1, product-focused. “Our product is great, investors should want it.” Features, technology, market size. Success depends on finding investors who get it instantly. Most first-time founders start here.

Level 2, metrics-focused. “Our traction proves we deserve investment.” Growth rates, unit economics, polished materials. Competent. This is where most founders plateau.

Level 3, psychology-focused. “We engineer the conditions where investors compete for allocation.” Process control, positioning, competitive dynamics. This is where elite founders operate, and the advantage compounds across every future round, because investors who experience a professional process become the advocates for your next one.

The jump from Level 2 to Level 3 does not require a better company. It requires a different operating system.

Do It Now

1. Call your existing investors first. Ask each one with a board seat or a meaningful position for a specific number in writing, and a yes or no on whether they would lead. Do it four weeks before you open. If they won’t re-up, you want to learn that now, from people who already take your calls.

2. Score your Offer Power Index. Ten questions, five minutes. Circle your two lowest items. Those are your next two weeks.

3. Rewrite how you describe the raise. Delete every sentence built on need. Replace it with what the capital accelerates and which alternatives you already have.

4. Map your champion’s battlefield. Write down the three objections your target partner will face in their committee. Build one piece of shareable evidence for each, before your first meeting.

What You Get When You Subscribe

Fundable Notes publishes three times a week.

Sunday: The Fundability Report. Every verified US mid-market round of the week, scored on the Eisen Fundability Score, with the market shifts that actually changed and exactly what to do about them in your raise. No news recap. A founder operating brief. Always free.

Wednesday: The Deep Dive. One fundrisisng framework, one deal pattern or one chapter of the Invisible Game taken apart in full. Alternates between free and paid.

Friday: The Strategy Essay. The thinking behind the system.

It is written for Seed to Series A founders raising in the next twelve months, and for angels and operators who want to see how the other side of the table reads a round.

Who Is Writing This

I’m Leon Eisen. I have been on both sides of the table.

I am a 4x founder. I founded Oxitone Medical, invented the first FDA-cleared wrist-worn pulse oximeter, and raised more than $20M for it, including the 2019 raise that taught me everything in this post the hard way. I hold a PhD in physics from the Weizmann Institute, which is probably why I see fundraising as a system of forces rather than a series of lucky meetings.

Today I am a Venture Partner at NetworkVC, where I read funding decisions from the investor’s chair, and President of Venture Growth Group, a venture studio. I built Fundables OS™ to help founders engineer fundability, investor access and round execution. Teams I have worked with have raised more than $100M. I host the Venture Growth Show, and I wrote Invisible Game: The Secrets of Term Sheet Magnet, the complete operating system behind everything above.

The Choice

You can keep playing the visible game. Perfect the deck. Send it wider. Wait for the investor who finally gets it.

Or you can learn the rules the best-funded founders already play by, and build the gravity that pulls investors into your orbit.

The invisible game stays invisible only to founders who choose not to look. Every Sunday, I’ll show you where it moved.

If this was useful, share it with a founder who is about to raise.

- Leon Eisen, 4x Founder, Venture Capitalist, and Creator of Fundables OS™

Playbook, Perspective and Pattern for founders raising now. This report strips out giant rounds and public market traffic so you can read the part of the market that actually prices your round. Every figure below was verified against at least two independent sources and rechecked in two further passes: the first adversarial and focused on date windows, amount composition, headquarters, and lead designation; the second on every claim resting on a single source.

Opening

The mid-market got shorter and thinner that week. In a like-for-like $10M to $100M band, seventeen verified rounds moved $655.0M against twenty-two rounds and $837.5M a week earlier. Capital fell 21.8%. Deal count fell 22.7%. The average check held at $38.53M, up 1.2%, but that number hides the week: the median fell 32.5%, from $38.5M to $26.0M.

The average held because five rounds of $55M or more took 56.0% of the band’s capital, and each brought back an investor from the prior round. The other twelve cleared at a median of $25.0M. The market did not reprice uniformly. It split, and the split ran along one line: whether somebody who had already underwritten the company was willing to write again, and larger.

The quality signal ran the other way from the money. The mean Eisen Fundability Score rose to 56.7 from 51.4 on the same rubric. Only two rounds cleared 65, and they share one feature no press release can manufacture: a regulator had already said yes. One carries an FDA authorization and acceptance from five national insurers. The other is dosing patients in a Phase 1 trial.

Consequence for Monday. If your round sits in the middle of the ladder, you are negotiating against a median check that just lost a third of its size, while the partners writing large checks are writing them to companies with an outside fact attached. The five rounds carrying an externally controlled checkpoint averaged 64.6 against 53.6 for the rest. Before you set a number this quarter, name the one fact about your company that someone outside your company has already confirmed. If you cannot, that is the work, and it comes before the deck.

The Week in One Sentence

Primary insight. Mid-market capital and deal count both fell by more than a fifth, while the average check held flat on the strength of five insider-backed large rounds, and the best-performing rounds carried a checkpoint controlled by a regulator, an auditor, or a federal agency.

Total tracked mid-market capital, 18 verified rounds: $661.7M in new primary capital, every deal between $5M and $100M, every company US-headquartered, every announcement dated September 21 to 25, 2026.

Like-for-like against the prior issue: $655.0M across 17 rounds in the $10M to $100M band, against $837.5M across 22 rounds. Capital down 21.8%, deal count down 22.7%.

Average round size: $36.76M across the full set. On a like-for-like basis, $38.53M against $38.07M, up 1.2%.

Median round size: $25.5M across the full set. On a like-for-like basis, $26.0M against $38.5M, down 32.5%.

Largest tracked round: Go.AI, an $85.0M Series A in on-premises AI infrastructure for regulated institutions. Smallest: Dextr AI, a $6.7M seed in hospitality AI agents.

Rounds with a designated lead investor: 17 of 18, or 94.4%, against 21 of 25, or 84.0%, last week. Atum is the only round whose company announcement designates no lead.

Rounds carrying strategic, corporate, or customer-side capital: 5 of 18, or 27.8%, moving $161.5M or 24.4% of capital, against 7 of 25, or 28.0%, last week. BigHat Biosciences, Ramona Optics, Chamelio, Atum and Teal Health.

Rounds with at least one prior investor returning: 8 of 18, or 44.4%, against 12 of 25, or 48.0%, last week. Those eight averaged 63.1 against 51.5 for the ten without, a gap of 11.6 against 6.8 a week earlier.

Highest Eisen Fundability Score: Teal Health at 77, the first score above 75 since the v2 rubrics began. Lowest: PicoJool at 43. A 34-point band, with 2 of 18 rounds clearing 65 and a mean of 56.7 vs. 51.4 last week.

Defining structural feature: a barbell inside the band. Five rounds of $55M or more took 56.0% of like-for-like capital, and all five carried a returning investor. Of the twelve rounds below that line, three did.

Framework note: this is the third issue on the v2 rubrics. Scores compare directly with the September 13 and September 20 issues and with no issue before them. Capital, deal count, check size, stage, sector, geography, and investor behavior remain comparable across the full series.

The Deal Scorecard

Eisen Fundability Scores are calculated across five weighted dimensions: Founder-Investor Dynamics (30), Traction to Conviction Conversion (25), Narrative Power (20), Deal Architecture (20) and Capital Planning (5). Scores of 90 and above signal an inevitable, market-defining outcome. Scores of 85 to 89 signal extremely strong execution. Scores of 75 to 84 signal solid fundamentals. Scores of 65 to 74 signal a good company with some gaps. Below 65 signals early-stage or structurally incomplete. Traction to Conviction measures only what third parties have already underwritten.

What the Scorecard Says at a Glance

The top of the band is a regulator story. Teal Health at 77 scored 10 of 10 on Independent Validation: an FDA authorization for its self-collection device, a body of peer-reviewed papers and presentations, and insurance acceptance from Aetna, Anthem, Cigna, Blue Cross Blue Shield and UnitedHealthcare. BigHat Biosciences at 74 scored 21 of 25 on Traction to Conviction, the highest mark on that dimension this week, because its lead antibody-drug conjugate is dosing patients in a Phase 1/2 study while Amgen Ventures, Eli Lilly and the Merck Global Health Innovation Fund sit on the cap table as returning investors. Last week’s best round scored 69. This week two rounds beat it, and both did it on facts a regulator owns.

The strongest single position in the issue costs $22M. Teal is the thirteenth largest round of eighteen and it finished first, with the highest Narrative Power mark at 19 of 20 and the joint highest Deal Architecture mark at 17 of 20. The round was sized to arrive ahead of a coverage requirement with a published start date, which is the most precisely constructed raise in the set.

The most expensive lesson costs $85M and sits at 60. Go.AI raised the week's largest round, holds two audited certifications that earned 8 of 10 on Independent Validation, and scored 0 of 7 on Market Adoption because no source named a customer. Auditors confirmed the controls. Nobody outside the company confirmed the buyers. A Series A seventeen times the size of a seed closed ten months earlier needs both.

The floor is a formation and solo-investor story. PicoJool at 43 announced its seed lead as prior backing, but that lead did not appear in the Series A and carries no external validation. Corridor at 44 is a formation round with no counterparty in the record. Baselayer at 46 has no returning investor identified, and the company reports headquarters in New York while Crunchbase lists San Francisco. The four formation rounds averaged 48.5, compared with 59.0 for the other fourteen.

Size and score remain uncorrelated for a sixth consecutive issue. Teal Health at $22.0M outscored Go.AI at $85.0M by seventeen points. Trebellar at $18.0M outscored Baselayer at $35.0M by fifteen. Chamelio at $26.0M outscored Ema at $77.0M by one point and Go.AI by three. If you calibrate your ask against the week’s largest rounds, you calibrate against a variable that predicts nothing.

What Changed This Week: Five Market Shifts

Each shift is verified against multiple sources and ranked by structural impact on founder fundraising, not by deal size. Every shift ends with what it means for your raise next week.

The Median Round Lost a Third

Pattern, what happened. On a like-for-like basis, capital fell 21.8% to $655.0M and deal count fell 22.7% to seventeen rounds. The average check rose 1.2% to $38.53M, the highest in six issues. The median fell 32.5%, from $38.5M to $26.0M. Five rounds of $55M or more- Go.AI, Ema, Firecrawl, BigHat Biosciences, and Confido- took $367.0M, or 56.0% of the band, and the other twelve cleared at a median of $25.0M.

Perspective, what it means. This is two markets sharing one headline. The large checks went exclusively to companies whose prior investors came back: all five rounds above $55M carried a returning investor, against three of the twelve below that line. A partner writing a $75M check this week was not pricing a pitch. The partner was pricing an insider’s decision, made with a year or more of board-level information, to write again. Everyone without that decision was priced on the median.

Founder Blindspot, what most miss. Founders read the average and anchor on $38M. The average is five companies whose last investors re-upped. For a round without that commitment, the honest comparable is $25.0M, and an ask anchored on the average opens a process that spends its first month being repriced.

Playbook, what to do. Write two numbers before you open. The first is the round you can defend if your existing lead re-ups at or above pro rata. The second is the round you can defend if nobody on your cap table writes again. If you do not hold the insider commitment in writing, the second number is your number.

Contrast. Last week capital rose 8.9% and the median rose 10.0%. The week of September 7, capital and deal count fell together while the check held. This week the count fell and the typical check fell with it. Only the top of the band held its price.

What this means for your raise: The average is a club price. Unless your insiders are writing larger, price to the median.

A Regulator’s Yes Outranked the Round Size

Pattern, what happened. Five rounds carried an externally controlled checkpoint scoring 7 or higher on Independent Validation: Teal Health with an FDA authorization and five named insurers, BigHat Biosciences with a lead program dosing in a Phase 1/2 study, HIFI as a participant in DTCC’s July production trades using tokenized securities, Go.AI with SOC 2 Type II and ISO 27001, and Pilgrim with a CDC biosurveillance agreement. They averaged 64.6 against 53.6 for the other thirteen, a gap of 11.0 that shrinks to 5.4 after removing the sub-dimension from both sides. Both rounds above 65 sit in this group.

Perspective, what it means. A checkpoint compresses diligence into a lookup. In a week with fewer deals and a smaller median check, partners paid for facts somebody else already owns. The ordering inside the group is the more useful signal. Checkpoints that certify the product itself, an FDA authorization and a dosed clinical program, scored 77 and 74. Checkpoints that certify a buyer relationship, a CDC agreement, and a DTCC selection scored 54 and 58. Certifications of process, SOC 2 and ISO 27001, scored 60 on the largest round in the set. Approval of what you sell outranks certification of how you run.

Founder Blindspot, what most miss. Founders treat a compliance certification as equivalent to a regulatory approval. SOC 2 says your controls operate as described. It says nothing about whether the product works or whether anyone buys it. Go.AI holds two audited certifications and still scored 0 of 7 on Market Adoption.

Playbook, what to do. Sort every checkpoint you hold into three columns: product checkpoints (a clearance, an authorization, a registered trial, a published benchmark), buyer checkpoints (a contract vehicle, a payer agreement, a named procurement), and process checkpoints (SOC 2, ISO, HIPAA attestations). Before you raise, hold at least one entry in each of the first two columns. Process certifications are table stakes, not signal.

Contrast. On September 20, the checkpoint gap was 13.7, and all five checkpoint rounds finished in the top ten. This week, two of the five finished outside the top eight, at 54 and 58, because a checkpoint did not rescue a sole-investor round or a thin syndicate.

What this means for your raise: Get the regulator’s yes before the investor’s, and know which kind of yes you hold.

Insiders Came Back, and Came Back Larger

Pattern, what happened. Eight of eighteen rounds carried a returning investor and averaged 63.1 against 51.5, a gap of 11.6 that holds at 10.6 after removing the two-point Insider Support sub-dimension. Last week the gap was 6.8. At Ema, every major existing investor, Accel, S32, and Prosus, increased its position. Footwork and Y Combinator backed Confido for a third consecutive round. Both of Chamelio’s seed co-leads returned within a year. Speed alone did not matter: the five rounds re-underwritten within eighteen months at a larger size averaged 56.4 against 56.8, no gap at all.

Perspective, what it means. An insider re-up is the only signal in an announcement that carries information a new investor cannot buy. A re-up at a larger size is a stronger version of the same signal, because the insider is increasing exposure with information nobody else has. That is why the residual gap survives almost intact once the mechanical component comes out: rounds with returning investors scored higher on founder quality, syndicate construction and round design at the same time.

Founder Blindspot, what most miss. A seed lead named in your release as prior backing, but absent from the new round, reads as a pass. PicoJool’s Series A announcement describes Playground Global’s earlier backing without Playground in the round. A new lead reads that sentence and asks one question, and the round scored 43.

Playbook, what to do. Four weeks before you open, get every lead from your last two rounds to state in writing whether they will take at least pro rata, and whether they would take more than pro rata. If a prior lead declines, keep them out of the announcement’s list of backers for this round and prepare a one-line answer for why.

Contrast. The insider gap was 17.6 on September 13 and fell to 6.8 on September 20 as seven formation rounds with no prior investors entered the set. This week, formation fell back to four rounds, and the gap rebounded to 11.6.

What this means for your raise: Your last investors are the first to get a term sheet. Make the re-up larger than last time, or have an honest reason it isn't.

Series B Got Scarcer, Bigger and Entirely Insider-Backed

Pattern, what happened. Four Series B rounds totaled $226.0M at an average of $56.50M, up 30.1% from seven rounds at $43.43M last week. All four carried a returning investor: Ema, Firecrawl, Confido and Mojave Energy Systems. Across the last two issues, ten of eleven Series B rounds have carried one. Series A produced eight rounds at an average of $34.44M, up 21.6% from $28.33M, but only three carried a returning investor.

Perspective, what it means. Insider continuity has moved from differentiator to entry requirement at Series B. Three of the four cleared at $55M or more, and all three scored 7 of 7 on Market Adoption on named enterprise customers: Unilever at Confido, Shopify and Canva at Firecrawl, NTT Data, ADP and Microsoft at Ema. The fourth, Mojave, is climate hardware at $19.0M with no named customer in the record, and scored 48.

Founder Blindspot, what most miss. Founders see the Series B average rise 30% and raise their ask. The lane that cleared was three enterprise AI platforms with named reference accounts and insiders writing larger. Without both, the relevant comparable is Mojave, not Ema.

Playbook, what to do. If you are inside six months of a Series B, secure two things before the first external meeting: a written re-up from your Series A lead, and three customers who have approved being named in the announcement and whose procurement contacts will take a partner’s call.

Contrast. Last week, Series B reopened to seven rounds at a lower check. This week it narrowed to four at a higher one. The insider condition held in both weeks.

What this means for your raise: A Series B without your last investors in it is not a round this market has cleared in the last two weeks.

Formation Capital Shrank to Credentials and Specialists

Pattern, what happened. Four companies took a first institutional round or came out of stealth: Corridor at $25.0M, Prime Minute at $15.0M, Atum at $13.5M and Dextr AI at $6.7M. Together, they raised $60.2M, or 9.1% of the week’s capital, with an average score of 48.5 against 59.0 for the other fourteen. Last week, seven formation rounds took $232.0M, or 26.9%. Seed and pre-seed rounds above $10M fell from five at an average of $37.20M to three at $21.67M.

Perspective, what it means. Every formation round was led by a thesis specialist and every one rests on a tier-one credential: a former Scale AI product lead at Corridor, the former head of Visa’s crypto product team at Atum, a former Meta executive as Dextr’s chief technology officer, and a team of Palantir and Forterra alumni at Prime Minute. The market is still funding formation. It stopped paying formation prices.

Founder Blindspot, what most miss. Founders read a low formation score as a verdict on the company. It is a statement about what is visible: nobody outside the company has underwritten anything yet. Prime Minute scored highest of the four at 53 because its launch release names a counterparty: the State of Colorado. Corridor, with a stronger lead and no counterparty in the record, scored 44.

Playbook, what to do. Before you come out of stealth, secure one named counterparty willing to appear in the release: a pilot customer, a state or federal agency, a design partner. This week it was a nine-point difference between two formation rounds.

Contrast. On September 20, formation rounds averaged 46.9 against 53.3. The gap widened this week from 6.4 to 10.5 as the non-formation rounds strengthened.

What this means for your raise: If you are raising a first institutional round now, bring a named counterparty and expect the check to be priced near $15M, not near $37M.

The Deals That Matter: Top 5

Five deep dives across at-home cancer screening, AI-designed antibodies, legal AI, enterprise agents and web data for AI agents. These are the week's five highest-scoring rounds. All facts are verified against two or more sources.

Teal Health

At-Home HPV Cervical Cancer Screening | Series A | $22.0M | Led by .406 Ventures

Eisen Fundability Score: 77 / 100

Why this scored. The first round on the v2 rubrics to clear 75, with the highest Narrative Power and Independent Validation marks in the issue. Every one of its strongest facts is owned by somebody else: the FDA, five national insurers, peer reviewers and a federal coverage requirement with a published start date.

The Setup. Teal Health, headquartered in San Francisco and founded in 2020 by Kara Egan and Dr. Avnesh Thakor, makes the Teal Wand, the first FDA-authorized self-collection device for at-home HPV cervical cancer screening. The device pairs with a telehealth visit, secure results delivery and connection to follow-up care. The company accepts insurance from Aetna, Anthem, Cigna, Blue Cross Blue Shield and UnitedHealthcare, and sits on the Cervical Cancer Roundtable, a collaboration between the American Cancer Society and Cancer Moonshot.

The Deal. $22.0M Series A led by .406 Ventures, announced September 22, 2026, with continued backing from Emerson Collective, Forerunner and Serena Ventures and new participation from Japan’s MPower Partners. Fierce Healthcare, Tech Funding News and FutureFemHealth also name Labcorp’s venture fund as a participant; the company release does not, and the conflict is recorded. Total capital: $45M, all equity. The round arrives ahead of broad insurance coverage of self-collected HPV screening beginning in January 2027.

The Pattern. This is the dated-mandate round. The round was sized and timed to land before a coverage requirement with a published start date, so the use of funds and the market’s opening date are the same sentence. A partner can verify the date, the authorization and the payer list without calling the company.

The Perspective. Count how many outside parties did work before this round opened. A regulator reviewed the device. Five insurers agreed to pay for it. Peer reviewers assessed the evidence. A federal guideline set the date the market widens. The investment committee’s job was reduced to confirming facts, which is why a $22M Series A scored 20 of 25 on Traction to Conviction while rounds four times its size scored half that.

The Playbook. Find the dated external event in your market, whether a coverage mandate, a compliance deadline, a standards effective date or a procurement cycle, and time your close to land three to six months ahead of it. Put the date and the body that set it in the first paragraph of your deck and your announcement.

The Founder Mistake to Avoid. Founders with a regulatory approval treat the approval as the story. Teal’s FDA approval date is May 9, 2025, more than a year before this round. What made this round a 77 was converting the approval into payer acceptance and a dated coverage event. An approval with no reimbursement path is a permission, not a market.

BigHat Biosciences

AI-Designed Protein Therapeutics | Series C | $75.0M | Co-led by DFJ Growth and Premji Invest

Eisen Fundability Score: 74 / 100

Why this scored. The highest Traction to Conviction mark in the issue at 21 of 25, because three kinds of outside confirmation stack in one round: a clinical program dosing patients, pharma collaborations, and the same pharma companies’ venture arms returning as investors.

The Setup. BigHat Biosciences, headquartered in San Mateo, California and led by co-founder and chief executive Peyton Greenside, combines AI protein design with autonomous, high-throughput experimentation that generates its own biological data. Lead program BHB810, a CDH17-directed antibody-drug conjugate, is in a Phase 1/2 study in advanced gastric and gastroesophageal junction adenocarcinoma and has dosed its first patient. The Pharma Letter dates the study start to July 2026, and TechEdgeAI to September 2026, and the conflict is noted. Second candidate BHB299, a CEACAM6 T-cell engager, is planned for human trials in 2027. The company’s release cites collaborations with Amgen, Merck, Johnson & Johnson, AbbVie and Lilly, including a completed collaboration with Johnson & Johnson and three project collaborations with Merck.

The Deal. $75.0M Series C co-led by DFJ Growth and Premji Invest, announced September 24, 2026, with new investors Catalio Capital Management, LG Technology Ventures and Sigmas Group, and existing investors 8VC, Alexandria Venture Investments, Amgen Ventures, Andreessen Horowitz, Discovery Ventures, GRIDS Capital, Intermountain Ventures, Eli Lilly and Company, Merck Global Health Innovation Fund, Quadrille Capital and Section 32. Total capital is about $223M, following an $80M Series B in 2022 and a $44M Series B extension in 2025. All equity.

The Pattern. This is the partner-as-shareholder round. The pharma companies are the collaborators buying the platform’s output and they are also on the cap table, returning. The investor who knows the science best is also the investor with the most to lose if the science is wrong, and that alignment is visible from outside.

The Perspective. Two growth-stage co-leads new to the company, with eleven existing investors staying in, tells a new investor the insiders did not merely hold their position: the partners paid twice, once through collaboration and again through equity. Combined with a dosed clinical program, that is the densest external underwriting in the set.

The Playbook. If you sell platform access to large companies, ask each collaboration partner’s venture arm to take a position in your next round, and ask before the partnership renews, when your leverage is highest and the partner’s internal champion is most motivated.

The Founder Mistake to Avoid. Founders read the AI framing as the reason this cleared. BigHat scored only 13 of 20 on Narrative Power because AI protein design is a crowded category. The round cleared on a dosed patient and on pharma money. Copying the framing without the wet-lab data loop and a clinical asset gets you the narrative score without the traction score.

Chamelio

AI-Native Platform for In-House Legal Teams | Series A | $26.0M | Led by Entrée Capital

Eisen Fundability Score: 63 / 100

Why this scored. The joint-highest Founder-Investor Dynamics mark (21 of 30) and the joint-highest Capital Planning mark (4 of 5), with a co-founder with a prior acquisition, both seed co-leads returning, and a re-underwriting within a year at 2.6x the seed.

The Setup. Chamelio is headquartered in New York after being established in Israel. It was founded in 2024 by chief executive Alex Zilberman, formerly vice president of growth and partnerships at Pagaya and a co-founder of AnyVision; chief technology officer Gal Lellouche, who co-founded Task Sheriff, acquired by Sage, and later served as senior director for AI at Sage; and chief operating officer Gil Banyas, a former general counsel. Named customers include Wiz, monday.com, Socure, AppsFlyer, Lightricks and Wonderful.ai.

The Deal. $26.0M Series A led by Entrée Capital, announced September 22, 2026, with existing investors Work-Bench and Emerge Ventures and new investor Bright Pixel Capital, the technology investment arm of Sonae. The seed was $10M in January 2026, co-led by Work-Bench and Emerge. The company describes the interval as five months; Work-Bench’s own post describes eight. Both are recorded. All equity.

The Pattern. This is the fast re-underwriting round. Both seed co-leads returned in a round 2.6 times their own, within a year, and one of them published its reasons publicly within days of the announcement.

The Perspective. A seed lead writing publicly, within days of the announcement, about why it is re-upping, with named customers and a specific account of what it saw during diligence, is a reference call performed in the open. Every future investor reads it before the first meeting. Chamelio is rated MEDIUM on geography: an independent outlet states a single New York headquarters, which distinguishes it from rounds excluded in earlier issues where reporting placed the headquarters across New York and Tel Aviv.

The Playbook. Ask your returning lead to publish its own account of why it wrote again, on announcement day, naming what it saw. It costs nothing and it answers the first question every new investor asks.

The Founder Mistake to Avoid. Founders with a strong team and returning insiders neglect category position. Chamelio scored 10 of 20 on Narrative Power because AI contract management is a crowded category with well-funded incumbents. And when two credible sources disagree on your seed date by three months, a diligence team will ask which one is true. Reconcile your own timeline before your investors describe it.

Ema

Enterprise AI Agent Platform | Series B | $77.0M | Led by Creaegis

Eisen Fundability Score: 62 / 100

Why this scored. The joint highest Founder-Investor Dynamics mark at 21 of 30, on a founder who is a former Google and Coinbase executive, and a round in which every major existing investor wrote a larger check than last time.

The Setup. Ema, based in Mountain View, California, was founded in 2023 by Surojit Chatterjee, a former Google and Coinbase executive, and Souvik Sen, formerly of Okta. It coordinates teams of AI agents that execute multi-step work across HR, IT and finance systems a company already runs. TechCrunch names customers including NTT Data, Hitachi, ADP, PwC, Google, KPMG, Wipro and Microsoft.

The Deal. $77.0M Series B led by Bengaluru-based Creaegis, announced September 23, 2026, with existing investors Accel, S32 and Prosus each increasing its investment. Ema confirmed to TechCrunch that the round is entirely primary equity, with no debt and no secondary sales. Total capital: $140M. The prior round closed in 2024.

The Pattern. This is the insider-escalation round. The existing syndicate did not hold or trim; it increased, and the company stated the structure: all primary, no secondary. That combination tells a new investor that no one took liquidity while insiders added exposure.

The Perspective. The phrase to notice is not the size. It is the structural disclosure. When a company confirms that insiders increased and no shares changed hands on the way out, a diligence team can check it against the cap table in minutes, and it removes the most common suspicion attached to a large later-stage round.

The Playbook. When your insiders increase, say so as a verifiable fact with the structure attached: each existing investor larger, all primary, no secondary. Then make sure the cap table says exactly that.

The Founder Mistake to Avoid. Ema scored 11 of 25 on Traction to Conviction because named customers are the only outside fact in the record. Microsoft and Google appear as customers, and neither appears as a contract vehicle, a certification or a cap table entry. Founders with blue-chip customers rarely convert even one into a structural fact, and that is where the points were.

Firecrawl

Web Data Infrastructure for AI Agents | Series B | $75.0M | Led by Smash Capital

Eisen Fundability Score: 62 / 100

Why this scored. Re-underwritten thirteen months after its Series A at roughly five times the size on the $14.5M Series A figure, with the Series A lead and Y Combinator back, and named adoption at reference-grade customers.

The Setup. Firecrawl, headquartered in San Francisco, turns web pages into structured data that AI agents can use and is launching Alexandria, a library that connects agents to official data providers under paid agreements, Firecrawl’s own indexes and the live web. It was founded by chief executive Caleb Peffer, Eric Ciarla and Nicolas Silberstein Camara, who previously built Mendable and SideGuide, and went through Y Combinator. The company’s website names Apple, Canva and Lovable among its users, and Dealroom and Exame add Shopify. Wikimedia Enterprise is a paid data provider.

The Deal. $75.0M Series B led by Smash Capital, announced September 22, 2026, with Altos Ventures, Nexus Venture Partners, Y Combinator, Freestyle and Offline Ventures. The Series A in August 2025 was led by Nexus and is reported at $14.5M by WOWTALE and RuntimeWire and at $20.7M by Dealroom. A Form D filed by the legal issuer, SideGuide Technologies, reports $82,063,463 of preferred stock sold to seven investors. RuntimeWire first reported the financing from that filing around September 14. A filing alone is not an announcement under this report’s standard, so the company’s September 22 announcement governs; the announced $75.0M is counted, and both differences are recorded.

The Pattern. This is the velocity round: thirteen months from Series A to Series B, a roughly fivefold step in size, with the prior lead returning. It is also a product-launch round, with the financing and Alexandria announced together.

The Perspective. Look at the filing. A Form D larger than the announcement usually reflects converted notes or a second close, and a diligence team will reconcile the two numbers whether or not the company does. Mojave Energy Systems attributed its own Form D gap to converted securities when asked this week. Firecrawl’s reconciliation is not in the record reviewed.

The Playbook. Before you announce, reconcile your announcement to your Form D. If they differ, prepare one sentence explaining why, and have it ready for the first investor who asks.

The Founder Mistake to Avoid. Firecrawl pays Wikimedia Enterprise for data and scored 0 of 8 on Customer-Side Capital. Suppliers and marquee users are both candidates for the cap table. A data provider or a reference customer with a small position would have converted a relationship into a structural fact.

The Fundraising Playbook: Five Tactical Plans

Five plans, each producing a concrete artifact you can use immediately. No vague tasks. Each is built directly from this week’s verified signals.

Lead With the Date Somebody Else Set (Narrative and Investor Framing)

Why this matters. The highest-scoring round of the week, Teal Health at 77, anchored its entire narrative to a coverage requirement with a published start date, and scored 19 of 20 on Narrative Power. Corridor’s launch named the fourth quarter as the window when most small employers choose health plans. The strongest stories this week borrowed their urgency from a party the company does not control.

Exact deliverable. One sentence, no longer than thirty words, that states your category, the dated external event that opens or widens your market, and the body that set the date. Test it on someone outside your industry. If they cannot repeat the date back to you, rewrite it.

Time estimate. Two hours to draft and test. One week to confirm the date against the primary source, whether a regulator’s notice, a standard’s effective date or a published procurement calendar.

Expected outcome. Your deck’s first slide stops arguing that the market is coming and starts citing when it arrives. A partner can verify the claim in a search, which is the fastest conviction you can hand an investment committee.

The reframe. Wrong approach: open with market size and a growth rate you calculated. Right approach: open with the date a regulator, standards body or buyer already fixed, and size the round to land before it.

Get a Product or Buyer Checkpoint, Not Just a Process One (Proof Architecture)

Why this matters. Five rounds carried an externally controlled checkpoint and averaged 64.6 against 53.6, a gap that holds at 5.4 after removing the sub-dimension. Within that group, product checkpoints scored 77 and 74, buyer-relationship checkpoints scored 54 and 58, and process certifications scored 60 in the week's largest round.

Exact deliverable. A three-column inventory: product checkpoints (clearance, authorization, registered trial, published benchmark), buyer checkpoints (contract vehicle, payer agreement, government agreement, named procurement) and process checkpoints (SOC 2, ISO 27001, HIPAA attestation). Mark what you hold. Then write a plan with a named owner and start date to obtain the fastest missing entry in either of the first two columns. The deliverable is a plan to obtain one, not a plan to announce one.

Time estimate. Three hours for the inventory. Two to six months for a buyer checkpoint such as a pilot agreement with a public agency; longer for a regulatory one, which is why the start date belongs in this quarter.

Expected outcome. You enter your next process with at least one fact that a regulator or a buyer owns, and you stop presenting an audit report as evidence that the product works.

The reframe. Wrong approach: treat a completed SOC 2 as your validation story. Right approach: treat SOC 2 as table stakes and go get a checkpoint on the product or the buyer.

Score Yourself Against This Week’s Band (Readiness)

Why this matters. The band ran from 43 to 77 with a mean of 56.7. Two rounds cleared 65. Eight of eighteen sat between 55 and 64, and the eight below 55 share one of two shapes: a formation round with no counterparty in the record, or a round with no returning investor and a thin syndicate.

Exact deliverable. Score your round on the v2 rubrics across Founder-Investor Dynamics (30), Traction to Conviction (25), Narrative Power (20), Deal Architecture (20) and Capital Planning (5). Then apply this week’s test. Above 65, you are in the top two of eighteen, so run a tight competitive process with a deadline. Between 55 and 64, you sit in the crowded middle and will be priced at the $25.0M median unless you fix your lowest dimension first. Below 55, the problem is structural, meaning no returning investor, no counterparty and no checkpoint, and no process design will fix it.

Time estimate. Two to three hours, repeated before every raise and again after any new checkpoint lands.

Expected outcome. A decision about process design rather than a list of weaknesses: compete now, or run a four- to eight-week repair sprint on your two lowest dimensions first.

The reframe. Wrong approach: score yourself, feel discouraged, and revise the deck. Right approach: score yourself, name your two lowest sub-dimensions, and decide this week between a competitive process and a repair sprint.

Put a Larger Insider Re-Up in Writing Before You Open (Deal Architecture)

Why this matters. Eight rounds with a returning investor averaged 63.1 against 51.5, a gap that holds at 10.6 after removing the sub-dimension. All five rounds of $55M or more carried one. Ten of the last eleven Series B rounds carried one. Where a prior lead was mentioned but absent, the round scored 43.

Exact deliverable. Four outputs, in order. First, a written statement from every lead of your last two rounds: whether they will take pro rata, whether they will take more, and whether they would lead if nobody else does. Second, a reconciliation of your planned announcement amount against your Form D, with one sentence explaining any difference. Third, a use of funds split into two columns: outcomes that are genuinely unproven and a predictable cash cycle such as inventory, receivables, or payment float, with the second column totaled and priced against a credit facility. Fourth, pre-drafted positions on information rights and pro rata for any strategic investor.

Time estimate. Two weeks of calendar for the insider conversations, four hours for the Form D reconciliation and the use of funds split.

Expected outcome. You open with a floor under the round, a larger-than-last-time insider signal to quote, a number that matches your filing, and a smaller equity ask if part of your need is financeable.

The reframe. Wrong approach: run the new-money process first and ask insiders to fill the gap. Right approach: get the insiders’ larger number in writing first, and let new money compete for the rest.

Make Every Claim in the Announcement Owned by Someone Else (Momentum and Conversion)

Why this matters. Prime Minute scored 53 and Corridor 44 as formation rounds with comparable leads, and the difference was a named state counterparty in the launch release. Three Series B rounds scored 7 of 7 on Market Adoption because customers were named. Chamelio’s seed lead published its own account of why it re-upped. Momentum this week came from facts third parties put their names to.

Exact deliverable. A one-page announcement plan. List every substantive claim you intend to make. Next to each, name the third party who owns it: the customer who approved being named, the agency or partner in the pilot, the insider willing to explain in writing why they wrote again. Remove or replace any claim without an owner. Then set a fourteen-day follow-up cadence for your process in which each touchpoint delivers one new dated fact from that list.

Time estimate. Four hours to build the list and three to five customer approvals, which typically take one to two weeks to clear legal review.

Expected outcome. Every follow-up carries new, verifiable information, and the investor waiting for proof gets it during the process rather than after the round closes.

The reframe. Wrong approach: announce with adjectives and follow up with enthusiasm. Right approach: announce with owned facts and follow up with the next one.

Looking Forward: Next 1 to 3 Weeks

Three evidence-based scenarios and one wild card. Every projection is anchored to this week’s verified data.

First, last week’s call. The September 20 issue projected that the barbell would hold, with formation rounds and Series B both staying wide, and named four or more Series B rounds as the threshold to watch. Half right. Series B held at exactly four. The formation end thinned, from five seed and pre-seed rounds above $10M to three, at less than two-thirds of the prior average check.

The Barbell Moves Inside the Band (Medium-High Probability)

Evidence from this week. Five rounds of $55M or more took 56.0% of like-for-like capital, while the median fell 32.5% to $26.0M. All five carried a returning investor. The top of the band is priced on insider decisions and the middle on everything else.

What to watch. Whether the like-for-like median stays below $30M while the average stays above $35M for a second week. If it does, the split is structural rather than a one-week mix effect, and every pricing conversation should start from the median.

What founders should do before others notice. Price your round to the median unless you hold a written insider re-up at or above pro rata. If you hold one, lead your process with it and quote it as a floor.

Series B Stays Insider-Only (High Probability)

Evidence from this week. Four of four Series B rounds carried a returning investor, after six of seven a week earlier. Ten of eleven across two issues. The three large ones all named enterprise customers.

What to watch. Whether any Series B without a returning investor clears above a score of 55 in the next two issues. A single one would signal the requirement is loosening. None would confirm it as a market rule.

What founders should do before others notice. If you are inside six months of a Series B, secure your Series A lead’s written re-up and three named, callable customers before your first external meeting.

Dated Coverage and Enrollment Windows Pull Healthcare Rounds Forward (Medium Probability)

Evidence from this week. Two of four healthcare rounds tied their timing to a dated window: Teal Health to broad self-collection coverage beginning January 2027, and Corridor to the fourth quarter, when most small employers choose health plans. Healthcare’s share fell to 22.2% this week, but the rounds that cleared were timed to a calendar someone else controls.

What to watch. Whether healthcare rounds announced in the next three weeks cite a coverage, enrollment or reimbursement date, and whether healthcare’s share rebounds above 25%.

What founders should do before others notice. If your market has a coverage, reimbursement or enrollment date in the next two quarters, close before it, not after it. The same round is a forecast before the date and a lagging indicator after.

Wild Card: Regulated Infrastructure Replaces AI-Native as the Premium Frame (Medium Probability)

Evidence from this week. Four rounds selling into regulated buyers: Go.AI to banks and credit unions, HIFI into tokenized securities settlement, Baselayer to financial institutions, and Pilgrim to the CDC, took $182.0M, or 27.5% of the week’s capital. Each was positioned on examiner readiness, settlement participation, or a government agreement rather than on the model.

What founders should do before others notice. If you sell to a regulated buyer, write down what that buyer’s examiner or auditor will ask about your product and build the answer into your data room now. Readiness for someone else’s inspection is becoming the premium frame, and it is verifiable in a way that the word AI-native is not.

The Bottom Line

The real insight is not the $661.7M. It is that the median check lost a third while the average held, and the rounds that scored highest carried a fact that a regulator, an auditor or a federal agency owns, backed by insiders who came back larger. That produced three conviction profiles.

Profile 1: Companies a regulator or auditor had already said yes to. Teal Health (77) holds an FDA authorization and five named insurers. BigHat Biosciences (74) is dosing patients in a Phase 1/2 study. Go.AI (60) holds SOC 2 Type II and ISO 27001. HIFI (58) took part in DTCC’s July production trades. Pilgrim (54) holds a CDC biosurveillance agreement. Five rounds averaged 64.6 against 53.6, and rankings within the group ran from product approval to process certification.

Profile 2: Companies whose insiders came back, and larger. Every major investor at Ema (62) increased its position. Footwork and Y Combinator backed Confido (59) for a third consecutive round. Both of Chamelio’s (63) seed co-leads returned within a year. Nexus and Y Combinator returned in Firecrawl’s (62) Series B. Eight rounds with a returning investor averaged 63.1 against 51.5, and every round of $55M or more was one of them.

Profile 3: Companies whose named customers do the reference calls. Trebellar (61) named Meta, Uber and Merck. Confido named Unilever. Chamelio named Wiz and monday.com. Seven rounds scored 7 of 7 on Market Adoption and averaged 65.4 against 51.1, the widest measured gap in the issue, holding at 9.1 after the sub-dimension came out.

Everything else competed for the residual. The four formation rounds averaged 48.5, and the floor, PicoJool at 43, Corridor at 44, and Baselayer at 46, share the same shape: no returning investor in the round and no counterparty, checkpoint, or customer named by anyone outside the company. These are real companies funded by credible investors. The score measures how much of the transaction a new investor could confirm without asking; for these three, the answer is the amount and the lead.

Five New Rules for Founders

1. Price to the median unless your insiders are writing larger. The like-for-like median fell 32.5% to $26.0M while the average held at $38.53M, and all five rounds above $55M carried a returning investor.

2. A regulator’s yes outranks an auditor’s. Product checkpoints scored 77 and 74; process certifications scored 60 on the largest round of the week. Hold at least one checkpoint on the product or the buyer before you raise.

3. A Series B now needs your last investors in it. Ten of the last eleven Series B rounds carried a returning investor.

4. Name your customers or lose the points. Seven rounds with named reference accounts averaged 65.4 against 51.1.

5. Come out of stealth with a counterparty in the release. A named state agency was a nine-point difference between two formation rounds this week.

Four Monday Actions

1. Write your two numbers: the round you can defend with a written insider re-up, and the round you can defend without one. Use the second until the first is in writing.

2. Build the three-column checkpoint inventory: product, buyer, and process, and put a start date on the fastest missing product or buyer checkpoint.

3. Ask three customers to approve being named in your next announcement, and send the legal review requests today.

4. Reconcile your planned announcement amount to your Form D, and remove any prior investor from your backer list who is not writing again.

Eighteen companies cleared this week and the typical check lost a third of its size. The two that finished on top had a regulator’s yes, and the five that raised the most had insiders who came back with larger checks. Neither of those facts is luck, and both can be started on Monday: one conversation with the people already on your cap table, and one application to the body whose approval your buyer already trusts.

Research Methodology, Sources and Verification

Data Collection and Verification Standard

Data collection period: September 21 to 27, 2026, with every verified primary announcement dated September 21 to 25. This issue was completed on Saturday, September 26, before the week closed; any round announced on September 26 or 27 will be carried in the next issue. Verification standard: a minimum of two independent sources per deal, with company releases and regulated newswires (BusinessWire, PR Newswire, GlobeNewswire, NewMediaWire) as anchor sources and at least one independent outlet for corroboration. We then rechecked every deal in two further passes. The first was adversarial and directed at four failure modes: announcements dated before the window and recirculated inside it, headline figures that blend more than one financing, headquarters outside the United States, and lead investors named by outlets but not by the company. The second re-checked every fact resting on a single source and every derived figure, and recomputed all arithmetic from the corrected deal record. Eisen Fundability Scores are proprietary analytical estimates, not endorsements or investment advice. All dollar figures reflect announced new primary capital at close unless noted.

Core Capital Totals and What They Include

The $661.7M weekly total includes only the eighteen verified US rounds in the scorecard. Mid-market is defined as a US-headquartered round of new primary capital between $5M and $100M. Every week-over-week comparison is calculated on the $10M to $100M subset used by the three issues before September 13: seventeen rounds totaling $655.0M at an average of $38.53M and a median of $26.0M, against twenty-two rounds totaling $837.5M at an average of $38.07M and a median of $38.5M in the prior issue. The one round below $10M, Dextr AI at $6.7M, is included in the scorecard, the scores and the sector and geography analysis and excluded from all structural comparisons, including every stage average.

Credit facilities, debt financings, secondary purchases, in-kind services, conditional commitments, grants and cumulative restatements are excluded from the counted amount. Announcements that combine two financing stages without separating them are excluded entirely. Arithmetic was recomputed after the adversarial pass. The four sector subtotals ($342.7M enterprise AI and software across seven rounds, $147.0M healthcare and life sciences across four, $86.5M hardware, defense, climate and semiconductors across four, and $85.5M fintech and payments across three) and the six stage subtotals ($275.5M across eight Series A rounds, $226.0M across four Series B rounds, $75.0M in one Series C, $56.7M across three seed rounds, $15.0M in one pre-seed and $13.5M in one round with no stage applied) each sum to $661.7M across eighteen deals. Geography: California $373.7M across eleven rounds (56.5%), New York $178.0M across five (26.9%), Illinois $85.0M in one and North Carolina $25.0M in one.

Scoring Calibration Notes

All eighteen rounds were scored on the v2 rubrics published with the September 13 issue, so scores compare directly with the September 13 and September 20 issues. Founder Track Record is scored from the public record located during the research window: 7 for a senior operating role at a tier-one company or a prior acquisition of undisclosed size, 4 for direct domain experience including multi-year tenure building in the category. Round-to-Round Velocity is scored 2 where prior institutional rounds exist but dates could not be confirmed, and 0 for formation rounds. Rounds with no designated lead are scored on the institutional quality actually present, which applied to Atum. Customer-Side Capital credits a corporate investor only where two or more sources place it in the round, which applied to Labcorp’s venture fund at Teal Health. No score reflects any operating metric a company published about itself.

Circularity control. Where a finding rests on a scored input, the sub-dimension is removed from both sides and the residual is published: named reference customers 14.3 and 9.1, returning investor 11.6 and 10.6, externally controlled checkpoint 11.0 and 5.4, strategic or corporate capital 11.0 and 6.6, and re-underwriting inside eighteen months at a larger size negative 0.4 and negative 2.0. Every one of these appears in Chart 4 in both forms. Score bands are stated once, in The Deal Scorecard.

Deal Citations, Two or More Sources per Deal

Teal Health, $22.0M Series A. PR Newswire company release dated September 22, 2026, read through BioSpace; Fierce Healthcare; MedCity News; MobiHealthNews; Tech Funding News; FutureFemHealth; Fortune Term Sheet of September 23; the company release of May 9, 2025, UPI and The ASCO Post for the FDA approval date. Labcorp participation reported by Fierce Healthcare, Tech Funding News and FutureFemHealth and absent from the release. Rated HIGH.

BigHat Biosciences, $75.0M Series C. BusinessWire company release dated September 24, 2026, read through BioSpace; allsci, which confirms the 2022 Series B and 2025 extension; The Pharma Letter, which confirms the Phase 1/2 dosing; HedgeCo Insights; The AI Insider; Tech Startups roundup of September 24; TechEdgeAI and The AI Insider, which, with the company release, confirm the pharma collaborations. Rated HIGH, with the Phase 1/2 start month recorded as a conflict.

Chamelio, $26.0M Series A. PR Newswire company release dated September 22, 2026, New York dateline; AlleyWatch daily report of September 22; Global Legal Post, which states the New York headquarters and the January seed; ynetnews; Dealroom; Work-Bench’s own post; VC News Daily. Rated MEDIUM on geography and an unreconciled seed interval.

Ema, $77.0M Series B. GlobeNewswire company release dated September 23, 2026, Mountain View dateline; TechCrunch of September 23, which confirms the all-primary structure; AI Weekly; The SaaS News; Tech Startups roundup of September 23. One weekly newsletter places Ema in San Francisco; the release dateline is followed. Rated HIGH.

Firecrawl, $75.0M Series B. Company blog post and PR.com release dated September 22, 2026, San Francisco dateline; company about page for the San Francisco headquarters; SiliconANGLE; RuntimeWire, which reported the Form D around September 14 and again on September 22; WOWTALE; Dealroom and Exame, which name Shopify alongside the users on the company website; Tech Startups roundup of September 22. Rated HIGH on amount with the Form D and Series A conflicts recorded.

Trebellar, $18.0M Series A. BusinessWire company release dated September 24, 2026, San Francisco dateline, which names Meta, Uber and Merck; Axios Pro exclusive; Dealroom; citybiz; Unite.AI; company blog. A fourth customer, Cohesity, appears in one outlet only and is not credited. Rated HIGH.

Go.AI, $85.0M Series A. BusinessWire company release dated September 22, 2026, Chicago dateline; Finovate, the Go Abacus BusinessWire release of March 24, 2026, and CUInsight, which confirm the certifications; FinTech Global; RuntimeWire, which confirms the $5M seed of November 2025; The Investor Society; Tech Startups roundup of September 22. Rated HIGH.

Confido, $55.0M Series B. BusinessWire company release dated September 22, 2026, New York dateline; AlleyWatch daily report of September 22; company blog; citybiz; The SaaS News; BevNET syndication. Rated HIGH.

Ramona Optics, $25.0M Series A. BusinessWire company release dated September 22, 2026, Durham dateline, read through BioSpace; Fortune Term Sheet of September 23; Hoodline citing Axios; Tech Startups roundup of September 22. Rated HIGH.

HIFI, $37.0M Series A. NewMediaWire company release dated September 24, 2026, New York dateline; company blog; Axios Pro exclusive; The Block; AlleyWatch daily report of September 24; CryptoPotato; Altcoin Buzz. Rated HIGH on amount with the total-funding conflict recorded.

Pilgrim, $25.0M Seed. Wall Street Journal report of September 23, 2026, read through Techmeme; AI Weekly; RuntimeWire; The Investor Society, which states the Redwood City headquarters and the CDC agreement; Tech Startups roundups of September 23 and 24; Axios for the 2025 seed. One outlet places Peter Thiel, a 2025 seed backer, in this round; with no second source, no returning investor is credited. Rated MEDIUM because no company release was located.

Prime Minute, $15.0M Pre-seed. PR Newswire company release dated September 24, 2026, Palo Alto dateline; Inc.; Dealroom; Silicon Valley Daily; VC News Daily; Tech Startups roundup of September 24. Rated HIGH.

Atum, $13.5M. PR Newswire company release dated September 22, 2026, San Francisco dateline; Crypto Briefing; RuntimeWire, which notes the company names no round or lead; Fintech Garden; VC News Daily. Rated HIGH on amount with the lead conflict recorded.

Mojave Energy Systems, $19.0M Series B. GlobeNewswire company release dated September 23, 2026, Sunnyvale dateline; company website; Axios Pro exclusive; Pulse 2.0; RuntimeWire, which reports the Form D; PR Newswire release of December 2024 for the $9.5M Series A. Rated HIGH.

Dextr AI, $6.7M Seed. Crunchbase News exclusive dated September 24, 2026; Dealroom; YourStory; Entrackr; RuntimeWire; The SaaS News. Rated HIGH.

Baselayer, $35.0M Series A. PR Newswire company release dated September 22, 2026, New York dateline; Crunchbase News exclusive, which places the company in San Francisco and dates its founding to 2023; Pulse 2.0; Finextra; FinTech Global; Tech Funding News. Rated HIGH on amount with the headquarters and founding-year conflicts recorded.

Corridor, $25.0M Seed. BusinessWire company release dated September 21, 2026, New York dateline; TechCrunch of September 21; The Next Web; FinTech Global; The SaaS News. Rated HIGH.

PicoJool, $27.5M Series A. BusinessWire company release dated September 24, 2026, Palo Alto dateline; SiliconANGLE, which confirms the November 2025 seed led by Playground Global; HPCwire; Converge Digest; Compound Semiconductor; citybiz. Rated HIGH.

Market Comparison Sources

Contrast set: Crunchbase News weekly ranking of the ten largest US rounds for September 19 to 25, 2026, published September 25, which lists Island ($400M), Cyera ($400M), Snorkel AI ($350M), Enveda ($311M), Precision Neuroscience ($250M), Hubble Network ($200M), Rightway ($155M), Rainmaker ($100M), Numeral ($100M) and Micro1 (more than $100M, reported), totaling at least $2,366M. Candidate sources: Tech Startups venture roundups for September 21, 22, 23 and 24 and funding news for September 24 and 25; AlleyWatch daily funding reports for September 22, 23, 24 and 25; VC News Daily listings for September 21 to 25, date-checked against primary releases in every case because its posting dates lag primary announcements; the Fierce Biotech and Fierce Healthcare fundraising trackers for 2026; FinSMEs; Dealroom news. Prior-period comparisons are limited to figures that do not depend on the scoring rubric, except where the September 13 and September 20 issues used the same v2 rubric.

Prior periods. September 14 to 20: twenty-five rounds totaling $861.7M, of which twenty-two totaling $837.5M sat in the $10M to $100M band at an average of $38.07M and a median of $38.5M; stage averages of $37.20M for seed and pre-seed above $10M, $28.33M at Series A and $43.43M at Series B; enterprise AI 41.7%, healthcare 27.7%, California 52.6%; mean score 51.4; returning investor gap 6.8; checkpoint gap 13.7. September 7 to 13: twenty-one rounds totaling $769.0M at an average of $36.62M. August 31 to September 6: twenty-five rounds totaling $924.6M at $36.98M. August 24 to 30: twenty-one rounds totaling $543.9M at $25.9M. August 17 to 23: fifteen rounds totaling $545.0M at $36.3M.

Verification Notes

Sixteen of the eighteen rounds are rated HIGH source confidence, meaning each was confirmed by a company, investor or regulated newswire source plus at least one independent outlet with no unresolved conflict affecting the counted amount, the stage or the inclusion decision. Two are rated MEDIUM. Chamelio is MEDIUM because it was established in Israel and its release was distributed through PR Newswire Israel, although an independent outlet states a single New York headquarters. Pilgrim is MEDIUM because the round is documented in the Wall Street Journal and independent outlets, but no company release was found.

Recorded source conflicts, not resolved by assertion. Firecrawl: a Form D reports $82,063,463 of preferred stock sold against the announced $75M, and the Series A is reported at $14.5M by WOWTALE and RuntimeWire, supported by Exame’s figure in reais, and at $20.7M by Dealroom. RuntimeWire’s filing-based report of the round preceded the window by about eight days; the company announcement on September 22 governs. Mojave Energy Systems: a Form D reports $24,976,722 sold, which the company attributes to previously issued convertible securities converting alongside the $19M round. HIFI: total funding reported at $37M by one outlet and $47M by another. Baselayer: headquarters reported as New York in the release and San Francisco by Crunchbase, founding year reported as 2023 and 2024. Chamelio: seed interval reported as five and as eight months; the Work-Bench post followed the announcement by about two days. BigHat Biosciences: Phase 1/2 study start dated July 2026 and September 2026. Pilgrim: a returning investor reported by one outlet only, not credited. Trebellar: Cohesity reported as a customer by one outlet only, not credited. Teal Health: Labcorp participation reported by three outlets and absent from the release. Atum: outlets name Variant as lead while the company names none. Confido: the release lists Footwork and Y Combinator as returning investors while the company blog lists all five participants as returning; the release is followed. Prime Minute: a Dealroom summary line cites $9.71M against the $15M stated by the company and every other source; $15.0M is counted. Soteris: investor lists differ between outlets.

Deals Analyzed and Excluded, With Rationale

Deals analyzed: 18 verified US mid-market rounds of new primary capital between $5M and $100M.

Outside the date window, marked news-cycle resurfaced and excluded from every total, chart and score. Raindrop, announced September 17 by BusinessWire and recirculated September 21; the $50M is total funding, and the Series A amount is undisclosed. CorePower Magnetics ($10.6M), announced September 17 and recirculated September 21. Soteris ($8M seed), announced as a stealth exit on September 22 but reported by Coverager in July 2025. Sling Therapeutics ($123M) and Arcee AI (at least $150M), both on September 16. Temporal ($550M), ranked in Crunchbase’s top ten for the prior week. Harvey ($550M), carried in the September 13 issue’s contrast set.

Structural exclusions. Kairos Power: Samsung C&T’s $70M equity is a committed strategic investment subject to regulatory approvals, with the agreement signing reported for September 23, not a closed round. Ande: more than $52M across seed and Series A with no split by stage or closing date, and a Dealroom summary citing $42M. Sela: $21M across seed and Series A with no split. Aqua Medical: Series B closed with no amount stated. Bird.com: $450M debt financing.

Giant rounds and public market events, excluded by editorial scope and used only as a contrast set: Island ($400M), Cyera ($400M), Snorkel AI ($350M), Enveda ($311M), Precision Neuroscience ($250M), Ridgeline ($250M), Cornelis ($205M), Hubble Network ($200M), Rightway ($155M, formally announced September 24 after an SEC filing carried in the September 13 issue), Nex (more than $150M in equity and debt), Mazama Energy ($135M), Rainmaker ($100M, at the ceiling), Numeral ($100M, at the ceiling) and Micro1 (more than $100M, reported).

Non-US rounds, excluded for scorecard comparability: Heidi Health (Australia, $100M equity plus a $240M facility), Amber Electric (Australia), HEO (Australia), Kheops (France), Sprive (United Kingdom), Xingyun Integrated Circuit (China), Zhongyi Embodied Intelligence (China), Jierendi Electronic Technology (China), Tekever (Portugal), Brahma AI (Los Angeles, London and Mumbai with no single headquarters), Basecamp Research (United Kingdom), UltraSight (Israel), NG.CASH (Brazil), Axya (Canada), Kasvu Therapeutics (Finland), CellPoint (United Kingdom), Benford (Norway), BCI-Sonics (China), Wealthcome (France) and Clastix (Italy).

Below the $5M floor: Snag ($4M), Beagle Labs ($4.1M), Topdog ($2.5M), Crux Analytics ($2.2M), Neurath ($1.52M, SEC filing) and ByteAsk ($1M).

Deals excluded: 7 outside the date window, 5 on structure, 14 giant rounds by editorial scope, 20 non-US rounds and 6 below the floor.

Research completion timestamp: September 26, 2026. After two further passes- the first adversarial and directed at date windows, blended amounts, headquarters, and lead designation; the second directed at every single-source claim- one returning-investor credit and one customer name were removed, and two further conflicts were recorded.

DISCLAIMER: This article is for informational and strategic intelligence purposes only. It does not constitute investment advice. The Eisen Fundability Score is a proprietary diagnostic within Fundables OS™, not a financial recommendation.

If this article was useful, share it with founders who are about to raise.

— Leon Eisen, 4x Founder, Venture Capitalist, and Author of Invisible Game: The Secrets of the Term Sheet Magnet.

Playbook, Perspective, and Pattern for founders raising now. This report strips out giant rounds and public market traffic so you can read the part of the market that actually prices your round. Every figure below was verified against at least two independent sources and re-checked in an adversarial pass directed at date windows, amount composition, and headquarters. This is the second issue scored on the v2 rubrics, making it the first week in this series where scores can be compared across issues on a consistent framework.

The mid-market grew and got weaker doing it. In a like-for-like $10M to $100M band, twenty-two verified rounds moved $837.5M, up from twenty-one rounds and $769.0M a week earlier. Capital rose 8.9%. Deal count rose 4.8%. The average check rose 4.0% to $38.07M, and the median rose 10.0% to $38.5M. Every size metric went up.

The quality metric went down. On the same v2 rubric used last week, the mean Eisen Fundability Score fell from 55.8 to 51.4. Last week, seven rounds cleared 65. This week, three did. More money bought less proof.

The gap has one source. Seven companies came out of stealth or took their first institutional check this week and together raised $232.0M, 26.9% of the week’s capital, at an average score of 46.6 against 53.3 for everyone else. Last week the market paid for continuity. This week it paid for formation, and a formation round carries the least that any third party has already underwritten.

Consequence for Monday. The door widened at both ends of the stage ladder: seed and pre-seed rounds above $10M went from one to five, and Series B went from two to seven. But the variable that decided who scored well moved. The returning investor premium shrank from 17.6 points to 6.8. The five rounds carrying a checkpoint an outside body controls averaged 62.4 against 48.7. If you open a round this quarter, the first question is no longer who already backed you. It is what somebody outside your company has already confirmed.

The Week in One Sentence

Primary insight. Mid-market capital rose 8.9% while the average fundability score fell 4.4 points, because a quarter of the money went to seven companies nobody had funded at scale before, and the rounds that scored highest carried a checkpoint an outside body controls rather than simply a returning investor.

Total tracked mid-market capital, 25 verified rounds: $861.7M in new primary capital, every deal between $5M and $100M, every company US-headquartered.

Like-for-like against the prior issue: $837.5M across 22 rounds in the $10M to $100M band, against $769.0M across 21 rounds. Capital up 8.9%, deal count up 4.8%.

Average round size: $34.47M across the full set. On a like-for-like basis, $38.07M against $36.62M, up 4.0%.

Median round size: $37.0M across the full set. On a like-for-like basis, $38.5M against $35.0M, up 10.0%.

Largest tracked round: Circle Pharma, a $92.5M Series E in oncology. Smallest: Gaia Dynamics at $7.0M.

Rounds with a designated lead investor: 21 of 25, or 84.0%, against 22 of 24, or 91.7%, last week. RegCell, Pave Finance, Ferry Health and Ravel closed without one.

Rounds carrying strategic, corporate or customer-side capital: 7 of 25, or 28.0%, moving $336.5M or 39.1% of capital, against 13 of 24, or 54.2%, last week.

Rounds with at least one prior investor returning: 12 of 25, or 48.0%, against 16 of 24 last week. Those twelve averaged 55.0 against 48.2 for the thirteen without.

Highest Eisen Fundability Score: Circle Pharma at 69. Lowest: Ravel at 28. A 41-point band, with 3 of 25 rounds clearing 65 and a mean of 51.4 against 55.8 last week.

Defining structural feature: the stage ladder widened at both ends and hollowed in the middle. Five seed and pre-seed rounds above $10M against one, seven Series B rounds against two, and Series A, last week’s only deep lane, down from fourteen rounds to nine.

Framework note: this is the second issue on the v2 rubrics. Scores are directly comparable to the September 13 issue and to no issue before it. Capital, deal count, check size, stage, sector, geography, and investor behavior remain comparable across the full series.

The Deal Scorecard

Eisen Fundability Scores are calculated across five weighted dimensions: Founder-Investor Dynamics (30), Traction-to-Conviction Conversion (25), Narrative Power (20), Deal Architecture (20), and Capital Planning (5). Scores of 90 and above signal an inevitable, market-defining outcome. Scores of 85 to 89 signal extremely strong execution. Scores of 75 to 84 signal solid fundamentals. Scores of 65 to 74 signal a good company with some gaps. Below 65 signals early-stage or structurally incomplete. Traction to Conviction measures only what third parties have already underwritten.

What the Scorecard Says at a Glance

The top of the band is a proof story, not a continuity story. Circle Pharma at 69 has a lead program in Phase 1 and was the Series C co-lead in an oversubscribed round. Evvy at 68 carries peer-reviewed research and a lab strategy coming back. AIUC at 66 is the only top-three round with no returning investor, and it got there by building the standard that named AI companies already certify against. All five rounds carrying an externally controlled checkpoint finished in the top ten. Last week’s top was bought by people already in the building. This week’s was bought by facts somebody else owns.

The strongest single position costs $16M. Ayble Health scored 14 of 25 on Traction to Conviction, the highest mark on that dimension in the issue, with more than fifteen published studies, including randomized controlled trials, a payer partnership with Priority Health, and a care model with Mayo Clinic. That is three separate institutions a diligence team can call without asking the company. It is the twentieth largest round of twenty-five, and it finished tied for ninth.

The most expensive lesson costs $53M and sits at 46. Hang Ten Systems raised a seed extension led by Temasek’s Xora weeks after a $32M seed, taking seed capital to $85M for a company founded in May. The founder is a former chief executive of Infosys, and the round scored 21 of 30 on Founder-Investor Dynamics, joint second in the issue. Deal Architecture scored 9 of 20 because $85M of seed is materially oversized for the stage, and Capital Planning scored 0 because an extension weeks after the first close is not a re-underwriting. A resume and a check size do not substitute for a structure.

The floor is a formation story. Ravel at 28 closed an oversubscribed $8.2M seed with no investor identified in any source reviewed, which leaves no lead, no alignment, and no insider to score. Ferry Health at 38 has a16z and Index on the cap table, with neither designated to set the price. Hello Haven and TypeSafe AI, both at 41, each took a large first check from a single fund. The money is real, and the founders are credible. The score measures how much of the transaction a new investor could reconstruct; for these four, that is the amount and the names.

Size and score remain uncorrelated for a fifth consecutive issue. Ayble Health at $16.0M outscored Hang Ten Systems at $53.0M by eight points. ReEmerge at $37.0M outscored TypeSafe AI at $40.0M by nineteen. Evvy at $40.0M outscored MIND at $72.0M by six. Calibrating your ask against the biggest rounds of the week calibrates against a variable that predicts nothing.

What Changed This Week: Five Market Shifts

Each shift is verified against multiple sources and ranked by structural impact on founder fundraising, not by deal size. Every shift ends with what it means for your raise next week.

Formation Capital Came Back

Pattern, what happened. Seven companies emerged from stealth or took their first institutional round: Noetive at $41.0M, TypeSafe AI at $40.0M, TeRAM at $37.0M, ReEmerge at $37.0M, Hello Haven at $15.0M and Ferry Health at $9.0M, plus Hang Ten Systems adding $53.0M to a seed that closed weeks earlier. Together, $232.0M, or 26.9% of the week’s capital. They averaged $ 46.6 M against $ 53.3 M for the other eighteen rounds. Seed and pre-seed rounds above $10M went from one last week to five, averaging $37.20M.

Perspective, what it means. A formation round is underwritten on the team and the thesis, because that is all that exists yet. The investors writing these checks are buying an option on a category before a competitor gets funded, and most of them bought it with a precise thesis: Eclipse on industrial software, DCVC on deep technology, U.S. Venture Partners and Santé on medtech, Primary Venture Partners on memory silicon. The money is rational. It is also the least verifiable money in the market, and that is why the average score fell in a week when capital rose.

Founder Blindspot, what most miss. Founders read a $41M seed as the new seed price. It is not a price for the stage. It is a price for a credential. Three of the four largest formation rounds were led by founders from Infosys’ chief executive seat, Meta’s generative AI leadership, and OpenAI’s research team, and the pre-seed was written by Mayfield into the co-founders of Rubicon Project, a company Mayfield also backed that went public in 2014. A first-time founder who anchors on these numbers opens three to five times too high and spends the process being repriced.

Playbook, what to do. Before you set a seed number, write the single fact about your founding team a partner could verify in one call that would make a large seed rational: a prior exit, a senior role at the category leader, or a published body of work. If you cannot write that sentence, size the round to your next dated milestone and let the milestone carry the Series A.

Contrast. Last week one seed round above $10M cleared in the entire mid-market, and this report flagged the risk that the $10M-plus seed was leaving the market. Seven days later it came back fivefold, concentrated in AI infrastructure, industrial AI and neurotechnology.

What this means for your raise: Large seed rounds are open, and they are priced on a credential. If yours is not in the first line of your deck, raise to a milestone, not to the headline.

Series B Reopened, and Insiders Walked Through First

Pattern, what happened. Seven Series B rounds cleared, totaling $304.0M, or 35.3% of the week’s capital, after exactly two Series B rounds in each of the three prior issues. The average Series B check fell 21.0%, from $55.00M to $43.43M. Six of seven carried a returning investor. Four of seven, MIND, Polaris Electro-Optics, BackOps, and Luzern Risk, were re-underwritten within eighteen months at a larger size. BackOps closed $42.0M six months after a $26M Series A with all four Series A investors back in the round.

Perspective, what it means. Series B is the first round priced on repeatability, and the prior investor has watched twelve to eighteen months of it. That is why the re-up matters most here. Six of seven is no coincidence: the lane reopened for companies whose last-round investors came back first. The one Series B without a returning investor, Footprint, scored 46, the lowest in the stage. The leads were specialists by stage or category: Crosspoint on security, Catalio on precision medicine, Walden Catalyst on semiconductors, Tidemark on vertical software, QED on fintech, and Insight Partners, a growth-stage specialist, twice. Insight led three rounds in the week across Series A and B.

Founder Blindspot, what most miss. Founders read that Series B is open and schedule a broad process. The lane opened for a specific kind of lead, not for everyone. Every one of the seven was led by a firm with a defined stage or category focus.

Playbook, what to do. If you are within six months of a Series B, get your Series A lead’s participation in writing before the first external meeting. Then build a target list of no more than fifteen firms that led a Series B in your category this quarter. This week’s seven leads are a starting list if your category matches one of theirs.

Contrast. Last week this report concluded that Series B had become rarer, more expensive, and conditional on a corporate strategy. This week it became more frequent and a fifth cheaper, and only three of seven carried corporate capital. The strategic condition dropped. The insider condition did not.

What this means for your raise: Series B is a live lane again at about $43M. It opened for companies whose last investors came back. Secure yours before you open.

The Insider Premium Collapsed and Validation Replaced It

Pattern, what happened. Twelve of twenty-five rounds carried a returning investor, or 48.0%, down from 66.7%. Those twelve averaged 55.0 against 48.2, a 6.8-point gap that shrinks to 5.7 after removing the Insider Support sub-dimension, from 17.6 to 16.2 last week. Among Series A and later rounds only, the eleven with a returning investor averaged 55.6 and the six without averaged 55.3. Meanwhile, the five rounds carrying a checkpoint controlled by an outside body averaged 62.4 against 48.7, a 13.7-point gap that holds at 7.3 after removing Independent Validation. That is the widest structural divider this week.

Perspective, what it means. Part of last week’s insider premium was composition: the rounds with insiders were also later-stage rounds with more of everything. This week, seven formation rounds could not have insiders by construction, so the comparison that matters is within Series A and later, and there the premium disappeared. What survived is the one signal no insider can manufacture: a checkpoint owned by a regulator, a journal, a trial registry or a government agency. Circle Pharma’s Phase 1 program, Evvy’s peer-reviewed research, RegCell’s government grant, ReEmerge’s published feasibility study and registered trial, and Ayble Health’s randomized trials.

Founder Blindspot, what most miss. Founders who acted on last week’s issue will spend this month securing insider commitments and stop there. Keep doing it. It is still worth 5.7 residual points across the set, and it still decided Series B. But an insider tells a new lead that the people who know you best are in. It does not tell the lead anything a third party has confirmed. At Series A and later this week, only the second kind of fact moved the score.

Playbook, what to do. Pair every insider conversation with one externally controlled checkpoint on a dated path. Write three things: the checkpoint, the body that grants it, and the date it can land inside your process window. If your category has no regulator, the fastest options are a security attestation, a peer-reviewed or preprint result with a named academic collaborator, a government grant, or a published standard you certify against.

Contrast. Last week the insider gap was the widest structural divider this report had measured. Last week’s third scenario said to watch whether the gap compressed as founders copied the structure. It compressed, but the share of rounds with insiders fell rather than rose, which says the premium was partly a mix effect rather than imitation.

What this means for your raise: Your insider is table stakes. Proof owned by someone else is what separated the field.

Healthcare Gave Back Half Its Share and Kept All the Proof

Pattern, what happened. Healthcare and life sciences took $238.5M across six rounds, or 27.7% of mid-market capital, after 54.1% last week and 40.3% two weeks ago, ending a three-issue climb. Enterprise AI and software took $359.0M across nine rounds, or 41.7%, up from 16.9%. Fintech and insurtech took 12.6% across four rounds, semiconductors and AI infrastructure 10.1% across two, and robotics, consumer and climate 7.9% across four. All five rounds carrying an externally controlled checkpoint were healthcare. The six healthcare rounds averaged 58.3, compared with 49.3 for the other nineteen.

Perspective, what it means. Healthcare’s share fell because fewer healthcare rounds cleared- six this week against ten last week- not because the quality of the rounds that cleared fell. The category still supplies external checkpoints by default: an IND, a trial registration, a peer-reviewed paper, a government grant. Enterprise AI took the capital, and its average was 53.0 across nine rounds. Only three of the nine carried a named counterparty an investor could call. The money moved to software. The proof did not move with it.

Founder Blindspot, what most miss. Enterprise AI founders read 41.7% as a green light. Look at what it bought: two formation rounds, five re-ups, one seed extension, and one standard-setter. It rewarded founders with credentials and companies with returning investors. It did not reward a category claim on its own.

Playbook, what to do. If you sell software, borrow healthcare’s structure. Identify the one institution in your buyer’s world that certifies, audits, or publishes, and get your product through it this quarter. AIUC is this week’s proof that software can build the checkpoint itself: it wrote the AIUC-1 standard and got named AI companies to certify against it.

Contrast. Total mid-market capital rose 8.9% while healthcare’s absolute capital fell from $426.0M to $238.5M. Last week was a genuine reallocation into healthcare. This week reversed it in one move.

What this means for your raise: If you are in software, you now compete on the dimension healthcare founders get for free. Build or borrow a checkpoint.

The Buyer Left the Cap Table

Pattern, what happened. Strategic, corporate or customer-side capital appeared in seven of twenty-five rounds, or 28.0%, moving $336.5M or 39.1% of capital, against thirteen of twenty-four and 61.6% of capital last week. The seven: Circle Pharma with Eli Lilly, Evvy with the Labcorp venture fund and U.S. Fertility’s innovation fund, Polaris Electro-Optics with M Ventures and Koch Disruptive Technologies, BackOps with Gradient Ventures, Hang Ten Systems with Aramco Ventures, RegCell with Mitsui Chemicals and LG Technology Ventures, and Pave Finance with the advisory firms that buy its platform. The gap was 8.1 points and holds at 3.8 after removing Customer-Side Capital, up from 12.1 and 6.4 last week.

Perspective, what it means. Last week’s strongest structures attached a commercial relationship to the check: a customer’s venture arm buying, a shipyard signing a production agreement. This week’s strategics were mostly corporate venture arms participating, which the rubric scores at 3 of 8, not 6 or 8. That is why the residual collapsed. A corporate logo without a commercial link is a weak signal, and the framework priced it that way.

Founder Blindspot, what most miss. Founders count any corporate venture participation as a customer investment. Pave Finance and Evvy show the real version. At Pave, advisory firms, the buyers of the platform, wrote into the Series A, which is why a round with no institutional lead still scored 6 of 8 on Customer-Side Capital. At Evvy, a physician-led fertility network that is also its research partner invested through its innovation fund, exactly where the company is expanding next.

Playbook, what to do. When a corporate venture arm offers, ask for the commercial link in the same conversation: a paid pilot, a supply agreement, or a distribution commitment from the operating business. If the operating business will not attach anything, price the check as financial capital and keep your exclusivity and first refusal terms clean.

Contrast. Across four issues, the strategic share ran 42.9%, 28.6%, 54.2%, and now 28.0%. That is volatility, not a trend. What held all four weeks is that buyer-investor structures with a commercial agreement attached scored highest.

What this means for your raise: Take corporate money when it brings a customer. Otherwise, it is financial capital with strings.

The Deals That Matter: Top 5

Five deep dives across oncology therapeutics, women’s health diagnostics, AI agent assurance, data security, and cell therapy. These are the week's five highest-scoring rounds. All facts are verified against two or more sources.

Circle Pharma

Oral Macrocycles Against Cyclins | Series E | $92.5M | Led by The Column Group

Eisen Fundability Score: 69 / 100

Why this scored. The highest score of the week and the highest Founder-Investor Dynamics mark at 22 of 30. Its Series C co-lead returns to lead an oversubscribed round; Eli Lilly is back beside it, and the program sits in Phase 1, a clinical stage that requires regulatory clearance before dosing patients.

The Setup. Circle Pharma, headquartered in South San Francisco and founded in 2012 with seed funding from Pfizer, builds orally available macrocyclic drugs against cyclins, cell-cycle regulators long considered undruggable by conventional small molecules. Chief executive David Earp leads a pipeline headed by CID-078, a cyclin A/B RxL inhibitor in Phase 1 for advanced solid tumors, and CID-165, a cyclin D1 RxL inhibitor for ER-positive breast cancer targeted to enter the clinic in the first quarter of 2027.

The Deal. $92.5M oversubscribed Series E led by The Column Group, announced September 15, 2026, with Nextech Invest, RA Capital Management, Euclidean Capital and Eli Lilly and Company participating. The Column Group and Nextech co-led the $66M Series C, where Euclidean and Lilly first entered. All equity.

The Pattern. This is the patient insider round. Fourteen years and five lettered rounds in, the Series C co-lead is back in the seat setting the price. That is the strongest form the returning investor signal takes, because the insider is leading rather than following.

The Perspective. Healthcare’s share of capital halved this week, and a $92.5M Series E still cleared oversubscribed. Nearly every dollar came from people who had already underwritten the company. The Column Group has seen every failed experiment. Lilly is a strategic sitting next to one of its own therapeutic franchises. A new lead would need months to rebuild that conviction. Here it was priced from inside, and the outside money competed for the remainder.

The Playbook. If you have a long-standing lead, ask them to lead again rather than participate, and ask before you market the round. An insider who leads turns a raise into a pricing conversation with people who already believe. Then let new money fill the oversubscription instead of setting the terms.

The Founder Mistake to Avoid. Founders assume a long funding history reads as maturity. It can just as easily read as a company that needed five rounds to reach the clinic. What makes Circle’s history an asset is the milestone attached to it: a Phase 1 program and a second program with a dated clinical start. Longevity without milestones reads as burn

Evvy

Microbiome Diagnostics for Women’s Health | Series B | $40.0M | Led by Catalio Capital Management

Eisen Fundability Score: 68 / 100

Why this scored. Joint second on Founder-Investor Dynamics at 21 of 30 on an explicitly oversubscribed round with seven returning investors, and one of five rounds in the issue carrying an externally controlled validation, in this case thirteen peer-reviewed publications that journals, not the company, control.

The Setup. Evvy, headquartered in New York, runs a vaginal microbiome diagnostics platform that combines metagenomic sequencing, clinical interpretation and a machine-learning system called EvvyAI. Its work has produced thirteen peer-reviewed publications, including the identification of new bacterial vaginosis subtypes. Founded in 2021 by Priyanka Jain, Laine Bruzek and Pita Navarro, the company is taking the platform into clinical validation of new diagnostic and care models, starting with fertility and IVF.

The Deal. $40.0M oversubscribed Series B led by Catalio Capital Management, announced September 15, 2026, with U.S. Fertility Innovation Fund, Rethink Impact, Muse Capital and Alumni Ventures as new investors and LabCorp Venture Fund, General Catalyst, Left Lane Capital, BBG Ventures, Amboy Street Ventures, Ingeborg and Foreground Capital returning. Total raised nearly $60M across three rounds. All equity.

The Pattern. This is the proprietary dataset round. The asset is a clinically linked dataset that grows with every patient served, and part of it has already been examined outside the company in peer-reviewed form.

The Perspective. Look at the two strategics. A national laboratory company’s venture arm came back, which says the party that runs testing at scale chose to stay in. And U.S. Fertility, a physician-led fertility network that is already Evvy’s research partner, came in through its innovation fund, which puts the channel for the next market on the cap table before the company enters it. Pair that with peer-reviewed output and a precision medicine specialist in the lead seat, and the round is legible on independent axes, none of which depends on the company’s own description.

The Playbook. If your product generates data, publish from it with a named academic collaborator before you raise. A peer-reviewed paper converts your dataset from a claim into a fact a journal owns, and it is the cheapest externally controlled checkpoint available to a data-driven company. Start the manuscript two quarters before the process opens.

The Founder Mistake to Avoid. Founders with proprietary data treat secrecy as the moat and keep everything inside. Evvy’s data became fundable because some of it left the building in reviewed form. A dataset nobody outside has examined is an assertion.

AIUC

Audit, Certification and Insurance for AI Agents | Series A | $40.0M | Led by Ribbit Capital

Eisen Fundability Score: 66 / 100

Why this scored. The highest Narrative Power mark in the issue at 19 of 20 and the only top-three round with no returning investor. AIUC was re-underwritten fourteen months after its seed at 2.7 times the size, and its external position is unusual: it does not hold a checkpoint; it issues one.

The Setup. The Artificial Intelligence Underwriting Company, headquartered in San Francisco, sells AIUC-1, an audit and certification standard for AI agents modeled on SOC 2 that runs roughly 5,000 adversarial scenarios per audit, developed with the law firm Orrick and input from more than 250 Fortune 1000 security chiefs, with insurance coverage tied to audit results. Co-founder Rune Kvist was Anthropic’s first product hire; co-founder Rajiv Dattani was a partner in McKinsey’s insurance practice and chief operating officer of METR; chief technology officer Brandon Wang previously founded a consumer underwriting business. Named adopters include Cursor, Lovable, Harvey and ElevenLabs.

The Deal. $40.0M Series A led by Ribbit Capital with First Harmonic participating, announced September 15, 2026. Total raised $55M including a $15M seed led by NFDG in July 2025. All equity.

The Pattern. This is the standard-setter round. The company is building the checkpoint that other companies need to clear, which is the most durable position in any category where trust is the bottleneck.

The Perspective. Ribbit in the lead seat is the thesis tell. A fintech specialist leading an AI company means the round was underwritten as insurance infrastructure, a business with a known shape: a standard, a testing regime, and a priced risk. Underwriters Laboratories compounded for a century because every new buyer required the mark. A standard with named adopters is a network asset, and that is why Narrative Power scored 19.

The Playbook. If your category lacks a trusted checkpoint, ask whether you should build it. Start with five design partners who will publicly certify against your standard, recruit one institution outside the company to co-author it, and price something off the result. Adoption is the proof. The document is not.

The Founder Mistake to Avoid. Founders copy the category claim without the adopters. A standard nobody certifies against is a PDF. What made AIUC-1 fundable is named AI companies on it, an outside law firm and security chiefs behind it, and an insurance product priced off the audit.

MIND

AI-Native Data Loss Prevention | Series B | $72.0M | Led by Crosspoint Capital Partners

Eisen Fundability Score: 62 / 100

Why this scored. The largest Series B of the week and its clearest velocity story: a $30M Series A to a $72M Series B in about a year, with existing backers YL Ventures and Paladin returning behind a cybersecurity specialist lead. MIND also carries named enterprise customers in two unrelated industries.

The Setup. MIND, headquartered in Seattle and founded by veterans of Israel’s Unit 8200, sells AI-native data loss prevention that monitors how sensitive information moves across people, applications, and increasingly autonomous AI systems. Named customers include Crunchyroll and Sungrow Power Supply. The product sits exactly where agent deployment creates new data paths that existing controls were not built to see.

The Deal. $72.0M Series B led by Crosspoint Capital Partners, announced September 17, 2026, with existing investors YL Ventures and Paladin Capital Group participating. Total raised: $112M. Series A of $30M closed roughly a year earlier. All equity. Headquarters is listed as Seattle in the company release dateline and independent coverage.

The Pattern. This is the agentic security round. Every autonomous agent a company deploys is a new identity with access to data, and the budget line to govern that is being created right now.

The Perspective. Crosspoint is a cybersecurity specialist, and YL Ventures and Paladin are existing security investors who have watched the product in production. When the specialist takes the lead one year after the Series A and the existing backers stay in, the round is a category bet reinforced by the people with the most information. The 2.4x step-in round size is the market pricing that information.

The Playbook. Anchor your round to the budget line the AI wave creates, not to AI itself. MIND’s story fits in one sentence: companies deploying agents must control what those agents can move. Find the control your buyer is forced to add because of AI adoption and put it in the first line of the deck.

The Founder Mistake to Avoid. Security founders chase logo counts over reference-grade accounts. Two named customers in media and energy do more work than twenty anonymous ones, because a diligence team can call them. Name fewer, deeper accounts, and make sure each will take the call.

RegCell

Epigenetically Reprogrammed Regulatory T Cells | Series A | $44.0M equity plus grant | No designated lead

Eisen Fundability Score: 61 / 100

Why this scored. The highest Deal Architecture mark in the issue at 18 of 20, on the only round this week whose capital stack pairs equity with non-dilutive government funding and states the split. The grant is also an externally controlled validation: a government agency ran its own review before committing.

The Setup. RegCell, headquartered in Emeryville, California per its release dateline, is developing epigenetically reprogrammed regulatory T cells to restore immune tolerance in autoimmune disease. The company is built on the Nobel-recognized science of regulatory T cells and is using this financing to move its therapies into the clinic.

The Deal. $66M in total: a $44.0M fully subscribed Series A plus a grant of about $22M from Japan’s Agency for Medical Research and Development, announced September 15, 2026. Investors include Playground Global, Global Brain, Mitsui Chemicals, LG Technology Ventures, Alumni Ventures, Medical Incubator Japan, Fast Track Initiative, The University of Tokyo Edge Capital Partners, Osaka University Venture Capital and Kyoto iCAP. The reviewed sources do not designate a lead. Total new equity: $ 44.0 M.

The Pattern. This is the blended stack done right. Equity funds the unproven clinical outcome, the grant funds research, and the two are announced side by side with the amounts separated.

The Perspective. The grant does two jobs. It extends runway without dilution, and it is a checkpoint the company does not control. The syndicate maps the science’s origin: three Japanese university-linked funds, including those of Kyoto University and Osaka University, where the foundational regulatory T cell work was done, two corporate investors, and a US deep technology investor. The weakness is the empty lead seat. Ten investors and no one identified as setting the price is why Round Competition scored 6, not 9.

The Playbook. List every non-dilutive program your science qualifies for, from SBIR and STTR to ARPA-H, NIH, Department of Defense programs and national agencies abroad, and structure the round so the grant and the equity close together with the split stated. Then name one investor to lead. A blended stack with a lead is the strongest architecture available to a preclinical company.

The Founder Mistake to Avoid. Founders announce the blended total as the round size. RegCell’s figures separate a $44M Series A from the grant, which is why this report credits both correctly. Blend them, and a diligence team discounts both numbers and starts asking what else is blended.

The Fundraising Playbook: Five Tactical Plans

Five plans, each producing a concrete artifact you can use immediately. Each is built directly from this week’s verified signals.

Name the Credential Your Round Is Priced On (Narrative and Investor Framing)

Why this matters. Seven formation rounds took $232.0M, 26.9% of the week’s capital. Three of the four largest rounds were led by founders from Infosys, Meta, and OpenAI, and the week’s only pre-seed went to the co-founders of Rubicon Project, which went public in 2014. Large early rounds are open, and they price a credential rather than a stage.

Exact deliverable. One sentence at the top of your deck that states the single verifiable fact about your founding team that makes this round size rational, followed by the name of one person outside the company who will confirm it on a call. If that sentence doesn't exist, use a second slide to size the round to your next dated milestone instead.

Time estimate. Ninety minutes for the sentence. One call to line up the reference.

Expected outcome. Your ask matches what the market prices you at. You stop opening at a formation-round number without a formation-round credential, and you skip the four weeks of repricing that follow.

The reframe. Wrong approach: anchor your seed on this week’s largest rounds. Right approach: anchor it on the credential you can prove or on the milestone the money buys.

Acquire One Externally Controlled Checkpoint Before You Open (Proof Architecture)

Why this matters. Five rounds carried a checkpoint an outside body controls, and they averaged 62.4 against 48.7, a gap that holds at 7.3 after removing the sub-dimension that scores it. All five finished in the top ten. At Series A and later, a returning investor was worth 0.3 points this week.

Exact deliverable. A three-column table: the checkpoint, the body that grants it, and the earliest date it can land. Include regulatory steps, trial registrations, peer-reviewed or preprint results with a named academic collaborator, government grants, security attestations, and standards you can certify against. Mark the fastest one and start it this week.

Time estimate. Three hours for the table. Two to four months for most checkpoints, which is why the start date goes in now rather than when you open.

Expected outcome. The central claim in your process becomes a fact somebody else owns. An investment committee can confirm it without you in the room, which is what separated the top of the band this week.

The reframe. Wrong approach: build a case an investor must accept on trust. Right approach: count the facts a third party already certifies about you, then get one more.

Eisen Self-Score, Now With a Benchmark (Readiness)

Why this matters. This is the first week the v2 score can be compared across issues. The mean fell from 55.8 to 51.4 while capital rose. Three of twenty-five rounds cleared 65, eleven sat between 50 and 65, and eleven sat below 50.

Exact deliverable. Score your round across the five dimensions on the v2 rubrics. Above 65 puts you in the top three of twenty-five this week: run a competitive process with a deadline. Between 50 and 65 puts you in the crowded middle: fix your lowest dimension before you open. Below 50 means the problem is structural, meaning no lead, no returning investor, no external checkpoint, and no process design fixes that. Write the two lowest dimensions and one action for each.

Time estimate. Two to three hours, repeated before every raise.

Expected outcome. A decision this week between a competitive process now and a repair sprint first, rather than one discovered in week nine.

The reframe. Wrong approach: score yourself, feel discouraged, and rewrite the deck. Right approach: score yourself, name the two lowest dimensions, and pick process or repair today.

Lock the Insider, Then Target Only Stage Specialists (Deal Architecture)

Why this matters. Seven Series B rounds cleared after three weeks, down from two. Six of seven carried a returning investor, and every lead had a defined stage or category focus. Insight Partners alone led three rounds in the week.

Exact deliverable. Two outputs in order. First, a written commitment from your last round’s lead: a specific amount and a yes or no on leading if nobody else does. Second, a target list capped at fifteen firms, each with the round it led in your stage and category this quarter written next to its name. Cut every firm where you cannot write that line.

Time estimate. Two weeks on the calendar for the insider conversation. Four hours for the list.

Expected outcome. You open with a floor under the round and a list of partners who are actively writing checks in your lane, instead of a brand list that takes a quarter to disprove.

The reframe. Wrong approach: run a broad process and go to insiders if it stalls. Right approach: secure the insider first and pitch only the specialists who led your stage this quarter.

Sequence the Round Around the Checkpoint Date (Momentum and Conversion)

Why this matters. The rounds that scored highest this week put an outside fact next to the money: a Phase 1 program, a registered trial, a government grant, a published result, a standard with named adopters. Momentum came from the checkpoint, not from the calendar.

Exact deliverable. A one-page process plan with three dates: the checkpoint landing date, the day you open to new money, and the target close, with the open date no more than four weeks before the checkpoint lands. Add a fourteen-day follow-up cadence in which every touchpoint carries a dated update on that checkpoint.

Time estimate. One hour for the plan. The cadence runs itself once the dates exist.

Expected outcome. Every follow-up carries new, verifiable information, and investors waiting for proof receive it during the process rather than after it closes.

The reframe. Wrong approach: open when the deck is ready and follow up with enthusiasm. Right approach: open four weeks before the checkpoint lands and follow up with the checkpoint.

Looking Forward: Next 1 to 3 Weeks

Three evidence-based scenarios and one wild card. Every projection is anchored to this week’s verified data.

First, last week’s calls. Last issue projected that Series A would stay deep while everything else stayed thin. Wrong: Series A fell from fourteen rounds to nine while seed and Series B surged. It projected that strategic capital would keep rising. Wrong: its share halved. It projected that the insider gap would narrow as founders copied the structure. Half right: the gap narrowed, but because of composition rather than imitation. The forecasts below are built with that record in view.

The Barbell Holds: Formation Rounds and Series B Stay Wide (Medium-High Probability)

Evidence from this week. Five seed and pre-seed rounds above $10M at $37.20M average, seven Series B rounds at $43.43M, and Series A down to nine rounds and 29.6% of capital against 53.6% a week earlier. Both ends of the ladder were led by specialists with a precise thesis, which is what a durable lane looks like rather than a one-week spike.

What to watch. Whether Series B holds at four or more rounds in either of the next two issues. Two more weeks at that level means the three-week drought was a pause, not a closure. Separately, watch whether Series A recovers above twelve rounds. If it stays near nine, the market is thinnest in the middle of the ladder.

What founders should do before others notice. If you are a Series B candidate with a returning lead, move this month while specialists are actively writing. If you are raising a Series A without a credential or a checkpoint, expect a thinner field than last week and build the checkpoint first.

External Validation Becomes the Divider at Every Stage (Medium Probability)

Evidence from this week. Five rounds carrying an externally controlled checkpoint averaged 62.4 against 48.7, a 7.3-point residual, while the insider premium at Series A and later fell to 0.3 points. All five were healthcare, where checkpoints come by default.

What to watch. Whether a checkpoint-carrying round appears outside healthcare in the next two issues: a certification, a government contract vehicle, a published benchmark. If it does and it scores near the top, the divider is structural rather than sectoral. If it does not, this week’s gap was a healthcare composition effect.

What founders should do before others notice. Start the checkpoint now. Most take two to four months, so founders who start this week will have one in hand when the pattern becomes consensus.

Rate Pressure Narrows the Formation Lane First (Medium Probability)

Evidence from this week. The Federal Reserve raised its benchmark rate by 25 basis points on September 16 to a 3.75% to 4.00% range, its first increase since 2023. Formation rounds are the longest-duration bets in venture: no revenue to discount, only a team and a thesis. This week they took 26.9% of capital at the lowest average score of any cohort.

What to watch. Whether the count of seed and pre-seed rounds above $10M falls back below three in the next two issues while Series B holds. That combination would mean investors are shortening duration by moving capital toward companies with operating history.

What founders should do before others notice. If you are planning a large first round on a credential, close inside the next six weeks rather than next quarter. If the lane narrows, it narrows at the top of the check sizes first.

Wild Card: The Standard-Setter Becomes a Category (Low to Medium Probability)

Evidence from this week. AIUC raised $40.0M to issue the checkpoint rather than hold one, scored the week’s highest Narrative Power, and did it with a fintech specialist in the lead seat, naming AI companies already certified against its standard.

What founders should do before others notice. If buyers in your category keep asking the same trust question, the company that answers it for everyone may be worth more than the company that answers it for itself. Test it cheaply: publish a draft standard with three design partners and see who asks to certify.

The Bottom Line

The real insight is not the $861.7M. It is that capital rose 8.9% while the average fundability score fell 4.4 points on a constant rubric, because a quarter of the money went to companies nobody had funded at scale before, and because the signal that decided last week, a returning investor, stopped separating the field at Series A and later. Instead, what separated it was a fact somebody outside the company controls. That produced three conviction profiles.

Profile 1: Companies carrying proof someone else owns. Circle Pharma (69) has a Phase 1 program. Evvy (68) has thirteen peer-reviewed publications. RegCell (61) has a government grant. ReEmerge (60) has a published feasibility study and a registered trial. Ayble Health (54) has randomized controlled trials and payer and health system relationships. Five rounds, averaging 62.4 against 48.7.

Profile 2: Companies whose investors came back into a larger round fast. MIND (62) went from a $30M Series A to $72M in about a year. Polaris Electro-Optics (55) stepped up fivefold from its Series A. BackOps (54) raised again six months after its Series A with all four backers in. Luzern Risk (53) and Comp AI (53) did the same inside eighteen months. Seven rounds re-underwritten inside eighteen months at a larger size averaged 55.9 against 49.7.

Profile 3: Founders priced on a credential. Noetive (57), Hang Ten Systems (46), TypeSafe AI (41), and Hello Haven (41) raised on who the founders are. Seven formation rounds took $232.0M at an average of 46.6. The credential opened the round. It did not carry the score.

Everything else competed for the residual. Thirteen rounds had no returning investor, and the floor, Ravel at 28 and Ferry Health at 38, shares one shape: no designated lead and nothing in the transaction a new investor could reconstruct beyond the amount and the names.

Five New Rules for Founders

1. A rising market is not a validating market. Capital rose 8.9% while the mean score fell from 55.8 to 51.4. Price your round on your proof, not on the week’s headline total.

2. A big seed prices a credential, not a stage. Seven formation rounds took $232.0M, and three of the four largest went to founders out of Infosys, Meta, and OpenAI. Without that line in your deck, raise to a milestone.

3. Your insider is table stakes. The returning investor gap fell from 17.6 points to 6.8, and to 0.3 at Series A and later. Secure the insider, then give the next lead something the insider cannot.

4. Own one fact someone else certifies. Five rounds carrying an externally controlled checkpoint averaged 62.4 against 48.7, with a 7.3-point residual. Every one finished in the top ten.

5. Series B is open to companies whose last investors come back. Seven Series B rounds cleared, six with a returning investor, averaging $43.43M; every one led by a firm with a defined stage or category focus.

Four Monday Actions

1. Write your checkpoint line. One outside body, one checkpoint, one date it can land inside your process window. Start the fastest one this week.

2. Call your last round’s lead. Ask for a specific number in writing and a yes or no on leading before the first external meeting.

3. Name your credential or resize your seed. One verifiable sentence at the top of the deck, or a round sized to the next dated milestone.

4. Cut your target list to fifteen specialists. Write beside each name the round it led in your stage and category this quarter, or it comes off the list.

The market opened wider this week and asked for less proof on the way in. The founders who will close first next quarter are the ones who treat that as a window, not a standard: they walk in with an insider already committed and one fact on the table that somebody outside their company owns. You can start building that fact on Monday.

Research Methodology, Sources and Verification

Data Collection Period and Verification Standard

Data collection period: September 14 to 20, 2026, with verified primary announcements clustered September 14 to 17. In the sources reviewed, items first appearing on Friday, September 18, were repostings of earlier announcements or failed verification, and research was completed on Saturday, September 19, so any weekend announcement will be assessed in the next issue. Verification standard: a minimum of two independent sources per deal, anchored on company releases and regulated newswire copies (BusinessWire, PRNewswire, GlobeNewswire), read directly or through syndication and dated newswire summaries, plus at least one independent outlet. The issue was built in three passes: a collection pass across daily funding roundups and trackers; a verification pass against primary and independent sources for every company, amount, stage, lead, date, and headquarters; and an adversarial pass focused on date windows, amount composition, and headquarters conflicts. Eisen Fundability Scores are proprietary analytical estimates, not endorsements or investment advice.

Core Capital Totals and What They Include

The $861.7M weekly total includes only the twenty-five verified US rounds in the scorecard. Mid-market is defined as a US-headquartered round of new primary capital between $5M and $100M, matching the prior two issues. Because issues before August 31 used a $10M to $100M band, every week-over-week structural comparison is calculated on the $10M to $100M subset: twenty-two rounds totaling $837.5M at an average of $38.07M and a median of $38.5M, against twenty-one rounds totaling $769.0M at an average of $36.62M and a median of $35.0M. The three rounds below $10M, Ferry Health, Ravel and Gaia Dynamics, totaling $24.2M, are included in the scorecard, scores, sector and geography analysis but excluded from every week-over-week structural comparison, including every stage average.

Credit facilities, venture debt, secondary purchases, convertible notes into listed companies, prior tranches, cumulative restatements and non-dilutive grants are excluded from counted amounts. Four amounts were restated or qualified. RegCell’s $66M headline includes a grant of about $22M from Japan’s Agency for Medical Research and Development, so $44.0M of Series A equity is counted, and the grant is credited only as independent validation. Hang Ten Systems’ $85M of cumulative seed capital includes a $32M seed closed weeks earlier, so only the $53.0M extension is counted. Pave Finance announced more than $15M and is counted at $15.0M. Gaia Dynamics announced a $7M seed, while an SEC Form D filed the same day reports $8,585,054 sold to six investors; no source reconciles the difference, so we count the announced $7.0M and rate the round MEDIUM.

We recomputed the arithmetic after the adversarial pass. The five sector subtotals ($359.0M enterprise AI and software across nine rounds, $238.5M healthcare and life sciences across six, $109.0M fintech and insurtech across four, $87.0M semiconductors and AI infrastructure across two, and $68.2M robotics, consumer and climate across four) and the five stage subtotals ($304.0M across seven Series B rounds, $255.0M across nine Series A rounds, $195.2M across seven seed rounds, $92.5M in one Series E and $15.0M in one pre-seed) each sum to $861.7M across twenty-five deals. Geography: California $503.5M across thirteen rounds (58.4%), New York $155.0M across five, Washington $101.2M across three, and Minnesota, Florida, Massachusetts, and Utah one round each.

Scoring Calibration Notes

All twenty-five rounds were scored on the v2 rubrics published with the September 13 issue, so scores are directly comparable to that issue. Founder Track Record is scored from the public record located during the research window: 10 for a prior exit above $100M, 7 for a senior operating or research role at a tier-one company, 4 for direct domain experience including multi-year tenure building in the category, and 0 where no relevant background was located for a newly emerged company. Round-to-Round Velocity is scored 2 where prior institutional rounds exist, but their dates could not be confirmed; 0 for newly formed companies and for extensions, which applied to Hang Ten Systems. Rounds with no designated lead are scored on the institutional quality actually present; Ravel is the only round scored 0 on Investor Quality because no investor is identified in any reviewed source. No score reflects any operating metric a company published about itself. Where a finding rests on a scored input, the sub-dimension is removed from both sides, and the residual is published: returning investor 6.8 and 5.7, external validation 13.7 and 7.3, strategic capital 8.1 and 3.8, velocity 6.1 and 4.2. The Deal Scorecard states score bands once.

Deal Citations, Two or More Sources per Deal

Circle Pharma, $92.5M Series E. BusinessWire company release dated September 15, 2026; Fierce Biotech fundraising tracker entry dated September 16; Pulse 2.0; prior BusinessWire releases for the South San Francisco headquarters and the Phase 1 status of CID-078; Alliance of Chief Executives syndication of the Series C release. Rated HIGH.

Evvy, $40.0M Series B. BusinessWire company release dated September 15, 2026; Fortune exclusive dated September 15; Fierce Healthcare; Pulse 2.0; Beauty Independent; and the U.S. Fertility Innovation Fund. Flywheel Ventures appears among returning investors in two outlets but not in the company-sourced lists, so it is not counted. Rated HIGH.

AIUC, $40.0M Series A. TechCrunch report of September 15, 2026, read through Runtimewire and aggregator summaries; Insurtech Insights; Coverager; Crypto Briefing; FourWeekMBA for the seed timeline. Rated HIGH.

MIND, $72.0M Series B. PR Newswire company release dated September 17, 2026; read through VC News Daily; The Wall Street Journal as cited by Tech Startups; Tech Startups roundup of September 17. Rated HIGH.

RegCell, $44.0M Series A. BusinessWire company release dated September 15, 2026; Fierce Biotech fundraising tracker; VC News Daily, which carries the Emeryville dateline. Rated HIGH.

ReEmerge, $37.0M Series A. PRNewswire company release dated September 15, 2026, read through Yahoo Finance syndication and Runtimewire; allsci; Tech Startups roundup of September 15. Rated HIGH.

Noetive, $41.0M Seed. PRNewswire company releases read through VC News Daily, which carries the San Francisco dateline; The Wall Street Journal as cited by Tech Startups; Tech Startups roundups of September 16. Rated HIGH.

Polaris Electro-Optics, $50.0M Series B. BusinessWire company release dated September 15, 2026, datelined Carlsbad, California, and read through 01net, Photonics Online, and NewsBreak syndication, naming Walden Catalyst Ventures as lead and Andy Kau joining the board; Raptor Group post on Socratic Partners’ participation; Tech Startups roundup of September 15; Preqin, CB Insights, and M Ventures for the $10M Series A of 2025. The company reports completed Telcordia reliability testing and independently verified modulation speed; neither is confirmable against the testing body’s own record, so neither is credited in Independent Validation. Rated HIGH.

BackOps, $42.0M Series B. PRNewswire company release read through VC News Daily; Pulse 2.0; Packaging World and Pharmaceutical Commerce for the March 2026 $26M Series A. Rated HIGH.

Ayble Health, $16.0M Series A. PRNewswire company releases read through VC News Daily and The SaaS News, as summarized by Digg, for lead attribution. Rated MEDIUM because a single secondary source attributes the lead.

Comp AI, $34.0M Series A. Pulse 2.0; The Next Web; TechCrunch, as summarized by Runtimewire, for the pre-seed history; VC News Daily. Rated HIGH.

Luzern Risk, $45.0M Series B. Axios Pro exclusive dated September 17, 2026; BusinessWire release read through VC News Daily; Captive Review and Captive International for the April 2025 $12M Series A. Rated HIGH.

Kastle, $24.0M Series A. PRNewswire company releases read through VC News Daily; Tech Startups roundup of September 17. Rated HIGH.

Adaptive, $30.0M Series B. Company release dated September 17, 2026, published by Construction Dive, naming Emergence Capital, Andreessen Horowitz, Pathlight, Definition, and 3KVC as existing investors; International Accounting Bulletin; CB Insights for the $19M Series A of July 2024. Rated HIGH.

Viabot, $24.0M Series A. Company announcement read through VC News Daily; Tech Startups roundup of September 17. Rated HIGH.

Pave Finance, $15.0M Series A. WealthManagement.com dated September 14, 2026; InvestmentNews dated September 15; fintech.global; AlleyWatch daily funding report of September 14. Rated MEDIUM because no institutional investor is named.

Gaia Dynamics, $7.0M Seed. Pulse 2.0; PRNewswire release read through VC News Daily; SEC Form D as reported by Runtimewire. Rated MEDIUM on the unreconciled amount.

Hang Ten Systems, $53.0M Seed extension. BusinessWire release read through VC News Daily, which carries the Menlo Park dateline; TechCrunch as cited by Tech Startups. Rated HIGH.

Footprint, $25.0M Series B. PRNewswire company release read through VC News Daily, which names QED Investors as lead; Tech Startups roundup of September 16. Rated HIGH.

TeRAM, $37.0M Seed. BusinessWire company release dated September 15, 2026, read through Yahoo Finance, Morningstar, and AOL syndication, which names founder and chief executive Charlie Cheng and identifies Primary Venture Partners as lead investor; Semiconductor Digest; Tech Startups roundup of September 15, which described four co-leads and is not followed here. Rated HIGH.

BuyWander, $21.0M Series A. BusinessWire company releases read through VC News Daily; Tech Startups roundup of September 15. Rated HIGH.

TypeSafe AI, $40.0M Seed. BusinessWire company release dated September 15, 2026; Tech Startups roundups of September 15 and 16. Rated HIGH.

Hello Haven, $15.0M Pre-seed. PRNewswire company releases read through VC News Daily; Tech Startups roundup of September 17; Magnite corporate history and Rubicon Project investor relations for the founders’ prior company, its 2014 IPO and Mayfield’s earlier investment in it. Rated HIGH.

Ferry Health, $9.0M Seed. PRNewswire company releases read through VC News Daily; Tech Startups roundup of September 16. Rated HIGH.

Ravel, $8.2M Seed. Company announcement read through VC News Daily; Tech Startups roundup of September 17 citing GeekWire and Dealroom. Rated MEDIUM because no investor is identified in any reviewed source.

Market Comparison Sources

Contrast set: Crunchbase News weekly ranking of the ten largest US rounds for September 12 to 18, 2026: Temporal Technologies ($550M), Impulse Space ($308M extension), Ridgeline ($250M), Cornelis Networks ($205M), Factory ($200M), Profound ($180M), Arcee AI ($150M, reported), Nex ($150M, equity and debt), Mazama Energy ($135M) and Sling Therapeutics ($123M). Those ten totaled $2,251M against $10,560M for the prior week’s ten, a 78.7% fall. Crusoe’s $3.9B Series F was formally announced during the week after earlier reporting. Other sources: Tech Startups daily funding roundups for September 15, 16, 17 and 18; VC News Daily records for September 16 to 18, date-checked against primary releases because its posting dates lag announcements by two to five days; AlleyWatch daily and weekly funding reports of September 14; Fierce Biotech and Fierce Healthcare fundraising trackers; Axios Pro; Pulse 2.0. The September 16 rate decision is sourced to Databoks and same-day Tech Startups coverage.

Prior-period comparisons use only figures that do not depend on a scoring rubric, except the mean score, band, and count above 65, which are comparable only to the September 13 issue. September 7 to 13: twenty-four rounds totaling $787.8M, of which twenty-one totaling $769.0M sat in the $10M to $100M band at an average of $36.62M and a median of $35.0M; stage averages of $50.0M at seed, $30.14M at Series A, $55.00M at Series B and $70.0M at Series C; healthcare at 54.1%; thirteen of twenty-four carrying strategic capital; sixteen of twenty-four with a returning investor; a mean score of 55.8 with seven of twenty-four clearing 65. August 31 to September 6: twenty-five rounds totaling $924.6M at an average of $36.98M. August 24 to 30: twenty-one rounds totaling $543.9M at $25.9M. August 17 to 23: fifteen rounds totaling $545.0M at $36.3M.

Exclusions and Documented Rationale

Giant rounds and rounds at or above the $100M ceiling, excluded by editorial scope and used only as contrast: Crusoe ($3.9B), Temporal Technologies ($550M), Impulse Space ($308M), Ridgeline ($250M), Cornelis Networks ($205M), Factory ($200M), Profound ($180M), Arcee AI (at least $150M, no company-stated amount), Nex (more than $150M blending equity and a credit facility), Mazama Energy ($135M), Sling Therapeutics ($123M), CADDi ($114M) and Delos Data (more than $100M).

Non-US rounds, excluded for scorecard comparability: EUCLYD (more than 200M euro, Netherlands), Open Cosmos (300M euro, United Kingdom), Jack & Jill ($40M, United Kingdom), Integral (18M euro, Germany), Arcos (5.5M euro, Germany), ETFBOOK ($13M, Switzerland), Circuits Integrated Hellas (undisclosed, Greece), Qubot (about $13.8M, China), ENCOS (more than RMB300M, China), Yincheng Intelligence (about RMB100M, China), Kangwei Vision (about RMB100M, China), Nutshell Therapeutics (tens of millions of dollars, China), DeepKernel (tens of millions of RMB, China), EVAS Intelligence (nearly RMB2B, China), Zhongke Guosheng (RMB600M, China), Starroad (more than $10M, Hong Kong), dtcpay ($25M cumulative Series A, Singapore), Yoom (700M yen, Japan) and Ocean (undisclosed, Japan).

Outside the date window, marked news-cycle resurfaced: Highstock ($30M Series A led by Andreessen Horowitz), which circulated on September 14 through a daily funding report but was published by trade coverage on September 11; UrgentIQ ($15M Series A), announced September 11 and scored in the prior issue; Rogo (about $30M, no company-stated amount), excluded in the prior issue and recirculated on September 14; and Ayar Labs ($150M), listed in the prior issue’s contrast set. VC News Daily also reposted The Boring Company, Cognition, Motive, Suniva, and Fab2 on September 18; all five belong to the prior week.

Structural and verification exclusions: Rune ($40M Series A), because only one independent report could be located inside the research window, so the round is excluded rather than counted on a single source; Rapta ($8M), single source with no stage or lead confirmed; Veridion ($20M Series A), because the only US location in the record is a Wilmington, Delaware dateline and US operating headquarters could not be verified; Robigo (Series A, no amount stated).

At or below the $5M floor: Aristotle ($5.0M seed) and CreatorFi ($5.0M), each sitting exactly at the floor and excluded on the same ground that excluded Savvy Wealth at the $100M ceiling in the prior issue.

Geography and date notes. Polaris Electro-Optics’ own release places its headquarters in Carlsbad, California, with operations in Boulder, Colorado; several data providers list Broomfield, Colorado. The company’s statement governs, and the round is counted in California. MIND is counted in Seattle per its release dateline and independent coverage. TeRAM’s financing closed September 10 and was announced September 15; the report counts announcements, so it is included. Circle Pharma’s release is dated September 15, and Fierce Biotech’s tracker dates the round September 16.

Verification Notes

Twenty-one of the twenty-five featured rounds are rated HIGH source confidence, meaning each was confirmed by a company, investor, or regulated newswire source plus at least one independent outlet with no unresolved discrepancy. Four are rated MEDIUM: Ayble Health for a lead attributed by a single secondary source, Gaia Dynamics for the unreconciled gap between its announced seed and its Form D, Pave Finance because no institutional investor is named, and Ravel because no investor is identified. We checked every third-party validation credited in Traction to Conviction against the announcement of the grant, trial, publication, or clinical status rather than against a company characterization of it.

Deals analyzed: 25 verified US mid-market rounds of new primary capital between $5M and $100M. Deals excluded: 13 giant or ceiling rounds, 19 non-US rounds, 4 rounds outside the date window plus 5 reposted prior-week giant rounds, 4 rounds on structural or verification grounds, and 2 rounds at the $5M floor.

Research completion timestamp: September 19, 2026, after the adversarial pass.

DISCLAIMER: This article is for informational and strategic intelligence purposes only. It does not constitute investment advice. The Eisen Fundability Score is a proprietary diagnostic within Fundables OS™, not a financial recommendation.

If this article was useful, share it with founders who are about to raise.

— Leon Eisen, 4x Founder, Venture Capitalist, and Creator of Fundables OS™

Playbook, Perspective, and Pattern for founders raising now. This report strips out giant rounds and public market traffic so you can read the part of the market that actually prices your round. Every figure below survived three independent verification passes against primary sources, the last of them adversarial.

The mid-market gave back most of last week’s rebound. On a like-for-like basis against the same $10M to $100M band the last three issues tracked, capital fell from $924.6M to $769.0M, down 16.8%, and the deal count fell from twenty-five rounds to twenty-one, down 16.0%. Those two numbers moved in lockstep, which matters. The average check barely moved, from $36.98M to $36.62M, down 1.0%, and the median rose 7.7% from $32.5M to $35.0M.

That sequence is the opposite of what this series recorded two weeks ago. In the week of August 24, the pool stayed flat, and the claimants rose 40%, so every check got 29% smaller. This week the pool shrank, and the claimants shrank with it, so the check did not move. Fewer companies got funded. The ones that did got the same round they would have gotten a week ago.

Now the number decided which companies got funded. Sixteen of twenty-four rounds had at least one investor from a prior round writing again. Those sixteen averaged 61.7. The eight rounds with no returning investor averaged 44.1. That is a 17.6-point gap, the widest structural divider this report has measured, and unlike most gaps that size it is almost entirely real: the sub-dimension scoring insider support is worth two points, so 16.2 of the 17.6 sits outside the thing measuring it.

The second number points the same direction from a different angle. Thirteen of twenty-four rounds carried strategic, corporate, or customer-side capital, or 54.2% of rounds and $485.3M of the week’s money. Last week that figure was eight of twenty-eight, or 28.6%. In seven days, the share of mid-market rounds funded in part by somebody who buys, distributes, or manufactures what the company sells nearly doubled.

Consequence for Monday. The queue got shorter, and the check did not, so the binding constraint this week is access, not price. And access is being granted disproportionately by people already in the building: your last round’s investors, and the corporates who already buy from you. Twenty-two of twenty-four rounds had a designated lead, and in two-thirds of them, somebody who had already underwritten this company once underwrote it again. This week’s money didn't come from the cold outbound list.

The Week in One Sentence

Primary insight. Mid-market capital and deal count fell 16.8% and 16.0% together, while the average check held flat, and the rounds that cleared were overwhelmingly the ones where somebody already inside the company’s orbit wrote the check again, whether that was a prior investor re-upping or a buyer joining the cap table.

· Total tracked mid-market capital, 24 verified rounds: $787.8M in new primary capital, every deal between $5M and $100M, every company US-headquartered.

· Like-for-like against prior issues: $769.0M across 21 rounds in the $10M to $100M band the last three issues used, against $924.6M across 25 rounds last week. Capital down 16.8%, deal count down 16.0%.

· Average round size: $32.83M across the full $5M to $100M set. On a like-for-like basis, $36.62M against $36.98M last week, down 1.0%.

· Median round size: $27.0M across the full set. On a like-for-like basis, $35.0M against $32.5M last week, up 7.7%.

· Largest tracked rounds: a tie at $70.0M between Inspiren, a Series C in senior living, and Moonwalk Biosciences, a Series B in obesity therapeutics. Smallest: Overroute at $5.5M.

· Rounds with a designated lead investor: 22 of 24, or 91.7%, against 24 of 28, or 85.7%, last week. Only System and Bulwark Dynamics closed without one.

· Rounds carrying strategic, corporate, or customer-side capital: 13 of 24, or 54.2%, moving $485.3M or 61.6% of the week’s capital, against 8 of 28, or 28.6%, last week.

· Rounds with at least one prior investor returning: 16 of 24, or 66.7%. Those sixteen averaged 61.7 against 44.1 for the eight without.

· Highest Eisen Fundability Score: Latitude at 73. Lowest: System at 30. A band of 43 points, with 7 of 24 rounds clearing 65.

· Defining structural feature: the top of the band is occupied by rounds nobody had to be sold on. All seven rounds clearing 65 carried a returning investor, and five also carried a buyer, channel, or manufacturer on the cap table.

· Framework note: this issue is the first scored on the v2 rubrics. Capital, deal count, check size, stage, sector, geography, and investor behavior remain directly comparable to prior issues. Scores do not, and this report includes no cross-issue score comparisons.

The Deal Scorecard

Eisen Fundability Scores are calculated across five weighted dimensions: Founder-Investor Dynamics (30), Traction-to-Conviction Conversion (25), Narrative Power (20), Deal Architecture (20), and Capital Planning (5). Scores of 85 and above signal an inevitable outcome. Scores of 75 to 84 signal solid fundamentals. Scores of 65 to 74 signal a good company with some gaps. Below 65 signals an early-stage or structurally incomplete company. This issue is scored on the v2 rubrics, in which Traction to Conviction measures what third parties have already underwritten.

What the Scorecard Says at a Glance

The top of the band belongs to rounds nobody had to be sold on. Latitude at 73 came with a seed syndicate re-upping into a round four times larger inside a year. TwoStep at 72 came with Stanford as a shareholder and Pfizer Ventures and M Ventures as co-leads. Inspiren at 71 is the third priced round in twenty months, with Insight Partners and Primary Venture Partners returning. Moonwalk at 70 has ARCH, Khosla, and Future Ventures returning, with Eli Lilly beside them. All seven rounds clearing 65 carried a returning investor, and five of the seven also carried a buyer, channel, or manufacturer on the cap table. Not one round reached the top of this band on new money alone. This is not a market-rewarding discovery. It is a market-rewarding continuity.

The strongest single position in the issue costs $12M and belongs to a construction software company. Buildcheck scored 18 of 20 on Deal Architecture, the highest mark on any dimension anywhere in the set, because WND Ventures is DPR Construction’s venture arm and DPR Construction is a named customer. The investor is the buyer. That collapses the two hardest questions in an enterprise Series A, whether the product works and whether anyone will pay for it, into one cap table entry a diligence team can confirm with a single call. It is the twentieth largest round of twenty-four, and it finished fifth.

The most expensive lesson in the scorecard costs $55M and sits at 42. Tectora Therapeutics raised a Series A co-founded by Schrödinger, New Enterprise Associates, and RA Capital Management, which is as strong an institutional trio as this issue contains, and scored 9 of 10 on Investor Quality accordingly. It then scored 0 of 10 on Founder Track Record because no chief executive, founder, or employee is named anywhere, 3 of 25 on Traction to Conviction because two preclinical program codes are the entire asset base, and 0 of 5 on Capital Planning because a newco has no prior round to be re-underwritten against. Elite investors do not carry a round on their own. They carry one dimension of five.

The floor is a structural story, not a quality story. System scored 30 on a $20.0M round with no stage, no designated lead, no headquarters, and seven investors, none of whom is identified as setting the price. UrgentIQ scored 39 on a sole-investor first institutional round with no counterparty of any kind in the record. Enigmata scored 39 emerging from stealth. These are real companies and the money is real. The score measures how much of the transaction a new investor could reconstruct; in all three cases, the answer is the amount and almost nothing structural.

Size and score remain uncorrelated for a fourth consecutive issue. Buildcheck at $12.0M outscored Poseidon Aerospace at $60.0M by seventeen points. Luminary at $22.0M outscored Tectora at $55.0M by twenty-four. Overroute at $5.5M outscored Vheda Health at $47.0M by eight. If you are calibrating your ask against what the biggest rounds got, you are calibrating against a variable that predicts nothing.

What Changed This Week: Five Market Shifts

We verify each shift against multiple sources and rank it by structural impact on founder fundraising, not deal size. Every shift ends with what it means for your raise next week.

Shift 1: The Queue Got Shorter, and the Check Did Not

Pattern, what happened. On a like-for-like $10M to $100M band, twenty-one verified rounds moved $769.0M against twenty-five rounds moving $924.6M the week before. Capital fell 16.8%, and deal count fell 16.0%, within a point of each other. Average check size fell 1.0%, from $36.98M to $36.62M. The median rose 7.7%, from $32.5M to $35.0M. Geography concentrated hard alongside it: California took $408.3M across ten of twenty-four rounds, or 51.8%, against 17.4% across six of twenty-eight last week.

Perspective, what it means. There are only two ways a capital pool can shrink. It can shrink per company, which is a repricing, or it can shrink by company count, which is a narrowing. Two weeks ago, this market repriced: flat capital across 40% more claimants cut every check 29%. This week it narrowed: capital and claimants fell together, and the check stayed the same size. Those two conditions demand opposite founder responses, and founders routinely apply the wrong one. In a repricing, you resize the ask. In a narrowing, the ask is fine, and the problem is getting into the shorter queue at all, because the same partners are writing the same checks to fewer companies.

Founder Blindspot, what most miss. Founders read a falling capital total as a signal to lower their number. Look at the median, which rose 7.7% in the same week the total fell 16.8%. The typical funded company got a larger round than the typical funded company a week earlier. If you cut your ask in response to the headline, you will be negotiating against a market that didn't cut anything, and you will hand back dilution you didn't have to give.

Playbook, what to do. Keep your number and change your qualification standard instead. Cut every name from your investor list where you cannot write one sentence naming a deal that firm led in your stage and category in the last ninety days. In a narrowing market, the constraint is not price; it is access to the specific partners still deploying, and a list built on brand rather than recent behavior takes three months to disprove. Then add back from the firms that actually led a mid-market round in these five days: Greylock, Oak HC/FT, Bessemer, FPV Ventures, Telescope Partners, Flare Capital, Five Elms, NewView Capital, Insight Partners, BVF Partners, Silverton Partners, AlleyCorp, Ten Coves Capital, Fin Capital, Inflection Equity, TQ Ventures, UP. Partners and Andreessen Horowitz.

Contrast. The week of August 24 held capital flat and added 40% more deals, cutting the average check by 28.7%. The week of August 31 reversed it, adding 70% more capital and 43% larger checks. This week did neither. It removed capital and companies in equal measure and left the price of a round untouched, which is the first week in this series where the round itself was stable.

What this means for your raise: The market did not get cheaper; it got smaller. Hold your ask, cut your list to the firms that actually wrote in your lane in the last ninety days, and spend the saved time on access rather than on price.

Shift 2: Healthcare Took More Than Half the Market

Pattern, what happened. Healthcare and life sciences took $426.0M across ten of twenty-four rounds, or 54.1% of the week’s mid-market capital. Last week, the sector took 40.3% across ten of twenty-eight rounds. Two weeks before that, it took 19.1% across five of twenty-one. The sector’s share has now risen for three consecutive issues and has nearly tripled from the August 24 trough. Inside the sector, the split runs $237.5M to therapeutics across four rounds and $188.5M to healthcare services and software across six. Enterprise AI and software took 16.9% across seven rounds, defense, aerospace, and industrial hardware 13.6% across three, fintech and payments 9.1% across three, and energy and climate 6.3% in a single round.

Perspective, what it means. Healthcare absorbing half a mid-market is a story about what can be underwritten quickly. Healthcare has the densest supply of externally controlled checkpoints. An FDA IND clearance is a dated, binary event owned by a regulator. A menin inhibitor selected for oral presentation at the European Association for the Study of Diabetes is a validation granted by a scientific body. A medical license, a payer contract, a CMS designation: all of these are facts a third party controls, which means an investment committee can verify them in an afternoon rather than a month. In a week when the market narrowed and partners had less time per company, capital flowed to the category where verification is cheapest.

Founder Blindspot, what most miss. Founders outside healthcare read this as a sector rotation and start hunting for a healthcare angle. Wrong lesson, and it costs a quarter to learn. The transferable move is structural, not thematic: these rounds cleared because they carried a checkpoint the company does not control. Impossible Objects proves it generalizes. It is not a healthcare company. It scored 9 of 10 on Independent Validation, the highest mark on that sub-dimension in the issue, on named Air Force, Air Force Research Laboratory, and Army Rock Island Arsenal relationships plus roughly $20M in government contracts and SBIR awards, and it cleared a $40M Series B from a lead most founders have never heard of.

Playbook, what to do. Write down every checkpoint in your business that a third party controls and could confirm without asking you: a certification, an audit, a regulatory clearance, a government contract vehicle, a state license, a published benchmark, a standards body listing. Count them. If the count is zero, every claim in your process depends on an investor taking your word for it, and in a narrowing market that is the slowest possible path. Then pick the one you can obtain fastest and start it this quarter, because these take two to four months and each one converts a claim into a fact somebody else owns.

Contrast. Last week healthcare’s 40.3% share arrived alongside a 70% rise in total capital, so every sector grew. This week, healthcare’s share rose again while the total fell 16.8%, meaning the sector grew in absolute terms as the market shrank around it. That is a genuine reallocation rather than a rising tide, and it is the second consecutive week the concentration has deepened.

What this means for your raise: Stop competing on category and start competing on verification speed. The question that decided this week was how much of your case an investment committee could confirm without you in the room.

Shift 3: Your Existing Investors Became the Signal

Pattern, what happened. Sixteen of twenty-four rounds carried at least one investor from a prior round. Those sixteen averaged 61.7 against 44.1 for the eight rounds with no returning investor, a 17.6-point gap and the widest structural divider in the issue. The Capital Planning sub-dimension scores insider support on a 2-point scale, so 16.2 of that 17.6 sits entirely outside the measure. Six rounds went further and were re-underwritten inside eighteen months at a larger size: Bluecore Energy, Lightfield, Latitude, Antioch, Buildcheck and Overroute. Those six averaged 62.0 against 53.8 for the other eighteen.

Perspective, what it means. An existing investor re-upping is the only signal in a funding announcement carrying information a new investor cannot get any other way. Every other party is underwriting from the outside. Your Series A lead has sat on your board, seen twelve months of monthly reporting, watched you miss a plan and recover, and watched how you behave when a key hire quits. When that person writes again, and writes larger, they are pricing information no diligence process can reproduce in six weeks. That is why the gap is 17.6 points and why it survives stripping the mechanical component almost intact: rounds with insider re-ups are not scoring higher because the framework hands them two points. They score higher across founder quality, syndicate strength, round construction, and velocity simultaneously because one underlying fact drives all of them.

Founder Blindspot, what most miss. Founders treat existing investors as a fallback to approach after the new-money process stalls, on the theory that going to insiders first signals weakness. This week’s data says the reverse, and the mechanism is simple: a new lead reads a round with no insider participation and asks one question, which is what the people who know this company best decided to do. No one has a good answer. Eight companies this week had to answer it, and they averaged 44.1. Note the asymmetry in effort too. Securing an insider commitment takes two conversations with people who already take your calls, versus a twelve-week process with people who don't.

Playbook, what to do. This is the highest leverage action in this issue. Before you open any process, go to every investor on your cap table with a board seat or a meaningful position and ask for a specific number in writing, not general support. Ask what they will put in at a price they consider fair, and ask whether they would lead if nobody else does. Do this four weeks before you plan to open, not after the first two passes. You are buying three things with those conversations: a floor under the round, a number to quote to new leads, and, if the answer is no, the single most valuable piece of diligence output available to you, delivered free and three months early. If the people who know you best will not re-up, fix that before you spend a quarter discovering it from strangers.

Contrast. Last week’s issue found four of twenty-eight rounds closing with no named institutional lead and treated the lead seat as the structural question. This week, the lead seat is close to universal at twenty-two of twenty-four, and the variable that separated the field moved one step further back: whether anybody who had already funded this company was willing to do it again.

What this means for your raise: Your existing cap table is not the backup plan. It is the first call; it is the cheapest diligence you will ever buy, and this week it was worth 17.6 points.

Shift 4: The Buyer Showed Up on the Cap Table

Pattern, what happened. Thirteen of twenty-four rounds carried strategic, corporate, or customer-side capital, or 54.2% of rounds and $485.3M, which is 61.6% of the week’s mid-market money. Last week that figure was eight of twenty-eight, or 28.6%. In eight of those thirteen, the investor is specifically a buyer, a distribution channel, or a manufacturer, and those eight averaged 63.9 against 51.8 for the other sixteen, a 12.1-point gap that holds at 6.4 after removing the sub-dimension scoring it. Buildcheck took money from DPR Construction’s venture arm while DPR is a named customer. Overroute was built with J.B. Hunt through UP. Labs and is deployed across all of J.B. Hunt’s business units. Luminary took money from BNY, Focus Financial Partners, and Rockefeller Capital Management, all of whom buy exactly what it sells. Bulwark Dynamics took money from Onomichi Dockyard and signed a serial production agreement with it in the same announcement. Moonwalk, TwoStep, Caspian, and Blee each carry a pharma or bank strategic.

Perspective, what it means. A financial investor is buying a claim about future demand. A strategic buyer has already tested that claim through its own procurement process, and the check is the receipt. That is why the structure compounds: it prices the round, it de-risks the top line, and it pre-clears the next twelve buyers in the pipeline, who no longer have to be the first mover in their peer group. In an enterprise sale with a nine-month cycle, that third effect is worth more than the capital. Bulwark Dynamics is the most extreme version this week. A $6.8M seed with no designated lead and a founder whose background is not on the public record scored 56, above rounds eight times its size, because the manufacturer that will build the vessels invested in the company that designed them.

Founder Blindspot, what most miss. Founders rank corporate money below venture money, assuming it is slower, more conditional, and a negative signal to the next round. This week, it was the second-strongest structural variable in the market. The real cost of strategic capital is not reputational; it is contractual: a right of first refusal on an acquisition, category exclusivity, or a channel lockout that shrinks your buyer universe permanently. Founders worry about the wrong risk and then sign the clause that creates the real one.

Playbook, what to do. Build a second target list this week, twelve names long, of corporates who either buy what you sell or sell to who you sell to. For each one, write the specific first customer they can deliver inside ninety days, and the name of the person who runs their venture arm. Then, before any of them offers, have counsel pre-draft your position on three clauses: right of first refusal on an acquisition, category exclusivity, and information rights that would let a strategic see your roadmap. Decide those positions in advance as policy, because deciding them under a live term sheet is how founders give away the buyer universe to close the round.

Contrast. Two weeks ago, nine of twenty-one rounds carried strategic money at 42.9%. Last week that fell to eight of twenty-eight (28.6%) as financial venture firms took back the lead seat. This week it jumped to thirteen of twenty-four at 54.2%, the highest share this series has recorded, and for the first time the strategics are not just participating. Onomichi Dockyard, UP. Partners and WND Ventures are structuring the companies they invest in.

What this means for your raise: Rank your investor list by which customer each name delivers, not by which name looks best in the announcement. And settle your exclusivity position before anyone offers, not after.

Shift 5: Series A Swallowed the Market

Pattern, what happened. Fourteen of twenty-four rounds were Series A, totaling $422.0M, or 53.6% of the week’s mid-market capital. Last week, seven of twenty-eight rounds were Series A, totaling $213.0M, or 22.6%. The deal count doubled, and the share more than doubled, while the average Series A check fell 0.9%, from $30.43M to $30.14M. Series B produced two rounds for a third consecutive issue, but the average check rose 111.5% from $26.00M to $55.00M on Moonwalk at $70.0M and Impossible Objects at $40.0M. Seed produced three rounds against six, and only one of them, Bluecore at $50.0M, fell inside the $10M to $100M band at all. Series C produced one round, Inspiren at $70.0M.

Perspective, what it means. A market that puts more than half its capital into one stage is telling you where its risk tolerance sits, and Series A is a very specific place. It is late enough that a team and a product exist and early enough that no repeatable unit economics are required. It is also the stage where an insider re-up is most available, because the seed investors are still close to the company and the round is small enough for them to move it. Ten of the fourteen Series A rounds this week carried a returning investor. Series B stayed at two rounds for a third week, which is now a pattern rather than a holiday effect, and both that cleared did so with a strategic attached and at more than double the price.

Founder Blindspot, what most miss. Founders at Series B have watched three consecutive weeks in which two rounds cleared out of twenty-one to twenty-eight, and keep reading the headline capital number instead of the lane number. Two of twenty-four is an 8.3% share of deals. What changed this week is that the two that cleared did so at a $55M average, up from $26M, and both carried a corporate strategic. Series B did not get easier. It got rarer, more expensive, and conditional on having a buyer or a pharma partner already committed.

Playbook, what to do. If you are twelve months or more from a Series B, spend one month instrumenting the three numbers that stage is priced on and nothing else: fully loaded customer acquisition cost, gross margin by product line, and the percentage of last year’s revenue base still present this year. Not a dashboard, three numbers with a defensible method behind each, ready to hand over within a week of being asked. If you are inside six months, make the honest call between an extension at your Series A price with existing investors and a tight process aimed only at firms that wrote a Series B in your category this quarter. No third path exists where a broad process works, because the lane is 8.3% of deals wide. And if you are raising a Series A, note that you are raising into the only stage in this market with real depth: fourteen rounds, more than half the capital, at a price that did not move.

Contrast. Last week, Series A was seven of twenty-eight rounds and 22.6% of capital, and the story was that seed and Series A had both reopened while Series B closed. This week, seed closed too, and Series A absorbed what seed and Series C gave up. The market has narrowed to a single funded stage plus exceptions.

What this means for your raise: If your round is a Series A, the depth is there, and the price did not move, so run it now. If it is a Series B, you are competing for one of roughly two slots a week, and the entry price has doubled.

The Deals That Matter: Top 5

Five deep dives across stablecoin settlement rails, oncology therapeutics, senior living AI, obesity therapeutics, and construction design review. These are the five highest-scoring rounds of the week. All facts are verified against two or more sources and re-checked in two further passes.

Latitude

Stablecoin Settlement into Local Payment Rails | Series A | $35.0M | Led by Oak HC/FT

Eisen Fundability Score: 73 / 100

Why this scored. The highest score of the week and the only round in the issue that is strong on all five dimensions at once. Latitude carries the most precisely assembled founding team in the set, a precise thesis lead, a licensing position a regulator confirms rather than the company, a four-times step in round size in a year, and seed investors coming back. Nothing here is spectacular in isolation. Nothing is weak either, and in a five-dimensional framework, that is what wins.

The Setup. Latitude, headquartered in San Francisco, converts stablecoin settlement into local currency on local rails: Pix in Brazil, UPI in India, mobile money in Kenya. The recipient never touches a wallet and never knows a stablecoin was involved. Co-founders Cyril Mathew, Brian Wrightson, and Vivek Morzaria came out of Stripe, Coinbase, Meta, Uber, and Zero Hash, the most exactly matched founding team in the issue for the problem being solved: one half has built payment infrastructure and the other half has built crypto settlement, and the entire product is the seam between them. Customers are payroll platforms, marketplaces, fintechs, and wallets.

The Deal. $35.0M Series A led by Oak HC/FT, announced September 9, 2026, with NEA, Coinbase Ventures, Lightspeed Faction, OpenFX, and Wilson Sonsini participating. Total capital $43M including an $8M seed earlier in 2026, which makes this a four times step inside twelve months with seed investors returning. Licensed or approved to operate in 45 US markets. Customers across more than 50 countries. All equity, no credit facility.

The Pattern. This is the regulatory surface round. Latitude’s strongest asset is not a product claim; it is permission: licensed or approved in 45 US markets, a status granted by fifty separate regulators, revocable by them, and checkable by any investor who opens a state register. In cross-border payments, that is the actual barrier to entry. It takes years to accumulate; you can't buy it with a larger round, and a competitor with more volume and fewer licenses isn't ahead.

The Perspective. Look at what the licensing position does to the round’s construction. A company whose moat is regulatory approval has a use of funds legible at a glance: more licenses, more corridors, more local rail integrations, each with a known cost and a known timeline. That is why Round Construction scored 7 of 8. Compare it to Poseidon Aerospace, which raised $60M ahead of a first flight and scored 3 on the same sub-dimension. Same market, same week, opposite clarity about what the money buys. When your moat has a unit cost, your round has a defensible size.

The Playbook. If you operate in a licensed, certified, or accredited category, count your permissions against the total available. Money transmitter licenses held against fifty states. Payer contracts against the top twenty. Certifications against the full standard. Corridors live against corridors targeted. Then build your use of funds directly on that denominator, so the ask and the moat are the same sentence. If your category has no licensing regime, find the nearest equivalent: a standards body listing, a security certification, a prime contract vehicle. The asset you want is one a third party grants and can take away.

The Founder Mistake to Avoid. Founders with an exceptional team treat the resume as the round and let everything else arrive late. Latitude’s founders are from Stripe, Coinbase, Meta, Uber, and Zero Hash, and the team is worth 7 of 10, not 10 of 10, because none of them carries a prior exit. The 73 came from the team, the licenses, the step-up, the insider re-up, and the thesis fit. Five things. If your case rests on one of them, you are one skeptical partner away from a slow no.

TwoStep Therapeutics

Peptide-Drug Conjugates in Oncology | Series A | $62.5M | Co-led by Insight Partners and Medical Excellence Capital

Eisen Fundability Score: 72 / 100

Why this scored. The joint strongest Founder-Investor Dynamics mark in the issue at 25 of 30, on four Stanford faculty founders including a Nobel laureate, four co-leads, and an explicitly oversubscribed round. It is also one of only five rounds in the week carrying an externally controlled validation, in this case an FDA clearance granted in the same announcement as the money.

The Setup. TwoStep Therapeutics, headquartered in San Carlos, California, builds peptide-drug conjugates designed to reach tumor targets antibodies cannot. Chief executive Caitlyn Miller founded the company with Jennifer Cochran, Carolyn Bertozzi, and Ronald Levy, all Stanford faculty, including Nobel laureate Carolyn Bertozzi. Stanford University itself is on the cap table. Lead program TS-104 couples a polyspecific integrin-binding peptide with an MMAE cytotoxic payload.

The Deal. $62.5M oversubscribed Series A co-led by Insight Partners and Medical Excellence Capital, announced September 9, 2026, with M Ventures and Pfizer Ventures as co-leads and NFX, 2048 Ventures, and Stanford University participating. Announced simultaneously with FDA clearance of the IND for TS-104. Phase 1 expected to begin later in 2026. Total capital raised: $71.2M.

The Pattern. This is the paired-announcement round, and the timing is the entire lesson. TwoStep did not announce a financing and then a clearance, or a clearance and then a financing. It announced both in one release, which means the round was structured so the IND landed inside the announcement window. That converts a funding release into a regulatory event, and a regulatory event is the one kind of news an investment committee can verify in a public database in under a minute.

The Perspective. Four co-leads is unusual, and it is worth understanding why it happened rather than treating it as a syndicate accident. Insight Partners brings capital scale, Medical Excellence Capital brings clinical development judgment, and M Ventures and Pfizer Ventures are the venture arms of two large pharmaceutical companies. Those last two are not financial investors. They are the acquirers, sitting on the cap table from the Series A, which means the exit conversation starts eighteen months before anyone needs it to. For a preclinical asset company, that structure is the closest thing to a de-risked path.

The Playbook. Time your next externally controlled milestone to land inside your financing window, and negotiate the announcement sequencing into the process rather than leaving it to your communications team. A clearance, a contract award, a certification, or a standards listing that arrives three weeks after your round closes is worth a fraction of the same event landing in the same release. Work backward: find the dated third-party event on your eighteen-month roadmap, then set your process to close within four weeks. This is deal architecture, not public relations, and it is why a preclinical company scored 72.

The Founder Mistake to Avoid. Founders see four co-leads and read it as overwhelming demand. Sometimes it is. It can also happen when no single firm will take the full position and the round is assembled from four partial commitments. The distinguishing fact here is the word oversubscribed alongside co-leads of that quality, not the count itself. If you find yourself with four co-leads and no oversubscription, you have a syndication problem wearing a validation costume, and the next round’s lead will read the cap table that way.

Inspiren

Physical AI for Senior Living | Series C | $70.0M | Led by NewView Capital

Eisen Fundability Score: 71 / 100

Why this scored. The highest Narrative Power mark in the issue at 19 of 20, and the clearest velocity story in the set: three priced rounds in twenty months with the Series B lead returning. Inspiren also has the deepest named-operator footprint of any healthcare services company this week, with three senior living operators whose procurement teams can be called by any investor running diligence.

The Setup. Inspiren, founded in 2016 and headquartered in New York, sells an ambient awareness platform combining sensors, AI, and clinical support to monitor residents, automate care documentation, predict falls, and respond to emergencies in assisted living communities. Founder and chief clinical officer Michael Wang is a former Green Beret who became a cardiothoracic nurse, and Alex Hejnosz is chief executive. That biography does real work in a category where the buyer is a director of nursing and the product has to survive a night shift.

The Deal. $70.0M Series C led by NewView Capital, announced September 10, 2026, with Insight Partners, Primary Venture Partners, Scale Venture Partners, Vintage Investment Partners, Lightbank, Avenir Growth Capital, Story Ventures and Camber Creek participating. Third priced round in twenty months, after a $35M Series A in early 2025 and a $100M Series B in September 2025. Total capital: $225M. Insight Partners led the Series B and returns here. Named operator relationships with Aegis Living, Clearwater Living, and Solera Senior Living.

The Pattern. This is the re-underwriting round, and the cadence is the signal. Three priced rounds in twenty months means Inspiren has been through institutional diligence three separate times in under two years, each time with a new lead taking the top of the round and the previous lead staying in. Each pass is an independent investment committee reaching the same conclusion with more information than the last. No single announcement can manufacture that. It accrues.

The Perspective. Camber Creek is the investor most founders will skip over, and it is the one worth studying. Camber Creek’s limited partners are real estate owners and operators, and senior living is a real estate business with a care operation inside it. That is a channel, not a logo. In a category where the purchase decision runs through property ownership as much as through clinical leadership, having the real estate capital side on your cap table shortens a sales cycle that otherwise requires convincing two separate constituencies independently. The lesson generalizes: in any category where the buyer and the budget holder are different people, find an investor whose limited partners are the budget holder.

The Playbook. Map your buying committee before you map your investor list. Write down every party who has to say yes for a sale to close: the operational user, the clinical or technical approver, the budget owner, and the party that owns the asset your product sits on. Then find one investor aligned to each constituency you do not already have covered, and rank your target list on that basis rather than on fund size. Inspiren has an institutional growth lead, a scale specialist, an early-stage believer, and a real estate channel on one cap table. That is not a party round. That is a buying committee mapped onto a syndicate.

The Founder Mistake to Avoid. Founders read a three-rounds-in-twenty-months cadence as proof that fast is good and go raise before they need to. Look at the sizes: $35M, then $100M, then $70M. The Series C is smaller than the Series B. A company raising faster than its milestones arrive eventually takes a round that does not step up in size, and the next investor reads that sequence exactly as written. Velocity is a signal when each round is bought on milestones. It is a warning when it is bought by a burn rate.

Moonwalk Biosciences

Adipose-Targeted RNAi for Obesity | Series B | $70.0M | Co-led by Alpha Wave and YK Bioventures

Eisen Fundability Score: 70 / 100

Why this scored. The joint strongest Founder-Investor Dynamics mark in the issue at 25 of 30, on a chief executive who ran technology at Illumina, two co-leads, an explicitly oversubscribed round, and three prior investors returning alongside Eli Lilly. It is one of three rounds in the issue to use the word oversubscribed and the only one where the dominant commercial player in the category is on the cap table.

The Setup. Moonwalk Biosciences, based in South San Francisco and San Diego, develops tissue-targeted siRNA medicines acting directly on fat tissue rather than through the incretin pathway GLP-1 drugs use. Chief executive and co-founder Alex Aravanis, a former chief technology officer of Illumina, built the company with Arash Jamshidi and Justin Valley. The positioning is a specific dissatisfaction with the incumbent class: incretins cause weight loss that includes lean muscle, and Moonwalk’s preclinical work targets fat mass while preserving lean mass, with non-human primate data supporting quarterly or twice-yearly dosing.

The Deal. $70.0M oversubscribed Series B co-led by Alpha Wave and YK Bioventures, announced September 8, 2026, with Eli Lilly and Company, Gaorong Ventures, ARCH Venture Partners, Khosla Ventures and Future Ventures participating. ARCH, Khosla, and Future Ventures all returned from the $57M Series A in January 2024. Total capital: $127M. Lead candidate MW101 expected to enter first-in-human studies in late 2027. Dr. Stephen Djedjos appointed senior vice president of clinical development alongside the round.

The Pattern. This is the incumbent-critique round backed by the incumbent. Moonwalk positioned not against other RNAi companies but against the world's best-selling drug class, on a specific defect patients and physicians already complain about. Then Eli Lilly, which owns a large share of that class, put money in. Read that as what it is: simultaneously a validation of the thesis and a hedge against it by the party with the most to lose if the thesis is right.

The Perspective. Three investors from the Series A returning into an oversubscribed Series B is the structural fact doing most of the work here, and it operates differently from the insider re-ups elsewhere in this issue. ARCH, Khosla, and Future Ventures have watched this platform through two and a half years of preclinical work. They have seen every experiment that did not work, which is information no new investor gets. When they write again into a round that is oversubscribed, they are competing for allocation against new money on the strength of what they know and the new money does not. That is the strongest form the signal takes.

The Playbook. If your existing investors are going to re-up, get them to commit before you open to new money, and then let the new money compete for what is left. The sequence matters more than founders think. Insiders committing after a new lead prices the round reads as support. Insiders committing first, so the round is partly filled before a new lead sees it, reads as competition, and it changes the price. Ask each existing investor for a specific number four weeks before you open, then use that number as the floor for new leads rather than the ask.

The Founder Mistake to Avoid. Founders take a strategic investor’s participation as endorsement and stop negotiating. Eli Lilly writing into a competitor in its own franchise is a hedge, and the attached terms decide whether it helps or constrains. Before taking strategic money from the company you are positioning against, have counsel write down your position on right of first refusal, category exclusivity, information rights, and board observation, because those terms determine whether the other eight potential acquirers can still bid in 2029.

Buildcheck

Vision-Based AI for Construction Drawing Review | Series A | $12.0M | Led by Telescope Partners

Eisen Fundability Score: 67 / 100

Why this scored. The highest Deal Architecture mark on any round in the issue at 18 of 20, in the twentieth largest round of twenty-four. Buildcheck scored 7 of 8 on Customer-Side Capital and 7 of 7 on Market Adoption because WND Ventures is DPR Construction’s venture arm and DPR Construction is a named customer, alongside four other named construction firms. The investor is the buyer, and the buyer brought four peers.

The Setup. Buildcheck, founded at Stanford and headquartered in San Francisco, runs vision-based AI over construction drawings to catch design errors before they reach the field. The problem is expensive and specific: design errors cost the construction industry more than $200B annually, and the review that would catch them still falls to a senior engineer reading sheets. Chief executive Alexander Michalatos co-founded the company with Andrei Molchynsky and chief technology officer Alex Gureiev.

The Deal. $12.0M Series A led by Telescope Partners, announced September 9, 2026, with WND Ventures, Uncork Capital, Salt VC and Xfund participating. Named customer relationships with DPR Construction, EllisDon, Power Construction Company, EMJ Construction, and IMC Construction. Total capital $18M including a $5.9M seed nine months earlier, with Uncork returning. Use of funds specified across four named product modules: Custom Checks, Diffs, Code Reviews, and Value Engineering.

The Pattern. This is the buyer-as-investor round in its purest form. The single cap table entry, WND Ventures, does three jobs at once. It prices part of the round. It confirms DPR ran the product through a real procurement process and chose to deepen the relationship with equity. And it gives every other general contractor in the pipeline permission to move, because a peer they respect has absorbed the first-mover risk. Four other named construction firms in the same announcement are what that permission looks like in practice.

The Perspective. Now look at the round size. $12.0M with four named product modules attached is the most precisely constructed raise in the issue, and precision is why it scored 8 of 8 on Round Construction against a set where most rounds scored 5 or 6. A $12M round with four named deliverables is a claim an investor can audit in twelve months. A $60M round to reach a first flight, which is what Poseidon raised, is not. Founders optimize for the largest number they can defend. The framework, and the market, reward the number that maps to something countable.

The Playbook. Ask your two best enterprise customers whether their organization has a venture arm, a strategic investment vehicle, or an innovation fund, and whether it would take a small position in your round. Most large contractors, health systems, utilities, banks, carriers, and retailers have one, and the check size they write is small enough that the ask is not awkward. You are not raising from them for the capital. You are raising so the next twelve buyers in your pipeline never have to be the first, and so the round has a party in it whose reference call is a procurement record, not an opinion.

The Founder Mistake to Avoid. Founders chase the strategic investor and forget that a venture arm and a purchase order are different things. WND Ventures investing means DPR’s innovation group approved a position. DPR Construction being a named customer means DPR’s operating business bought the product. Buildcheck has both, and the second is what makes the first worth something. If a corporate venture arm wants in but the operating business has not bought, you have an option on a relationship rather than a purchase, and the next round’s lead will find that out.

The Fundraising Playbook: Five Tactical Plans

Five plans, each producing a concrete artifact you can use immediately. No vague tasks. Each is built directly from this week’s verified signals.

1. The Buying Committee Map (Narrative and Investor Framing)

Why this matters. Thirteen of twenty-four rounds carried strategic, corporate, or customer-side capital, or 54.2% of rounds and 61.6% of the week’s capital, up from 28.6% of rounds last week. Inspiren has an institutional growth lead, a scale specialist, an early believer, and a real estate channel on one cap table. Buildcheck has the investor and the buyer as the same institution. These are not party rounds. They are buying committees mapped onto syndicates.

Exact deliverable. One page, two columns. Left column: every party who must say yes for a sale to close, meaning the operational user, the technical or clinical approver, the budget owner, and whoever owns the asset your product sits on. Right column: which investor on your target list is aligned to each of those constituencies, and what specifically they can unlock in ninety days. Any row with an empty right column is a gap in your syndicate, not a gap in your pitch.

Time estimate. Three hours to build the map, plus two calls with your best customer’s procurement contact to confirm you have the committee right rather than guessing at it.

Expected outcome. Your investor target list is ranked by what each name removes from your sales cycle, not by fund size. In a week when more than half the mid-market took money from someone with a commercial relationship, that ranking is the difference between a syndicate and a cap table that sells for you.

The reframe. Wrong approach: rank investors by brand and treat corporates as a fallback. Right approach: rank by which member of your buying committee each investor already controls.

2. Acquire One Externally Controlled Checkpoint (Proof Architecture)

Why this matters. Five of twenty-four rounds carried a checkpoint controlled and confirmed by an outside body, and those five averaged 65.4 against 53.3 for the other nineteen, a 12.1-point gap that holds at 6.6 after removing the sub-dimension. Impossible Objects scored 9 of 10 on that sub-dimension on Air Force, AFRL, and Army Rock Island Arsenal contract vehicles and cleared $40M from a lead most founders have never heard of. TwoStep announced an FDA clearance in the same release as the round. Latitude counts 45 US market licenses it does not grant itself.

Exact deliverable. A one-page inventory of every checkpoint in your business a third party controls and could confirm without asking you, in three columns: the checkpoint, the body that grants it, and whether you currently hold it. Certifications, audits, regulatory clearances, government contract vehicles, state licenses, standards body listings, published benchmarks, accreditations. Count the ones you hold. Then mark the single missing one you could obtain fastest and put a start date on it this quarter.

Time estimate. Three hours for the inventory. Two to four months to obtain the first missing checkpoint, which is exactly why the start date goes in this quarter rather than when you open a process.

Expected outcome. You stop asking an investment committee to take your word for your business's central claim. In a narrowing market where partners have less time per company, the proportion of your case a third party already owns is what determines how fast a decision can be made.

The reframe. Wrong approach: build a case an investor has to accept on trust. Right approach: count the facts about you somebody else already certifies, and go get one more.

3. Eisen Self-Score and Gap Diagnosis (Readiness)

Why this matters. The band ran 30 to 73 this week with a mean of 55.8 and seven of twenty-four rounds clearing 65. A 43-point spread means the market is discriminating sharply, and the discrimination is structural rather than narrative: Tectora raised $55M from NEA and RA Capital and scored 42 because four of five dimensions were thin. Buildcheck raised $12M and scored 67 because none of them were.

Exact deliverable. Score your round across the five dimensions on the v2 rubrics: Founder-Investor Dynamics (30), Traction to Conviction (25), Narrative Power (20), Deal Architecture (20), and Capital Planning (5). Then apply this week’s specific test. Above 65, and you are in the top third of what actually cleared, so run a parallel process with a deadline. Between 50 and 65, you are in the crowded middle where ten of twenty-four rounds sat, so you will be priced like them unless you fix your lowest dimension first. Below 50, your problem is structural: no lead, no returning investor, no external checkpoint, and no amount of process design fixes that.

Time estimate. Two to three hours, repeated before every raise.

Expected outcome. A decision about process design rather than a list of weaknesses. The score tells you whether to run a competitive process now or spend a repair sprint first, and running the wrong one costs a quarter.

The reframe. Wrong approach: score yourself, feel discouraged, revise the deck. Right approach: score yourself, identify your two lowest dimensions, and decide this week between a competitive process and a repair sprint.

4. Secure the Insider Commitment Before You Open (Deal Architecture)

Why this matters. This is the highest leverage plan in the issue. Sixteen of twenty-four rounds carried a returning investor and averaged 61.7 against 44.1 for the eight that did not, a 17.6-point gap, of which 16.2 sits outside the sub-dimension scoring it. Moonwalk’s oversubscribed Series B had three Series A investors competing for allocation. Inspiren’s Series C had the Series B lead returning. Six rounds were re-underwritten inside eighteen months at a larger size and averaged 62.0.

Exact deliverable. Two outputs, in this order. First, four weeks before you plan to open, go to every investor on your cap table with a board seat or a meaningful position and ask for a specific number in writing, plus a yes or no on whether they would lead if nobody else does. Not general support. A number and a lead answer. Second, build your new-money target list only after you have those answers, and quote the insider number as the floor rather than the ask. If any existing investor declines, ask one question and write down the answer: what would have to be true for you to write again. That answer is diligence output you would otherwise pay a quarter to obtain from strangers.

Time estimate. Two weeks of calendar for the conversations, four hours of preparation. Compare that to a twelve-week process with people who have never met you.

Expected outcome. You open with a floor under the round, a number to quote, and either a strong signal to lead with or the single most valuable piece of negative information available to you, three months early and free.

The reframe. Wrong approach: run the new-money process first and go to insiders if it stalls. Right approach: get the insider number in writing before you open, and let new money compete for what is left.

5. Pick Your Lane Before You Pick Your Letter (Momentum and Conversion)

Why this matters. Fourteen of twenty-four rounds were Series A, taking 53.6% of the week’s capital at an average check of $30.14M, flat for two weeks. Series B produced two rounds for a third consecutive issue, an 8.3% share of deals, at an average check that rose 111.5% to $55.00M, and both carried a corporate strategic. This market has one deep lane and two narrow ones.

Exact deliverable. Answer three questions in numbers, with a defensible method behind each, before you attach a letter to your round: fully loaded customer acquisition cost, lifetime value, and the percentage of last year’s revenue base still present this year. If all three are ready to hand over within a week of being asked, you are a Series B, and you should run a tight process against the small set of firms that actually wrote one this quarter. If they are not, you are a Series A regardless of what your last round was called, and you should run into the lane with fourteen slots a week and a price that has not moved. Then write one page naming the milestone the round buys and the date it lands.

Time estimate. Four hours with your finance lead on the three numbers, one hour on the milestone page. If the three numbers do not exist yet, one month to instrument them, which is the honest answer for most companies.

Expected outcome. You stop running a process the market does not have slots for. The most expensive mistake available right now is opening a Series B process into an 8.3% lane and discovering it in week nine, having repriced yourself on the way out.

The reframe. Wrong approach: raise the letter that comes after your last one. Right approach: raise the letter your three numbers can defend, and take the lane with depth.

Looking Forward: Next 1 to 3 Weeks

Three evidence-based scenarios and one wild card. Every prediction is anchored to this week’s verified data, not speculation.

Scenario 1: Series A Stays Deep and Everything Else Stays Thin (High Probability)

Evidence from this week. Series A took 53.6% of mid-market capital across fourteen of twenty-four rounds at an average check of $30.14M, against $30.43M last week, a move of less than one percent. Series B produced two rounds for a third consecutive issue. Mid-market seed fell from five rounds to one. Series C produced one. The market has concentrated into a single stage while the price at that stage sat still, which is what a stable equilibrium looks like rather than a transition.

What to watch. Whether Series A holds above ten rounds and $28M average in either of the next two issues. Two more weeks at that level makes it the reference price for the rest of 2026, and every Series A deck built on a $40M ask is misaligned. Separately, watch whether mid-market seed recovers above three rounds. A second week near one would mean the $10M-plus seed has effectively left this market, which would be the first stage this series has watched disappear rather than compress.

What founders should do before others notice. If you are raising a Series A in the next quarter, open it now rather than in January. The depth is there, the price has been stable for two weeks, and ten of this week’s fourteen Series A rounds carried a returning investor, which means the insider conversation is the one to start this month. If you are pre-seed or seed and planning a $10M-plus first institutional round, plan a smaller one and a faster Series A instead, because the stage you were aiming at produced one round in the entire mid-market this week.

Scenario 2: Strategic and Customer-Side Capital Keeps Rising (Medium-High Probability)

Evidence from this week. Strategic, corporate, or customer-side capital appeared in 13 of 24 rounds, or 54.2%, up from 28.6% last week and 42.9% two weeks ago. The trajectory isn't a clean line, but this week's level is the highest this series has recorded, and the composition changed as well: Onomichi Dockyard, UP Partners and WND Ventures are not passive participants; they are manufacturing, building, and buying from the companies they funded.

What to watch. Whether any of this week’s strategic rounds later disclose exclusivity terms, and whether corporate leads start appearing at Series B and later rather than concentrating at Series A and seed. The first tells you what the pattern costs. The second tells you it is deepening rather than being an early-stage convenience. Also watch for a second manufacturer-investor structure, because Bulwark Dynamics taking money from the shipyard that will build its vessels is either an anomaly or the start of a template for capital-intensive hardware.

What founders should do before others notice. Have the exclusivity conversation with counsel before a corporate offer, not after. Pre-draft your position on right of first refusal on an acquisition, category exclusivity, and channel lockout, and treat those as policy rather than as a negotiation you open under time pressure. The terms are far easier to hold as a stated position than as a reaction to a specific term sheet with a signing date attached.

Scenario 3: The Insider Gap Narrows as Founders Copy the Structure (Medium Probability)

Evidence from this week. The 17.6-point gap between rounds with and without a returning investor is the widest structural divider this report has measured, and 16.2 of it survives once you remove the mechanical component. Gaps that large attract imitation. Founders reading the same market will start sequencing insider commitments before opening, and the six rounds re-underwritten inside eighteen months at a larger size are the visible template.

What to watch. Whether the share of rounds with a returning investor rises above 70% in either of the next two issues, and whether the score gap between the two groups compresses when it does. If the share rises and the gap holds, insider support is a durable quality signal. If the share rises and the gap collapses, it was a scarcity effect, and the advantage will have moved somewhere else, most likely to the second-order question of whether the insider led or merely participated.

What founders should do before others notice. Move in the month the signal appears, not the quarter after. The window on any structural advantage in this series has been about three weeks between the pattern becoming visible and becoming standard. Get the insider number in writing now, while a round with insider support still stands out against a field where a third of companies had none.

Wild Card: The Manufacturer Becomes the Seed Investor (Medium Probability)

Evidence from this week. Bulwark Dynamics raised $6.8M with no designated lead and a founder whose background isn't in the public record, and scored 56, ahead of rounds eight times its size, because Onomichi Dockyard both invested and signed a memorandum of understanding for serial production of the vessels Bulwark designs. A shipyard founded in 1943 that delivers roughly 350,000 gross tons annually took an equity position in the company whose product it will build. Impossible Objects points the same way from the customer side, with roughly $20M in government contracts and SBIR awards functioning as non-dilutive capital alongside a $40M Series B.

What founders should do before others notice. If you build a physical product, your contract manufacturer is a capital source you have probably never approached as one. They carry the capacity risk, they benefit directly from your volume, and an equity position aligns them to a production ramp in a way a supply agreement does not. Approach the two manufacturers you would most want to build with and ask whether they invest at seed. The worst outcome is a manufacturing relationship on better terms. The best outcome is what Bulwark got, which is a production line and a cap table entry in the same announcement.

The Bottom Line

The real insight is not the $787.8M. It is that capital and deal count fell 16.8% and 16.0% together while the price of a round did not move at all, and that the shorter queue was filled overwhelmingly by people already in the building. Sixteen of twenty-four rounds carried a returning investor. Thirteen of twenty-four carried a strategic, corporate, or customer-side investor. Twenty-two of twenty-four had somebody willing to take the lead seat. That produced exactly three conviction profiles.

Profile 1: Companies whose existing investors wrote again. Latitude (73) had its seed syndicate return into a round four times larger within twelve months. Inspiren (71) had Insight Partners return after leading the Series B. Moonwalk (70) had ARCH, Khosla, and Future Ventures all return into an oversubscribed round. Buildcheck (67) had Uncork return nine months after the seed. Sixteen companies had a returning investor and averaged 61.7 against 44.1 for the eight that did not. The cheapest thing a founder can do to change their position costs two conversations with people who already take their calls.

Profile 2: Companies whose investor was also the buyer, the channel, or the manufacturer. Buildcheck (67) took money from DPR Construction’s venture arm while DPR is a named customer. Luminary (66) took money from BNY, Focus Financial Partners, and Rockefeller Capital Management, all of whom buy the product. Overroute (56) was built with J.B. Hunt through UP Labs and deployed across all of its business units. Bulwark Dynamics (56) took money from the shipyard that will build its vessels. Eight companies had this structure and averaged 63.9 against 51.8, and the gap holds at 6.4 after the mechanical component comes out.

Profile 3: Companies carrying a checkpoint somebody else controls. Impossible Objects (61) named Air Force, Air Force Research Laboratory, and Army Rock Island Arsenal contract vehicles, plus roughly $20M in government contracts and SBIR awards. TwoStep (72) announced an FDA IND clearance in the same release as the money. Latitude (73) counts licenses in 45 US markets granted by fifty separate regulators. Caspian (66) had preclinical data selected for oral presentation by a scientific body. Five companies carried this and averaged 65.4 against 53.3. None of these facts can be manufactured by a press release, which is precisely why they are worth something.

Everything else competed for the residual. Eight companies raised with no returning investor, and the three at the bottom of the band, System at 30, UrgentIQ at 39, and Enigmata at 39, share the same structural shape: a single investor or none designated, no counterparty of any kind in the record, and nothing an outside party has validated. These are real companies with real money from real investors. The score measures how much of the transaction a new investor could reconstruct; in those three cases, the answer is the amount and very little else.

Five New Rules for Founders

1. A shrinking market is not a cheaper market. Capital fell 16.8%, and deal count fell 16.0%, while the average check moved 1.0% and the median rose 7.7%. Hold your ask. Cut your investor list to the firms that actually led a round in your stage and category in the last ninety days.

2. Your existing cap table is the first call, not the fallback. Sixteen of twenty-four rounds carried a returning investor and averaged 61.7 against 44.1. Get a specific number in writing four weeks before you open, and a yes or no on leading.

3. Rank investors by which customer they deliver. Thirteen of twenty-four rounds carried strategic, corporate, or customer-side capital, moving 61.6% of the week’s money. The investor who is also the buyer prices the round and clears your pipeline in one check.

4. Count the facts you do not control. Five rounds carried an externally controlled checkpoint and averaged 65.4 against 53.3. Clearances, contract vehicles, licenses, certifications, standards listings. If your count is zero, every claim in your process runs on trust, and trust is slow.

5. Take the lane with depth in it. Series A was fourteen of twenty-four rounds and 53.6% of capital at a flat price. Series B was two rounds for a third straight week at double the check, and both carried a corporate strategic. Raise the letter your three numbers can defend.

Four Monday Actions

1. Call your existing investors. Ask each one with a board seat or a meaningful position for a specific number in writing and a yes or no on leading. Do it four weeks before you plan to open, not after the first two passes.

2. Build the buying committee map. Every party who must say yes for a sale to close, and which investor on your list already controls each one. Empty rows are syndicate gaps, not pitch gaps.

3. Inventory your externally controlled checkpoints. One page, three columns: the checkpoint, the body that grants it, whether you hold it. Pick the fastest missing one and put a start date on it this quarter.

4. Settle your strategic-capital terms before anyone offers. Right of first refusal on an acquisition, category exclusivity, channel lockout, information rights. Decide them as policy this week, not under a term sheet with a signing date.

Twenty-four companies cleared this week, and the shorter queue went to the ones nobody had to convince. Sixteen had an investor who had already funded them once. Thirteen had somebody on the cap table who buys what they sell. The founder who spends Monday calling the people already on their cap table, instead of the two hundred names on a list, is doing what separated this market by 17.6 points.

Research Methodology, Sources and Verification

Data collection period: September 7 to 13, 2026, with verified primary announcements clustered September 8 to 11. No verified US mid-market round was announced on September 7 (Labor Day) or on September 12 and 13, which fall on a Saturday and Sunday. Verification standard: a minimum of two independent sources per deal, with company press releases and regulated newswires (BusinessWire, PRNewswire, GlobeNewswire, AccessNewswire) prioritized as anchor sources, plus at least one independent outlet for corroboration. This issue then went through two further independent verification passes in which we rechecked every company, amount, stage, investor, date, headquarters, and third-party validation against primary sources; the second pass was adversarial and specifically designed to find errors in the first. Those passes removed nine deals, restated three headline amounts to new primary capital, and corrected six attributions. Eisen Fundability Scores are proprietary analytical estimates, not endorsements or investment advice. All dollar figures reflect announced new primary capital at close unless noted.

Core Capital Totals and What They Include

The $787.8M weekly total includes only the twenty-four verified US rounds in the scorecard, each independently confirmed at the stated amount. For this issue, mid-market is defined as a US-headquartered round of new primary capital between $5M and $100M, matching the band used in the August 31 issue. Because the two issues before that used a $10M to $100M band, every week-over-week comparison in this report is calculated on the $10M to $100M subset: twenty-one rounds totaling $769.0M at an average of $36.62M and a median of $35.0M, against twenty-five rounds totaling $924.6M at an average of $36.98M and a median of $32.5M in the prior issue. The three rounds below $10M, totaling $18.8M, are included in the scorecard, the scores and the sector and geography analysis but excluded from all week-over-week structural comparisons, including every stage average quoted in this issue.

Secondary share purchases, credit facilities, venture debt, convertible notes into listed companies, SAFE conversions from prior periods, previously closed tranches, non-dilutive grants and cumulative restatements are excluded from the counted amount even where a headline figure includes them. Announcements that do not separate new capital from cumulative totals are excluded entirely. We did not treat any aggregator-only figure as fact without corroboration in a company release or an independent outlet. Arithmetic on the total, the average, the median and every chart value was recomputed and reconciled after the adversarial pass: the five sector subtotals ($426.0M, $133.0M, $106.8M, $72.0M and $50.0M) and the five stage subtotals ($422.0M across fourteen Series A rounds, $122.5M across four rounds with no series letter, $110.0M across two Series B rounds, $70.0M in one Series C and $63.3M across three seed rounds) each sum to $787.8M across twenty-four deals.

Scoring calibration notes. Rounds with no designated lead are scored on the institutional quality actually present rather than at zero, which applied to Bulwark Dynamics; System is the only round scored at zero on Investor Quality because no party in it is identified as institutional or as setting the price. Founder Track Record is scored on the verifiable public record, meaning prior companies, exits, operating roles, and domain tenure, regardless of whether the funding release mentions any of it. Newly formed companies with no prior round score zero on the velocity component of Capital Planning by construction, which applied to Tectora Therapeutics and Caspian Therapeutics. Score bands are stated once, in Section 2, and are not restated with different cutoffs elsewhere.

Exclusions and Documented Rationale

· Giant rounds and public market events, excluded by editorial scope: The Boring Company ($3B), Cognition ($2B), Motive ($1.3B), Stoke Space ($1B), Suniva ($835M), Mach Industries ($600M), Harvey ($550M), Fab2 ($500M), Positron ($500M as ranked, $875M as announced), Celero Communications ($275M), Encoded Therapeutics ($275M), Cylake ($245M), Solstice Oncology ($225M), Rightway Healthcare ($155M), Forus ($150M), Ayar Labs ($150M), Split Pay ($125M), TAR ($120M), BrainChild Bio ($116M), Clay ($115M), Perry Weather ($110M) and Savvy Wealth ($100M, at the ceiling).

· Non-US rounds, excluded for scorecard comparability: Cymphony ($30M, New York and Tel Aviv), Euno ($23M, San Francisco and Tel Aviv), WINT ($36M, Israel), Implicity ($40M, France), The Exploration Company ($450M, Germany), Xapien ($56M, United Kingdom), CloudNC ($20M, United Kingdom), ARC Ride ($33.3M, Kenya), Swish ($24M, India), Graph AI ($13.3M, India), Provilac ($14M, India), Pixxel ($100M, India), Navana.ai ($4.2M, India), Safebox ($1.11M, India), Kinetix AI (over RMB500M, China), Yuedian Technology (tens of millions RMB, China), AIDIN Robotics (KRW16B, South Korea), nocall.ai (about 800M yen, Japan), Blue Farm (350M yen, Japan), 9lione (120M yen, Japan), EdTechX (amount not stated, Japan), Furo ($4M, Germany), Cato (6M euro, Italy), Ethris (30M euro, Germany), Jaipur Robotics (4.3M euro, Switzerland) and Jet Zero (A$30M, Australia).

· Outside the date window: Sapiom ($35M Series A, August 5 to 6) and Yellow Card ($40M strategic, August 4 to 5), both marked news-cycle resurfaced despite circulating inside this window through aggregator republication.

· Structural exclusions: Rogo Technologies (no amount stated by the company, approximate secondary-source figure only), Every Media ($16M, SEC filing reported by a single aggregator), Malayy ($10.1M, same), Catalyst Power ($15M revolving credit facility), Glucotrack ($11.5M convertible note into a listed company) and FAZE Security ($6M, US headquarters unverifiable).

· Below the mid-market floor: AlgoX2 ($4.5M), Concorda ($3.8M, Kildeer, Illinois), Viv ($2M) and Active Learning Sciences ($1.5M), each below the $5M threshold used in this issue. Verily’s investment from NVIDIA and the CU Healthcare Innovation Fund is excluded because no amount was stated. BrightPlan’s Series C is excluded on the same grounds.

Deal Citations, Two or More Sources per Deal

· Latitude, $35.0M Series A. Fortune exclusive dated September 9, 2026; citybiz; Pulse 2.0; The Defiant; Dealroom; The SaaS News. Led by Oak HC/FT, which several roundups omit. Rated HIGH.

· TwoStep Therapeutics, $62.5M Series A. Business Wire company release dated September 9, 2026, describing an oversubscribed round and simultaneous FDA IND clearance for TS-104; Endpoints News; Pharmaceutical Technology; Fierce Biotech fundraising tracker; AllSci for the Stanford spinout origin. Co-led by Insight Partners and Medical Excellence Capital, with M Ventures and Pfizer Ventures as co-leads. Rated HIGH.

· Inspiren, $70.0M Series C. PRNewswire company release dated September 10, 2026; Health Technology Net for the full release text and named operator relationships; MobiHealthNews; Forbes; AlleyWatch daily funding report of September 10, 2026; Insight Partners and PRNewswire for the September 2025 $100M Series B used in the velocity check. Rated HIGH.

· Moonwalk Biosciences, $70.0M Series B. BioSpace company release dated September 8, 2026, datelined South San Francisco and San Diego and describing the round as oversubscribed; PharmExec; BioPharm International; Tech Startups venture funding roundup of September 8, 2026; Fierce Biotech fundraising tracker; BioPharma Dive and Crunchbase for the Illumina background used in Founder Track Record. Rated HIGH.

· Buildcheck, $12.0M Series A. GlobeNewswire company release dated September 9, 2026, naming DPR Construction, EllisDon, Power Construction Company, EMJ Construction, and IMC Construction and confirming WND Ventures as DPR’s venture arm; Technology Magazine syndication; Yahoo Finance syndication; Daily Guardian; FinSMEs; VC News Daily. Rated HIGH.

· Caspian Therapeutics, $50.0M. GlobeNewswire release from Kura Oncology dated September 9, 2026; BioSpace syndication; The Manila Times syndication; StockTitan; Fierce Biotech fundraising tracker. No series letter is applied by Kura or by any outlet. Rated HIGH.

· Luminary, $22.0M Series A. PRNewswire company release dated September 10, 2026, read through Morningstar syndication; company resources page for the named customers and platform position; ThinkAdvisor; FinSMEs; The SaaS News; AlleyWatch daily funding report of September 10, 2026. Rated HIGH.

· Antioch, $32.0M Series A. AccessNewswire company release dated September 8, 2026, read through Yahoo Finance and Morningstar syndication; SiliconANGLE; The Next Web; AlleyWatch daily funding report of September 9, 2026; FinSMEs. Rated HIGH.

· Impossible Objects, $40.0M Series B. BusinessWire company release dated September 11, 2026, read through 01net and AOL syndication, naming the Air Force, Air Force Research Laboratory, Army Rock Island Arsenal, the National Institute for Aviation Research, and the Oregon Manufacturing Innovation Center; Start Midwest weekly funding report, which independently confirms Inflection Equity as lead and Northbrook, Illinois as the headquarters; WOWTALE; Interesting Engineering; 3D Printing Industry for prior funding history. Rated HIGH.

· Lightfield, $47.0M Series A. PRNewswire company release dated September 9, 2026; Andreessen Horowitz investment post; SiliconANGLE; FinSMEs; The SaaS News; VentureBeat for the founders’ Tome background used in Founder Track Record. Rated HIGH.

· Blee, $20.0M Series A. Company release dated September 8, 2026; FinSMEs; Corporate Compliance Insights; fintech.global; AlleyWatch daily funding report of September 8, 2026; Tech Startups roundup of September 8, 2026. Rated HIGH.

· Bulwark Dynamics, $6.8M Seed. BusinessWire company release dated September 9, 2026; Offshore Source, confirming the Onomichi Dockyard memorandum of understanding for serial production; Smart Maritime Network; Tectonic Defense exclusive; The AI Insider; Next Gen Defense. Four investors named with no designated lead. Rated HIGH.

· Overroute, $5.5M. Company stories page dated September 9, 2026; FreightWaves, which confirms the J.B. Hunt deployment across all business units and the UP.Labs origin; Arkansas Democrat-Gazette; Northwest Arkansas Democrat-Gazette; StockTitan via J.B. Hunt. Led by UP.Partners. No stage label applied. Rated HIGH.

· Epsilon Health, $20.0M Series A. Axios exclusive dated September 9, 2026, read through Techmeme; Fierce Healthcare fundraising tracker dated September 10, 2026 at $27.6M; company announcements page; PitchBook profile. Rated MEDIUM on the unreconciled amount conflict and the absent headquarters.

· Bluecore Energy, $50.0M Seed. TechCrunch dated September 8, 2026; World Nuclear News, which independently confirms the $50M is separate from the July pre-seed and that total capital is $60M; Axios dated September 8, 2026; ESG Today, whose expansion-of-the-pre-seed phrasing is the outlier and is not followed here; Tech Startups roundup of September 8, 2026. Rated HIGH on amount.

· Piston, $15.0M Series A. SiliconANGLE dated September 10, 2026; FinSMEs for the Cupertino headquarters; Entrackr; Retail Technology Innovation Hub; YourStory. Rated HIGH.

· Poseidon Aerospace, $60.0M Series A. TechCrunch exclusive dated September 8, 2026; company news page; Defense Daily; defense-blog; Tech Startups roundup of September 8, 2026. Rated HIGH.

· GenHealth.ai, $16.5M Series A. AccessNewswire company release dated September 8, 2026, read through Morningstar syndication; MobiHealthNews, which confirms Craft Ventures and Obvious Ventures co-led the 2023 seed and return here; MedCity News; Health Technology Net; The SaaS News. Rated HIGH.

· Vheda Health, $47.0M. AccessNewswire company release dated September 10, 2026; Health Technology Net; PR Inside syndication; Tech Startups roundup of September 10, 2026; FinSMEs. No series letter is applied. Rated HIGH.

· Harmoni, $10.0M Series A. PRNewswire company release dated September 9, 2026, datelined Akron, Ohio, and New York; FinSMEs; The SaaS News; VC News Daily; Start Midwest weekly funding report, which dates the round September 11. Bessemer Venture Partners is the only investor named. Rated HIGH.

· Tectora Therapeutics, $55.0M Series A. Schrodinger company release dated September 9, 2026, read through BioSpace; BioWorld dated September 10, 2026; Securities.io; allsci; Fierce Biotech fundraising tracker, which lists the round at $55M led by New Enterprise Associates. Rated MEDIUM because no headquarters, chief executive, or employee is named in any source.

· UrgentIQ, $15.0M Series A. PRNewswire company release dated September 11, 2026; citybiz; Health Technology Net; InfotechLead; The SaaS News. Five Elms Capital is the sole named investor. Rated HIGH.

· Enigmata, $6.5M Seed. PRNewswire company release dated September 10 to 11, 2026; FinSMEs; Tech Startups funding news of September 11, 2026 for the Nashville headquarters; InfotechLead; The SaaS News. Led by Blockchange Ventures. Rated HIGH.

· System, $20.0M. PRNewswire company release dated September 9, 2026; citybiz; Pulse 2.0; Athletech News; Beauty Independent. The company and any outlet do not state a stage label, lead investor, or headquarters. Rated MEDIUM.

Market Comparison Sources

Market comparison and contrast set: Crunchbase News weekly ranking of the ten largest funding rounds for the week of September 5 to 11, 2026, which lists The Boring Co. ($3B), Cognition ($2B), Motive ($1.3B), Stoke Space ($1B), Suniva ($835M), Mach Industries ($600M), Harvey ($550M), Fab2 ($500M), Positron ($500M), and Celero Communications ($275M). Tech Startups venture capital and startup funding roundups for September 7, 8, 9, 10, and 11, 2026. VC News Daily funding records for September 8 to 11, 2026, used as a candidate source and date-checked against primary releases in every case, since its posting dates lag primary announcements by two to five days. AlleyWatch daily funding reports for September 8, 9, and 10, 2026. FinSMEs USA listings for September 8-11, 2026. Fierce Healthcare and Fierce Biotech fundraising trackers for 2026. Start Midwest weekly funding report for the week ending September 11, 2026. Business Wire and PR Newswire funding newsrooms for September 9 to 12, 2026.

Prior-period structural comparisons are drawn from the preceding issues of this series and are limited to figures that do not depend on the scoring rubric. August 31 to September 6: twenty-eight verified US mid-market rounds totaling $943.6M, of which twenty-five rounds totaling $924.6M sat in the $10M to $100M band at an average of $36.98M and a median of $32.5M, with stage averages of $30.82M at seed, $30.43M at Series A, $26.00M at Series B and $69.00M at Series C, healthcare at 40.3%, California at 17.4%, four of twenty-eight rounds with no named lead and eight of twenty-eight carrying strategic capital. August 24 to 30: twenty-one rounds totaling $543.9M at an average of $25.9M and a median of $25.0M, healthcare at 19.1%, nine of twenty-one carrying strategic capital. August 17 to 23: fifteen rounds totaling $545.0M at an average of $36.3M.

Verification Notes

Twenty-one of the twenty-four featured rounds are rated HIGH source confidence, meaning each was confirmed by a company, investor, or regulated newswire source plus at least one independent outlet, with no unresolved discrepancy. Three are rated MEDIUM. Tectora Therapeutics is MEDIUM because no source names a headquarters, chief executive, or employee, and the company’s US domicile is inferred from its three co-founding institutions. System is MEDIUM because the company and any outlet state no stage, lead investor, or headquarters. Epsilon Health is MEDIUM because the originating exclusive and the company release differ by $ 7.6 M ($20M vs. $27.6M), and no source reconciles them. Every third-party validation credited in Traction to Conviction was checked against the granting body’s own record or against the announcement of the grant, not against a company characterization of it.

· Deals analyzed: 24 verified US mid-market rounds of new primary capital between $5M and $100M.

· Deals excluded: 22 giant rounds and public market events by editorial scope, 26 non-US rounds for comparability, 2 rounds outside the date window, 6 rounds on structural or verification grounds, and 6 rounds below the $5M floor or with no amount stated.

· Corrections applied across the verification passes: 9 deals removed, 3 headline amounts restated to new primary capital, 3 stage or attribution corrections, 3 geography corrections, and 3 source confidence ratings set to MEDIUM. All 24 rounds were rescored from zero on the v2 rubrics.

· Research completion timestamp: September 13, 2026, after a third verification pass, adversarial and directed at finding errors in the second.

Disclaimer: This report is for informational and strategic intelligence purposes only. It does not constitute investment advice. Eisen Fundability Scores are analytical frameworks, not financial recommendations. All data is sourced from publicly available information and primary company announcements. Powered by the Eisen Fundability Framework.

DISCLAIMER: This article is for informational and strategic intelligence purposes only. It does not constitute investment advice. The Eisen Fundability Score is a proprietary diagnostic within Fundables OS™, not a financial recommendation.

If this article was useful, share it with founders who are about to raise.

— Leon Eisen, 4x Founder, Venture Capitalist, and Creator of Fundables OS™

Playbook, Perspective, and Pattern for founders raising now. This report strips out giant rounds and public market traffic so you can read the part of the market that actually prices your round. Every figure below survived three independent verification passes against primary sources, the last of them adversarial.

The mean Eisen Fundability Score fell to 52.5, down from 58.0, down from 63.7, down from 72.3 in June. That is a fourth consecutive decline, and it happened in the week the money came back. Three of twenty-eight rounds cleared 65. Last week five of twenty-one did. The share of well-scored rounds fell from 23.8% to 10.7% while the capital available to them rose 70%.

Something else broke open. The score band ran 42 to 70 last week. This week it runs 25 to 73, a 48-point spread and the widest this report series has recorded. The ceiling rose three points. The floor fell seventeen. Dispersion is back, and it is almost entirely a disclosure story.

Seven of twenty-eight companies put a hard financial number about themselves on the record. Those seven averaged 64.4. The other twenty-one averaged 48.5. That is a 16-point premium for doing the one thing almost nobody did last week, when zero of twenty-one companies disclosed a revenue figure. This week, three did: Scan.com at a $165M annualized run rate; Capacity above $100M in ARR; and Clipto at $15M in ARR, profitable on a net income basis.

Consequence for Monday. The capital constraint eased, and the credibility constraint did not. There is 70% more money in the mid-market than there was a week ago, and it is being handed to a set of companies whose average conviction score is the lowest this series has measured. That gap is your opening. The founder who walks in with a growth rate, a denominator, and a named lead is competing against a field where the average company brought none of the three.

The Week in One Sentence

Primary insight. Mid-market capital rose 70%, and average check size rose 43% on a like-for-like basis, while mean conviction fell for a fourth consecutive issue and the score band blew out to its widest ever, because the money came back faster than the proof did and the market started paying a 16-point premium to the seven companies that put a real number on the record.

• Total tracked mid-market capital, 28 verified rounds: $943.6M in new primary capital, every deal between $5M and $100M, every company US-headquartered.

• Like-for-like against prior issues: $924.6M across 25 rounds in the $10M to $100M band the last three issues used, against $543.9M across 21 rounds last week. Capital up 70.0%, deal count up 19.0%.

• Average round size: $33.7M across the full $5M to $100M set. On a like-for-like basis, $37.0M against $25.9M last week, up 42.8%.

• Median round size: $31.0M across the full set. On a like-for-like basis, $32.5M against $25.0M last week, up 30.0%.

• Disclosed revenue or ARR figures: 3 of 28, against 0 of 21 last week. Scan.com at a $165M annualized run rate, Capacity above $100M in ARR, Clipto at $15M in ARR with disclosed net income profitability.

• Disclosed growth rates: 6 of 28, or 21.4%, against 1 of 21, or 4.8%, last week. A fourfold rise in one week.

• Disclosed valuations: 1 of 28. Clipto at $250M post-money. That is a 96.4% opacity rate, up from 95.2% last week, 93.3% the week before, and 80% in June. A fourth consecutive rise.

• Largest tracked round: Scan.com at $90.0M of new primary equity, restated down from a $220M headline that blends $130M in debt facilities.

• Highest Eisen Fundability Score: a tie at 73 between Light, a $46M Series A, and Clipto, a $15M round that was the twenty-first largest of the twenty-eight. The top of this market was not bought with size.

• Lowest Eisen Fundability Score: Resect AI at 25, a $25M round with no disclosed stage, no disclosed investor of any kind, no revenue, no customer, and no valuation. The lowest score this series has recorded by seventeen points.

• Defining structural feature: a 48-point score band against 28 points last week. The ceiling rose 3 points, and the floor fell 17 points. The market re-opened at the top and blew out at the bottom in the same week.

Data Integrity Notes

All twenty-eight featured rounds were verified against at least two independent sources, then rechecked in two further independent verification passes against primary sources. Those passes removed seven deals for date-window violations, removed four more for structural reasons, restated four headline amounts to new primary capital, corrected three stage labels, and corrected eleven attributions. Resolutions applied:

• Editorial scope excludes giant rounds and public market events by request. Removed from the tracked set and used only as a contrast set: Crusoe ($3B), Fluidstack ($1.5B), Wonderful ($550M), Higgsfield ($400M), Gimlet Labs ($300M), Upwind Security ($300M), David ($250M), Medici Brands ($250M), HiBob ($166M), Lyte AI ($165M), TabaPay ($155M), Thyme Care ($125M) and HiddenLayer ($100M). The week’s ten largest rounds totaled $6,061M against $1,512M the prior week, a fourfold rise driven almost entirely by two AI infrastructure deals, Crusoe and Fluidstack, which together account for $4.5B of it. HiddenLayer sits exactly at the $100M ceiling and also appears on the week’s top 10 list, so it is excluded on both counts.

• Four headline amounts were restated to new primary capital. Scan.com’s announcement totals $220M; the company's release separates $90M in Series C equity from $130M in debt facilities provided by VerisFi Capital and Atempo Growth, so $ 90 M is counted. Félix’s announcement carries $200M; the release separates $87M of Series C equity led by Andreessen Horowitz from a $113M credit facility from the General Catalyst Customer Value Fund, so $87.0M is counted. Odyssey Energy Solutions’ announcement carries $74M; the release and independent trade coverage separate $27M of equity from $47M of debt provided by British International Investment and three development finance institutions, so $27.0M is counted. Capacity’s headline reads over $50M; the company release body and two independent sources state over $54M, so $54.0M is counted.

• Date window control removed seven deals. Each circulated widely inside this window through aggregator republication against an earlier primary release: Smack Technologies ($61M Series B, company journal dated August 18), Deep Cogito ($43M Series A, BusinessWire August 26), CivilGrid ($26M Series A, August 28, already counted in the prior issue), RQD Clearing ($74M, August 28), Workweek ($17M Series B, Adweek August 27 to 28), Axle ($17.5M Series A, PRNewswire August 11) and SiteVue AI ($7.5M Seed, PRNewswire August 6). All seven are marked as news-cycle resurfaced and excluded from all totals, charts, and scores.

• Four further deals were excluded on structure. Chariot Claims ($9.46M) exists only as an SEC Form D filing, with no company announcement or media confirmation of terms, and its widely repeated founder attribution does not hold up under a check against the company’s own materials. Bolt’s raise of up to $27M is a pay-to-play bridge into a distressed company, is stated as a range rather than a closed amount, and is not a priced round. Helogen ($7.1M) is the sharpest catch of the verification passes: the only company document carrying the figure is a September 1 BusinessWire release about October orbital missions and an FDA pathway, which states that the company has raised $7.1 million to date, a cumulative past-tense figure rather than a newly closed round; no dedicated financing announcement exists from the company, from RRE Ventures or from Oceans, and no Form D is on file under the company name, so the single aggregator headline reading raises $7.1M is a repackaging of prior capital and is excluded. Emberos ($5.5M) announced an oversubscribed seed on September 3, but its SEC Form D shows $2,490,000 fully sold with a first sale dated July 2, 2026 and a filing dated August 7, 2026; the September release does not separate that pre-window tranche from new money, and the residual falls below this issue’s $5M floor, so the round is excluded under the same rule applied to every other blended announcement.

• Stage opacity is reported rather than filled in. Eight of twenty-eight rounds carry no stage label from the company: Hi Rasmus, Reframe Systems, Cari, Odyssey Energy Solutions, Resect AI, Clipto, Konko AI and Blue Voice. Reframe Systems is the sharpest case. The company release calls it additional venture-backed equity financing and declines to label it a Series letter, while one trade outlet assigns it as a Series B and three others decline to do so. No stage is asserted here, and each of the eight was penalized in Deal Architecture rather than assigned a stage by inference.

• Non-US rounds were excluded for scorecard comparability. Aitan ($41M, Ramat Gan), AIR Security ($50M across two seed tranches, forty employees in Israel with a New York commercial entity), Lasso Security ($30M, Tel Aviv and New York), Guardio ($40M, Tel Aviv), Huskeys ($27M, Israel), HubX ($75M, Turkey), Ultrahuman ($70M, India), WeRoad ($58M, Italy), Conveo ($50M, Belgium), HyImpulse (over €50M, Germany), Gridsight ($26M, Australia), Moment ($22M, Ghana), Enhance ($18.2M, UAE), iPremom (€15M, Spain), Octave.energy (€10M, Belgium), Sirdab ($10M, Saudi Arabia), Outlier Space (NZ$10.5M, New Zealand), Hivebotics ($6M, Singapore), Zeit AI (€5M, Germany), Backbone (€4M, Belgium) and NeuShen Therapeutics (over $80M, Shanghai and Boston). AIR Security is the closest call: three sources place its engineering base in Israel, and one places its headquarters in New York, so it is excluded and the conflict documented rather than resolved by assertion.

• Metric provenance. Every operating figure in this issue is company-supplied. Scan.com’s run rate, Capacity’s ARR and growth multiple, Clipto’s ARR and profitability, Light’s 10x run rate growth, Félix’s transaction volume, Norbert Health’s compliance figures, Konko AI’s customer outcomes and Blue Voice’s agency count are treated as verifiable rather than independently audited, and scored on that basis. Wafer’s reported post-money valuation above $200M comes from a single secondary outlet rather than the company and is not counted as a disclosed valuation. Reframe Systems’ claims of 3x faster delivery and 35% lower cost are company comparisons against traditional construction, not measured customer results, and are attributed rather than asserted.

• What this report can and cannot see. Scores reflect proof that was verifiable at announcement. Investors receive far more in a private data room, and a company that puts nothing on the record may have answered every question during diligence. The public record is a proxy for whether the numbers existed in a defensible form while the round was running, not a measure of what a company knows about itself, nor a requirement to publish anything.

The Deal Scorecard

Eisen Fundability Scores are calculated across five weighted dimensions: Founder-Investor Dynamics (30), Traction-to-Conviction Conversion (25), Narrative Power (20), Deal Architecture (20), and Capital Planning (5). Scores of 85 and above signal an inevitable outcome. Scores of 75 to 84 signal solid fundamentals. Scores below 65 signal early-stage or missing elements. Missing metrics are scored conservatively, and opacity is penalized rather than assumed strong.

What the Scorecard Says at a Glance

The band tells you the market stopped agreeing with itself. June produced a 13-point band around a mean of 72.3, a market that agreed on what it paid for. Last week produced a 28-point band around 58.0, a market that had stopped paying a premium for anything. This week produced a 48-point band around 52.5. The ceiling went up, and the floor fell out at the same time. That is not a harder market or an easier one. It is a market that has stopped applying a common standard, which means the price you get now depends far more on what you brought than on what stage you are at.

Three companies cleared 65, and all three disclosed their own numbers. Light at 73 disclosed a 10x revenue growth run rate over 12 months. Clipto at 73 disclosed $15M in ARR, net income profitability, and the only valuation in the issue. Félix, at 72, disclosed $8B in cumulative transaction volume, 6 million users, and 2.5x year-over-year revenue growth. No other company in the set cleared 65, and the fourth-place finishers sat twelve points back at 61. The gap between third and fourth is the largest single break in the distribution, and it falls exactly where self-disclosure stops.

The most expensive lesson on the scorecard costs $54M and ranks 49th. Capacity crossed $100M in ARR, disclosed 20x revenue growth over three and a half years, named 20,000 customer organizations, ranked 432 on the Inc. 5000, and is run by a founder who co-founded Answers Corporation, acquired for roughly $900M in 2014. On traction, it scored 18 out of 25, the third-highest in the set, and its founder, David Karandish, co-founded Answers Corporation, which was acquired by Apax Partners in 2014 for roughly $900M, earning full marks on founder track record. It still finished tied for twelfth of twenty-eight and just below the weekly mean, because the only party named as a lead investor in the company’s own release is an individual, and no institutional investor is named anywhere in it. The strongest traction disclosure in the issue, plus a nine-figure founder exit, still landed 21 points below the top because nobody set the price. Whoever does that is a scoring dimension, not a formality.

The floor is a disclosure story, and it fell seventeen points. Resect AI raised $25M, disclosed no stage, named no investor of any kind beyond the phrase private equity investors, and put no revenue, customer, or valuation on the record. It scored 25. Cradlewise at 41 raised a $12M Series A with no revenue, no customer count, and no unit economics on the record. Elucid at 41 raised an oversubscribed $55M Series D round, with no investor taking the lead seat. These are real companies with real capital from real investors. What the score measures is what a new investor could verify without asking, and in these cases the answer was close to nothing.

Round size stopped predicting conviction. The three largest clean rounds of the week after restatements, Physical Superintelligence at $58M, Typewriter Therapeutics at $56M, and Elucid at $55M, averaged 45.3 against a weekly mean of 52.5. Clipto, the twenty-first largest of twenty-eight at $15M, tied for the highest score in the issue. If you are calibrating your ask against the biggest rounds, you are calibrating against the part of the distribution that scored below average.

What Changed This Week: Five Market Shifts

Each shift is verified against multiple sources and ranked by structural impact on founder fundraising, not by deal size. Every shift ends with what it means for your raise next week.

Shift 1: The Money Came Back, and the Bar Went Down

Pattern, what happened. On the like-for-like $10M to $100M band, twenty-five verified rounds moved $924.6M against twenty-one rounds moving $543.9M the week before. Capital rose 70.0%, deal count rose 19.0%, average check rose 42.8% from $25.9M to $37.0M, and the median rose 30.0% from $25.0M to $32.5M. Over the same seven days, the mean Eisen Fundability Score fell from 58.0 to 52.5, marking the fourth consecutive decline since 72.3 in June. Three of twenty-eight rounds cleared 65, or 10.7%, against five of twenty-one, or 23.8%, a week earlier.

Perspective, what it means. Two constraints govern a fundraise: how much capital is available and how much proof it demands. Founders treat them as a single constraint, but they are not. This week the capital constraint eased sharply, and the proof constraint did not tighten; it simply stopped being applied consistently. Partners who wrote a $25.9M check last week wrote a $37.0M check this week into a set of companies whose average conviction score is the lowest this series has measured. When more money chases a field with less proof in it, price dispersion widens, and the founder who supplies proof captures a disproportionate share of the widening.

Founder Blindspot, what most miss. Founders read a capital rebound as permission to relax and go raise. The arithmetic says the opposite. The number of rounds clearing 65 fell from five to three in absolute terms, even with seven more deals and 70% more money. Fewer companies separated themselves while more capital was available to reward separation. That is the single best set of conditions a well-prepared founder gets, and it is the set of conditions in which unprepared founders raise at bad prices and call it a win.

Playbook, what to do. Reopen your use of funds at 143% of the number you sized in August, because that is what the average check did. Then ask one question about the difference: does the extra capital buy a milestone that changes your next round’s price, or does it buy eighteen more months of the same plan? If it is the second, do not raise the larger number. Take the smaller round at a better price and keep the dilution.

Contrast. The last two issues tracked a market rationing capital across more claimants: average check down 24% into the week of August 17, then down a further 28.7% into the week of August 24. This week reversed both moves at once and overshot, landing 43% above last week and 2% above the week of August 17. What has not been reversed is the conviction, which has now been overturned in four consecutive issues.

What this means for your raise: The market that priced your round in August is not the market pricing it in September. Resize the ask upward and raise the proof standard at the same time, because the money moved and the bar did not.

Shift 2: The Series B Lane Closed

Pattern, what happened. Two of twenty-eight rounds were Series B, totaling $52.0M, or 5.5% of the week’s mid-market capital. Last week, five of twenty-one rounds were Series B, totaling $132.0M, or 24.3%. On the like-for-like $10M to $100M band the prior issues used, average Series B check size sat at $26.00M against $26.40M a week earlier, down 1.5%, the only stage that did not move. Seed rose 79.7% to $30.82M across five rounds, and Series A rose 11.8% to $30.43M across seven. Separately, eight of twenty-eight rounds, or 28.6%, carry no stage label from the company, compared with three of twenty-one, or 14.3%, last week.

Perspective, what it means. Capital returned to the two ends of the market, skipping the middle. Seed and Series A are priced on narrative, team, and early proof, and those are cheap for an investor to underwrite quickly when sentiment turns. Series B is priced on repeatable unit economics, and nothing about the underlying evidence base improved in seven days. So the money that was returned went where it could be deployed against the existing proof. The rise in unlabeled rounds is the same phenomenon from the other side: eight companies raised capital without accepting a stage designation, which happens when a company cannot meet the next letter’s bar and will not accept the previous one’s price. Note what that did not cost them, because it is the most useful number in this shift: the eight unlabeled rounds averaged 52.8, compared with 52.4 for the twenty labeled ones. The letter is cosmetic. What the letter is standing in for- a priced round with somebody accountable for the price- is not.

Founder Blindspot, what most miss. Founders at Series B read about a market-wide capital rebound and assume it will reach them. It did not reach them this week. Two rounds cleared in the entire mid-market. A founder who opens a Series B process now, on the strength of a headline market recovery, is walking into the thinnest lane in the market with the highest evidentiary bar, and the process will run long before anyone tells them why.

Playbook, what to do. If you are raising a Series B, stop calling it one until you can answer three questions in numbers: what does a customer cost to acquire, what do they pay over their life, and what percentage of last year’s revenue base is still there this year. If you cannot answer all three, run an extension at your Series A price with your existing investors and spend two quarters building the answers. An extension at a fair price beats a Series B process that dies in week nine and reprices you on the way out.

Contrast. Last week, Series B fell by 42% in average check size and still accounted for a quarter of mid-market capital across five rounds. This week, the check size held almost exactly flat, and the lane itself nearly vanished, from five rounds to two. The stage did not get cheaper. It got rarer.

What this means for your raise: Seed and Series A are open and paying more. Series B is not open. Pick the lane the market is actually funding and structure your round to fit it, rather than insisting on the letter you planned for in the spring.

Shift 3: Your Own Number Came Back as the Divider

Pattern, what happened. Seven of twenty-eight companies put a hard financial number about themselves on the record, either an absolute revenue figure or a growth rate. Those seven averaged 64.4 against 48.5 for the other twenty-one, a 16-point premium. Three disclosed absolute revenue: Scan.com at a $165M annualized run rate with revenue doubled year over year, Capacity above $100M in ARR with 20x growth over three and a half years, and Clipto at $15M in ARR with net income profitability. Six disclosed a growth rate against one of twenty-one last week. All three companies that cleared 65 are in that group of seven.

Perspective, what it means. Last week the divider was the customer’s number, because nobody would show their own and the buyer’s result was the only thing an investor could model. That was a scarcity effect, not a permanent shift in what investors want. The moment capital returned, the premium moved back to the primary evidence: what you earn and how fast it is growing. Investors were never indifferent to your revenue. They were pricing in its absence. A growth rate is worth more than a customer testimonial because it is the only figure that compounds, and an investor underwriting a five-year hold is buying the compounding, not the anecdote.

Founder Blindspot, what most miss. Founders think disclosure is a leverage question, that showing revenue early weakens their negotiating position. The data says the opposite in both directions. The seven who disclosed scored roughly 16 points higher, and the one company that disclosed a valuation, Clipto, is the smallest round in the top three and tied for the highest score. Withholding does not preserve leverage. It removes the basis on which anyone could pay you a premium, which is why 96.4% valuation opacity and a 52.5 mean arrived in the same week.

Playbook, what to do. This is the single highest-leverage action in this issue. Pick the one number in your business you have been withholding and decide this week whether you are withholding it because it is weak or because you were advised to. If it is weak, you have a business problem, and a raise will not fix it. If it is not weak, put it on the first five slides in this exact form: the metric, the current value, the value from 12 months ago, and the multiple between them. Light achieved 10x run-rate growth in 12 months. Félix did it at 2.5x year-over-year. Capacity did it at 20x in three and a half years. Three different businesses, one identical structure.

Contrast. Last week, the divider was proof of what the customer received, worth 8.6 points across five companies. This week it moved one step back inward to proof of what the company earns, and the premium nearly doubled to 16 points. The evidence bar did not rise. It moved from the buyer’s books to yours.

What this means for your raise: Your customer’s number gets you a meeting. Your own number gets you a price. In a week when only one of twenty-eight companies disclosed a valuation, the seven that disclosed a financial figure took every slot above 61.

Shift 4: Nobody Wanted the Lead Seat

Pattern, what happened. Four of twenty-eight rounds, or 14.3%, closed with no named institutional lead investor. Those four averaged 43.8 against 53.9 for the twenty-four with a named lead, a 10-point gap. Elucid raised an oversubscribed $55M Series D in which the release names existing participants and an unnamed publicly traded medtech strategic, and designates no lead. Cari raised $32.5M, funded entirely by seven banks, with no lead. Capacity raised $54M at $100M in ARR, with a founder carrying roughly $900M in prior exit, and only an individual named as the lead investor. Resect AI raised $25M, describing its backers only as private equity investors and naming none. Set that against the thing founders actually agonize over: the eight rounds carrying no stage label at all averaged 52.8, against 52.4 for the twenty that carried one. The series letter moved the score by 0.4 points. The absence of someone to set the price caused it to move by 10.

Perspective, what it means. A lead investor is not a label; it is a service. The lead does the diligence the syndicate free-rides on, sets the price, negotiates the terms, and takes the board seat that makes the price defensible to the next round. When no one takes that seat, three things follow: the price is set by nobody and therefore by the founder’s ask, the diligence is thinner than it looks, and the next investor has no anchor to underwrite against. That is why Capacity, with the best traction figures in the issue and a founder who sold his last company for roughly $900M, still finished tied for twelfth. And it is why the stage label turns out to be worth nothing: a Series B letter on a round nobody led tells the next investor less than a letterless round that one firm priced and took a seat on. Founders negotiate hard for the letter and accept the party round. They have it backward.

Founder Blindspot, what most miss. Founders treat a party round with no lead as a win, because it means no single investor dictated terms. It reads to the next investor as a round nobody was willing to underwrite. Every strong participant you name is also a partner who declined to lead, and a sophisticated Series B investor reads the cap table that way in about ninety seconds. A smaller signal points the same way and is worth naming with its own caveat: the three releases this week that used the word oversubscribed averaged 48.3 against 53.0 for the twenty-five that did not, 4.6 points lower. Three observations are not a finding; they are a direction: the word tends to appear where a number is missing.

Playbook, what to do. Before you take a second commitment, get one investor to say in writing that they will lead, set the price, and take the seat. If nobody will, that is diligence output, not a logistics problem, and you should treat the reluctance as information about your round rather than as an obstacle to route around. Then stop negotiating for the letter. The eight letterless rounds scored the same as the twenty lettered ones, so spend that leverage on the lead commitment and the price instead. And open your draft announcement: if the strongest thing in it is the word oversubscribed, the release is telling you what your deck is missing.

Contrast. Last week the story was strategic capital taking the lead seat that venture firms had vacated: two of twenty-one rounds led outright by a corporate, a third funded by strategics with no lead, and nine of twenty-one carrying strategic money. This week strategic capital retreated from the front. One of twenty-eight rounds was led outright by a corporate, Labcorp Venture Fund at N-Power Medicine, and eight of twenty-eight carried strategic money, down from 42.9% to 28.6%. Financial venture firms returned to the lead seat, and the rounds that could not secure one scored 10.0 points below those that did.

What this means for your raise: A named lead is worth 10 points, and the letter on your round is worth 0.4. Spend your leverage on the first and stop spending it on the second.

Shift 5: $102M Bought Two Companies With No Product

Pattern, what happened. Physical Superintelligence raised a $58M seed, and SciFin raised a $44M seed. Together, that is $102.0M, or 10.8% of the week’s mid-market capital, going to two companies that disclosed no revenue, no customers, no benchmarks, and no product in market. Physical Superintelligence was founded in 2026 and launched with the announcement. SciFin emerged from stealth. They scored 43 and 46, both below the mean of 52.5. Both were funded on pedigree: Breakthrough Energy Ventures led a research lab with a twenty-five-person team drawn from Harvard, MIT, Los Alamos, and Nvidia, and Mohit Aron, who co-founded Nutanix and founded Cohesity, raised the second-largest seed of the week with nothing else on the record. Meanwhile, the week’s geography dispersed: Massachusetts took $215.0M across five rounds, or 22.8%, outraising California at $164.0M across six rounds, or 17.4%, while ten states and the District of Columbia outside California, Massachusetts and New York took $524.6M, or 55.6%, across fourteen rounds.

Perspective, what it means. Pedigree is the only asset that prices instantly, which is why it gets the largest checks in the weeks when capital returns first, and evidence arrives later. But look at what pedigree actually bought. It bought size, not score. Both rounds landed below the weekly mean because a founder’s history answers whether the team can build but says nothing about whether anyone will pay. The geography number is the same lesson at market scale. Capital is dispersed across eleven jurisdictions because this week's underwriting is for a specific company, not the ecosystem it sits in, and a specific company can be anywhere. Boston outraising the Bay Area is not a story about Boston. It is a story about the Bay Area’s default premium no longer clearing on its own.

Founder Blindspot, what most miss. Founders without a marquee background read these two deals as proof the game is rigged and stop competing on the dimension where they can win. The scores say the game is open. Physical Superintelligence and SciFin sit at 43rd and 46th, below 23 and 22 other companies, respectively, several of which raised a tenth as much. Blue Voice raised $6M in Boston with a Harvard Law dropout, a former Google engineer, and a retired police deputy chief; disclosed elevenfold customer growth and 225 agencies; and scored 59. Pedigree buys check size. Evidence buys score, and score is what your next round is priced against.

Playbook, what to do. Write down the three facts an investor would need to believe to fund you if your resume were blank, then find the cheapest experiment that produces evidence for each one this quarter. If you do have a marquee background, do the inverse exercise: assume it is worth exactly one meeting and nothing else, and build the round on what happens after that meeting. And stop discounting your location. Fourteen of the twenty-eight rounds this week closed outside California, Massachusetts, and New York, accounting for 55.6% of the capital.

Contrast. Last week the largest and most confident checks went to companies with named customers and quantified outcomes, and the top of the band was a company that disclosed profitable operations. This week, the third- and ninth-largest rounds went to companies with no product at all, and both landed below the mean. The market widened enough to fund both kinds of story in the same week, at very different implied standards.

What this means for your raise: If you have pedigree, it will get you a larger round than your evidence supports and a worse score than your peers. If you do not, it costs you size and not standing. Build the evidence either way, because the score is what gets repriced next time.

Section 4: The Deals That Matter, Top 5

Five deep dives across embedded energy infrastructure, consumer AI, cross-border fintech, medical imaging networks, and emerging markets energy finance. These are the five highest-scoring rounds of the week. All metrics are company-supplied, verified against two or more sources, and re-checked in a second pass.

Light

Embedded Electricity Infrastructure | Series A | $46.0M | Valuation Undisclosed

Eisen Fundability Score: 73 / 100

Why this scored. Tied for the highest score of the week, and it earned it on the most complete disclosure in the issue. Light put four different kinds of evidence on the record at once: a growth rate (10x run rate revenue growth in twelve months), a market share denominator (100% of new electricity brands entering the Texas market in the first half of 2026 launched on its platform, up from over 70% in 2025), a distribution number (partners reaching more than 30% of US residential solar sales) and a scale figure (over 500,000 homeowners and more than one million multifamily units). No other company in the set produced all four. Founder-Investor Dynamics scored 19 out of 30 on a Plaid product lead and a Matrix-led syndicate, and Narrative Power scored 19 out of 20, the highest single dimension score in the issue.

The Setup. Light, founded in 2023 and headquartered in Austin, sells the infrastructure that lets any company become an electricity provider without becoming a utility. Chief executive Baker Shogry was previously Head of Product at Plaid, which matters more than a typical resume line here, because Light is doing to electricity what Plaid did to bank data: turning a regulated, fragmented, integration-heavy category into an API that a product team can ship against in two weeks. The company is now moving from the deregulated Texas market into PJM, with New Jersey, Pennsylvania, and Illinois named, and is targeting hyperscale data center developers as a new buyer class.

The Numbers. $46.0M Series A led by Matrix, announced September 1, 2026, with Activate Capital, Spark Capital, Mischief, Gigascale Capital, MCJ, and BoxGroup participating. Run-rate revenue grew 10x over twelve months. 100% of new electricity brands entering the Texas market in the first half of 2026 launched on Light’s platform, against over 70% in 2025. Partner network reaches more than 30% of US residential solar sales. Over 500,000 homeowners served and more than one million multifamily units covered. New plan launches in roughly two weeks via API. Named partners include Palmetto, GoodLeap, Emporia, and Lunar Energy. 35 employees, with plans to double within a year. Cumulative funding roughly $60M. Absolute revenue, margins, and valuation not disclosed. Note that a widely repeated figure of a total capital base above $100M blends this equity round with a separate credit facility and is not the round size.

The Pattern. This is the market share round. Light never states its revenue and does not need to, because it states the share of a countable population it already holds: every new entrant in the largest deregulated retail electricity market in the country. That figure is verifiable by anyone who can list the new brands in Texas, and it converts an unknown company into a measurable position in about one sentence. Pair it with the 10x growth rate and an investor can size both the current business and its slope without a single company financial.

The Perspective. A growth multiple and a market share figure answer two different questions and only work together. 10x growth alone invites the obvious skeptical reading that the base was near zero. 100% of new entrants alone invites the second reading, that the population is small. Together, they foreclose both, because a company that captures every new entrant in a large market while growing 10x is, by definition, not operating at a trivial scale. This is the same defensive structure Yardstik used last week with growth plus retention, executed with different variables. Find the pair of figures that cannot both be flattering under a hostile reading, and disclose the pair.

The Playbook. Identify the population your product competes for, restrict it to new entries in a defined period and geography, and calculate what share of that population chose you. Not total market share, which you probably do not have and cannot verify. New-entrant share in a named market over a named period, which you might dominate and which anyone can check. Then state it alongside your growth multiple in the same sentence. That sentence is worth more than a slide of logos, because it is a claim about the market’s behavior rather than a claim about your sales team’s.

The Founder Mistake to Avoid. Founders copy the API-for-a-regulated-industry framing without the regulatory work underneath it. Light’s two-week plan launch is only possible because the company absorbed the licensing, settlement, and compliance burden that made it hard to enter the electricity market in the first place. The wedge is not the API. The wedge is being the entity that holds the regulatory position so the customer does not have to. If your integration layer sits on top of a burden your customer still carries, you have built a convenience, not infrastructure, and the pricing power will show it.

Clipto

AI Media Search and Local Memory Layer | Stage Not Disclosed | $15.0M | $250M Valuation

Eisen Fundability Score: 73 / 100

Why this scored. The twenty-first largest round of twenty-eight tied for the highest score, and it did so by being the only company in the issue that disclosed all three of the numbers everyone else withheld: revenue ($15M ARR), profitability (positive on a net income basis), and valuation ($250M post-money). It scored 21 out of 25 on Traction to Conviction, the highest in the set by three points, and 16 out of 20 on Deal Architecture, also the highest, because a disclosed valuation is the only way to score above 3 on Valuation Reasonableness in a week with 96.4% opacity.

The Setup. Clipto, founded in 2023 with teams in San Francisco, Singapore, and Hong Kong, indexes and searches the video, audio, and document files on a person’s machine and increasingly serves that index as a memory layer that AI agents can query. Founder Henry Kang previously built Zenvideo, which Tencent acquired in 2020 for an undisclosed price, and has a background in robotics research at Carnegie Mellon. The company reached $15M in ARR and net income profitability with roughly twenty employees, which is the fact that does most of the work in this round: the business proved it did not need the money before it raised it.

The Numbers. $15.0M led by HSG, announced August 31, 2026, at a $250M post-money valuation, with GL Ventures, EnvisionX Capital and Palm Drive Capital participating alongside angels Hans Tung and Lu Zhang. $15M ARR as of early 2026. Profitable on a net income basis. More than 30 million users since launch. Hundreds of thousands of paying subscribers. A significant share of subscribers have been retained for more than two years. Roughly 20 employees. Founded in 2023. No stage label of any kind is used by the company or any of its outlets. Growth rate not disclosed as a percentage.

The Pattern. This is the disclosure arbitrage round. In a week when twenty-seven of twenty-eight companies withheld their valuation, the one company that published it also published the two numbers that justify it, and the combination let an investor complete the entire underwriting from the press release: 16.7 times ARR for a profitable, capital-efficient business with multi-year retention. Every other company in the issue forced the investor to construct that ratio from the outside with a missing numerator, a missing denominator, or both.

The Perspective. Founders believe disclosing a valuation costs them negotiating room. In a market with 96.4% opacity, it does the opposite because it is the only way to be priced at all, rather than compared to a distribution. When nobody publishes a multiple, an investor prices you against the worst comparable they can imagine, and the absence of information is scored as risk, not as optionality. Clipto published a number that stands up to arithmetic, and the arithmetic did the persuading. Note also that profitability, not growth, is what makes the multiple defensible: the company disclosed no growth percentage at all and still tied for the top score, because a profitable business at $15M ARR does not need to explain its burn.

The Playbook. Find the slice of your business that is already profitable, even if it is one product line, one region, or one cohort, and reconcile the full economics of that slice this quarter: revenue, direct cost, allocated overhead, contribution. Then decide whether you can state it. You are not disclosing company profitability; you are disclosing that a defined unit of your business works without subsidy, which is the question an investor is trying to answer anyway. In a week where the mean score was 52.5, that single disclosure was worth more than $40M of additional round size.

The Founder Mistake to Avoid. Founders read this deal as permission to publish a valuation and go do it without the two numbers underneath. A valuation with no revenue attached is not a disclosure; it is a claim, and the first investor who divides it by an estimate of your revenue will arrive at a number you did not choose. Clipto’s $250M is credible only because $15M ARR and net income profitability are printed beside it. Publish the ratio or publish nothing.

Félix

Cross-Border Remittance and Stablecoin Rails | Series C | $87.0M new primary equity | Valuation Undisclosed

Eisen Fundability Score: 72 / 100

Why this scored. The strongest investor quality mark in the issue, 10 out of 10, on an Andreessen Horowitz lead with QED Investors, Castle Island Ventures and Endeavor Catalyst, paired with the largest disclosed volume figure of the week at more than $8B transferred. Félix also disclosed 2.5x year-over-year revenue growth and six million users across eleven markets. It is the only company in the set that combined a top-tier lead, a disclosed growth rate, and a nine-figure volume denominator.

The Setup. Félix, headquartered in Miami, moves money from the United States to Latin America over messaging apps, settling on stablecoin rails underneath a consumer experience that never mentions them. The company disclosed that its valuation tripled from its 2025 Series B, which was itself a $75M round, without stating either the old or new number in dollars. The structure of the raise is the part founders should study: $87M of new primary equity from Andreessen Horowitz to build the platform, and a separate $113M credit facility from the General Catalyst Customer Value Fund to fund the working capital that a remittance business consumes as it grows. Two different costs of capital for two different jobs.

The Numbers. $87.0M of new primary Series C equity led by Andreessen Horowitz, announced September 1, 2026, with QED Investors, Castle Island Ventures, Switch Ventures, Contour Venture Partners and Endeavor Catalyst participating, alongside a separate $113M credit facility from the General Catalyst Customer Value Fund. More than $8B in cumulative transaction volume processed. More than six million users. Eleven markets served. 2.5x revenue growth year over year. Valuation stated as tripled since the 2025 Series B, with no dollar figure disclosed. Headline announcement of $200M restated here to $87.0M of new primary equity.

The Pattern. This is the capital stack round, and it is the most replicable structural lesson in the issue. Félix did not raise $200M of equity. It raised the equity it needed for the parts of the business that carry equity risk and borrowed the rest against receivables that a lender can underwrite far more cheaply than a venture investor can. Every founder whose business consumes working capital as it scales, which includes every payments, lending, marketplace, inventory, and hardware company, is systematically over-raising equity to fund something a credit facility should be funding.

The Perspective. The reason this matters is dilution arithmetic, not sophistication. If Félix had raised $200M in equity at the same valuation, its founders and early employees would have owned materially less of a business whose additional $113M in funding was float, not product. Venture equity is the most expensive form of capital available and should be used only for the risk no lender will take: building something that does not yet exist. Working capital is not that risk. The moment your business has a predictable, collateralizable asset on its balance sheet, some portion of your raise stops being a venture question and becomes a credit question, and the two should be negotiated with different counterparties.

The Playbook. Split your use of funds into two columns this week. Column one is everything that funds an unproven outcome: engineering, new market entry, brand. Column two is everything that funds a predictable, recurring cash cycle: float, inventory, receivables, and customer acquisition with a known payback period under 12 months. Total column two. That is the number you should be raising as credit rather than equity, and it is almost certainly larger than you assumed. Then find one venture debt provider or one receivables lender and open the conversation before your equity round closes, not after, because the equity round is what makes the credit cheap.

The Founder Mistake to Avoid. Founders announce the blended number. Félix’s press coverage puts the round at $200M, and the market now files Félix under giant rounds rather than a disciplined $87M Series C. That is a reputational choice with a cost: the next investor who reads $200M and then sees your revenue will apply a multiple to the wrong numerator. If you raise blended capital, publish the split. The discipline is the story, and hiding it inside a bigger headline converts your best structural decision into a number that makes you look expensive.

Scan.com

Medical Imaging Network and API | Series C | $90.0M new primary equity | Valuation Undisclosed

Eisen Fundability Score: 61 / 100

Why this scored. The largest tracked round of the week and the only company in the issue to disclose both an absolute revenue figure and the growth rate behind it: a $165M annualized run rate with revenue doubled year over year. That single pairing carried Traction to Conviction to 16 out of 25 in a set where twenty-three companies scored below 10 on the same dimension. It scores 61 rather than higher because the valuation is undisclosed, no margin or retention figure accompanies the run rate, and the founder record is thin on the public record.

The Setup. Scan.com launched in the United Kingdom in 2017, became the largest medical imaging network there, entered the United States in 2023, and is now raising to build the largest US imaging network. The problem statement is the most legible in the issue: roughly 600 million imaging scans happen annually in the United States, and about 85% of them are still booked by fax or phone. Co-founder and chief executive Charlie Bullock is building an API layer atop a market in which the incumbent booking technology predates the web. This round is datelined in Atlanta and is explicitly a US expansion raise, which is why it is included here, and the UK origin is flagged rather than resolved.

The Numbers. $90.0M Series C equity led by Noteus Partners, announced August 31, 2026, with Aviva, Concord Health Partners, YZR Capital and Oxford Capital participating, alongside $130M in debt facilities from VerisFi Capital and Atempo Growth for a $220M combined headline. Revenue doubled year over year to a $165M annualized run rate. More than 900,000 patients have used the platform. Addressable market cited at more than $100B in the United States. Approximately 600 million imaging scans annually in the United States, with roughly 85% still booked by fax or phone. Founded in 2017 in the United Kingdom; US operations since 2023. Gross margin, retention, customer counts, and valuation not disclosed.

The Pattern. This is the run-rate round, and the disclosure choice is deliberate and worth copying. Scan.com published an annualized run rate rather than trailing revenue, which is the more favorable framing for a fast-growing business, and then immediately constrained it by publishing the growth rate that produced it. A run rate without a growth rate invites the suspicion that it annualizes a single good month. A run rate that doubled year over year cannot be read that way. The company gave itself the flattering metric and then handed the reader the tool to check it.

The Perspective. Notice what Scan.com did not disclose: margins, retention, customer count, and valuation. It disclosed exactly two numbers, and both of them are about the top line. That is a defensible position for a marketplace scaling into a new geography, where gross margins are genuinely thin and disclosing them would invite the wrong comparison set. The lesson is that selective disclosure works when the numbers you select are the ones a skeptic would ask for first, and fails when they are the ones that happen to look best. Revenue and growth are the first two questions. Answering them buys you the right to hold the third.

The Playbook. Write your annualized run rate and the same figure from twelve months ago on one line, then calculate the multiple. If the multiple is greater than 2, publish both numbers and let the run rate stand. If it is below 1.5, do not publish the run rate at all, because publishing it invites the growth question you cannot answer, and you will spend the meeting on the defensive. Then separately, before you raise, ask your lender what portion of your growth capital they will fund against receivables. Scan.com raised 59% of its total capital as debt. Most founders in comparable businesses raise 0% debt and dilute for all of it.

The Founder Mistake to Avoid. Founders announce the blended figure and lose control of the story, exactly as Félix did. Scan.com’s $220M headline puts a company with a $165M run rate into the giant-round conversation, where it will be compared against businesses with three times its revenue. Worse, it obscures the actual achievement: a marketplace doubled revenue and financed the majority of its growth with debt rather than dilution. Lead with the equity number and the run rate. Put the debt facility in the second paragraph, where a lender-literate investor will find it and be impressed.

Odyssey Energy Solutions

Distributed Energy Finance and Procurement | Stage Not Disclosed | $27.0M new primary equity | Valuation Undisclosed

Eisen Fundability Score: 61 / 100

Why this scored. The third capital stack round in the top five and the clearest denominator disclosure of the week: $3.6B in capital facilitated to date across 6,000 solar installers in more than 50 countries, with 1.5 gigawatts of projects unlocked and 205% platform growth in India over twelve months. Odyssey scored 15 out of 25 on Traction to Conviction without disclosing a single company's financials, because it published the volume running through the platform instead.

The Setup. Odyssey Energy Solutions, headquartered in Boulder, is the financing and procurement infrastructure for distributed renewable energy in emerging markets. Co-founders Emily McAteer and Piyush Mathur built a platform that solves the problem nobody else in climate software will touch: a solar installer in Nigeria or India cannot access equipment financing at a price that makes a project viable, because no lender can underwrite them individually. Odyssey aggregates them. The round’s structure reflects exactly that business: $27M of equity from venture investors and development finance institutions, and $47M of debt from British International Investment and three other development finance vehicles, which will be lent on.

The Numbers. $27.0M of new primary equity, announced September 1, 2026, with Broadscale Group, FMO and Al Mada Ventures leading on the equity side and Union Square Ventures, Equal Ventures, Abstract Ventures, Twelve Below, FJ Labs, MCJ and Transition Ventures participating, alongside $47M of debt from British International Investment as lead, BIO, the Facility for Energy Inclusion via Cygnum Capital and the Energy Entrepreneurs Growth Fund via TripleJump, for a $74M combined headline. More than 6,000 solar installers and engineering firms on the platform. $3.6B in capital facilitated to date. Operating in more than 50 countries. 1.5 gigawatts of projects unlocked through the procurement platform since its 2024 launch. 205% platform growth in India over twelve months. Total capital raised to date: $94M. No stage label disclosed. Company revenue, take rate, and valuation not disclosed.

The Pattern. This is the flow-through denominator round. Odyssey’s own revenue is invisible, and its platform volume is enormous, and the company chose to publish the latter. $3.6B facilitated tells an investor the size of the pipe. 1.5 gigawatts tells them the physical output. 6,000 installers report the network density to them. 205% in India tells them the slope. Four countable numbers, none of which is a company financial, and together they let an investor size the business by applying any take rate assumption they like. That is a deliberate trade: you give up control of the margin assumption in exchange for never having to defend a revenue number.

The Perspective. The development finance institutions on both sides of this round are the part most founders will misread. FMO, British International Investment and BIO are not impact-flavored venture funds reaching for returns. They are the institutions whose mandate is to move capital into exactly the markets Odyssey serves, which makes them simultaneously the investor, the eventual source of the lending capital, and the credibility signal to every ministry and utility in the pipeline. Getting a DFI onto your cap table in an emerging markets business is worth more than the check, because it converts a regulatory conversation from a cold call into a warm introduction from an institution the regulator already answers to.

The Playbook. Calculate the total value of everything that flows through your product in a year: transactions, claims, gigawatt hours, tons, acres, prescriptions, whatever the unit is. Then calculate what percentage of your addressable version of that flow you handle. Publish both numbers. If your flow number is large and your percentage is small, you have a market size story. If your percentage is large and the flow is small, you have a dominance story. Either is underwritable. What is not underwritable is a customer count with no volume attached, which is what twenty-three companies in this issue brought.

The Founder Mistake to Avoid. Founders announce the blended $74M and let the market believe they raised $74M of equity. Odyssey raised $27M of equity, which is a very different company from one that raised $74M, and the difference will matter at the next round when a new investor benchmarks progress against capital deployed. Worse, in Odyssey’s case, the debt is not even corporate leverage; it is capital lent to customers, which makes the blended headline actively misleading about the company’s own balance sheet. If money you raise is going to be lent onward, say so in the first sentence, because it is a strength that reads as risk when it is discovered later.

The Fundraising Playbook, Five Tactical Plans

Five plans, each producing a concrete output you can use immediately. No vague tasks. Each is built directly from this week’s verified signals.

1. The One Number You Have Been Withholding (Narrative and Investor Framing)

Why this matters. Seven of twenty-eight companies put a hard financial number on themselves on the record, averaging 64.4 against 48.5 for the other twenty-one. That is a 16-point premium, nearly double the 8.6-point premium the customer’s number earned last week. All three companies that cleared 65 are in the group of seven, and no company that withheld everything got above 61.

Exact deliverable. One line, in this exact form: the metric, its value today, its value twelve months ago, and the multiple between them. Light published it as 10x run-rate growth in 12 months. Félix published it as 2.5x year-over-year. Scan.com published it as revenue doubled to a $165M annualized run rate. Capacity published it as 20x in three and a half years. Put that line on slide two. If the multiple is below 1.5, do not publish it and go fix the business instead, because publishing weak growth is worse than publishing nothing.

Time estimate. Two hours with your finance lead to reconcile the 12-month comparison with what your accounting system actually shows, plus 1 hour to rewrite the slide.

Expected outcome. You move from the 48.5 bucket to the 64.4 bucket without changing anything about the business. More importantly, you become priceable, which in a week with 96.4% valuation opacity means you are competing against a field the investor cannot price at all.

The reframe. Wrong approach: hold your revenue for the data room and lead with logos and vision. Right approach: lead with the number and its slope, and hold off on the margin details for the data room.

2. The Flow-Through Denominator (Proof and Metrics Packaging)

Why this matters. Odyssey Energy Solutions scored 61 without disclosing a single company's financials, by publishing $3.6B in capital facilitated across 6,000 installers in 50 countries with 1.5 gigawatts unlocked. Light scored 73 partly on holding 100% of new Texas market entrants. Félix scored 72 partly on $8B transferred. Three of the top five rounds were driven by volume rather than revenue.

Exact deliverable. One sentence naming the total value that flows through your product in a year and the addressable population it sits inside. Transactions, claims, gigawatt hours, patients, acres, prescriptions, seats, tons. Both numbers must be countable by a stranger who calls two people in your industry. Then hand the sentence to someone outside your company and ask them to state your market share back to you. If they cannot, the denominator is wrong, and you should rebuild it before the sentence goes in the deck.

Expected outcome. An investor can size your position without asking you for revenue, and can do so during the meeting rather than after. This is the substitute for a price conversation you are not ready to have, and it is what let three of this week’s top five clear without stating their earnings.

The reframe. Wrong approach: claim 500 customers and rapid growth. Right approach: state $3.6B facilitated across 6,000 installers in more than 50 countries.

3. Eisen Self-Score Against a Widening Band (Readiness Diagnosis)

Why this matters. The score band ran from 25 to 73 this week, compared with 42 to 70 last week. The mean fell to 52.5 while the ceiling rose to 73. Only three of twenty-eight rounds cleared 65, down from five of twenty-one, even as capital rose 70%. When dispersion widens, the return to being above average rises and the cost of being below it rises with it, because the market is no longer applying a common price.

Exact deliverable. Score your round across the five dimensions: Founder-Investor Dynamics (30), Traction to Conviction (25), Narrative Power (20), Deal Architecture (20), and Capital Planning (5). Penalize every blank as a zero, the way an investor does. Then apply this week’s specific test. Above 65, you are in the top tenth of those who actually cleared, and you should run a parallel process with a deadline. Between 50 and 65, you are in the crowded middle where fifteen of twenty-eight companies sat, and you will be priced like them. Below 50 and your problem is not the process; it is that a new investor cannot verify anything, and two weeks of disclosure work will move you more than two months of meetings.

Expected outcome. A decision about process design rather than a list of weaknesses. The score tells you whether to run a competitive process now or spend a repair sprint first, and running the wrong one costs a quarter.

The reframe. Wrong approach: score yourself, feel discouraged, and revise the deck. Right approach: score yourself, decide between a competitive process and a repair sprint, and commit to one this week.

4. Secure the Lead Seat Before the Syndicate (Deal Architecture)

Why this matters. Four of twenty-eight rounds closed with no named institutional lead and averaged 43.8 against 53.9 for the twenty-four that had one, a 10-point gap. Capacity crossed $100M in ARR, with a founder carrying a roughly $900M prior exit, yet still scored 52 because the only lead named in its release is an individual. Set against that, the eight rounds carrying no series letter averaged 52.8 against 52.4 for the twenty that did, a difference of 0.4 points. Founders spend their leverage on the wrong one of these two.

Exact deliverable. Two outputs. First, before you accept a second commitment, get one investor to confirm in writing that they will lead, set the price, and take the board seat. Track it as a binary gate in your pipeline, not a preference. Second, stop trading concessions for a series letter. It is worth 0.4 points, and the lead seat is worth 10, so if a firm will lead and price the round but will not call it the letter you wanted, take the lead. Then draft your announcement around three things: the amount, the lead’s name, and one number about the business. If you cannot fill the third slot, that gap is what your deck is missing, and you have found it before an investor did.

Time estimate. Six to eight hours rebuilding the target list around lead-capable funds, plus one hour on the announcement draft.

Expected outcome. A process in which someone is accountable for setting your price. Without one, the price defaults to your own ask, which the next round’s investor will discount because nobody underwrote it.

The reframe. Wrong approach: collect soft commitments and hope a lead emerges from the group. Right approach: treat the lead commitment as a gate that must clear before the second check is accepted.

5. Move Working Capital Off Your Cap Table (Capital Efficiency)

Why this matters. Three of the week’s top five rounds split equity from debt: Scan.com at $90M equity and $130M debt, Félix at $87M equity and $113M credit, Odyssey at $27M equity and $47M debt. Between them, they raised $290M of debt that most founders in comparable businesses would have raised as equity. Scan.com financed 59% of its total capital without dilution.

Exact deliverable. Split your use of funds into two columns. Column one funds unproven outcomes: engineering, new market entry, brand. Column two funds a predictable, repeating cash cycle: float, inventory, receivables, and any customer acquisition with a measured payback period under twelve months. Total column two. That number is your credit ask, not your equity ask. Then open one conversation with a venture debt provider or receivables lender before your equity round closes, because the equity round is what makes the credit cheap.

Expected outcome. You raise the equity you actually need and borrow the rest at a fraction of the cost. On a $50M plan with $20M of working capital, moving that $20M to credit is roughly a third of the permanent dilution you would otherwise incur.

The reframe. Wrong approach: raise one large equity round to cover everything and describe the total as momentum. Right approach: raise equity for the risk no lender will take, borrow the rest, and publish the split so the discipline is visible.

Looking Forward, Next 1 to 3 Weeks

Three evidence-based scenarios and one wild card. Every prediction is anchored to this week’s verified data, not speculation.

Scenario 1: Series A Holds Above $30M and Series B Stays Thin (High Probability)

Evidence from this week. On the like-for-like $10M to $100M band, Series A averaged $30.43M across seven rounds against $27.22M last week, up 11.8%, and seed averaged $30.82M across five rounds against $17.15M, up 79.7%. Series B averaged $26.00M against $26.40M, down 1.5%, and produced two rounds against five. Capital returned to the stages that price on narrative and early proof and skipped the stage that prices on repeatable unit economics.

What to watch. Whether the Series B count recovers above four rounds in either of the next two issues. Two consecutive weeks below four would confirm that the mid-market Series B has structurally thinned rather than paused for a holiday week. Also watch whether the eight unlabeled rounds in this issue are a one-week artifact or the start of a trend. Stage opacity has doubled in a week, from 14.3% to 28.6%, and it cost those companies nothing in score, which is the condition under which a norm actually changes.

What founders should do before others notice. If your Series B is six months out, spend one of those months instrumenting acquisition cost, lifetime value, and net revenue retention so the numbers exist in defensible form when the lane reopens. If it is two months out, consider an extension at your Series A price with existing investors instead, and reopen at the letter you can actually clear.

Scenario 2: Disclosure Rises and the Premium Compresses (Medium-High Probability)

Evidence from this week. Absolute revenue disclosure went from zero in 2021 to three in 2028 in one week. Growth rate disclosure went from one of twenty-one to six of twenty-eight. The premium for disclosing was 16 points. Premiums that large attract imitation, and the founders reading the same market signals will start publishing next month.

What to watch. Whether valuation opacity finally turns. It has now risen for four consecutive periods, from 80% in June to 93.3%, then 95.2%, then 96.4%. Opacity that high alongside rising revenue disclosure is an unstable combination, because a company willing to publish its ARR has already crossed the harder disclosure threshold. The first three or four companies to publish a valuation alongside a revenue multiple will reset the standard announcement format, and Clipto has already demonstrated this format.

What founders should do before others notice. Publish now, while the premium is still 16 points. The window for any disclosure advantage is the period between when the market starts rewarding it and when everybody does. Last week the customer’s number was worth 8.6 points; this week your own number is worth 16. Neither premium will survive broad adoption, and the founders who capture it are the ones who move in the month the signal appears rather than the quarter after.

Scenario 3: The Score Floor Stays Broken (Medium-High Probability)

Evidence from this week. The floor fell from 42 to 25 in one week. Resect AI raised $25M, naming no investor at all and describing its backers only as private equity investors. Elucid raised an oversubscribed $55M Series D with no designated lead. Cari raised $32.5M from seven banks, with no single bank in the lead seat. Four of twenty-eight rounds had no named institutional lead, against a prior issue whose lowest scorer at least named its sole investor. When capital returns quickly, the marginal deal at the bottom of the market gets funded on terms nobody has to explain.

What to watch. Whether any round in the next two issues scores below 25, and whether the share of rounds with no named lead stays near 15%. Both would indicate the bottom of the mid-market has permanently detached from the disclosure norms the top operates under, which changes what a mid-band score means. A 55 in a market with a 25 floor is a different signal than a 55 in a market with a 42 floor.

What founders should do before others notice. Do not read a falling floor as a falling bar. The floor fell because more unverifiable rounds cleared, not because standards dropped for anyone competing at a price. The gap between 25 and 73 is the entire opportunity: in a market this dispersed, moving from 50 to 65 changes your price more than it would in any market this series has measured.

Wild Card: A Credit Facility Becomes Standard Below $50M (Medium Probability)

Evidence from this week. Three of the top five rounds split equity from debt, and together they moved $290M of debt alongside $204M of equity. Scan.com financed 59% of its capital without dilution, and Odyssey financed 64%. Each of the three is a business with a predictable, collateralizable cash cycle, and none is unusual in that respect: payments, marketplaces, lending, inventory, and hardware companies all share this profile.

What founders should do before others notice. The structure appeared in headlines of $74M, $200M, and $220M this week, suggesting the lenders currently doing it are targeting larger companies. That is where the opportunity is. If your round is $15M to $40M and $5M to $12M of it funds a repeating cash cycle, you are almost certainly the first founder in your lender’s pipeline to ask for that structure at your size, and you will get better terms for being early than you will for being large. Open this month's conversation with your equity term sheet in hand before it's signed.

The Bottom Line

The real insight is not the $943.6M. It is that capital rose 70% and average check size rose 43% in the same week, which means conviction fell to 52.5, its fourth consecutive decline, and the score band blew out to 48 points. The market did not get more generous or more selective. It got less consistent, and inconsistency is a pricing opportunity for anyone who can supply what the average company did not. This week that produced exactly three conviction profiles.

Profile 1: Companies that published their own number. Light (73) disclosed 10x run rate revenue growth in twelve months and 100% of new Texas retail electricity entrants. Clipto (73) disclosed $15M in ARR, net income profitability, and the only valuation in the issue. Félix (72) disclosed $8B in cumulative volume and 2.5x year-over-year growth. Scan.com (61) disclosed a $165M annualized run rate with revenue doubled. All four sit in the top five. Seven companies published a hard financial figure, averaging 64.4, compared with 48.5 for the other twenty-one.

Profile 2: Companies that published a flow-through denominator. Odyssey Energy Solutions (61) published $3.6B in capital facilitated, 6,000 installers, 50 countries, and 1.5 gigawatts unlocked, without a single company financial. Diameter Pay (59) published more than $10B in payment volume year-to-date across roughly 20 employees. Cari (57) published a network of thirty-plus banks representing more than $10 trillion in assets. None of the three disclosed revenue. All three cleared the mean by at least six points, because a volume figure lets an investor build the model themselves.

Profile 3: Companies whose round was structured rather than simply raised. Scan.com split $90M of equity from $130M of debt. Félix split $87M of equity from a $113M credit facility. Odyssey split $27M of equity from $47M of onward lending capital. Together, they raised $290M in debt against $204M in equity, and all three landed in the top five. The counter-example is instructive: four rounds this week had no lead investor setting a price at all, and they averaged 43.8. Structure is not an afterthought applied to a round. It is the round.

Everything else competed for the residual. Twenty-one companies raised real money from real investors with no financial figure on the record and averaged 48.5. Two of them, Physical Superintelligence and SciFin, took $102.0M between them on pedigree alone and scored 43 and 46. Each of these companies answered diligence questions that never became public, and none of them owed anyone a press release. The difference is that the top of the band handed the investor a number that did the underwriting for them, in a week when the money was there to reward it, and almost nobody supplied it.

Five New Rules for Founders

Rule 1. A capital rebound is not a bar reduction. Capital rose 70.0%, and the mean score fell to 52.5. The number of rounds clearing 65 fell from five to three in a week, with seven more deals. More money and less proof is the best market a prepared founder gets and the worst one for everybody else.

Rule 2. Publish your own number before someone makes you defend its absence. Seven of twenty-eight did, averaging 64.4 against 48.5. The metric: the value today, the value twelve months ago, the multiple. One line, slide two.

Rule 3. Somebody has to set the price. Four rounds closed with no named institutional lead and averaged 43.8 against 53.9. Capacity crossed $100M in ARR alongside a nine-figure founder exit, yet still finished tied for twelfth out of twenty-eight without one. Get the lead commitment in writing before the second check.

Rule 4. Stop negotiating for the letter. The eight rounds that carried no series label at all averaged 52.8, against 52.4 for the twenty that carried one, a difference of 0.4 points, while a missing lead cost 10. Trade the letter for the lead every time.

Rule 5. Stop paying equity prices for working capital. Three of the top five rounds split equity from debt, moving $290M of debt against $204M of equity. Everything in your plan that funds a predictable, repeating cash cycle is a credit question, and you are diluting for it.

Four Monday Actions

1. Write the one line. Your metric, its value today, its value twelve months ago, the multiple. Reconcile it with your accounting system, then place it on slide two and move the vision slide to slide five.

2. Build your flow-through denominator. The total value moving through your product in a year and the addressable population it sits inside, both countable by a stranger. Hand the sentence to an outsider and ask them to state your market share back to you.

3. Make the lead commitment a gate. Before you accept a second commitment, get one investor to confirm in writing that they will lead, price, and take the seat. If nobody will, that is diligence output about your round, not a scheduling problem.

4. Split the use of funds into two columns. Unproven outcomes in one, predictable cash cycle in the other. Total the second column and open one credit conversation this month, before your equity term sheet signs.

Twenty-eight companies were cleared this week, and twenty-one of them are indistinguishable from one another in the public record. The mean round score was 52.5, and the money available to it rose by 70%. The founder who walks in Monday with one growth rate, one verifiable denominator, and one investor who will set the price is not competing against the top of this market. There were three companies at the top of this market. They are the fourth.

Research Methodology and Sources

Data collection period: August 31 to September 6, 2026, with verified primary disclosures clustered August 31 to September 4. No verified US mid-market round was announced on September 5 or 6, both of which fell on Saturdays ahead of the Labor Day holiday weekend. Verification standard: a minimum of two independent sources per deal, with company press releases and regulated newswires (BusinessWire, PRNewswire, GlobeNewswire) prioritized as anchor sources, plus at least one independent outlet for corroboration. This issue was then put through two further independent verification passes, in which every company, amount, stage, investor, date, headquarters, and reported metric was rechecked against primary sources, the second of which was adversarial and specifically designed to find errors in the first. Those passes removed eleven deals, restated four headline amounts to new primary capital, corrected three stage or lead attributions, and corrected eight geography or identity errors. Eisen Fundability Scores are proprietary analytical estimates, not endorsements or investment advice. All dollar figures reflect the announced new primary capital at close unless noted otherwise.

Core Capital Totals and What They Include

The $943.6M weekly total includes only the twenty-eight verified US rounds in the scorecard, each independently confirmed at the stated amount. Mid-market is defined for this issue as a US-headquartered round of new primary capital between $5M and $100M, a wider band than the $10M to $100M used in prior issues. Because that change breaks comparability, every week-over-week comparison in this report is calculated on the $10M to $100M subset: twenty-five rounds totaling $924.6M at an average of $36.98M and a median of $32.5M, against twenty-one rounds totaling $543.9M at an average of $25.9M and a median of $25.0M in the prior issue. The three rounds below $10M, totaling $19.0M, are included in the scorecard, the scores, and the sector and geography analysis, but are excluded from all week-over-week structural comparisons, including every stage average quoted in this issue.

Secondary share purchases, credit facilities, venture debt, SAFE conversions from prior periods, previously closed tranches, non-dilutive grants and cumulative restatements are excluded from the counted amount even where a headline figure includes them. Announcements that do not separate new capital from cumulative totals are excluded entirely. No aggregator-only figure was treated as fact without corroboration in a company release or an independent outlet. Arithmetic on the total, the average, the median and every chart value was recomputed and reconciled after the second verification pass: the five sector subtotals ($380.0M, $257.0M, $129.5M, $120.0M and $57.1M) and the seven stage subtotals ($213.0M across seven Series A rounds, $207.0M across three Series C rounds, $201.5M across eight rounds with no disclosed stage, $161.1M across six seed rounds, $55.0M in one Series D, $54.0M in one Series E and $52.0M across two Series B rounds) each sum to $943.6M across twenty-eight deals.

Scoring calibration note. Undisclosed valuations are scored at 2 of 8 on Valuation Reasonableness rather than 0, matching the calibration used in the prior two issues of this series so that mean and band figures remain comparable across issues. Rounds with no disclosed stage were penalized in Round Construction. Rounds without a named institutional lead were capped at 4 out of 10 on Investor Quality. Founder track record is scored on the verifiable public record rather than on what a release chose to disclose, consistent with prior issues: Capacity’s David Karandish is credited with co-founding Answers Corporation, which Apax Partners acquired in 2014 for roughly $900M, even though the funding release mentions no prior exit. Where a founder background rests only on a low-authority bio aggregator, as with Félix’s co-founders, it is scored conservatively and not credited. Company-supplied metrics are scored as verifiable rather than independently audited.

Exclusions and Documented Rationale

• Giant rounds and public market events, excluded by editorial scope: Crusoe ($3B), Fluidstack ($1.5B), Wonderful ($550M), Higgsfield ($400M), Gimlet Labs ($300M), Upwind Security ($300M), David ($250M), Medici Brands ($250M), HiBob ($166M), Lyte AI ($165M), TabaPay ($155M), Thyme Care ($125M) and HiddenLayer ($100M). The week’s ten largest rounds totaled $6,061M against $1,512M for the prior week.

• Non-US rounds, excluded for scorecard comparability: Aitan ($41M, Israel), AIR Security ($50M, Israel and New York), Lasso Security ($30M, Israel and New York), Guardio ($40M, Israel), Huskeys ($27M, Israel), HubX ($75M, Turkey), Ultrahuman ($70M, India), WeRoad ($58M, Italy), Conveo ($50M, Belgium), HyImpulse (over €50M, Germany), Gridsight ($26M, Australia), Moment ($22M, Ghana), Enhance ($18.2M, UAE), iPremom (€15M, Spain), Octave.energy (€10M, Belgium), Sirdab ($10M, Saudi Arabia), Outlier Space (NZ$10.5M, New Zealand), Hivebotics ($6M, Singapore), Zeit AI (€5M, Germany), Backbone (€4M, Belgium), NeuShen Therapeutics (over $80M, Shanghai and Boston), Tripo AI (RMB 3B, China), PeopleX (¥5.45B, Japan), Metal ($4.5M, Pakistan), Meissner ($2.6M, Canada) and Plenti ($3M, Colombia).

• Outside the date window: Smack Technologies ($61M, August 18), Deep Cogito ($43M, August 26), CivilGrid ($26M, August 28), RQD Clearing ($74M, August 28), Workweek ($17M, August 27 to 28), Axle ($17.5M, August 11) and SiteVue AI ($7.5M, August 6).

• Structural exclusions: Chariot Claims ($9.46M, SEC Form D filing only), Bolt (up to $27M, distressed pay-to-play bridge stated as a range), Helogen ($7.1M, cumulative figure restated inside a non-financing release) and Emberos ($5.5M, prior tranche of $2.49M sold July 2 and filed August 7, not separated in the announcement).

• Unverifiable, single-source: Icon ($30M, reported by one aggregator with no corroboration and inconsistent with the company’s disclosed funding history) and Koxa ($8.7M, traceable to a 2022 press release ID).

• Below the mid-market floor: Elm AI ($3.84M) and Swissclear Global ($900K), both otherwise in window and US-based.

Deal Citations, Two or More Sources per Deal

• Scan.com, $90.0M Series C equity. BusinessWire company release dated August 31, 2026, headlined at $220M and separating the equity and debt components; company press page; Fierce Healthcare; HIT Consultant; MobiHealthNews. Rated HIGH on amount and metrics, with the dual-country headquarters flagged.

• Félix, $87.0M Series C equity. Company announcement dated September 1, 2026, read through Tech Startups and the September 1 and September 2 venture funding roundups; Andreessen Horowitz as named lead; QED Investors, Castle Island Ventures, Switch Ventures, Contour Venture Partners and Endeavor Catalyst named as participants; General Catalyst Customer Value Fund named as the source of the $113M credit component.

• Physical Superintelligence, $58.0M Seed. Company release dated September 1, 2026, distributed via Yahoo Finance; HPCwire; Siliconsnark, which independently notes that no pricing, efficiency benchmark, capital cost reduction, or live facility result has been disclosed.

• Typewriter Therapeutics, $56.0M Series A. PRNewswire company release; Endpoints News dated September 2, 2026; Pharma Journalist dated September 3, 2026; Pharmaceutical Technology; company site confirming the Cambridge, Massachusetts headquarters and a Tokyo office. Co-led by RA Capital Management and AN Venture Partners, with ANRI, Gemseki, and the SBI US Gateway Fund participating. Outlets differ by one day on the announcement date.

• Elucid, $55.0M Series D. BioSpace press release dated September 2, 2026, describing an oversubscribed Series D; HIT Consultant; MassDevice; Pulse 2.0. All four describe IAG Capital Partners and Elevage Medical Technologies as existing participants rather than leads, and the new anchor as an unnamed publicly traded medical device company.

• Capacity, over $54.0M Series E. PRNewswire company release dated September 2, 2026, headlined at over $50M with the body stating over $54M and naming Kathy Ireland as the lead investor; The SaaS News; Cultivation Capital, an existing investor, confirming over $54M; the company’s own PRNewswire release of June 18, 2026 for the $100M ARR milestone; public record for the 2014 Apax Partners acquisition of Answers Corporation, co-founded by David Karandish, at roughly $900M, a figure some profiles render as $950M. Release states $100M+ ARR as of June 2026, 20x growth in three and a half years, 20,000+ organizations, Inc. 5000 rank 432, and over $159M raised to date.

• Hi Rasmus, $50.0M. GlobeNewswire company release dated September 3, 2026, describing a strategic minority growth investment from Updata Partners with founders retaining majority ownership; Behavioral Health Business; Acuity, which notes that valuation, stake size, secondary composition, and post-closing board composition were all undisclosed.

• Light, $46.0M Series A. Company press release dated September 1, 2026; Axios exclusive dated September 1, 2026; Tech Startups; FinSMEs, which incorrectly states a Houston headquarters against four sources confirming Austin; company careers materials confirming Austin.

• SciFin, $44.0M Seed. BusinessWire company release dated September 1, 2026, read through Morningstar syndication; SiliconANGLE; Pulse 2.0 for the full syndicate; citybiz, which states explicitly that no customer count, revenue figure, or valuation was disclosed. Co-led by Altimeter and Madrona with Foundation Capital, S32, and Zetta Ventures. Founder Mohit Aron co-founded Nutanix and founded Cohesity.

• Wafer, $40.0M Series A. Company blog post dated September 1, 2026; Wilson Sonsini deal announcement confirming the $40M Series A; Pomegra for the reported post-money above $200M and the 50x step-up from an April 2026 $4M seed, which is a secondary-source figure and is not counted as a disclosed valuation.

• Reframe Systems, $40.0M. BusinessWire company release dated August 31, 2026, describing additional venture-backed equity financing with no series letter and confirming the prior $20M Series A of August 2025; HousingWire; The Robot Report and Coverager, both of which also decline a series letter; Dealroom, the one outlet assigning Series B; HUD PDR Edge for the Andover microfactory and Banker and Tradesman for the new Billerica headquarters lease.

• EIT Pharma, $35.0M Series A. PRNewswire company release dated August 31, 2026, describing an oversubscribed round led by Propel Bio Partners; BioSpace syndication; Pulse 2.0. FDA acceptance of the lonafarnib NDA is stated in the release.

• Cari, $32.5M first tranche. BusinessWire company release dated September 2, 2026, read through Morningstar syndication and headlined as the first tranche of an initial funding round backed entirely by banks; Ledger Insights for the $32.5M figure; CityBiz for the 30-plus bank network and $10T-plus in represented assets. Named bank investors: Glacier Bank, First Horizon, Huntington, KeyBank, M&T, Old National and SouthState.

• N-Power Medicine, $32.0M Series B. BusinessWire company release dated September 1, 2026, read through Morningstar syndication; Pulse 2.0; HIT Consultant; citybiz; FinSMEs; plus the company’s own BusinessWire release of July 1, 2024 announcing a prior Series B led by Merck Global Health Innovation Fund, used for the round-history check.

• PatientIQ, $30.0M Series C. Company press release dated September 3, 2026, and matching PRNewswire wire text; HIT Consultant; FinSMEs; The SaaS News. Metrics: 870+ healthcare organizations against roughly 200 at the 2022 Series B, 17 million patients, 70 million-plus outcomes, 20-plus specialties, 50-plus EHR integrations.

• Odyssey Energy Solutions, $27.0M equity. PRNewswire company release dated September 1, 2026; Latitude Media, which independently confirms the $27M equity and $47M debt split; Mercom Capital Group. Equity led by Broadscale Group, FMO, and Al Mada Ventures; debt led by British International Investment.

• Resect AI, $25.0M. PRNewswire company release dated September 3, 2026, which datelines Seattle, describes the backers only as private equity investors and cites an office in the greater Portland area; GeekWire, which reports the team is in Washougal, Washington, with a Seattle office planned; SiliconANGLE. Rated MEDIUM because no stage, no investor name, and no operating metric of any kind is disclosed.

• Empirik, $21.0M Seed. PRNewswire company release dated September 2, 2026, with the full syndicate and customer list; TechCrunch exclusive dated September 1, 2026, which confirms Sequoia incubated the company from 2023 and names a third co-founder, Sudheer Dhurjati; Dealroom; AI Weekly. Named customers per the release: Guardant Health, Avahi Systems, TCBPay, a Fortune 50 CPG company, and a Fortune 500 financial data services company.

• Aslan Protects, $20.8M Seed. Axios exclusive dated September 1, 2026, which names the FBI and Homeland Security Investigations and describes an agent running autonomously for 21 days; FinSMEs dated September 2, 2026, which supplies the seed label Axios does not use; 2048 Ventures confirming its own participation. No company release was located.

• Easy Aerial, $20.0M Series B. BusinessWire company release dated August 31, 2026, read through Morningstar and Yahoo Finance syndication, datelined New York with no borough or facility named; citybiz, whose headline reads Series A over a Series B body and which supplies the founder background the release omits; DroneXL and Brooklyn Eagle for the February 2026 non-renewal of the company’s Brooklyn Navy Yard lease, which is why no borough is asserted here.

• Clipto, $15.0M at $250M valuation. TechCrunch dated August 31, 2026, as the originating interview-based report; FinSMEs; Yahoo Finance syndication. No stage label is used by the company or any of its outlets. Metrics: $15M ARR, net income profitability, 30 million-plus users, hundreds of thousands of paying subscribers, roughly 20 employees.

• Norbert Health, $14.0M Series A. PRNewswire company release dated September 1, 2026; TipRanks; FinSMEs; AlleyWatch. Metrics: live in production since August 2025, 96% patient acceptance, 82% monitoring compliance against a roughly 41% manual baseline.

• Cradlewise, $12.0M Series A. Entrackr dated September 3, 2026; YourStory dated September 3, 2026; Business Standard; company about page confirming the Fremont, California headquarters and Pune manufacturing. Founding year conflicts between the company site (2017) and press coverage (2019) are not asserted.

• Critical Materials Group, $10.3M Seed. PRNewswire company release dated September 2, 2026; Morningstar syndication; Defense Daily; SiliconANGLE, whose headline misnames the company as Critical Munitions Group, but the body is correct.

• Diameter Pay, $10.0M Series A. PRNewswire company release dated September 3, 2026; The Block; PYMNTS; FinSMEs. Metrics: more than $10B in payment volume year-to-date 2026, 10,000-plus end users, roughly 20 employees, founded in 2023. The round closed between April and July 2026 and was first disclosed publicly on September 3, so it is treated as a first announcement rather than a resurfaced deal.

• Molten Salt Solutions, $7.0M Seed. PRNewswire company release dated August 31, 2026, describing an oversubscribed round led by Dolby Family Ventures; company site naming Dr. John Elling as founder and chief executive and the Los Alamos National Laboratory origin; Dealroom; FinSMEs. Commercial agreements named with Type One Energy, Gauss Fusion, and Fissionaire. A separate $3M pre-seed and more than $5M in non-dilutive grants are prior capital and are excluded from the counted amount.

• Konko AI, $6.0M. PRNewswire company release; CityBiz dated September 2 to 3, 2026, for the customer outcome figures; FinSMEs dated September 2, 2026; AIJourn. Rated MEDIUM because three sources name Michael Haddad as the second co-founder alongside chief executive Jean-Marc Goguikian, while CityBiz names Dr. Juliana Vallejo, and no company page resolves it.

• Blue Voice, $6.0M. TechCrunch dated August 31, 2026, as the originating interview-based report; FinSMEs dated September 1, 2026. Neither source applies a stage label. Metrics: 225 county agencies across 25 states, elevenfold customer growth over the past year.

Market Comparison Sources

Market comparison and contrast set: Crunchbase News weekly ranking of the ten largest funding rounds for the week of August 29 to September 4, 2026, which lists Crusoe ($3B), Fluidstack ($1.5B), Gimlet Labs ($300M), Upwind Security ($300M), David ($250M), HiBob ($166M), Lyte AI ($165M), TabaPay ($155M), Thyme Care ($125M) and HiddenLayer ($100M). Tech Startups venture capital and startup funding roundups for August 31, September 1, September 2, September 3, and September 4, 2026. VC News Daily funding records for September 1 to 4, 2026, used as a candidate source and date-checked against primary releases in every case, since its posting dates lag primary announcements by two to five days. AlleyWatch daily funding reports for September 1, 2, 3, and 4, 2026. Fierce Healthcare and Fierce Biotech fundraising trackers for 2026. Axios Pro deal coverage for the week of August 31, 2026.

Prior-period comparison figures for August 24 to 30, 2026 are drawn from the preceding issue of this report series, which tracked twenty-one verified US mid-market rounds totaling $543.9M at an average of $25.9M, a median of $25.0M and an Eisen score band of 42 to 70 with a mean of 58.0, and reported stage averages of $17.15M at seed, $27.22M at Series A and $26.40M at Series B. Comparison figures for August 17 to 23, 2026 are drawn from that issue, which tracked fifteen rounds totaling $545.0M at an average of $36.3M with a score band of 36 to 82 and a mean of 63.7. Comparison figures for June 1 to 7, 2026, are drawn from that issue, which tracked 10 rounds totaling $479.5M at an average of $48.0M, with a score band of 67 to 80 and a mean of 72.3.

Research completion timestamp: September 7, 2026, after a third verification pass, adversarial and directed at finding errors in the second.

DISCLAIMER: This article is for informational and strategic intelligence purposes only. It does not constitute investment advice. The Eisen Fundability Score is a proprietary diagnostic within Fundables OS™, not a financial recommendation.

If this article was useful, share it with founders who are about to raise.

— Leon Eisen, 4x Founder, Venture Capitalist, and Creator of Fundables OS™

Playbook, Perspective, and Pattern for founders raising now. This report strips out the megarounds and the public market traffic so you can read the part of the market that actually prices your round. Every figure below survived a second independent verification pass against primary sources.

Last week the mid-market moved $545.0M across fifteen verified rounds. This week it moved $543.9M across twenty-one. That is a difference of 0.2% in capital and 40% in deal count. The pool did not grow. The queue did.

The average check fell 28.7%, from $36.3M to $25.9M. The median fell 16.7%. Every stage fell. Seed fell hardest, down 49% from a week ago. And the Eisen Fundability band did something it has not done in this report series: the ceiling came down. The top score last week was 82. This week the top score is 70. Not one of twenty-one rounds reached 75, the threshold this framework calls solid fundamentals.

Here is the number that explains the rest. None of the 21 companies disclosed a revenue figure. Twenty of twenty-one disclosed no growth rate. Twenty of twenty-one disclosed no valuation. The market did not stop funding. It stopped pricing on the company’s own numbers, because almost nobody put one on the record.

So the five rounds that cleared 65 did something else. They led with the customer’s number instead. Onos Health disclosed a 6% reduction in its health plan clients’ behavioral health program costs. Arintra reported a 5.1% increase in compliant revenue capture and a 43% decrease in coding denials at named health systems. CivilGrid disclosed more than $60M in paving conflicts eliminated at PG&E. Those five averaged 64.6, compared to 56.0 for everyone else.

Consequence for Monday. You are now one of twenty-one companies asking for a check that got 29% smaller, in a week where no sector took more than a fifth of the money, and no round scored above 70. Your own metrics will not set you apart, because most founders are holding theirs back, too. The number that separates you is your customer’s number, and you probably have not asked them for it.

The Week in One Sentence

Primary insight. With megarounds and public market traffic removed, the mid-market held its capital flat while spreading it across 40% more companies, dissolving sector concentration entirely and pulling the top of the fundability band down ten points, so the only thing that separated a funded round was proof of what the customer got.

● Total tracked mid-market capital (21 verified rounds): $543.9M in new primary capital, every deal between $10M and $100M.

● Average round size: $25.9M, down 28.7% from $36.3M last week.

● Median round size: $25.0M, down 16.7% from $30.0M. The midpoint sits inside a two-way tie at $25.0M between Arintra and Transfyr, with Digs just above at $25.3M.

● Disclosed valuations: one of twenty-one. Blank Street at $650M, up from $500M in 2025. That is a 95.2% opacity rate against 93.3% last week and 80% in June, a third consecutive rise.

● Disclosed revenue figures: zero of twenty-one. Disclosed growth rates: one of twenty-one, Yardstik at 149% year over year.

● Largest tracked round: Blank Street, $75.0M of new primary capital at a $650M valuation, reported as a Series C, which also ranked tenth on the week’s list of ten largest rounds. A coffee chain made the megaround tape because it had thinned.

● Highest Eisen Fundability Score: Standard Metrics at 70, the lowest weekly high this report series has recorded.

● Lowest Eisen Fundability Score: Celera Semiconductor at 42, a $30M Series B funded entirely by the single investor that also wrote its $20M Series A twelve months earlier, with no customer, revenue, or growth figure of any kind on the record.

● Defining structural feature: a 28-point score band against 46 points last week, and the compression happened downward. The floor rose six points, from 36 to 42. The ceiling fell twelve points, from 82 to 70.

Data Integrity Notes

All twenty-one featured rounds were verified against at least two independent sources, then rechecked in a second independent verification pass against primary sources. That pass removed four deals, restated three headline amounts, corrected one stage label, and corrected eight attributions. Resolutions and exclusions applied:

● Editorial scope excludes giant rounds and public market events by request. Removed from the tracked set: Instinct ($250M), Owner ($240M), Generalist AI ($200M), Gatik ($200M), Socure ($156M), Emerald AI ($150M), Regent Craft ($120M), AusperBio ($120M) and Starcloud ($250M). These are used only as a contrast set. The week’s ten largest rounds, excluding Blank Street, which sits inside the mid-market set at $75M and ranked tenth on that list, totaled $1,512M against $3,215M for the prior week’s ten largest. The megaround tape fell 53% while the mid-market held flat. One of those ten, Stability AI at $76M, is UK-headquartered and is separately excluded from the mid-market set for comparability.

● Three headline amounts were restated to new primary capital. Blank Street’s announcement carries $105M; the company release and independent reporting separate that into $75M of primary capital and $30M of secondary share purchases, so $75.0M is counted. Airway Therapeutics’ announcement includes $50M; the primary source breaks that down into $26M from a prior SAFE financing and $24M from a Series E-2, so $24.0M is counted. Agentry's announcement carries $24.5M; the primary source breaks that down into a $19.1M seed and a previously closed $5.4M pre-seed, so $19.1M is counted.

● Two rounds were excluded because new in-window capital could not be isolated. Hike Medical announced $22.5M in combined seed and Series A financing with no breakdown between the two, so it is excluded from all totals, charts, and scores rather than counted at its headline figure. Quaise Energy announced the close of a $180M Series B with a $35M investment from Nabors Industries; the round total sits above the mid-market ceiling, and the in-window money is a tranche of it, so it is excluded on both counts.

● Date window control removed two deals. Princeton Critical Minerals ($16M) circulated widely within this window via aggregator republication, but the announcement is dated August 12, 2026 in its exclusive coverage and August 20 in the trade press. Discern Security ($13M Series A) recirculated on August 26 against a July 30, 2026 primary release. Both are marked as news-cycle resurfaced and excluded from every total.

● Stage opacity is reported rather than filled in. Mantel’s round is described by the company as a strategic investment and reported by two aggregators as either a Series A extension or a Series C extension; no stage is asserted here. Metriport disclosed no stage. Hivemind Digital Group disclosed no stage. Three of twenty-one rounds carry no stage label at all, and each was penalized in Deal Architecture rather than assigned a stage by inference.

● Blank Street has no primary source and is not a Series B. No company release, no lead investor post, and no newswire announcement exists. The story broke in the Financial Times on August 24, and the primary and secondary split traces to an SEC filing reported by trade press at $104,999,981, which is not yet indexed in EDGAR. Blank Street already closed a $20M Series B in March 2023, so the Series B label carried by one aggregator is wrong; two outlets report this round as a Series C, and the filing applies no series label. It is reported here as a Series C at MEDIUM confidence. Store count is 106 locations worldwide, and the footprint extends beyond New York and London to Boston, Washington, DC, multiple UK cities, and now Los Angeles. Tiger Global’s participation is contested and is not asserted: three outlets name it, while Axios names HOF Capital instead.

● Metric provenance. Every operating figure in this issue is company-supplied. Arintra’s revenue capture and denial reduction figures, Onos Health’s cost and adherence figures, CivilGrid’s PG&E savings figures, Corvus Robotics’ customer discrepancy counts, and Yardstik’s growth and retention figures are treated as verifiable rather than independently audited, and scored on that basis. Mantel’s claim that its system reduces energy losses by 97% is company boilerplate describing its own technology, not a customer result, and is attributed rather than asserted. TerraBlaster’s per-acre savings are projections, not realized results, and are not scored as customer proof.

● What this report can and cannot see. Scores reflect proof that was verifiable at announcement. Investors receive far more in a private data room, and a company that puts nothing on the record may have answered every question during diligence. The public record is a proxy for whether the numbers existed in a defensible form while the round was running, not a measure of what a company knows about itself, nor a requirement to publish anything.

The Deal Scorecard

Eisen Fundability Scores are calculated across five weighted dimensions: Founder-Investor Dynamics (30), Traction-to-Conviction Conversion (25), Narrative Power (20), Deal Architecture (20), and Capital Planning (5). Scores of 85 and above signal an inevitable outcome. Scores of 70 to 84 signal strong execution. Scores below 70 signal early-stage or the need for repositioning. Missing metrics are scored conservatively, and opacity is penalized rather than assumed strong.

What the Scorecard Says at a Glance

The ceiling is the message. For three issues, this report has watched the mean fall: 72.3 in June, 63.7 last week, 58.0 this week. That alone reads as a market getting harder. What happened this week is different and worse. The floor rose six points, from 36 to 42. The ceiling fell twelve points, from 82 to 70. Nothing reached 75. When the bottom of a band rises, and the top falls, the market is not becoming more selective. It is becoming less willing to pay a premium for anything.

Nobody disclosed their own numbers, so the customer’s number decided the order. Zero of twenty-one companies put a revenue figure on the record. One put a growth rate on it. The five deals that disclosed a quantified customer outcome averaged 64.6. The sixteen that did not averaged 56.0. That is an 8.6-point spread earned entirely by describing what the buyer got rather than what the seller has.

Standard Metrics (70) took the top spot without a single customer outcome, and did so by 10 points more than last week’s winner. It scored 20 out of 30 on Founder-Investor Dynamics, the highest in the set, on a founder who spent five years investing at Spark Capital before building the company, 8VC leading, and Salesforce Ventures and Spark participating alongside roughly twenty times business growth since its Series A. It then named General Catalyst, Bessemer, and Accel as customers and disclosed that its platform carries more than $400B in assets across 150 firms. That is scale as a substitute for outcomes. It works only when the logos on your customer list are the same firms your investor calls every week. Note what it did not have: no revenue, no growth rate, no valuation, and no competitive-round language anywhere in the release. The top of this market was reachable without any of it.

The bottom of the band is a disclosure story, not a quality story. Celera Semiconductor (42) raised $30M for a Series B funded entirely by Maverick Silicon, the same sole investor that wrote its $20M Series A twelve months earlier, disclosed no customer, no revenue, no growth, and no valuation, and announced an acquisition in the same release. A 50% larger re-up from the same investor within a year is real conviction, and it is why Celera does not score lower. Airway Therapeutics (44) raised $24M of new money with roughly 94% of its existing investors participating and no institutional lead named. Both are real companies with real capital. What the score measures is what a new investor could verify without asking, and in both cases the answer was close to nothing.

Two rounds show what a corporate check is worth. Digs scored 14 out of 30 on Founder-Investor Dynamics, the lowest in the set, and still cleared $25.3M because Builders FirstSource led the round outright and attached a five-year integration agreement across 140,000 builder clients and 565 locations in 43 states. Mantel scored 11 on the same dimension, the second-lowest, and cleared $18M on a strategic investment from Constellation Technology Ventures, the venture arm of the largest carbon-free power producer in the United States, which makes the investor the customer. Neither round was won on founder brand. Both were won on channel. Note the asymmetry: Digs got a named lead and Mantel did not, and that single difference is six points of separation between them.

What Changed: Five Market Shifts

Each shift is verified against multiple sources and ranked by structural impact on founder fundraising, not by deal size. Every shift ends with what it means for your raise next week.

Shift 1: Same Money, Forty Percent More Claimants

Pattern, what happened. Twenty-one verified mid-market rounds moved $543.9M. Fifteen rounds moved $545.0M the week before. That is a 0.2% difference in capital against a 40% increase in deal count. Average check size fell from $36.3M to $25.9M, a 28.7% decline. Median fell from $30.0M to $25.0M, a 16.7% decrease. Every stage fell: seed from $33.7M to $17.15M, down 49%; Series A from $32.8M to $27.22M, down 17%; and Series B from $45.5M to $26.40M, down 42%.

Perspective, what it means. A flat pool split more ways is not a broadening market. It is a rationing market. Partners who wrote one $36M check last week wrote one and a half $26M checks this week, which means they took the same portfolio risk across more companies and gave each of them less runway to prove it. That changes what a round has to buy. At $36M you fund a two-year plan. At $26M you fund an eighteen-month plan and a second raise, which means your next milestone has to arrive faster than the one you were planning.

Founder Blindspot, what most miss. Founders read a rising deal count as evidence the window is opening and accelerate their process to catch it. The deal count rose because check sizes fell, not because appetite grew. Running faster into a market that pays 29% less per round is how founders end up accepting the first term sheet at a size that does not meet the milestone they promised.

Playbook, what to do. Recut your use of funds against 72% of your target raise before you open. Write down the one milestone that survives at the smaller number and the two that do not. If the surviving milestone is not enough to price a Series A or B, your problem is not the raise; it is the plan to raise funds, and you should fix that this week rather than in a partner meeting.

Contrast. Last week, the story was capital broadening from ten deals in June to fifteen, with an average check 24% smaller. This week it broadened again, to twenty-one at a further 29% smaller check, without adding a dollar. Two consecutive weeks of dilution in the size of the average opportunity.

What this means for your raise: Size your ask to the check the market is actually writing, then design a milestone that fits inside it. A right-sized round that funds a real milestone beats an oversized ask that funds a slide.

Shift 2: Sector Rotation Stopped Existing

Pattern, what happened. Six categories split the week, and none took more than 19.1% or less than 13.8%. Healthcare and life sciences took $104.0M across five rounds. Energy, climate and autonomous hardware took $93.0M across four. Enterprise and financial infrastructure took $92.0M across four. Vertical software for physical industries took $90.8M across four. Semiconductors and photonics took $89.1M across three. Consumer retail took $75.0M in a single round. Last week, healthcare accounted for 67.1% of the mid-market across nine of fifteen deals. This week it took 19.1% across five of twenty-one.

Perspective, what it means. A 48-point swing in one sector’s share in seven days is not a rotation, because rotations move money from one place to another. This moved money to no place in particular. Investors did not conclude that healthcare was over and semiconductors were on. They stopped underwriting by category and started underwriting one company at a time. That is what a flat capital pool split across more deals looks like from the inside: fewer thesis-driven bets, more case-by-case decisions.

Founder Blindspot, what most miss. Founders spend the week after a hot sector report repositioning into that sector. Anyone who rewrote their deck last weekend to sound like healthcare, on the evidence of a week where healthcare took two-thirds of the mid-market, is now pitching into a category that took a fifth. The sector signal has a shelf life of about seven days, and a repositioning takes three weeks. You will always arrive late.

Playbook, what to do. Delete the market timing slide. Replace the sentence “the market for X is growing at Y percent” with one sentence naming the specific customer budget line your product gets paid from, and the specific event that opened it. Category momentum is not underwritable this month. A budget line is.

Contrast. In June, the mid-market spread across many sectors, with no single dominant sector. Last week, one sector accounted for more than two-thirds. This week, the spread returned and widened beyond June, with the largest and smallest categories separated by 5.3 percentage points.

What this means for your raise: Stop competing to be in the right category. Nobody has one this week. Compete to be the company whose buyer has a funded reason to move this quarter.

Shift 3: The Ceiling Fell, Not the Floor

Pattern, what happened. The score band ran from 42 to 70, a spread of 28 points, compared with 46 points last week. But the compression was one-sided. The lowest score rose from 36 to 42. The highest fell from 82 to 70. Zero of twenty-one rounds reached 75. The mean fell to 58.0 from 63.7 last week and 72.3 in June, a third consecutive decline. Only five of twenty-one rounds cleared 65, or 23.8%, against nine of fifteen the week before, or 60%.

Perspective, what it means. A widening band means uncertainty. A band that compresses downward means something else: the market has stopped paying for excellence. Last week Hopscotch Primary Care scored 82 because it disclosed profitable operations, retention above 90%, an NPS of 89, and a 25-point improvement in medical loss ratio. This week nobody offered anything close, and the market cleared twenty-one rounds anyway. When the best available evidence weakens, and the money still moves, investors are not raising the bar. They are lowering their expectation of what the bar can tell them.

Founder Blindspot, what most miss. Founders read a falling mean as permission to bring less. The opposite is true, and the arithmetic proves it. Last week, nine of fifteen rounds cleared 65, or 60%. This week, five of twenty-one cleared it, or 23.8%. The proportion of rounds that scored well fell by more than half. In a market where almost nobody is separating themselves, the cost of separating yourself has never been lower, and the return has never been higher, because the second-place company is at 58.

Playbook, what to do. Score your own round against the five dimensions this week, honestly, penalizing every blank as a zero the way an investor does. If you land above 65, you are in the top quartile of what actually got funded this week, and you should be running a competitive process, not a sequential one. If you land below 55, understand that you are indistinguishable from most of the sixteen other companies that also cleared, which means you will get funded at their price, not yours.

Contrast. June produced a 13-point band with a mean of 72.3, a market that agreed on what it paid for. Last week produced a 46-point band with a mean of 63.7, a market that had stopped agreeing. This week produced a 28-point band with a mean of 58.0 and no top end.

What this means for your raise: The bar for getting funded has fallen. The bar to get priced well did not move, and almost nobody cleared it. That gap is the entire opportunity in this market.

Shift 4: The Customer’s Number Replaced Yours

Pattern, what happened. None of the 21 companies disclosed a revenue figure. One disclosed a growth rate. Twenty withheld valuation. Against that blackout, five companies disclosed a quantified result their customers received, and those five averaged 64.6, compared with 56.0 for the other sixteen. Onos Health disclosed a 35% improvement in clinical standard adherence, a 75% improvement in clinical review efficiency, and more than a 6% reduction in behavioral health program costs within twelve months at health plans including Aetna. Arintra disclosed a 5.1% increase in compliant revenue capture, a 32% reduction in cost to collect, and a 43% decrease in coding-related denials across named health systems processing $5B in annual claims. CivilGrid disclosed more than $60M in paving conflicts eliminated at PG&E, a 40% reduction in field research and up to an 85% reduction in due diligence time. Corvus Robotics disclosed 35,000-plus inventory discrepancies identified at Southern Glazer’s and a 600% increase in imaging frequency at Dermalogica. Yardstik disclosed 149% revenue growth, 98% account retention over three years, and 99.4% customer satisfaction.

Perspective, what it means. An investor underwriting a company with no disclosed revenue is underwriting a hypothesis about future revenue. A quantified customer outcome converts that hypothesis into arithmetic by telling the investor the buyer’s payback period and, therefore, how hard the next hundred sales will be. A 43% reduction in coding denials at a health system with $50B in net patient revenue is a renewal argument, an expansion argument, and a pricing argument in one figure. Your own ARR is none of those things. It tells an investor what you already sold, not why the next buyer signs.

Founder Blindspot, what most miss. Founders treat customer results as marketing material and their own metrics as investor material, and then wonder why a deck full of ARR and logos produces polite second meetings. The order is backward. In a week when the whole market went dark on its own numbers, the founders who put the buyer’s number on slide two were the only ones giving an investor anything to model. And note what this does not require: none of these five disclosed their revenue either.

Playbook, what to do. This is the single highest-leverage action in this issue. Call your three best customers this week and ask one question: what changed in a number you already track since you started using us? Not “are you happy?” A number, with a before and an after, and permission to use it. Then write three lines in this exact form: customer name, metric, before, after, time elapsed. Put those three lines on slide two and move your own metrics to slide nine.

Contrast. Last week the divider was proof readiness, whether a company’s own numbers existed in defensible form when the round opened, worth 13.4 points. This week the divider moved one step outward. It is no longer whether you can produce your numbers. It is whether you can produce your customers, and the premium is 8.6 points in a market where the ceiling itself fell twelve.

What this means for your raise: Your metrics prove you exist. Your customers’ metrics prove you matter. In a week when nobody showed either, the second one was worth nearly nine points and four of the top five slots.

Shift 5: Distribution Replaced the Lead Investor

Pattern, what happened. Two of twenty-one rounds were led outright by a corporate or strategic investor rather than a venture firm, a third was funded by corporate strategics with no lead designated at all, and nine of twenty-one carried strategic money. Builders FirstSource led Digs’ $25.3M Series A as sole lead and attached a five-year commercial agreement extending Digs across 140,000 builder clients and 565 locations in 43 states. M&G Investments led Hivemind Digital Group’s $17M round and took a board seat; M&G is precisely the institutional asset manager Hivemind’s tokenization infrastructure is built to serve. Mantel’s $18M came as a strategic investment from Constellation Technology Ventures and Azimut, with no lead named; Constellation is the largest carbon-free power producer in the United States and therefore the buyer. MediaTek led Agentry’s pre-seed round and returned in the seed round. CVS Health Ventures joined Onos Health, whose customers are health plans. Yale New Haven Health and Endeavor Health Ventures joined Arintra, and both are exactly the kind of health system that buys revenue cycle software. Ciena joined Quintessent, and GrainInnovate and the Hort Innovation Venture Fund joined TerraBlaster. Outside the counted set, Orthofeet joined Hike Medical as both investor and commercial partner.

Perspective, what it means. When the average check falls 29%, and the deal count rises 40%, a purely financial lead is buying less influence per dollar than it used to. A strategic that is also a buyer or a channel does two jobs with one check: it prices the round, and it removes the top-line risk. Digs is the clearest evidence. It scored 14 out of 30 on founder and investor dynamics, the lowest in the set, and cleared $25.3M anyway, because the lead investor was the distribution. Mantel is the counter-evidence and the caution. Its strategic funding came from the right buyer, yet it still scored 52, second-from-bottom, because no investor took the lead seat and no stage was disclosed. Strategic capital substitutes for founder brand. It does not substitute for someone setting the price.

Founder Blindspot, what most miss. Founders rank corporate money below venture money on the assumption that it is slower, more conditional, and a negative signal to the next round. This week it was the fastest path to a priced round for companies whose own proof was thin. The trap is real, but it is not the one founders name: the danger in strategic capital is a right of first refusal or an exclusivity clause that shrinks your buyer universe, not the reputational question, which nobody in this week’s data appears to have been penalized for.

Playbook, what to do. Build a second target list this week, twelve names long, of corporates who buy what you sell or sell to who you sell to. For each one, write the specific first customer they can deliver in the first ninety days. Then read your existing term sheet template and delete any language granting exclusivity, right of first refusal on an acquisition, or category lockout, because that is the only part of strategic money that actually costs you.

Contrast. Last week’s leads were almost entirely venture and specialist funds: ARCH, New Leaf, 8VC, Costanoa, Section 32, Battery, OrbiMed, ARCHIMED. Two of fifteen rounds carried a corporate as a co-lead, Olympus Innovation Ventures at MaxQ Medical and Aramco Ventures at Twin1 AI, and neither led alone. This week, two rounds were led outright by a corporate or strategic asset manager; a third was funded by corporate strategics with no lead at all; and nine of twenty-one carried strategic money.

What this means for your raise: Rank your investor list by which customer each one delivers, not by which name looks best in the announcement. In a rationed market, the check that comes with a buyer is worth more than the check that comes with a brand.

The Deals That Matter, Top 5

Five deep dives across private markets infrastructure, behavioral health AI, healthcare revenue assurance, workforce risk, and subsurface infrastructure data. These are the five highest-scoring rounds of the week. All metrics are company-supplied, verified against two or more sources, and re-checked in a second pass.

Standard Metrics

AI Portfolio Management for Private Markets | Series B | $20M | Valuation Undisclosed

Eisen Fundability Score: 70 / 100

Why this scored. The highest score of the week, and the smallest round in the top five. Standard Metrics did not disclose revenue, growth rate, or valuation. What it disclosed was position: more than 10,000 portfolio companies on the platform, 150 firms managing more than $400B in assets, roughly twenty times business growth since its Series A, General Catalyst, Bessemer, and Accel named as customers, and a claim that 30% of Forbes Midas List investors are customers. It then paired that with the highest Founder-Investor Dynamics score in the set, 20 out of 30, on an 8VC lead with Salesforce Ventures and Spark Capital participating.

The Setup. Standard Metrics, founded in 2020 and headquartered in San Francisco, sells portfolio monitoring and reporting infrastructure to venture and private equity firms. Chief executive John Melas-Kyriazi co-founded the company after roughly five years as an investor at Spark Capital, which participates in this round. That biography matters more than usual here, because the buyer is a venture investor and the founder was one. He is not selling into a market he researched. He is selling the thing he wanted and could not buy.

The Numbers. $20M Series B led by 8VC, announced August 24, 2026, with Salesforce Ventures, Spark Capital, January Capital, First Trust Capital Partners, Socii Capital, Kindergarten Ventures, Calm Ventures, and Gaingels participating. More than 10,000 portfolio companies supported. 150 firms managing more than $400B in assets. Approximately twenty times business growth since the Series A, a company-stated and undefined multiple that does not specify revenue. Named customers: General Catalyst, Bessemer Venture Partners, and Accel. The company states that 30% of the current Forbes Midas List are customers. Announced alongside launches of AI document parsing, an AI Analyst tool, and MCP interoperability. Founded in 2020. Revenue, growth rate, and valuation not disclosed, and the release contains no oversubscription or competitive-round language.

The Pattern. This is scale substituting for outcomes. Standard Metrics is the only company in the top five that did not disclose a quantified customer result, and it reached the top anyway by disclosing how much of the market it already holds. Assets on the platform are not a customer outcome but a defensible, countable, third-party-verifiable position, and at $400B, they answer the only question an investor has about an infrastructure company: is it already the standard?

The Perspective. There are exactly two ways to win an infrastructure round without revenue disclosure. Prove that the customer’s economics have improved, or prove that you already hold the market. The second is only available if you actually hold it, and most founders overstate their version of it by counting logos instead of volume. Standard Metrics counted volume: companies, firms, and dollars on the platform. Three countable denominators, each verifiable by any investor who asks two peers.

The Playbook. Find the one denominator in your category that a stranger could verify by calling two people, and measure yourself against it. Not “500 customers.” Assets, transactions, patients, acres, claims, seats under management. Then state your number and the denominator in the same sentence. A number without a denominator is a brag. A number with one is a market share claim, and market share is the only metric that survives a week when nobody discloses revenue.

The Founder Mistake to Avoid. Founders read this deal as proof that a big customer list wins rounds and go collect logos. Standard Metrics’ customers are the firms its investors talk to daily, which means every reference call was pre-cleared before the process opened. If your customer list cannot be checked by your target investor in a single text message, it is not doing the work you think it is, and you should be building the outcome numbers instead.

Onos Health

Behavioral Health Clinical Intelligence for Payers | Series A | $17M | Valuation Undisclosed

Eisen Fundability Score: 69 / 100

Why this scored. The best customer-outcome disclosure of the week, in the second smallest round in the top five. Onos scored 14 out of 25 on Traction to Conviction with zero disclosed revenue, because it disclosed what its customers got instead: a 35% improvement in clinical standard adherence, a 75% improvement in clinical review efficiency, and more than a 6% reduction in behavioral health program costs within twelve months. It then named the buyers: three of the six largest health plans in the United States, including Aetna. CVS Health Ventures, which is Aetna’s corporate parent’s venture arm, invested.

The Setup. Onos Health, headquartered in San Francisco, sells an AI platform that reads the unstructured clinical documentation health plans already hold and turns it into behavioral health quality and cost signals. It has three co-founders. Chief executive Akshay Agrawal advised health plan executives at Bain and Company, invested in healthcare at Bain Capital, and held executive roles at mPulse and Presence. Chief product officer Josh Levitan spent fifteen years building technology for health plans and government healthcare programs. Chief technology officer Suhaas Prasad holds a master’s degree from Stanford in machine learning and 15 years of experience in enterprise software and AI. Agrawal frames the problem precisely: roughly 70% of behavioral health care quality signals sit in unstructured documentation that no payer system can read. Behavioral health carries more than $140B in direct annual medical cost in the United States, and more than 23% of adults experience a mental health condition each year, and payers have almost no visibility into whether the care they paid for was any good.

The Numbers. $17M Series A led by Costanoa, announced August 26, 2026, with Flare Capital Partners and CVS Health Ventures participating. Three of the six largest US health plans are customers, including Aetna. 35% improvement in adherence to clinical standards. 75% improvement in clinical review efficiency. More than 6% reduction in behavioral health program costs within twelve months. Approximately 70% of behavioral health quality signals found in unstructured documentation. Headquartered in San Francisco. Revenue, growth rate, retention, and valuation not disclosed.

The Pattern. This is the customer-number round in its purest form. Onos disclosed nothing about itself, three specific details about its buyers, and one of those buyers invested in the round. The 6% program cost reduction is the load-bearing figure because behavioral health spend at a top-six plan runs into the billions, making 6% a number a payer executive can take to a budget meeting without a slide.

The Perspective. A cost-reduction percentage with a named payer is worth more than your ARR because it reflects the deal from the buyer’s perspective. An investor can multiply 6% by the plan’s behavioral health spend, subtract your contract value, and see the payback period without asking you a question. That calculation is what converts a second meeting into a term sheet. Founders who lead with their own revenue force investors to do the harder version of the same math from the outside, with less information.

The Playbook. Identify the single line item in your customer’s budget that your product moves, then measure the movement and publish the percentage with the time window attached. 12 months is the right window because it aligns with a renewal cycle. If you cannot yet measure the movement, instrument it this quarter with one customer and one metric. One measured customer beats ten unmeasured ones, and it takes a quarter rather than a year.

The Founder Mistake to Avoid. Founders copy the format and produce percentages without a denominator, a named customer, or a time window: “improves efficiency by 75%.” Onos attached its figures to health plans a diligence team can call and a window a finance team can audit. An unattributed percentage in a deck is worse than no percentage, because the first reference call exposes it and the investor stops believing the rest of the page.

Yardstik

Continuous Workforce Risk Monitoring | Series B | $30M | Valuation Undisclosed

Eisen Fundability Score: 66 / 100

Why this scored. The only company in twenty-one to disclose a growth rate, and it scored 17 out of 25 on Traction to Conviction, the second highest in the set. Yardstik disclosed 149% year-over-year revenue growth, 98% account retention over a three-year period, and 99.4% customer satisfaction across more than a thousand customers, naming Gopuff, TaskRabbit, Liveops, Sharetown, HUNGRY, and H&R Block among them. In a week when 20 companies disclosed nothing about their own trajectory, one company disclosing 3 verified numbers is a competitive act, not a communications choice.

The Setup. Yardstik, headquartered in Minneapolis, began as a background screening company for the gig economy and has repositioned into continuous post-hire workforce monitoring. The category insight is that screening someone once at hire is a snapshot in a world where identity fraud, credential expiration, and changes to driving records occur continuously. The new product surface is motor vehicle report monitoring, inspector general exclusion tracking, and automated credential expiration alerts. Founder Matt Meents previously built Magnet 360 and sold it to Mindtree in 2016 for up to $50M, and remains on the board; Andrew Johnson, previously chief operating officer, became chief executive in October 2024.

The Numbers. $30M Series B led by Harbert Growth Partners, announced August 27, 2026, with Rally Ventures, MissionOG, Crosslink Capital, Grotech Ventures and Great North Ventures participating. 149% year over year revenue growth. 98% account retention over a three-year period. 99.4% customer satisfaction. Ranked 861 on the 2026 Inc. 5000. Total funding of $65M. More than a thousand customers, including Gopuff, LiveOps, Sharetown, TaskRabbit, HUNGRY, and H&R Block. Use of funds is broken down across fraud prevention, motor vehicle report monitoring, exclusion tracking, and credential expiration alerts. Valuation not disclosed.

The Pattern. Yardstik is the category-extension round. It did not defend background screening, a crowded and price-compressed category. It reframed the purchase as continuous risk monitoring and shifted the buying decision from a one-time procurement to a subscription tied to ongoing exposure. The 98% retention over three years is the proof that the reframe held, because retention is the only metric that distinguishes a repositioning from a rebrand.

The Perspective. Growth rate plus retention is the complete story, and neither alone is. 149% growth without retention could be churn masked by new logos. 98% retention without growth could be a stagnant base. Together, they say the same customers are spending more, which is the closest thing to net revenue retention available without disclosing it. Yardstik found the disclosure that carries the information without giving away the dollar figure, and that is a deliberate, replicable choice.

The Playbook. Pick the two-metric pair in your business that constrains the interpretation of both. Growth plus retention. Volume plus margin. Users plus frequency. Disclose the pair and hold the absolutes. A single metric invites a skeptical reading; a pair that cannot both be flattering under a bad interpretation forecloses that reading. Then write down, in one line, the bad interpretation each metric alone would invite, and confirm your pair kills it.

The Founder Mistake to Avoid. Founders in a repositioning announce a new category while continuing to sell the old product. Yardstik shipped the surface that only makes sense in the new frame: continuous monitoring of records that change after hire. If your repositioning does not create a product feature that would be incoherent in your old category, you have renamed something rather than moved it, and the retention number will eventually say so.

Arintra

Autonomous Medical Coding and Revenue Assurance | Series B | $25M | Valuation Undisclosed

Eisen Fundability Score: 66 / 100

Why this scored. The deepest customer-outcome disclosure in the set, attached to the most named customers. Arintra disclosed a 5.1% increase in compliant revenue capture, a 32% reduction in cost to collect, and a 43% decrease in coding-related denials, then named seven health systems: UC Davis Health, Mercyhealth, Meritus Health, Rochester Regional Health, Reid Health, Mercy Medical Center, and Endeavor Health. Two health system venture arms invested in the round, which converts a reference call into a cap table entry.

The Setup. Arintra, founded in 2020 and headquartered in San Francisco, sells autonomous medical coding across more than twenty-three specialties, and this round is the moment it stopped selling that. The company repositioned the purchase as revenue assurance, a category framing that moves it out of a coding software line item and into the chief financial officer’s margin problem. Chief executive Nitesh Shroff put the reframe in one line: revenue assurance is no longer optional; it is how health systems build a financial foundation that matches the quality of care they deliver.

The Numbers. $25M Series B led by Define Ventures, announced August 26, 2026, with Peak XV Partners, Yale New Haven Health Center for Health Care Innovation, Endeavor Health Ventures, Y Combinator, Counterpart Ventures, Ten13 and Spider Capital participating. Processes $5B in annual claim value. Customers represent $50B in combined net patient revenue. 5.1% increase in compliant revenue capture. 32% reduction in cost to collect. 43% decrease in coding-related denials. Meritus Health went live within two months and expanded across multiple specialties. Total funding: $51M. Founded in 2020. Revenue, growth rate, and valuation not disclosed.

The Pattern. Arintra is the denominator round. It never states its own revenue, and it does not need to, because it states the volume it runs through: $5B in annual claims for customers with $50B in net patient revenue. An investor can size the opportunity from the denominator without a single company figure. That is the same move Standard Metrics made with $400B in assets, executed in healthcare, and both landed in the top four.

The Perspective. The two health-system venture arms are the parts most founders will miss. Yale New Haven and Endeavor Health are not financial investors reaching for healthcare exposure. They are buyers whose parent organizations are exactly the customers Arintra sells to, and their presence on the cap table signals to every other health system in the pipeline that two peers have already run diligence. In an enterprise sale with a nine-month cycle, that is worth more than the capital.

The Playbook. Ask your two best enterprise customers whether their organization has a venture arm, a strategic investment vehicle, or an innovation fund, and whether it would take a small position in your round. Most large health systems, utilities, banks, and retailers have one. You are not raising money from them. You are raising from them so the next twelve buyers in your pipeline never have to be the first.

The Founder Mistake to Avoid. Founders copy the reframe without the receipts. “Revenue assurance,” rather than “medical coding,” is a stronger frame only because Arintra can show 5.1%, 32%, and 43% against seven named systems. A category reframe with no measured outcome underneath it reads as a positioning exercise, and sophisticated investors have seen the same rename in every vertical software category this year. Earn the frame with numbers before you claim it.

CivilGrid

Subsurface and Regulatory Data for Infrastructure | Series A | $26M | Valuation Undisclosed

Eisen Fundability Score: 65 / 100

Why this scored. The strongest investor quality mark in the set, 9 out of 10, on a Spark Capital lead with Energy Impact Partners, paired with the largest single dollar outcome disclosed anywhere this week: more than $60M in paving conflicts eliminated at PG&E through portfolio optimization. CivilGrid also disclosed a 40% reduction in field research and survey activity and up to an 85% reduction in due diligence time, against named customers including PG&E, Atmos Energy, Mark Thomas and GHD.

The Setup. CivilGrid, headquartered in San Francisco, consolidates fragmented subsurface and regulatory data into a single mapping environment for infrastructure teams. Chief executive and co-founder Josh Mackanic is a former PG&E engineer, and the company sells back into the utility he came from. The problem is specific and expensive: utility strikes and project delays cost roughly $30B annually in the $2.2 trillion US construction industry, and the data required to avoid them is scattered across dozens of unconnected municipal, utility, and regulatory systems. The framing that stuck with the press was Google Maps for the underground.

The Numbers. $26M Series A led by Spark Capital, announced August 27, 2026, with Energy Impact Partners, Afore Capital, A*, Ford Street Ventures, and SNR Ventures participating. PG&E realized more than $60M in paving conflicts eliminated through portfolio optimization. 40% reduction in field research and survey activities at PG&E. Project timelines up to four months faster. Up to 85% reduction in due diligence time. Named customers: PG&E, Atmos Energy, Mark Thomas, and GHD. Leadership team with more than 70 years of combined industry experience. Headquartered in San Francisco. Revenue, growth rate, contract value, and valuation not disclosed.

The Pattern. CivilGrid is the operator-turned-vendor round, and the $60M figure is what makes it work. Most infrastructure software sells time savings, which a procurement team discounts by half on instinct. CivilGrid sold an avoided cost with a dollar sign on it at a named utility, which a procurement team cannot discount because it appears in their own accounting. The founder, being a former PG&E engineer, is what made that number attainable in the first place.

The Perspective. Energy Impact Partners’ limited partners are utilities. That is not a logo on the cap table; it is a customer pipeline, and in a $26M Series A it is worth more than a larger check from a generalist. Pair it with a Spark Capital lead, and the round has both halves of what an early enterprise infrastructure company needs: a firm that prices growth and a firm that opens doors. Founders routinely optimize for one and treat the other as filler.

The Playbook. Convert your best time-savings claim into an avoided-cost claim in dollars this week. Take the hours you save, find what the customer pays for those hours or what the failure they avoid costs them, and get one customer to confirm the arithmetic in writing. Then name the customer. A percentage is a claim about your product. A dollar figure at a named account is a claim about their books, and only one of those survives diligence intact.

The Founder Mistake to Avoid. Founders with a marquee customer treat it as a logo slide and never extract the number. PG&E is not the asset here; the $60M PG&E can attribute is. The trap is spending a year winning a lighthouse account and then never asking it to quantify what changed, which leaves you pitching the same reference call that every other vendor in your category is also pitching.

The Fundraising Playbook: Five Tactical Plans

Five plans, each producing a concrete output you can use immediately. No vague tasks. Each is built directly from this week’s verified signals.

1. The Three Customer Numbers (Narrative and Investor Framing)

Why this matters. Zero of twenty-one companies disclosed revenue, and one disclosed a growth rate. The five that disclosed a quantified customer outcome averaged 64.6, compared with 56.0 for the other sixteen. In a week when the whole market went dark on its own metrics, the customer’s metric was the only thing an investor could model.

Exact deliverable. Three lines, each in this form: customer name, the metric, the value before, the value after, the time elapsed. Onos Health’s version reads as a 6% reduction in behavioral health program costs within twelve months at a top-six health plan. Arintra’s reads as a 43% decrease in coding denials at named health systems. CivilGrid’s reads as more than $60M in paving conflicts eliminated at PG&E. Get written permission to use the customer name and the figure. Put the three lines on slide two and move your own metrics to slide nine.

Expected outcome. You move from the 56.0 bucket to the 64.6 bucket without changing anything about the business. An investor can compute your buyer’s payback period from your second slide, which is the calculation that converts a second meeting into a term sheet.

The reframe. Wrong approach: lead with your ARR and use customer results as marketing collateral. Right approach: lead with the customer’s result and hold your ARR for the data room.

2. The Verifiable Denominator (Proof and Metrics Packaging)

Why this matters. Standard Metrics took the top score of the week at 70, with no revenue, no growth rate, and no valuation disclosed, by citing three countable denominators: 10,000-plus companies, 150 firms, and $400B-plus in assets on the platform. Arintra did the same in healthcare with $5B in annual claim value across customers representing $50B in net patient revenue. Both landed in the top four.

Exact deliverable. One sentence naming the volume that runs through your product and the market denominator it sits inside. Assets, claims, transactions, acres, patients, seats, gigawatts, cattle, miles. Both numbers must be countable by a stranger who calls two people in your industry. Write it, then hand it to someone outside your company and ask them to tell you how big your market share is. If they cannot, the denominator is wrong.

Expected outcome. An investor can size your position without asking you for revenue. In a market with a 95.2% valuation opacity rate, that is the substitute for a price conversation you are not ready to have.

The reframe. Wrong approach: 500 customers, growing fast. Right approach: $5B in annual claim volume for customers representing $50B in net patient revenue.

3. Eisen Self-Score Against a Falling Ceiling (Readiness)

Why this matters. The top score this week was 70, and nothing reached 75. Only five of twenty-one rounds cleared 65, down from nine of fifteen last week, so the share of well-scored rounds fell from 60% to 23.8%. The cost of separating yourself has never been lower, and the return has never been higher, because sixth place this week was a 61, and the median round score was 58.

Exact deliverable. Score your round across the five dimensions: Founder-Investor Dynamics (30), Traction to Conviction (25), Narrative Power (20), Deal Architecture (20), and Capital Planning (5). Penalize every blank as a zero, the way an investor does. Then apply this week’s specific test: if your score is above 65, you are in the top quartile of what actually cleared, and you should run a parallel process with a deadline rather than a sequential one. If you are below 55, you are indistinguishable from the 16 companies that also cleared, and you will be priced like them.

Expected outcome. A decision about process design, not just a list of weaknesses. The score tells you whether to run a competitive process or fix the gaps first, and running the wrong one costs a quarter.

The reframe. Wrong approach: score yourself, feel discouraged, revise the deck. Right approach: score yourself, decide whether you are running a competitive process or a repair sprint, and commit to one.

4. The Channel-Weighted Target List (Deal Architecture)

Why this matters. Two of twenty-one rounds were led outright by a corporate or strategic investor, a third came from corporate strategics with no lead named, and nine of twenty-one carried strategic money. Digs scored 14 out of 30 on founder and investor dynamics, the lowest in the set, and cleared $25.3M because Builders FirstSource led outright and attached a five-year agreement across 140,000 builder clients. Mantel cleared $18M in strategic funding from Constellation Technology Ventures, the buyer, but scored 52 because no one took the lead seat.

Exact deliverable. Two lists. First, a financial list cut to 30 names, where each name passes one test: you can write a sentence naming the specific deal they led in your category in the last twelve months. Second, a strategic list of 12 corporates who either buy what you sell or sell to whom you sell, and for each one, the specific customer they can introduce in the first ninety days. Then decide which list your lead comes from, because Mantel’s work shows that strategic money without a designated lead prices worse than either alone. Finally, open your term sheet template and pre-draft your position on exclusivity, right of first refusal on acquisition, and category lockout, because that is the only part of strategic capital that actually costs you.

Expected outcome. A process where every conversation carries either a price or a customer, and you know which before you take the meeting.

The reframe. Wrong approach: rank investors by fund size and brand, treat corporate money as a fallback. Right approach: rank by the number of customers each one delivers, and negotiate the exclusivity language before you need it.

5. The Milestone That Survives a Smaller Check (Momentum and Conversion)

Why this matters. Average check size fell 28.7% in one week, and every stage fell. Seed fell 49%, Series B fell 42%, and Series A fell 17%. Founders planning against last quarter’s round sizes are building a use of funds that the market will not finance, and they will discover it in week six of a process rather than week zero.

Exact deliverable. Re-cut your use of funds at 72% of your target raise, which is what the average check did this week. Write down the one milestone that still lands and the two that do not. Then write the one sentence you would say to a partner about what the smaller round buys. If that sentence is weaker than your current one, the round is not the problem; the plan is, and you have two weeks to fix it before you open rather than six weeks to discover it after.

Time estimate. 3 hours with your finance lead, plus 1 hour to rewrite the use-of-funds slide.

Expected outcome. You walk into the first meeting already priced for the existing market, which means you negotiate on terms rather than on size, and you do not spend a month defending an ask the market has stopped writing.

The reframe. Wrong approach: hold the ask, hope for the exception, discount later under pressure. Right approach: size to the market, fund one real milestone, and let the competitive process push the number back up.

Looking Forward, Next 1 to 3 Weeks

Three evidence-based scenarios and one wild card. Every prediction is anchored to this week’s verified data, not speculation.

Scenario 1: Check Sizes Stay Compressed (High Probability)

Evidence from this week. Two consecutive weeks of the same pattern. Average check fell 24% into last week and a further 28.7% into this one, while total capital moved less than 1%. Every stage fell this week, not just one, which rules out a mix effect and points to a repricing of the round itself. Series B fell the hardest in dollar terms, from $45.5M to $26.40M, and now trades at a 3% discount to Series A.

What to watch. Whether Series A settles below $30M for a third week and whether the Series B premium stays gone. Six Series A rounds averaged $27.22M this week against $32.8M last week, and five Series B rounds averaged $26.40M against $45.5M. If the next issue lands in the mid-twenties again at both stages, that is a new normal rather than a summer effect, and every Series A deck built on a $35M ask, and every Series B deck built on a $45M ask, is misaligned.

What founders should do before others notice. Rebuild your use of funds at the smaller number now, while you have time to design the milestone rather than defend the ask. Founders who reprice in week six of a process do so under pressure and lose terms.

Scenario 2: Disclosure Keeps Falling, and Customer Proof Keeps Rising (High Probability)

Evidence from this week. Valuation opacity rose for a third consecutive period, from 80% in June to 93.3% last week to 95.2% this week. Zero companies disclosed revenue and one disclosed growth. Against that, five companies disclosed quantified customer outcomes and took five of the top six slots.

What to watch. Whether customer-outcome disclosure spreads outside enterprise software and healthcare. Corvus Robotics did it in warehouse robotics this week with named accounts and specific counts, which suggests the pattern is not category-bound. When a hardware or climate company leads with a named customer’s avoided cost rather than a product specification, the pattern has generalized.

What founders should do before others notice. Instrument one customer this quarter. Pick the account most likely to say yes, agree on the metric before you start measuring, and set a twelve-month window. You are building the asset the market will price in six weeks, and it takes a quarter to produce, which means starting after you see it in a report is starting too late.

Scenario 3: Strategic Capital Keeps Taking the Lead Seat (Medium-High Probability)

Evidence from this week. Two rounds led outright by corporate or strategic investors, a third funded by corporate strategics with no lead, and nine of twenty-one carrying strategic money. The lowest founder-dimension score in the set, Digs at 14 out of 30, still cleared $25.3M because its corporate lead brought distribution. Compressed check sizes make a check that also carries a customer structurally more attractive to both sides.

What to watch. Whether corporate leads start appearing at Series B and later rather than concentrating at Series A and seed, and whether any of this week’s strategic rounds later disclose exclusivity terms. The first tells you the pattern is deepening. The second tells you what it costs.

What founders should do before others notice. Have the exclusivity conversation with counsel before a corporate offers to lead, not after. The terms that matter- right of first refusal on acquisition, category exclusivity, and channel lockout- are far easier to negotiate as a stated policy than as a reaction to a specific term sheet.

Wild Card: The First 75 in Six Weeks Resets the Ceiling (Medium Probability)

Evidence from this week. The ceiling has fallen from 82 to 70 in one week, and nothing reached 75. The proof that produced last week’s 82 was a single disclosure: profitable operations in a defined region alongside a 25-point improvement in medical loss ratio. That is not a rare business condition. It is a rare disclosure decision, and it is available to any company with a profitable segment, region, cohort, or product line.

What founders should do before others notice. Find the one slice of your business that is already profitable, even if it is a single region, one product, or one customer cohort, and reconcile the economics for that slice specifically. You are not disclosing company profitability. You are disclosing that a defined unit of your business works, which is what an investor is trying to determine anyway. In a week where the ceiling fell to 70, the first company to bring that slice will be the only one in its category at 80.

The Bottom Line

The real insight is not the $543.9M total. It is that the total did not move while the number of companies competing for it rose 40%, and the market responded by paying less for everything and less again for the best of it. The ceiling fell twelve points. The floor rose six. Nothing reached 75. That is what a rationing market looks like from the inside, and it produced exactly three conviction profiles.

Profile 1: Companies that disclosed the customer’s number. Onos Health (69) disclosed a 6% reduction in behavioral health program costs at a top-six health plan. Arintra (66) disclosed a 43% drop in coding denials across seven named health systems. CivilGrid (65) disclosed more than $60M in paving conflicts eliminated at PG&E. Corvus Robotics (57) disclosed 35,000-plus discrepancies found at Southern Glazer’s. None of them disclosed their own revenue. All of them gave an investor a number to model. Five such companies averaged 64.6, compared with 56.0 for the other sixteen.

Profile 2: Companies that disclosed a verifiable denominator. Standard Metrics (70) took the week’s top score with more than $400B in assets across 150 firms and three tier-one venture firms named as customers. Arintra (66) processed $5B in annual claims for health systems representing $50B in net patient revenue. Neither stated a revenue figure. Both let an investor size the position from the outside. When you cannot show what you earn, show what runs through you.

Profile 3: Companies whose lead investor was the channel. Digs (58) posted the lowest founder and investor dynamics score in the set, 14 out of 30, and cleared $25.3M because Builders FirstSource led outright and attached five years of access to 140,000 builder clients. Hivemind (53) cleared $17M because M&G Investments led and took a board seat. Mantel (52) secured $18M in strategic funding from the buyer itself, Constellation Technology Ventures, but ranked lowest of the three because no investor took the lead seat and no stage was disclosed. When your own proof is thin, the fastest available substitute is an investor who is also a buyer. It only works if that investor is willing to lead.

Everything else competed for the residual. Sixteen companies raised real money from real investors with nothing on the record that a new investor could verify, and they averaged 56.0. Each of them answered questions in diligence that never became public, and none of them owed anyone a press release. The difference is that the top of the band handed the investor a number that did the underwriting for them. In a week when the ceiling fell to 70, the founder who brings one verified customer outcome does not just clear. They lead.

Five New Rules for Founders

1. Size to the check the market is writing. Average round size fell 28.7% in one week, and every stage fell with it. Recut your use of funds to 72% of your ask and find the milestone that survives before a partner finds it for you.

2. Your customer’s number outranks yours. Zero of twenty-one companies disclosed revenue. The five who disclosed a quantified customer outcome averaged 64.6, compared with 56.0. Name the customer, name the metric, name the window.

3. Category is not a strategy this month. Six sectors split the week inside a 5.3-point range after one sector took 67.1% seven days earlier. Underwriting went company by company. Pitch the budget line, not the market size.

4. When you cannot show revenue, show volume. Standard Metrics took the top score on $400B in assets on platform. Arintra tied for third on $5B in annual claim value. A countable denominator is the substitute for a number you are not ready to publish.

5. The best check may come with a customer attached, but somebody still has to lead. Two of the twenty-one rounds were led outright by a corporate or strategic investor, and the company with the lowest founder score in the set raised $25.3M in one of them. The round that took strategic money without a designated lead scored 52. Get the strategic, and get it to lead. Negotiate the exclusivity terms first, then take the money.

Four Monday Actions

1. Call three customers and get one number each. Metric, before, after, elapsed time, permission to name them. Three lines on slide two. Everything about your own performance moves to slide nine.

2. Write your denominator sentence. The volume that runs through your product and the market it sits inside, both countable by a stranger. Hand it to an outsider and ask them to state your market share back to you.

3. Re-cut the use of funds at 72% of the ask. Name the one milestone that survives and the two that do not. If the surviving milestone does not include pricing for your next round, fix the plan this week.

4. Build the twelve-name strategic list. Corporates who buy what you sell or sell to who you sell to, each with the specific customer they can deliver in ninety days. Then pre-draft your exclusivity position with counsel.

Twenty-one companies were cleared this week, and sixteen of them are indistinguishable from one another in the public record. The median round scored a 58. The founder who walks in on Monday with one named customer, one measured outcome, and one verifiable denominator is not competing against the top of this market because there was no top this week. They are the top.

Research Methodology, Sources and Verification

Data collection period: August 24 to 30, 2026, with verified primary disclosures clustered August 24 to 27. No verified US mid-market round was announced on August 29 or 30. Verification standard: a minimum of two independent sources per deal, with company press releases and regulated newswires (BusinessWire, PRNewswire, GlobeNewswire) prioritized as anchor sources, plus at least one independent outlet for corroboration. This issue was then put through a second, independent verification pass in which every company, amount, stage, investor, date, and reported metric was re-checked against primary sources. That pass removed four deals, restated three headline amounts to new primary capital, and corrected five attributions. Its findings are documented in the Data Integrity Notes and the corrections log below. Eisen Fundability Scores are proprietary analytical estimates, not endorsements or investment advice. All dollar figures reflect the announced new primary capital at close unless noted otherwise.

Core Capital Totals and What They Include

The $543.9M weekly total includes only the twenty-one verified US rounds in the scorecard, each independently confirmed at the stated amount and stage. Mid-market is defined for this issue as a US-headquartered round of new primary capital between $10M and $100M. Secondary share purchases, SAFE conversions from prior periods, previously closed tranches, and cumulative restatements are excluded from the counted amount even where a headline figure includes them. Announcements that do not separate new capital from cumulative totals are excluded entirely. No aggregator-only figure was treated as fact without corroboration in a company release or an independent outlet. Arithmetic on the total, the average, the median, all stage and sector subtotals and every chart value was recomputed and reconciled after the second verification pass: the six sector subtotals ($104.0M, $93.0M, $92.0M, $90.8M, $89.1M and $75.0M) and the seven stage subtotals ($163.3M across six Series A rounds, $132.0M across five Series B rounds, $75.0M in one Series C, $68.6M across four seed rounds, $61.0M across three rounds with no disclosed stage, $24.0M in one Series E-2 and $20.0M in one growth round) each sum to $543.9M across twenty-one deals.c

Exclusions and Documented Rationale

● Giant rounds and public market events, excluded by editorial scope: Instinct ($250M), Owner ($240M), Generalist AI ($200M), Gatik ($200M), Socure ($156M), Emerald AI ($150M), Regent Craft ($120M), AusperBio ($120M), Starcloud ($250M) and Unrivaled ($106M). The week’s ten largest rounds excluding Blank Street totaled $1,512M and are used only as the contrast set.

● Non-US rounds, excluded for scorecard comparability: Stability AI (UK, $76M, which ranked ninth on the week’s list of ten largest rounds), Liner (South Korea, $36.1M), WRTN Technologies (South Korea, $72.2M), PayRewards and Pay.com.au (Australia, $28M), W4 Games (Ireland, $18M), Airbound (India, $37M), Fasset (UAE, $68M), Cyclic Materials (Canada, $75M), Purple Style Labs (India, $40M), Certain Energy (UK), Ringg AI (India), M Village (Vietnam), Lupin Dental (France) and ColibriTD (France).

● Outside the date window: Princeton Critical Minerals ($16M, announced August 12) and Discern Security ($13M Series A, announced July 30), both marked news-cycle resurfaced despite circulating inside the window through aggregator republication.

● New capital could not be isolated: Hike Medical ($22.5M combined seed and Series A with no breakdown) and Quaise Energy ($180M Series B close with a $35M in-window tranche).

● Below the mid-market floor: Bevel ($6M), Teragen Energy ($6M), Mara ($7M), Stellaria ($6.8M), Light Links ($6M), Boldr ($5M), Soctera ($4M), EULER ($4.3M) and Embedd ($2.7M), each below the $10M threshold used in this issue.

Deal Citations, Two or More Sources per Deal

● Blank Street, $75.0M Series C (reported). Financial Times coverage dated August 24, 2026; Axios for the primary and secondary split, quoted as $75M of primary capital and $30M of secondaries; Daily Coffee News for the SEC filing figure of $104,999,981 and the 106 location count; Benzinga Private Markets and AlleyWatch, both of which label the round a Series C; Dealroom, which labels it a Series B and is not followed here; SEC EDGAR filing history (CIK 0001815159) confirming a $20M Series B in March 2023. No company release, investor post, or newswire announcement exists; rated MEDIUM confidence on that basis.

● Quintessent, $40.0M Series A. Company release syndicated via Yahoo Finance dated August 24, 2026; Photonics Spectra; Santa Barbara Independent; citybiz; Light Reading; innovosource GAP Pipeline Brief for the UC Santa Barbara spinout origin.

● Voya Energy, $35.0M Series A. Company release dated August 26, 2026; FinSMEs; Mercom Capital Group; Bloomberg; MINING.COM; Axios Pro climate deals for the week of August 24.

● Yardstik, $30.0M Series B. PRNewswire company release dated August 27, 2026; Pulse 2.0 for the growth, retention, and satisfaction figures; SiliconANGLE; ID Tech Wire; FinSMEs; Tech Funding News.

● Celera Semiconductor, $30.0M Series B. PRNewswire company release dated August 25, 2026, stating the round was fully funded by Maverick Silicon; company PRNewswire release dated August 5, 2025 for the prior $20M Series A from the same investor; Semiconductor Digest; citybiz; Latham & Watkins deal announcement.

● Breedr, $27.0M Series B. FinSMEs dated August 26, 2026, for the Austin headquarters and total raised; Tech Startups funding roundup of August 27, 2026; Partech investor materials.

● CivilGrid, $26.0M Series A. BusinessWire company release dated August 27, 2026, for the PG&E figures and customer names; TechCrunch; Dealroom; Morningstar syndication; FinSMEs; The SaaS News.

● Metriport, $26.0M. PRNewswire company release dated August 27, 2026; Pulse 2.0 for the named customers and total funding; Endpoints News; HIT Consultant; citybiz.

● Digs, $25.3M Series A. PRNewswire joint Builders FirstSource and Digs release dated August 25, 2026, confirming Builders FirstSource as sole lead, the five-year agreement, 140,000 builder clients and 565 locations across 43 states; GeekWire; Dealroom for the founding date and headcount; HousingWire; Modern Distribution Management; Silicon Florist.

● Transfyr, $25.0M Seed. Company release syndicated via Yahoo Finance dated August 26, 2026; Morningstar BusinessWire syndication; citybiz; FinSMEs; company site for founder backgrounds.

● Arintra, $25.0M Series B. BioSpace press release dated August 26, 2026, for the customer names and outcome figures; Fierce Healthcare; MobiHealthNews; HIT Consultant; Dealroom.

● Airway Therapeutics, $24.0M Series E-2. PRNewswire company release dated August 25, 2026, with an Atlanta dateline, stating that the E-round consists of $26M previously raised through a SAFE financing and $24M through the Series E-2, and that approximately 94% of existing investors participated; company locations page confirming Atlanta headquarters and a Cincinnati laboratory; citybiz; Clinical Trials Arena.

● Standard Metrics, $20.0M Series B. PRNewswire company release dated August 24, 2026, read through Yahoo Finance syndication; Pulse 2.0 for the platform metrics; January Capital investment memo and the founder’s own site for the Spark Capital background; Finextra; The SaaS News; FinSMEs.

● SiFly, $20.0M Series A. PRNewswire company release dated August 26, 2026 for the round, investors, and Guinness record; University of Maryland Innovation Hall of Fame and Wikipedia for Brian Hinman’s PictureTel, Polycom, and 2Wire co-foundings, none of which appear in the funding release; DroneLife; Aviation Week; citybiz; Robotics Tomorrow.

● Corvus Robotics, $20.0M. GlobeNewswire company release dated August 25, 2026 for the leadership transition; Robotics 24/7 dated August 27, 2026 for the round, investors, deployment counts, and customer figures; DroneLife; Supply Chain 24/7.

● Agentrys, $19.1M Seed. Semiconductor Digest for the seed and pre-seed split and founder background; Silicon Valley Daily dated August 27, 2026, for the San Jose headquarters; SemiWiki; Ventureburn; Tech Startups roundup of August 27, 2026.

● Mantel, $18.0M. GlobeNewswire company release dated August 24, 2026, describing a strategic investment from Constellation Technology Ventures and Azimut with no lead designated and no stage disclosed, total funding of $50M, and three named project sites; ESG Today; Carbon Herald, which supplies the led-by framing not used here; Axios Pro climate deals; Hydrocarbon Engineering.

● Onos Health, $17.0M Series A. PRNewswire company release dated August 26, 2026 for the customer and outcome figures; company about page for the three co-founders' backgrounds; Behavioral Health Business; MedCity News; HIT Consultant; Axios Pro health tech deals. Tech Funding News’ ex-Bain operators framing is not followed here.

● Hivemind Digital Group, $17.0M. PRNewswire company release dated August 25, 2026; Morningstar syndication; TradingView via Reuters; The Next Web; citybiz; Dealroom.

● TerraBlaster, $12.5M Seed. AgFunderNews dated August 25, 2026, for the investor list, the 0.15-acre resolution, and the commercial timeline; Ulu Ventures’ own investment post confirming Heraud co-founded the company with Matt Colgan; separate AgFunderNews interview for Heraud’s Blue River Technology background and his arrival from an advisory role; Precision Farming Dealer; FinSMEs; AgNavigator, which is the sole source for the oversubscription characterization.

● Legato, $12.0M. GlobeNewswire company release dated August 26, 2026; TechCrunch; Hearing Health and Technology Matters; HearingTracker; HLTH.

Research completion timestamp: August 30, 2026.

DISCLAIMER: This article is for informational and strategic intelligence purposes only. It does not constitute investment advice. The Eisen Fundability Score is a proprietary diagnostic within Fundables OS™, not a financial recommendation.

If this article was useful, share it with founders who are about to raise.

— Leon Eisen, 4x Founder, Venture Capitalist, and Creator of Fundables OS™

Playbook, Perspective, and Pattern for founders raising now. This report deliberately strips out the megarounds and the public market traffic so you can read the part of the market that actually prices your round. Every figure below survived a second independent verification pass against primary sources.

The week of August 17 to 23, 2026 produced two completely different markets, and almost nobody noticed. Above $100M, capital went to hypersonics, inference silicon, and satellites. Below $100M, where your round actually lives, 67.1% of the money went to healthcare and life sciences. Healthcare took 2.3% of the week’s ten largest rounds and 67.1% of the mid-market. Same week. Opposite conclusion.

Fifteen verified rounds moved $545.0M. In June, this same mid-market moved $479.5M across ten rounds. That is 50% more deals at a 24% smaller average check. Capital broadened. And the moment it broadened, the Eisen Fundability Score band blew open, from a 13-point spread in June to a 46-point spread this week.

One variable explains that spread. The nine companies whose commercial proof was built and verifiable averaged 69.1. The six with none averaged 55.7. Same week, same investors, same capital. Thirteen points of fundability separated by whether the numbers already existed in defensible form while the round was live. Investors request that details be kept private in every process, so this is not an argument for publishing. It is an argument for having the answer before the question.

Here is the consequence. A partner will ask you for your numbers, separately and in their own time. The founders who send a defensible answer within 24 hours move to the front. The ones who need three weeks to assemble it are not being rejected. They are being outrun, in a market that just added five more companies asking for the same check. Read every shift below through that lens.

The Week in One Sentence

Primary insight. With megarounds and public market traffic removed, the mid-market broadened into healthcare and life sciences, and proof readiness replaced sector and stage as the variable that separated a fundable round from a funded one.

· Total tracked mid-market capital (15 verified rounds): $545.0M in new primary capital, every deal under $100M.

· Average round size: $36.3M across the fifteen.

· Median round size: $30.0M. The midpoint sits inside a two-way tie at $30.0M between Rundoo and Leal Therapeutics.

· Disclosed valuations: one of fifteen. Astromech at a company-stated $3.8B, against no disclosed revenue and no disclosed customers. That is a 93% opacity rate, up from 80% in June.

· Largest tracked round: Happy Health, $75M Series A, an FDA-cleared sleep apnea ring and at-home testing platform. It was also the smallest round on the week’s megaround list.

· Highest Eisen Fundability Score: Hopscotch Primary Care at 82, the highest this report series has recorded, and the only company in the set to disclose profitable operations.

· Lowest Eisen Fundability Score: Queen One at 36, a $25M round with no disclosed stage, no designated lead investor, and no operating metric.

· Defining structural feature: a 46-point score band against 13 points in June. Mean score fell from 72.3 to 63.7. More companies cleared, for less money each, at lower conviction.

Data Integrity Notes

All fifteen featured rounds were verified against at least two independent sources, then rechecked in a second independent verification pass against primary sources. Resolutions and exclusions applied:

· Editorial scope excludes giant rounds and public market events by request. Removed from the tracked set: Castelion ($800M equity plus $250M credit), Etched ($700M), Higgsfield ($400M), Groq ($350M), Wispr ($280M), Muon Space ($250M), Gravis Robotics ($200M), ALSO ($150M), Velaura AI ($110M) and Rillet ($100M). IPO and public market traffic, including the Anthropic offering coverage that ran on August 21, is out of scope. Those ten rounds are used only as a contrast set, sized at $3,215M.

· Date window control removed one deal. Trajectory ($40M Series A at a $300M post-money, led by Sequoia) circulated widely inside this window through aggregator republication on August 17 and 18. The announcement itself is dated August 11, 2026. It is marked as news-cycle resurfaced and excluded from all totals, charts, and scores in this issue. Sapiom ($35M Series A) is likewise dated August 6 in its primary source and excluded.

· Cumulative-versus-new capital removed two more. Sonic Fire Tech’s company release states the round closes out its seed financing at $15M, a cumulative figure that includes a $3.5M seed from October 2025, while some trade coverage reports $15M as new money. Channel Medsystems’ release is headlined as its Series C reaches $30M, led by an investor that has backed the company since 2021, with no new investor named. In both cases, the amount of new capital closed this week is not separately disclosed, so it is excluded from the totals rather than counted at its headline figure.

· Source discrepancy corrected. One trade outlet reported that Network Bio’s $30M co-development agreement is with NVIDIA. The company release describes two separate things: a $30M-plus co-development and licensing agreement with an unnamed Fortune 100 top-ten healthcare company, and a distinct technology collaboration with NVIDIA carrying no disclosed value. This report uses the primary source. An earlier draft of this issue carried the incorrect version.

· Unresolved item, flagged rather than smoothed over. Happy Health is labeled a Series A by the trade press and the weekly Megaround ranking, but the company raised a $60M Series A in August 2022, also led by ARCH. One major outlet reports total funding of $75M since 2019, with the round closing in 2025. New money versus cumulative restatement could not be resolved from primary sources. The round is retained on the strength of its August 18 announcement date and independent corroboration of the $75M figure, with MEDIUM confidence; no total amount raised is stated. Treat its contribution to the weekly total as the single largest uncertainty in this issue.

· Metric provenance. Hopscotch Primary Care’s headline metrics, Apollo Atomics’ criticality and letter-of-intent claims, and Abcuro’s subgroup result are all company-supplied. They are treated as verifiable rather than independently audited, and scored on that basis. Letters of intent are non-binding and are not scored as revenue.

· What this report can and cannot see. Scores reflect proof that was verifiable at announcement. Investors receive far more in a private data room, and a company that puts nothing on the record may have answered every question during diligence. The public record is therefore a proxy for whether the numbers existed in a defensible form while the round was running, not a measure of what a company knows about itself, nor a requirement to publish anything. Read every score below as fundability at the moment of announcement, not as a judgment of the business.

The Deal Scorecard

Eisen Fundability Scores are calculated across five weighted dimensions: Founder-Investor Dynamics (30), Traction-to-Conviction Conversion (25), Narrative Power (20), Deal Architecture (20), and Capital Planning (5). Scores of 85 and above signal an inevitable outcome. Scores of 70 to 84 signal strong execution. Scores below 70 signal early-stage or the need for repositioning. Missing metrics are scored conservatively, and opacity is penalized rather than assumed strong.

What the Scorecard Says at a Glance

The band is the message, and this week the band broke. Scores ran from 36 to 82. That 46-point spread is more than three times the 13-point spread recorded in June, and the mean fell from 72.3 to 63.7. When a market widens like this, it is not getting pickier. It is getting less certain. More companies cleared at smaller checks, with wider quality dispersion underneath.

Proof readiness, not sector and not stage, drew the line. The nine companies whose commercial proof was built and verifiable averaged 69.1. The six with none averaged 55.7. The gap holds inside categories, not just across them. Two medtech companies sit 14 points apart: Renata Medical at 69 held a premarket approval and a reimbursement code worth up to $22,685 per case, while MaxQ Medical at 55 had an investigational device with clinical evaluations underway. Same category, same week, similar round size. Neither gap is about press strategy. One company had a funded payment pathway to point at, and the other did not.

Hopscotch Primary Care (82) is the cleanest case in this report series. It did not lead with a famous investor or a valuation. It led with proof: 15,000 patients, consistently above 90 % retention, an NPS of 89, a medical loss ratio improved by more than 25 percentage points over a patient’s first two years, and profitable operations in Western North Carolina. Add a CEO who ran Caravan Health to a $250M acquisition and served at CMS and the White House Domestic Policy Council, and the round underwrites itself. One disclosure the release does not make: Gronniger is an advisor to Town Hall Ventures, which co-led this round.

The bottom of the band is not a bad-company list. Queen One (36), Astromech (52), and MaxQ Medical (55) all raised real money from real investors, and each of them will have answered detailed diligence questions that never reached the record. What the score measures is what a new investor could verify without asking. The scoreboard separates a fundable company from a fundable round, and this week the gap between the two was mostly a question of what was ready before anyone asked.

One deal proves the score is not a popularity contest. Astromech posted the highest founder and narrative marks in the set, a Colossal spinout co-founded by Ben Lamm and Harvard geneticist George Church, with Bob Nelsen leading, and a company-stated $3.8B valuation, and still landed second from bottom because it scored zero on traction to conviction and zero on valuation reasonableness. A $20M round at $3.8B is not a round. It is a mark. Twin1 AI (74), a seed, outscored eleven later-stage deals because it arrived with five named enterprise customers and one of them on the cap table.

What Changed This Week: Five Market Shifts

Each shift is verified against multiple sources and ranked by structural impact on founder fundraising, not by deal size. Every shift ends with what it means for your raise next week.

Shift 1: The Mid-Market Went Healthcare While the Tape Went Defense

Pattern, what happened. Nine of fifteen rounds and $365.5M of $545.0M, or 67.1% of tracked mid-market capital, went to healthcare and life sciences: Happy Health ($75M), Abcuro ($66M), Hopscotch ($53M), Network Bio ($50M), MaxQ Medical ($31.5M), Leal Therapeutics ($30M), Renata Medical ($25M), Astromech ($20M) and Ours Privacy ($15M). The week’s ten largest rounds went the other way: hypersonics, inference silicon, generative video, satellites, micromobility and ERP. Exactly one healthcare deal appeared on that list: Happy Health at $75M, and it was the smallest round. Healthcare took 2.3% of the megaround tape and 67.1% of the mid-market.

Perspective, what it means. These are two different underwriting engines running in the same week. Investors above $100M are buying capacity: compute, power, silicon, launch, and missiles. Scarcity prices those rounds. Below $100M, investors are buying a reimbursed clinical outcome, priced based on whether someone is contractually obliged to pay for it. Capacity underwriting rewards a credible claim on a scarce input. Reimbursement underwriting rewards a code, a clearance, and a payer.

Founder Blindspot, what most miss. Founders read the megaround headlines as a signal about their own category and adjust their narrative to match. A week that reads as defense and AI infrastructure on the front page was a healthcare week for every company raising under $100M. The tape above your round size tells you nothing about who will lead it.

Playbook, what to do. Rebuild your comparable set this week from rounds within 2x of your target size in your sector, from the last 90 days, and delete every comp outside that range. Then check which investors led those specific rounds. That list, not the headline list, is your process.

Contrast. In June, the mid-market spread across healthcare, energy, industrials, robotics data, fintech, and applied AI with no dominant sector. This week, one sector took more than two-thirds of the capital and nine of the fifteen deals in a category the headlines never mentioned.

What this means for your raise: Stop benchmarking your round against the news. Benchmark it against the eight to twelve rounds closest to your size and sector, and target the investors who actually led them.

Shift 2: Proof Readiness Became the Price, Not the Pitch

Pattern, what happened. The nine companies whose commercial proof was built and verifiable averaged an Eisen score of 69.1. The six with none averaged 55.7. Hopscotch had profitable operations in a region to point at and scored 82. Twin1 had five named enterprise customers at seed and scored 74. Ours Privacy had 200 healthcare organizations at its 2024 founding and scored 70. Queen One raised $25M with no stage, no lead, and no operating metric anywhere in its materials, and scored 36. Fourteen of fifteen rounds carried no valuation, a 93% opacity rate, up from 80% in June.

Perspective, what it means. Every investor asks for your numbers separately. That is what diligence is, and nothing here argues you should publish them instead. The question this gap answers is whether the answer exists in defensible form on the day they ask. When capital narrows, a partner will wait three weeks while you build the cohort analysis. When capital broadens, and this week it broadened by 50% in deal count, they move on to the company that already had it. Speed of proof, not volume of proof, separated this band.

Founder Blindspot, what most miss. Founders hear the word "disclosure" and think "press release," then argue about whether to publish. That was never the requirement. The requirement is that the numbers are assembled, reconciled, and defensible before the process opens. Most founders build the proof stack during diligence, under time pressure, off a partner’s question list. That is three weeks spent proving you can count, while a competitor spends them negotiating.

Playbook, what to do. Build three numbers now, before anyone asks: one usage number, one retention or expansion number, one economics number. Reconcile each against your own systems so a second query does not change the figure. Put them on slide two and hold a one-page backup with the work behind each. You are not publishing anything. You are removing the three weeks a request would otherwise cost you.

Contrast. June’s mid-market clustered inside 13 points because the market agreed on what it paid for. This week the band ran 46 points, and the divider was not category or stage. It was whether a company could answer the first hard question immediately.

What this means for your raise: Assume every investor is triaging. The founder who answers the numbers request in a day gets read first, priced first, and closed first. The one who needs three weeks gets delayed, and delay burns the runway you raised to protect.

Shift 3: Seed Outraised Series A

Pattern, what happened. Three seed and launch rounds averaged $33.7M. Five Series A rounds averaged $32.8M. Seed cleared above Series A this week, and Apollo Atomics’ $31M seed outsized three of the five Series A rounds outright. Every large seed carried a proof asset acquired before the round opened: Apollo’s reactor system demonstrator, built and tested inside MIT’s Department of Nuclear Science and Engineering, had fuel that reached criticality at full output, alongside more than 20 GW in signed letters of intent; Network Bio launched with $50M and a $30M-plus co-development and licensing agreement with a Fortune 100 healthcare company already signed; Twin1 came in with Linklaters, Orrick and Dechert as customers, one of them also writing a check, and a prior company behind the founding team.

Perspective, what it means. Seed is now a post-proof round for anything capital-intensive or regulated. The money is not buying the chance to find out whether the thing works. It is buying the scale-up of something that already does. That is why a $31M seed and a $31.5M Series A priced within half a million dollars of each other this week: the label described the cap table, not the risk.

Founder Blindspot, what most miss. Founders still sequence the raise as seed first, proof second. The seeds that cleared above $20M completely inverted that order. Every one of them held an asset at the moment of the raise that a competitor could not have bought that day. Note the counterweight: Apollo’s letters of intent are non-binding, and its criticality claim is company-supplied, which is why it scored 62 and not 75. A proof asset raises your ask. It does not replace revenue.

Playbook, what to do. Write down every asset you hold right now that a well-funded competitor could not acquire this week: a signed agreement, a clearance, a dataset, a named logo, a physical result. If the list is empty, you are raising a $2M seed with a $20M deck. Spend the next quarter buying one item onto that list instead of scheduling more meetings.

Contrast. June’s mid-market had no seed rounds in its top ten at all. Series A carried that week. This week, seed took $101M across three deals and priced above Series A.

What this means for your raise: Do not let the stage label set your ask. Let the asset set it. Price the round off what you already hold, and say what that is in the first thirty seconds.

Shift 4: Insiders Carried the Round, and Two Rounds Were Not Rounds

Pattern, what happened. Abcuro’s $66M Series D named sixteen investors, and fifteen of them were already on the cap table, with Rock Springs Capital the sole new name. Leal’s $30M was a Series A extension, a second close. Rundoo’s $30M Series B had Bessemer and CRV re-upping behind a new Battery lead. Hopscotch’s Series D brought aMoon, Citi Impact, Alumni Ventures and K2 HealthVentures back alongside its new leads. Two further announcements did not survive the integrity gate at all: Sonic Fire Tech’s release closes out its seed at a cumulative $15M rather than raising $15M new, and Channel Medsystems’ Series C reaches $30M from an investor that has backed it since 2021 with no new investor named.

Perspective, what it means. Existing investors are the fastest source of capital in a market where new leads need 60 days to underwrite, and this week they were doing most of the work. But an insider round without a new price-setter caps the outcome, and two of them were packaged as new rounds, even though the primary sources describe cumulative totals. Abcuro shows the version that works: it converted a Phase 2/3 study that missed its overall endpoint into a funded registrational program in a predefined subgroup, with a start date and a readout date, and secured 15 existing holders to underwrite it.

Founder Blindspot, what most miss. Founders treat an insider re-up as validation. It is a bridge until a new investor prices it. And when the announcement restates a cumulative total as though it were a fresh close, sophisticated investors notice before you finish the meeting. Two such announcements landed in a single week.

Playbook, what to do. Before you open the round, ask every existing investor for a written pro rata commitment with a number attached. Use that as your floor, then run a new-lead process against it. Attach the insider money to a specific, dated milestone in the announcement, as Abcuro attached its raise to a Q4 2026 study start and a second-half 2028 readout. And state new capital as new capital.

Contrast. June’s rounds were dominated by new leads taking board seats and setting price. This week, the majority of the capital came from people already on the cap table, and two announcements had to be excluded from the weekly total because new capital was never disclosed separately.

What this means for your raise: Secure the insider floor in writing first. Then go get the new lead. Never let the insider round be the whole round, and never announce a cumulative total as a close.

Shift 5: The Clearance Became the Traction Slide

Pattern, what happened. Renata Medical raised a $25M Series D on an FDA premarket approval granted August 28, 2024, and a CMS New Technology Add-on Payment effective October 1, 2025, worth up to $22,685 per case, not on disclosed revenue, and scored 69. Happy Health raised the largest mid-market round of the week, $75M, on two FDA clearances while explicitly declining to disclose revenue. Ours Privacy sold HIPAA compliance itself as the product to more than 200 healthcare organizations. RockRose Risk is acquiring tree-trimming and roofing companies so it can control the mitigation that makes a wildfire risk underwriteable at all. Abcuro’s entire raise is structured around the design of a registrational study.

Perspective, what it means. In regulated categories, the clearance and the reimbursement code are proof of revenue because they convert a product into a billable event. An investor underwriting Renata is not underwriting a stent. They are underwriting the fact that a hospital can bill up to $22,685 per case above the standard payment. The regulatory asset is not the cost of entering the market. It is the market access itself.

Founder Blindspot, what most miss. Founders, file regulatory milestones in the compliance appendix, and add a market size chart to the traction slide. The clearance is the traction slide. The gap between Renata at 69 and MaxQ at 55 is that one company had cleared and been assigned a payment pathway with a dollar figure, and the other had an investigational device with clinical evaluations underway.

Playbook, what to do. Rebuild your traction slide around the payment path: the clearance or license you hold, with its date; the code or contract vehicle that pays for it; the amount paid per unit or procedure; and the number of buyers already able to pay under it. If you are pre-clearance, put the specific filing date and the specific pathway on the slide instead of a market size.

Contrast. In June, the regulated build was framed as the moat, the thing a competitor could not clone in a quarter. This week it went one step further. The regulatory asset was the metric investors priced, serving as a proxy for revenue that had not yet arrived.

What this means for your raise: If you are in a regulated category, lead with the payment path rather than the product. The clearance plus the code is worth more on slide two this quarter than any revenue projection you can build.

The Deals That Matter, Top 5

Five deep dives across rural care delivery, enterprise AI, healthcare data infrastructure, pediatric medtech, and clinical-stage therapeutics. Four are the four highest-scoring rounds of the week. The fifth, Abcuro, is included because it is the most instructive deal in the set. All metrics are verified against two or more sources and re-checked in a second pass.

Hopscotch Primary Care

Tech-Enabled Rural Primary Care | Series D | $53M | Valuation Undisclosed

Eisen Fundability Score: 82 / 100

Why this scored. The highest score this report series has recorded, and it is not close. Hopscotch is the only company in the set to disclose profitable operations, and it also disclosed four other verifiable numbers. Everything a diligence team needs sits in the press release: 15,000 patients, retention consistently above 90%, an NPS of 89, a medical loss ratio improved by more than 25 percentage points across a patient’s first two years, and profitable operations in Western North Carolina. That is usage density, satisfaction, clinical economics, and unit economics in one paragraph. All five are company-supplied, and none is independently audited, which is normal at this stage. The competitive act is not that Hopscotch published them. It is that they existed, were reconciled, and were ready at the moment the round was running.

The Setup. Hopscotch was founded in 2021 to run primary care in rural communities that lost their clinics, and it operates twelve locations concentrated in Western North Carolina. CEO Tim Gronniger took over in November 2024. He led Caravan Health as CEO from 2019 through its acquisition by Signify Health in March 2022 for $250M, building it into the leading accountable care enabler for rural health systems. Before that, he was deputy chief of staff and director of delivery system reform at CMS, and served on the White House Domestic Policy Council and on Capitol Hill. He is, in other words, the person who helped write the payment model his own company now operates inside. Note one relationship the release does not disclose: Gronniger is an advisor to Town Hall Ventures, a co-lead of this round.

The Numbers. $53M Series D co-led by 8VC and Town Hall Ventures. Returning investors include aMoon Fund, Citi Impact Fund, Alumni Ventures, and K2 HealthVentures. New participants include the Autism Impact Fund, John Doerr, Dr. Richard Merkin, and the Leon Levine Foundation. More than 15,000 patients. Retention consistently above 90%. Net Promoter Score of 89. Medical loss ratio improved by more than 25 percentage points over the first two years of care. Profitable operations in Western North Carolina. Twelve clinical locations. Founded in 2021. Announced August 18, 2026, with a correction filed August 19 that changed only the spelling of Town Hall Ventures. Use of funds: deepen access in the existing region, enter additional rural markets, build clinical and technology infrastructure.

The Pattern. Hopscotch is the operator model in its purest form. It does not sell software into rural clinics. It is the clinic. That means every efficiency it creates lands in its own medical loss ratio rather than a customer’s, which is why it can disclose profitability at all. It also explains the score: the operator model converts product improvement directly into disclosable economics.

The Perspective. A 25-point improvement in the medical loss ratio is not a marketing claim. It is the single number a value-based care investor uses to model the entire business, because it determines whether the company keeps the shared savings. Hopscotch led with the number that does the underwriting, not the number that sounds impressive. Most founders lead with the opposite.

The Playbook. Identify the one metric your investor uses to build their model, not the one you use to build your roadmap. For value-based care, it is medical loss ratio. For consumption software, it is net revenue retention. For marketplaces, it is take rate against repeat rate. Put that number, and its trend, on the second slide. Everything else in your deck is supporting evidence for it.

The Founder Mistake to Avoid. Founders copy the language and claim they are the tech-enabled operator of their vertical while still selling a product into someone else’s P&L. Hopscotch scored 82 because it carries the patients, the clinicians, the payer contracts, and the downside risk. If you do not own the economics, you cannot produce them on demand, and a number you cannot produce on demand is worth nothing in a live process.

Twin1 AI

Digital AI Twins for Knowledge Workers | Seed | $20M | Valuation Undisclosed

Eisen Fundability Score: 74 / 100

Why this scored. A seed round that outscored eleven later-stage deals. Twin1 posted a perfect 30 out of 30 on Founder-Investor Dynamics, the only company in the set to do so, on a repeat founding team out of Eigen Technologies, three co-leads, and a syndicate deep enough that its own customer took equity. Then it backed the syndicate with five named enterprise logos at seed stage: Linklaters, Orrick, Dechert, Customers Bank and Aegis Energy.

The Setup. Twin1 builds a privacy-first platform that creates an individual digital twin for each professional, integrating with Slack, Teams, Outlook, Gmail, Drive and SharePoint, with six layers of governance control and a peer-to-peer coordination network between twins. The team is led by Dr. Lewis Z. Liu, who previously co-founded Eigen Technologies with Tom Cahn, Huiting Liu, and Dr. Jonathan Budd. Offices in San Mateo and London. The claim is that the platform automates 30% to 50% of the communications work knowledge workers do, which is a specific, testable assertion rather than a productivity slogan.

The Numbers. $20M seed round co-led by Bessemer Venture Partners, Tribeca Venture Partners, and Aramco Ventures, announced August 20, 2026. Participants include EJF Ventures, F-Prime, Lakestar, Notion Capital, Neo, AGI House Ventures, Tin Alley Ventures, and Orrick as a strategic investor. Angels include a Dawn Capital co-founder, a Wiz co-founder, and a former McKinsey senior partner. Named customers: Linklaters, Orrick, Dechert, Customers Bank, Aegis Energy. Stated automation of 30% to 50% of knowledge worker communications volume. Use of funds: team expansion in San Mateo and London, go-to-market, core technology. No revenue disclosed.

The Pattern. Twin1 is the clearest example this week of the post-proof seed. The round did not buy the chance to find out whether three global law firms would deploy the product. It bought the scale-up of a deployment that had already happened. That is why a seed round priced like a Series A and scored like one.

The Perspective. Orrick appears twice in the announcement, as a customer and as a strategic investor. That is the strongest single fundability signal available at seed: a buyer who has used the product putting money behind it. It converts a reference call into a cap table entry, and it removes the two questions that kill most seed enterprise rounds: whether the buyer is real and whether the buyer will stay.

The Playbook. Before your next raise, ask your three best customers whether they will invest, even in small amounts. You are not raising money from them. You are raising from them so the rest of your syndicate never has to take your word for the customer relationship. One customer on the cap table is worth more than ten reference calls.

The Founder Mistake to Avoid. Founders read this deal as proof that enterprise logos win seed rounds and go chase pilots with big names. Twin1’s logos were not pilots. They were deployments deep enough that one of the firms wrote a check. A named logo attached to an unpaid trial is a liability in diligence, because the first reference call exposes it.

Ours Privacy

HIPAA-Compliant Customer Data Platform | Series A | $15M | Valuation Undisclosed

Eisen Fundability Score: 70 / 100

Why this scored. The smallest round in the set and the third-highest score. Our Privacy scored 24 out of 30 on Founder-Investor Dynamics, on the back of a round that its own release calls "multiple times oversubscribed," which is the only explicit demand signal disclosed anywhere during the week. It backed that with 200 healthcare organizations as customers, having been founded in 2024, and a regulatory tailwind that does the selling for it.

The Setup. Ours Privacy sells a HIPAA-compliant customer data platform that lets healthcare marketers run growth programs without patient data ever entering their ad tools. The company was founded in 2024 by Jessica Holton, Adam Putterman, and Tyler Zey, who built the product after struggling to find a compliant way to run marketing and analytics at their own telehealth company, Ours Wellness. That origin matters: they are not outsiders selling to healthcare marketers; they were the customer. The wedge is narrow, and the buyer is under active enforcement pressure, which is close to the ideal starting position for a vertical infrastructure company.

The Numbers. $15M Series A co-led by Lightbank and Health Velocity Capital, announced August 19, 2026, with Rock Health, Lakehouse, TMV, Switch Ventures, Starfire Ventures, and GreyMatter participating. More than 200 healthcare organization customers spanning providers, payers, and digital health companies. Founded in 2024. Headquarters in Houston. Round described by the company as multiple-times oversubscribed; independent coverage says only oversubscribed. Use of funds: platform investment and adoption among enterprise healthcare organizations. Revenue not disclosed.

The Pattern. Ours Privacy is the compliance-as-product template. It does not sell a marketing tool that happens to be compliant. It sells the compliance, and the marketing capability is the delivery mechanism. That inversion is what turns a crowded category, customer data platforms, into a defensible one, because the buyer’s alternative is legal exposure rather than a competing vendor.

The Perspective. Health Velocity Capital’s limited partners are health systems and payers. That is not a brand on the cap table; it is a distribution channel, and in a $15M round it is worth more than a larger check from a generalist. The lesson generalizes: at small round sizes, the correct question is not which investor has the best name but which one shortens your sales cycle.

The Playbook. For every investor on your target list, write one sentence naming the specific customer they can introduce you to and the specific deal they did in your category. If you cannot write that sentence, cut the name. A 35-name list where every entry passes that test converts faster than a 120-name list built on fund size.

The Founder Mistake to Avoid. Founders in regulated categories position as the friendly modern alternative to the incumbent tool and compete on interface. Ours Privacy is positioned against the buyer’s legal exposure, not against a competitor’s feature list. If your compliance story is a checkbox on a comparison table rather than the reason the deal closes, you have built a feature inside someone else’s category.

Renata Medical

Pediatric Cardiovascular Devices | Series D | $25M | Valuation Undisclosed

Eisen Fundability Score: 69 / 100

Why this scored. The purest example in the set of a round underwritten on a regulatory asset rather than revenue. Renata disclosed no ARR, no unit volume, and no revenue figure. What it disclosed was an FDA premarket approval granted August 28, 2024, and a CMS New Technology Add-on Payment effective October 1, 2025, worth up to $22,685 per case. ARCHIMED underwrote a purchase order that already has funding attached, and that scored 18 out of 20 on Narrative Power because the product is genuinely category-creating.

The Setup. Renata Medical, based in Newport Beach, California, and led by co-founder and CEO Dustin Armer, makes the Minima Stent System, the first balloon-expandable growth stent designed specifically for neonates, infants, and young children with pulmonary artery stenosis or coarctation of the aorta. A conventional stent placed in a newborn has to be surgically replaced as the child grows. Minima expands with the patient. The device previously held FDA Breakthrough Device designation and launched commercially in 2024.

The Numbers. A $25M Series D, led by ARCHIMED, a global healthcare-only investment firm, was announced on August 19, 2026, with existing investors participating but not individually named. FDA premarket approval was granted on August 28, 2024, a full PMA rather than a 510(k) clearance. CMS New Technology Add-on Payment announced August 12, 2025, for fiscal 2026, effective October 1, 2025, at a maximum of $22,685 per case. Company states adoption has exceeded internal expectations since commercial launch in 2024. No revenue, unit, or customer figure disclosed. Use of funds: accelerate US commercialization, expand internationally, develop additional pediatric cardiovascular technologies.

The Pattern. This is the reimbursement-first medtech round. Renata secured the payment mechanism a full year before it needed the revenue, and that mechanism is what was priced. An NTAP is Medicare paying an add-on above the standard diagnosis-related group payment, which means the hospital’s budget objection disappears before the sales call starts.

The Perspective. Investors in regulated hardware do not underwrite the device. They underwrite the moment money changes hands. A PMA says the device may be sold. An NTAP with a dollar amount indicates that a specific buyer has a specific funded line item. Those are two different assets, and only the second one closes rounds. Renata held both, and it is why a $25M Series D with zero disclosed revenue outscored a $75M Series A and a $50M launch financing.

The Playbook. Find the payment mechanism that already exists in your category and get named in it: an NTAP, a CPT code, a GSA schedule, an approved formulary, a state contract vehicle, a rebate program. Then put the per-unit or per-case dollar figure on your traction slide. If none exists, the specific pathway and filing date go on the slide instead. A founder who can name what a buyer gets paid to buy their product is describing revenue, not compliance.

The Founder Mistake to Avoid. Founders treat reimbursement as a post-launch commercial workstream that starts once the product is selling. Renata inverted that, and it is the entire reason this round priced. The trap is assuming a clearance alone is the milestone. A clearance without a payment pathway gives you permission to sell into a budget that does not exist yet, which is exactly the gap that separates Renata at 69 from MaxQ at 55.

Abcuro

Clinical-Stage Autoimmune Therapeutics | Series D | $66M | Valuation Undisclosed

Eisen Fundability Score: 66 / 100

Why this scored. Included as the most instructive deal of the week rather than the highest-scoring. Abcuro is the only company in the set that raised $66M after its lead program failed to meet its overall endpoint. The Phase 2/3 MUSCLE study of ulviprubart in inclusion body myositis did not achieve statistical significance and showed a trend toward slowing disease progression relative to placebo, with roughly a 50% slowing in a predefined subgroup of less severe patients. Abcuro recut that finding into a defined population, designed a potentially registrational study around it, and funded it with 16 investors, 15 of whom were already holders.

The Setup. Abcuro is a Newton, Massachusetts clinical-stage company led by CEO Alex Martin, developing ulviprubart, a first-in-class antibody targeting KLRG1, for inclusion body myositis, a progressive muscle-wasting disease with no approved therapy. The company did not restructure, pivot, or rebrand after the readout. It kept the asset, narrowed the population, named the next study, and put dates on it.

The Numbers. $66M Series D led by New Leaf Venture Partners, announced August 18, 2026. Fifteen existing investors participated, including abrdn, Bain Capital Life Sciences, Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital Management, Pontifax, Sanofi Ventures, Foresite Capital, NEA, Eurofarma Ventures, Kaitai Capital, and Soleus Capital, with Rock Springs Capital the sole new investor. The Phase 2/3 MUSCLE study did not achieve statistical significance overall and showed a trend toward slowing disease progression, with roughly a 50% slowing in the predefined subgroup scoring above 29 on the IBM functional rating scale. Potentially registrational study expected to start Q4 2026, top-line results anticipated in the second half of 2028. Pre-revenue.

The Pattern. Abcuro is the risk-recut template, and it is the most replicable move in this entire issue. The company did not argue that the trial was misread. It accepted the result, isolated the predefined population where the effect held, and repriced the program around that population using a dated study and a dated readout. Fifteen existing investors funded the narrower, more certain thing.

The Perspective. Investors do not fund optimism after a miss. They fund a smaller claim they can believe. The instinct after a bad result is to widen the story: more indications, more markets, more optionality. Abcuro did the opposite and narrowed it to the one population where the evidence held. A defensible smaller claim is fundable. An indefensible larger one is not, and the difference is worth $66M. Note that the subgroup was predefined rather than identified afterward, which makes it credible to regulators and diligence teams.

The Playbook. If a core assumption in your business broke this quarter, do not rewrite the narrative to route around it. Segment your data and find the cohort, channel, or customer type where the result actually held, and check whether you defined that cut in advance. Then rebuild the round around that cohort, with a named next milestone and a date, and take it to your existing investors first. They already carry the loss, and they are the fastest capital available to you.

The Founder Mistake to Avoid. Founders respond to a bad number by expanding the story. The market reads expansion after a miss as an inability to face the result. The second trap is subtler: presenting the 50% figure without the words did not achieve statistical significance next to it. A subgroup result quoted without its failed primary endpoint is the fastest way to lose a sophisticated investor in diligence.

The Fundraising Playbook, Five Tactical Plans

Five plans, each producing a concrete output you can use immediately. No vague tasks. Each is built directly from this week’s verified signals.

1. The Three Numbers, Ready Before the Ask (Positioning and Investor Framing)

Why this matters. Proof readiness was worth 13.4 points of Eisen score this week. The nine companies whose commercial proof was built and verifiable averaged 69.1, compared with 55.7 for the six with none, and the gap held within categories rather than only across them. Investors request this detail privately in every process, so the deliverable below is not a publication plan. It is a readiness plan.

Exact deliverable. Three numbers, assembled and reconciled before you open the round: one usage number (units, patients, stores, seats, transactions), one retention or expansion number, and one economics number (gross margin, medical loss ratio, contribution margin, payback). Each must be reconciled against your own systems so that a second query does not change the figure. Put them on slide two of the deck, keep a one-page backup carrying the working and the source query behind each, and set an internal standard that any investor request for detail is answered within 24 hours. What you make public is a separate decision and stays yours.

Expected outcome. You move from the 55.7 bucket to the 69.1 bucket without changing anything about the business. When the diligence request lands, you answer the same day rather than spending three weeks proving you can count.

The reframe. Wrong approach: build the proof stack during diligence, off the partner’s question list. Right approach: build it before the process opens, so the request costs you a day rather than a month.

2. The Payment Path Traction Slide (Proof and Metrics Packaging)

Why this matters. Renata Medical raised a $25M Series D with no disclosed revenue on an FDA premarket approval plus a CMS add-on payment worth up to $22,685 per case, and scored 69. MaxQ Medical raised $31.5M with an investigational device and clinical evaluations underway and scored 55. In regulated categories this week, the funded payment pathway was the traction.

Exact deliverable. Rebuild your traction slide around four lines: the clearance, license, or approval you hold with its date; the code, contract vehicle, or reimbursement pathway that pays for it; the amount paid per unit or procedure; and the number of buyers already able to pay under it. If you are pre-clearance, replace line one with the specific pathway and the specific filing date. Delete the market size chart from the traction slide entirely and move it to the appendix.

Expected outcome. An investor can model your revenue from the slide without asking you a question. That is the difference between a second meeting and a follow-up request.

The reframe. Wrong approach: regulatory milestones in the compliance appendix; market size on the traction slide. Right approach: the payment path on the traction slide, market size in the appendix.

3. Eisen Self-Score and Gap Diagnosis (Readiness)

Why this matters. This week’s scores ran 36 to 82, a 46-point band against 13 points in June, and the mean fell from 72.3 to 63.7. In a wide, uncertain band, knowing precisely which dimension is pricing you down matters more than it did when everyone clustered together.

Exact deliverable. Score your round across the five dimensions: Founder-Investor Dynamics (30), Traction to Conviction (25), Narrative Power (20), Deal Architecture (20), and Capital Planning (5). Score conservatively and penalize your own opacity the way an investor will, which means every undisclosed figure loses points rather than getting the benefit of the doubt. Identify your two lowest dimensions and write one concrete action for each, with a date.

Expected outcome. A ranked list of the two dimensions actually pricing your round down, so the next two weeks go to the gap instead of to another deck revision.

The reframe. Wrong approach: improve everything at once and assume missing data reads as neutral. Right approach: fix the lowest two dimensions and assume every blank scores zero.

4. The Insider Floor Before the Outside Process (Deal Architecture)

Why this matters. Insider participation appeared in at least six of fifteen rounds, and two further announcements had to be excluded from this issue’s totals because they restated cumulative figures rather than disclosing new capital. Abcuro funded $66M with fifteen of sixteen investors already on the cap table, attached to a dated registrational study, and scored 66 after a failed primary endpoint.

Exact deliverable. A written pro-rata commitment, with a dollar figure attached, from every existing investor, secured before you open the round. Then a target list of new leads cut to 35 names, where every name passes one test: you can write a sentence naming the specific deal they led in your category and the specific customer or validation they bring. Finally, one dated milestone the round funds, stated in the announcement, and new capital stated as new capital.

Expected outcome. A priced floor you control, a shorter and faster outside process, and an announcement that reads as conviction rather than maintenance.

The reframe. Wrong approach: treat the insider re-up as the win and announce the cumulative total. Right approach: treat it as the floor, attach it to a dated milestone, and go get the new lead who sets the price.

5. The Forcing Function Sentence (Momentum and Conversion)

Why this matters. RockRose is entering a wildfire season that has already burned more acreage than in all of 2025. Ours, Privacy, sells into active federal enforcement pressure and closed a round it describes as multiple-times oversubscribed. Apollo Atomics is selling into a data center power crunch with more than 20 GW of letters of intent already signed. Every fast close in this set had a deadline underneath it that belonged to the customer, not the founder.

Exact deliverable. One sentence naming the forcing function that makes your customer act this quarter rather than next year: a cost line that broke, a regulation with a date, a platform migration already committed, a contract renewal, a season. Then a 14-day follow-up cadence where each touch reports movement against that forcing function rather than movement in your own roadmap.

Expected outcome. Your process runs at the speed of your customer’s urgency, which is the only speed an investor believes. Each follow-up includes new external evidence rather than an internal update.

The reframe. Wrong approach: create urgency with a fake deadline on the round. Right approach: surface the real deadline that already exists in your customer’s world and report against it every two weeks.

Looking Forward, Next 1 to 3 Weeks

Three evidence-based scenarios and one wild card. Every prediction is anchored to this week’s verified data, not speculation.

Scenario 1: The Healthcare Mid-Market Stays Crowded (High Probability)

Evidence from this week. Nine of fifteen mid-market rounds and 67.1% of tracked capital went to healthcare and life sciences, spread across therapeutics, medtech, care delivery, biomedical AI, and healthcare data infrastructure. That is breadth, not a single hot subsector, which is the pattern that persists rather than spikes.

What to watch. Whether more healthcare rounds arrive with operating proof already assembled. Hopscotch had profitable operations in a region to point at and scored 82. Most founders will keep that detail inside diligence rather than in a release, which is reasonable. The signal to watch is how quickly companies in your category can respond to a metrics request, because that speed is now your benchmark.

What founders should do before others notice. If you are raising in healthcare within the next quarter, assume you are being read against a comparison set that includes a company with profitable operations, which it can evidence on request. Get one economics number reconciled and ready before you open, even if it covers a single region, site, or cohort.

Scenario 2: Seed Round Sizes Stay Detached From the Label (High Probability)

Evidence from this week. Three seeds averaged $33.7M against five Series A rounds at $32.8M, and every large seed carried a pre-existing proof asset: criticality reached at full output on an MIT-built demonstrator, a signed $30M-plus co-development agreement with a Fortune 100 healthcare company, three global law firms deployed with one of them investing. The mechanism is structural, not sentiment.

What to watch. Seed announcements that lead with an asset rather than a team: a signed agreement, a regulatory step, a physical result, a named customer. Watch particularly for seeds in capital-intensive categories closing above $25M, which is where the label detaches entirely from the risk profile.

What founders should do before others notice. Audit what you hold today that a competitor could not buy this week. If the list is empty, reset your ask to match the risk you are actually asking someone to take, and spend the quarter buying one item onto the list rather than running a process you will lose.

Scenario 3: Valuation Opacity Keeps Rising (Medium-High Probability)

Evidence from this week. Fourteen of fifteen rounds withheld valuation, a 93% opacity rate, up from 80% in June. The one company that disclosed was Astromech at a company-stated $3.8B with no revenue and no customers disclosed against it. That is not an example the rest of the market wants to follow, and it does nothing to encourage disclosure by companies with real but unspectacular numbers.

What to watch. Whether operating metric disclosure rises while valuation disclosure continues to fall. That combination, more numbers about the business and fewer about the price, is the signature of a market where founders are competing on proof and protecting on terms.

What founders should do before others notice. Separate the two decisions deliberately. Build operating proof so it can be produced within a day, and hold price until you have leverage. Founders who conflate the two build nothing until diligence forces it, and that is what put six companies in the 55.7 bucket this week.

Wild Card: A Second Failed Readout Gets Funded on a Recut (Medium Probability)

Evidence from this week. Abcuro raised $66M from sixteen investors after its Phase 2/3 missed statistical significance by isolating a pre-defined, less severe subgroup showing roughly 50% slowing and designing a registrational study around it, with a Q4 2026 start and a second-half 2028 readout. Fifteen of the sixteen investors were already holders. The template is now visible to every board in the sector.

What founders should do before others notice. If you are approaching a binary readout of any kind, clinical or commercial, pre-commit with your board to the subgroup analysis you will run if the primary result misses, and define the cut in advance so it is credible afterward. Identify now which existing investors would fund a narrower program. Deciding this before the result removes the two weeks of narrative drift that usually follows a miss, and those two weeks are where most recuts die.

The Bottom Line

The real insight is not the $545.0M total. It is that two markets ran in the same week and the loud one was irrelevant to you. Above $100M, capital chased capacity. Below $100M, where your round lives, capital chased proof of payment, and it paid a 13.4-point premium to the founders whose proof was already built when the process opened. Three conviction profiles took the week.

Profile 1: Operators who own the economics. Hopscotch Primary Care (82) runs the clinics, carries the payer contracts, and can therefore disclose profitable operations and a 25-point improvement in medical loss ratio. Ours Privacy (70) sells the compliance itself to 200 organizations rather than a tool that happens to be compliant. When you own the economics, you can produce them on demand, and that speed is what priced this week.

Profile 2: Post-proof seeds that arrived holding an asset. Twin1 AI (74) arrived at seed with three global law firms deployed, one of which is on the cap table. Apollo Atomics (62) arrived with fuel that had reached criticality on a demonstrator built inside MIT. Network Bio (65) launched with a $30M-plus co-development agreement already signed. None of these rounds bought the chance to find out. All three bought the scale-up of something already true, and seed outraised Series A because of it.

Profile 3: Regulated assets standing in for revenue. Renata Medical (69) raised on a premarket approval plus a reimbursement code worth up to $22,685 per case, with no revenue disclosed at all. Abcuro (66) funded a registrational study after a missed primary endpoint by narrowing to the predefined population in which the effect held. Happy Health (65) raised $75M on two FDA clearances while declining to disclose revenue. The clearance and the code did the work revenue usually does.

Everything else competed for the residual. Six companies raised real money with no commercial proof built into the record, and they averaged 55.7, compared with 69.1 for the rest. Every one of them will have answered questions in diligence that never became public, and none of them owed anyone a press release. The difference is that the top of the band had the answer ready before the question arrived. In a broadening market, the proof you can hand over the day it is asked for is the moat.

Five New Rules for Founders

Rule 1. Read the tape at your own round size. The headlines above $100M went to defense and silicon. The mid-market went 67.1% to healthcare. Build your comp set from rounds within 2x of your target, or you will optimize your pitch for a market you are not raising in.

Rule 2. Proof readiness is worth 13.4 points. Three reconciled numbers- one usage, one retention, one economics- separated 69.1 from 55.7 this week with nothing else about the underlying businesses changing. Investors will ask you for them privately. Have the answer before the question.

Rule 3. The stage label no longer sets the check. Seed outraised Series A, and every large seed held an asset before the round opened. Price your ask off what you already hold, not off the round name.

Rule 4. Insider money is a floor, not a round, and a cumulative total is not a close. Secure written pro-rata first, attach it to a dated milestone, then find the lead who sets the price. Two of this week’s announcements failed that test and were excluded from these totals.

Rule 5. In a regulated category, the clearance is the traction slide, and the reimbursement code is the revenue line. Renata raised $25M with no revenue disclosed because it could not disclose what a hospital is paid to use its product.

Four Monday Actions

1. Assemble the three numbers. One usage, one retention, one economics, each reconciled against your own systems. Slide two of the deck, plus a one-page backup carrying the work behind each, ready to send the day it is requested.

2. Rebuild the traction slide as a payment path. Clearance or license with its date, the code or contract vehicle that pays, the amount per unit, the number of buyers able to pay. Market size moves to the appendix.

3. Secure the insider floor in writing. Ask every existing investor for a pro rata commitment, including the dollar amount, before you open. Then attach the round to one dated milestone, and never let a cumulative total be described as a close.

4. Write the forcing function sentence. Name the deadline that belongs to your customer, not to you. If they could wait a year without consequence, fix that before you fix the deck.

Your competitors are reading the same tape, and most of them are reading the wrong half. The founders whose three numbers are already reconciled get read first, priced first, and closed first. The ones who start assembling when the request lands will spend three weeks proving they can count, while five other companies answer in a day.

Research Methodology and Sources

Data collection period: August 17 to 23, 2026, with verified primary disclosures clustered August 17 to 21. No verified US mid-market round was announced on August 22 or 23. Verification standard: a minimum of two independent sources per deal, with company press releases and regulated newswires (BusinessWire, PRNewswire, GlobeNewswire) prioritized as anchor sources, plus at least one independent outlet for corroboration. This issue was then put through a second, independent verification pass in which every company, amount, stage, investor, date, and reported metric was re-checked against primary sources by researchers who did not write the first draft. That pass removed three deals, corrected six attributions, and reversed one sourcing error. Its findings are documented in the Data Integrity Notes and the corrections log below. Eisen Fundability Scores are proprietary analytical estimates, not endorsements or investment advice. All dollar figures reflect the announced new primary capital at close unless noted otherwise.

Core Capital Totals and What They Include

The $545.0M weekly total includes only the fifteen verified US rounds in the scorecard, each independently confirmed at the stated amount and stage. Mid-market is defined for this issue as a US-headquartered priced round of new primary capital between $10M and $100M. Regulation A+ and other retail securities offerings are excluded because they are not priced venture rounds. Announcements that restate a cumulative total rather than disclosing new capital closed in the window are excluded. No aggregator-only figure was treated as fact without corroboration in a company release or an independent outlet. Arithmetic on the total, the average, the median, all stage and sector subtotals and every chart value was recomputed and reconciled after the second verification pass: the four sector subtotals ($365.5M, $75.0M, $61.0M and $43.5M) and the five stage subtotals ($101.0M, $164.0M, $91.0M, $144.0M and $45.0M) each sum to $545.0M across fifteen deals.

Deal Citations, Two or More Sources per Deal

· Happy Health, $75M Series A. Fierce Healthcare deal coverage dated August 18, 2026; MedCity News; Medical Device Network; VC News Daily round record; Crunchbase News weekly ranking for the week of August 15 to 21, 2026; FDA 510(k) database records K240236 (cleared October 8, 2024) and K242224 (cleared June 18, 2025); company clearance release of June 19, 2025 for the 97% polysomnography concordance figure. Business Insider coverage of August 18, 2026 conflicts on total raised and close date; see Data Integrity Notes.

· Abcuro, $66M Series D. BusinessWire company release dated August 18, 2026; BioSpace press release archive; Clinical Trials Arena; FinSMEs; citybiz.

· Smack Technologies, $61M Series B. PRNewswire company release dated August 18, 2026; Smack Technologies company journal post; The Next Web; Tectonic Defense; FinSMEs; company BusinessWire release of March 2, 2026 for the $32M prior financing and founder backgrounds.

· Hopscotch Primary Care, $53M Series D. PRNewswire company release dated August 18, 2026 with formal correction filed August 19, 2026; Pulse 2.0; Crain’s Chicago Business; FinSMEs; Hopscotch CEO announcement of November 13, 2024 and Town Hall Ventures partner biography for founder background; BusinessWire release of March 1, 2022 and Fierce Healthcare for the $250M Signify Health acquisition of Caravan Health.

· Network Bio, $50M launch financing. Company release dated August 19, 2026; Pharmaphorum; BusinessWire release of August 19, 2026 covering the separate NVIDIA collaboration; The Pharmaletter; Longevity.Technology. GenomeWeb coverage contains the NVIDIA conflation corrected in this issue.

· MaxQ Medical, $31.5M Series A. PRNewswire company release dated August 20, 2026; S3 Ventures investor announcement; Medical Device Network; Yahoo Finance syndication.

· Apollo Atomics, $31M Seed. PRNewswire company release dated August 20, 2026; Tech Startups; Tech Funding News; Interesting Engineering; Dealroom.

· Rundoo, $30M Series B. BusinessWire company release dated August 19, 2026; SiliconANGLE; Tech Startups; Hardware Retailing; Pulse 2.0.

· Leal Therapeutics, $30M Series A extension. PRNewswire company release dated August 17, 2026; BioSpace; Reuters via TradingView; Clinical Trials Arena; citybiz; company releases of October 30, 2024, and August 27, 2025, for prior financings.

· Renata Medical, $25M Series D. PRNewswire company release dated August 19, 2026; BioSpace; Pulse 2.0; Medical Device Network; Cardiac Interventions Today for the CMS NTAP approval; BusinessWire release of August 12, 2025 for the NTAP designation and per-case amount.

· Queen One, $25M. PRNewswire company release dated August 19, 2026; MarTech Cube; Pulse 2.0; TipRanks private company coverage; FinSMEs.

· Twin1 AI, $20M Seed. BusinessWire company release dated August 20, 2026; Twin1 company newsroom; CityBiz; FinancialContent.

· Astromech, $20M. Axios Pro Biotech Deals dated August 20, 2026; Yahoo Finance; Dallas Innovates; Tech Funding News; Dealroom; FinSMEs. Prior round context from Axios Pro of April 7, 2026.

· Ours Privacy, $15M Series A. PRNewswire company release dated August 19, 2026; Fierce Healthcare; Pulse 2.0; MarTech Cube; The SaaS News; FinSMEs.

· RockRose Risk, $12.5M Series A. Business Wire company release dated August 19, 2026; Insurance Business Magazine; Insurance Journal; FF News; Fintech Global; separate RockRose release for the McCloud Condominium savings figure in North Lake Tahoe, Nevada.

Research completion timestamp: August 23, 2026.

DISCLAIMER: This article is for informational and strategic intelligence purposes only. It does not constitute investment advice. The Eisen Fundability Score is a proprietary diagnostic within Fundables OS™, not a financial recommendation.

If this article was useful, share it with founders who are about to raise.

— Leon Eisen, 4x Founder, Venture Capitalist, and Creator of Fundables OS™

Playbook, Perspective, and Pattern for founders raising now. This report strips out the megarounds and the public-market traffic so you can read the part of the market that actually prices your round.

Six of the ten mid-market rounds tracked this week carried a corporate balance sheet on the cap table, and in two of them the corporate held the lead or co-lead seat. That is no longer a late-stage phenomenon. A pharmaceutical venture arm co-led a Series A for a company whose lead antibody targets the same pathway as its own blockbuster. An enterprise hardware maker co-led a Series C after leading the B. A derivatives exchange and a chip manufacturer wrote into the first institutional round of a two-year-old data company. Across the ten scored rounds, $595.5M moved, with every deal under $100M.

The old sequencing rule said to take financial money first and strategic money last, because a corporate on the cap table signals to buyers, constrains your exit, and slows your process. That rule assumed strategics arrive after the risk is gone. This week they arrived while the risk was still there, and they paid for the seat.

Look at what sits behind those seats and the logic gets sharper. Two companies in the tracked set had already signed commercial collaborations with the same pharmaceutical groups that then invested, totaling roughly $950M and $838M in potential upfront and milestone payments. Combined, that is close to $1.8B of contracted optionality sitting behind $152M of equity. The corporate did not turn up as a validator. It turned up as a counterparty that had already run the diligence and paid for the answer.

Here is the second thing the tape did, and it runs counter to a reflex almost every founder has. Check size told you nothing about fundability. Fit a line through the data on round size and Eisen Fundability Score (EFS) across the ten, and it is flat. The largest round of the week sits mid-table at 65. The highest score belongs to a company that raised barely half as much. The lowest belongs to the fourth-largest round. The number in the headline and the strength of the position underneath it are statistically unrelated.

The consequence for Monday is specific. If you are running a generalist process because you believe strategics are a later problem, you are competing for the smaller pool. And if you are benchmarking your raise against the biggest headline in your sector, you are benchmarking against noise. Read every shift below through those two lenses.

The Week in One Sentence

Primary insight: With the megarounds and the public-market traffic removed, mid-market capital concentrated around two things: evidence that cannot be reversed, and investors who are also buyers. Corporate and strategic money moved down-stage into Series A and B, and round size carried no signal about the strength of the position underneath it.

▪ Total tracked mid-market capital (10 scored rounds): $595.5M, every round under $100M.

▪ Average round size: $59.55M across the ten.

▪ Median round size: $61.5M, the midpoint between Heaviside Industries and Skan AI.

▪ Disclosed valuations: two of ten. Blacksmith at $550M and Heaviside Industries at $600M. Eight rounds were undisclosed, and each one incurred a score deduction for opacity.

▪ Largest tracked round: MarginEdge, $80M Series D, a restaurant operations and finance platform running across more than 13,000 restaurants.